<SEC-DOCUMENT>0001437749-19-005927.txt : 20190328
<SEC-HEADER>0001437749-19-005927.hdr.sgml : 20190328
<ACCEPTANCE-DATETIME>20190328163204
ACCESSION NUMBER:		0001437749-19-005927
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190328
DATE AS OF CHANGE:		20190328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ATOSSA GENETICS INC
		CENTRAL INDEX KEY:			0001488039
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				264753208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35610
		FILM NUMBER:		19712414

	BUSINESS ADDRESS:	
		STREET 1:		107 SPRING STREET
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98104
		BUSINESS PHONE:		206.588.0256

	MAIL ADDRESS:	
		STREET 1:		107 SPRING STREET
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98104
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>atos20181231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<html>
<head>
	<title>atos20181231_10k.htm</title>
	<!-- Created by RDG HTML Converter v1.1.0.0 2/22/2019 3:27:39 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="padding: 0in 0.1in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; cursor: auto;">
<div contenteditable="false" docsect="2" id="49379" sectdesc="Cover Page">&nbsp;</div>

<div data-td-statement-type="cover" data-td-v2v-id="1551720478567">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#toc" style="-sec-extract: exhibit;">Table of Contents</a></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>UNITED STATES</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Washington, D.C. 20549</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FORM 10-K</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(Mark one)</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9746;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Annual Report Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of&nbsp;1934</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>For the fiscal year ended December 31, 2018</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>OR</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9744;</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Transition Report Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>For the transition period from:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 40%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Commission File Number 001-35610</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ATOSSA GENETICS INC.</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Delaware</b></p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>26-4753208</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(State or other jurisdiction of</b></p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(I.R.S. Employer</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>incorporation or organization)</b></p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Identification No.)</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>107 Spring Street</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Seattle, WA 98104</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(Address of principal executive offices)</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registrant&rsquo;s telephone number, including area code: <b>(206) 325-6068</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 49%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Title of each class</p>
			</td>
			<td style="width: 2%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 49%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name of each exchange on which registered</p>
			</td>
		</tr>
		<tr>
			<td style="width: 49%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Common Stock, $0.18 par value</p>
			</td>
			<td style="width: 2%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 49%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The NASDAQ Capital Market</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(g) of the Act: None</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities Act. Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&#9746;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act. Yes&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&#9746;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Exchange Act during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days. Yes&nbsp;&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&#9744;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&sect;232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit such files). Yes&nbsp;&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&#9744;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K is not contained herein, and will not be contained, to the best of registrant&#39;s knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III of this Form&nbsp;10-K or any amendment to this Form&nbsp;10-K.&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &quot;large accelerated filer,&quot; &quot;accelerated filer,&quot; &quot;smaller reporting company,&quot; and&nbsp;&quot;emerging growth company&quot; in Rule&nbsp;12b-2 of the Exchange Act.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 23%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Large&nbsp;accelerated&nbsp;filer&nbsp;&nbsp;&nbsp;&#9744;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 20%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Accelerated&nbsp;filer&nbsp;&nbsp;&nbsp;&#9744;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 23%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Non-accelerated&nbsp;filer&nbsp;&nbsp;&nbsp;&#9744;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 31%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Smaller&nbsp;reporting&nbsp;company&nbsp;&nbsp;&nbsp;&#9746;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 25%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Emerging growth company &nbsp;&nbsp;&nbsp;&#9744;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended&nbsp;transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. &nbsp;&#9744;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act).&nbsp;Yes&nbsp;&#9744;&nbsp;No&nbsp;&nbsp;&nbsp;&#9746;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">As of June 30, 2018, the last business day of the registrant&rsquo;s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates was $4,874,099. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the Company. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The number of shares outstanding of the registrant&#39;s common stock, par value $0.18, as of March 25, 2019 was 9,116,490<a class="rdg_comment commentapprove" name="doccmt-526">.</a></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="3" id="49380" sectdesc="Table of Contents">&nbsp;</div>

<div data-td-statement-type="toc" data-td-v2v-id="1551720486042">
<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><a id="toc" name="toc"></a>ATOSSA GENETICS INC.<br>
2018 FORM 10-K REPORT<br>
TABLE OF CONTENTS</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>PAGE</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#parti" style="-sec-extract: exhibit;"><b>PART I</b></a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item1" style="-sec-extract: exhibit;">Item&nbsp;1.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item1" style="-sec-extract: exhibit;">Business</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a class="rdg_comment commentapprove" name="doccmt-525">&nbsp; 6</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item1a" style="-sec-extract: exhibit;">Item&nbsp;1A.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item1a" style="-sec-extract: exhibit;">Risk Factors</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">24</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item1b" style="-sec-extract: exhibit;">Item&nbsp;1B.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item1b" style="-sec-extract: exhibit;">Unresolved Staff Comments</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">40</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item2" style="-sec-extract: exhibit;">Item&nbsp;2.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item2" style="-sec-extract: exhibit;">Properties</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">40</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item3" style="-sec-extract: exhibit;">Item&nbsp;3.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item3" style="-sec-extract: exhibit;">Legal Proceedings</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">40</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item4" style="-sec-extract: exhibit;">Item&nbsp;4.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item4" style="-sec-extract: exhibit;">Mine Safety Disclosure</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">41</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#partii" style="-sec-extract: exhibit;"><b>PART II</b></a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item5" style="-sec-extract: exhibit;">Item&nbsp;5.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item5" style="-sec-extract: exhibit;">Market for the Registrant&#39;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">41</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item6" style="-sec-extract: exhibit;">Item&nbsp;6.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item6" style="-sec-extract: exhibit;">Selected Financial Data</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">41</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item7" style="-sec-extract: exhibit;">Item&nbsp;7.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item7" style="-sec-extract: exhibit;">Management&#39;s Discussion and Analysis of Financial Condition and Results of Operations</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">42</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item7a" style="-sec-extract: exhibit;">Item&nbsp;7A.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item7a" style="-sec-extract: exhibit;">Quantitative and Qualitative Disclosures about Market Risk</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">49</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item8" style="-sec-extract: exhibit;">Item&nbsp;8.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item8" style="-sec-extract: exhibit;">Financial Statements and Supplementary Data</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">49</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item9" style="-sec-extract: exhibit;">Item&nbsp;9.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item9" style="-sec-extract: exhibit;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">49</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item9a" style="-sec-extract: exhibit;">Item&nbsp;9A.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item9a" style="-sec-extract: exhibit;">Controls and Procedures</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">49</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item9b" style="-sec-extract: exhibit;">Item&nbsp;9B.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item9b" style="-sec-extract: exhibit;">Other Information</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">49</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#partiii" style="-sec-extract: exhibit;"><b>PART III</b></a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item10" style="-sec-extract: exhibit;">Item&nbsp;10.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item10" style="-sec-extract: exhibit;">Directors, Executive Officers and Corporate Governance</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">50</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item11" style="-sec-extract: exhibit;">Item&nbsp;11.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item11" style="-sec-extract: exhibit;">Executive Compensation</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">50</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item12" style="-sec-extract: exhibit;">Item&nbsp;12.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item12" style="-sec-extract: exhibit;">Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">50</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item13" style="-sec-extract: exhibit;">Item&nbsp;13.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item13" style="-sec-extract: exhibit;">Certain Relationships and Related Transactions, and Director Independence</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">50</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item14" style="-sec-extract: exhibit;">Item&nbsp;14.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item14" style="-sec-extract: exhibit;">Principal Accounting Fees and Services</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">50</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#partiv" style="-sec-extract: exhibit;"><b>PART IV</b></a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item15" style="-sec-extract: exhibit;">Item&nbsp;15.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item15" style="-sec-extract: exhibit;">Exhibits and Financial Statement Schedules</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">50</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item16" style="-sec-extract: exhibit;">Item 16.</a></p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#item16" style="-sec-extract: exhibit;">Form 10-K Summary</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">50</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 82%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#signatures" style="-sec-extract: exhibit;">Signatures</a></p>
			</td>
			<td style="width: 9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">78</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="12" id="49381" sectdesc="Other">&nbsp;</div>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Statements made in this report on Form 10-K that are not statements of historical information are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the <b><i>&ldquo;Securities Act</i></b><b>&rdquo;</b>) and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the <b>&ldquo;</b><b><i>Exchange Act&rdquo;</i></b>). We have made these statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties, which could cause actual results to differ materially from those projected or anticipated. Although we believe our assumptions underlying our forward-looking statements are reasonable as of the date of this report we cannot assure you that the forward-looking statements set out in this report will prove to be accurate. We typically identify these forward-looking statements by the use of forward-looking words such as &ldquo;expect,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;seek,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate&rdquo; or the negative version of those words or other comparable words. Forward-looking statements contained in this report include, but are not limited to, statements about:</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">whether we can obtain approval from the U.S. Food and Drug Administration, or FDA, and foreign regulatory bodies, to commence our clinical studies and to sell, market and distribute our therapeutics and devices under development;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to successfully initiate and complete clinical trials of our pharmaceutical candidates under development, including our oral and topical Endoxifen (an active metabolite of Tamoxifen) and our intraductal microcatheters to administer therapeutics, including our study using fulvestrant;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the success, cost and timing of our product and drug development activities and clinical trials, including whether the ongoing clinical study using our intraductal microcatheters to administer fulvestrant and our study using our oral Endoxifen in the window of opportunity prior to surgery will enroll a sufficient number of subjects or be completed in a timely fashion or at all;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">whether we will successfully complete our clinical study of topical Endoxifen to reduce mammographic breast density and whether the study will fail to achieve its objective, including because some participants have discontinued the study prior to completing the full six months of dosing because of skin irritation issues or for other reasons;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to contract with third-party suppliers, manufacturers and service providers, including clinical research organizations, and their ability to perform adequately;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to successfully develop and commercialize new therapeutics currently in development or that we might identify in the future and in the time frames currently expected;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to successfully defend litigation and other similar complaints that may be brought in the future, in a timely manner and within the coverage, scope and limits of our insurance policies;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to establish and maintain intellectual property rights covering our products;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our expectations regarding, and our ability to satisfy, federal, state and foreign regulatory requirements;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the accuracy of our estimates of the size and characteristics of the markets that our products and services may address;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">&#9679;</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">whether the final study results will vary from preliminary study results that we may announce;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our expectations as to future financial performance, expense levels and capital sources;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to attract and retain key personnel; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to raise capital.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">This Annual Report also contains estimates and other statistical data provided by third parties and by us relating to market size and growth and other industry data. These and other forward-looking statements are presented as of the date on which the statements are made. We have included important factors in the cautionary statements included in this Annual Report, particularly in the section titled &ldquo;ITEM 1A. RISK FACTORS,&rdquo; that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any new information, future events or circumstances that may affect our business after the date of this Annual Report. Except as required by law, we do not intend to update any forward-looking statements after the date on which the statement is made, whether as a result of new information, future events, circumstances or otherwise.&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CORPORATE INFORMATION</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our corporate website is located at <i>www.atossagenetics.com</i>. Information contained on, or that can be accessed through, our website is not a part of this report. We make available, free of charge through our website or upon written request, our Annual Reports on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K and other periodic SEC reports, along with amendments to all of those reports, as soon as reasonably practicable after we file the reports with the SEC.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Unless otherwise noted,&nbsp;the term &ldquo;Atossa Genetics&rdquo; &ldquo;Atossa,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; refers to Atossa Genetics Inc., a Delaware corporation. We were incorporated in Delaware in April 2009. Our principal executive offices are located at 107 Spring Street, Seattle, Washington 98104, and our telephone number is 206-325-6086.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our name and logo, Atossa, and Atossa Genetics (stylized) are our registered trademarks. This report also includes additional trademarks, trade names and service marks of third parties, which are the property of their respective owners. You are advised to read this Annual Report on Form 10-K in conjunction with other reports and documents that we file from time to time with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). In particular, please read our definitive proxy statement, which will be filed with the SEC in connection with our 2019 Annual Meeting of Stockholders, our Quarterly Reports on 10-Q and any Current Reports on Form 8-K, and any amendments thereto, that we may file from time to time. You may obtain copies of these reports after the date of this annual report from the SEC at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. In addition the SEC maintains information for electronic filers (including Atossa) at its website <u>www.sec.gov</u>. The public may obtain information regarding the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="parti" name="parti"></a>PART I</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item1" name="item1"></a>ITEM 1. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>BUSINESS</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Overview</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 7.5pt 0pt 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Company Overview</b></p>

<p style="margin: 0pt 7.5pt 0pt 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are a clinical-stage biopharmaceutical company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. Our lead program is the development of Endoxifen, which is an active metabolite of tamoxifen, an FDA-approved drug to treat and prevent breast cancer. We are developing an oral and topical form of Endoxifen. Our Endoxifen is being developed to potentially treat a number of conditions, including: mammographic breast density (or, MBD); breast cancer in the &ldquo;window of opportunity&rdquo; between diagnosis of breast cancer and surgery; gynecomastia, which is male breast enlargement; and the recurrence of breast cancer in patients who do not benefit from taking tamoxifen meaning that they are &ldquo;refractory&rdquo; to tamoxifen. We are also developing our patented intraductal microcatheter technology to potentially target the delivery of therapies, including fulvestrant, immunotherapies and Chimeric Antigen Receptor T-cell therapies (CAR-T therapies), directly to the site of breast cancer.</p>

<p style="margin: 0pt 7.5pt 0pt 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In 2017, we completed a Phase 1 placebo-controlled clinical study of our proprietary oral and topical formulations of Endoxifen in 48 healthy women. All objectives were met: there were no clinically significant safety signals and no clinically significant adverse events, and both the oral and topical Endoxifen were well tolerated. In the topical arm of the study, low but measurable Endoxifen levels were detected in the blood in a dose-dependent fashion. In the oral arm of the study, participants exhibited dose-dependent Endoxifen levels that met or exceeded the published therapeutic level. The median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of oral Endoxifen was 7 days. Published literature indicates that it takes approximately 50-200 days for patients to reach steady-state Endoxifen levels from daily doses of oral tamoxifen. In September 2018, we completed a Phase 1 placebo-controlled clinical study of our proprietary topical Endoxifen in 24 healthy men. All of our objectives of safety, tolerability and pharmacokinetics were successfully met.</p>

<p style="margin: 0pt 7.5pt 0pt 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are currently conducting two Phase 2 studies of our proprietary Endoxifen: one in Stockholm, Sweden using our topical Endoxifen for reduction of MBD and another in Australia using our oral Endoxifen for patients in the window of opportunity between diagnosis of breast cancer and surgery. In October 2018, the MBD study in Sweden was fully-enrolled with all 90 participants:&nbsp;60 participants on two different dose levels and 30 participants on placebo. We expect dosing in this study to be completed in April 2019 and to report preliminary results in the second quarter 2019.</p>

<p style="margin: 0pt 7.5pt 0pt 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In December 2018, we began providing our oral Endoxifen to a pre-menopausal, estrogen-receptor positive (ER+), lacking CYP2D6 function, breast cancer patient under an FDA-approved &quot;expanded access&quot; program. The purpose of this therapeutic approach was to reduce activity of the cancer cells prior to surgery. The patient received daily doses of our oral Endoxifen for approximately three weeks prior to surgery. There were no safety or tolerability issues and her surgery was successfully completed. The cancer cell biological activity was reduced, based on the estrogen receptor activity of the tumor cells and a 50% reduction in Ki-67. The FDA has also issued a &quot;safe to proceed&quot; letter allowing the patient to continue oral Endoxifen therapy post-surgery. Under the FDA expanded access IND program, the use of our proprietary oral Endoxifen is restricted solely to this patient.</p>

<p style="margin: 0pt; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are currently conducting a Phase 2 study at Montefiore Medical Center, Bronx, New York, using our intraductal microcatheter technology to deliver fulvestrant directly to the site of the tumor via the breast ducts. Our program to use our intraductal microcatheters to deliver CAR-T and other immunotherapies is in the pre-clinical phase.</p>

<p style="margin: 0pt 7.5pt 0pt 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our key objectives are to advance our programs through Phase 2 trials and then evaluate further development independently or with partners.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our common stock is currently quoted on The NASDAQ Capital Market under the symbol &ldquo;ATOS.&rdquo;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Our Programs Under Development</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt -18pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Endoxifen</i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Background</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Oral tamoxifen has been widely used for over 40 years to both treat and prevent breast cancer. It is a &ldquo;pro-drug&rdquo;, in that it must be metabolized into active components (&ldquo;metabolites&rdquo;) in order to be effective. One of these active metabolites is endoxifen.&nbsp; Despite the success of tamoxifen in reducing the risk of estrogen-receptor-positive breast cancer, its systemic side effects have led to generally low acceptance. These systemic side effects relate to estrogen agonist activity on the endometrium and the activation of coagulation pathways, leading to an increased risk of uterine events and thromboembolism. Hot flashes and vaginal symptoms are additional barriers to acceptance.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Up to 50% of breast cancer survivors who are taking tamoxifen do not produce therapeutic endoxifen levels (meaning they are &ldquo;refractory&rdquo;) for a number of reasons including that they, due to their genotype, do not have the requisite liver enzymes. Additionally, it can take from 50-200 days for tamoxifen to reach &ldquo;steady-state&rdquo; meaning that the drug may be providing little or no benefit for up to several months after starting treatment. By providing endoxifen directly to the body, a steady-state is achieved within ~7 days.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Phase 1 Studies</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In 2017 we completed a comprehensive Phase 1 study in 48 healthy women in Australia using both the topical and oral forms of our proprietary Endoxifen. The objectives of this double-blinded, placebo-controlled, Phase 1 study were to assess the pharmacokinetics of our proprietary Endoxifen dosage forms as single (oral) and repeat (oral and topical) doses, as well as to assess safety and tolerability. The study was conducted in two parts based on route of administration.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">All objectives were successfully met in both arms of the study: there were no clinically significant safety signals and no clinically significant adverse events and both the oral and topical Endoxifen were well tolerated. In the topical arm of the study, there were low but detectable&nbsp;Endoxifen levels in the blood in a dose-dependent fashion and in the oral arm of the study participants exhibited dose-dependent Endoxifen levels consistent with&nbsp;published reports of the therapeutic range. The median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of oral Endoxifen was ~7 days. Published literature indicates that it takes approximately 50-200 days for patients to reach steady-state Endoxifen levels when taking daily doses of oral tamoxifen. Finally, the median time for patients in the study to reach the maximum serum level of Endoxifen after taking Atossa&rsquo;s oral Endoxifen ranged from 4 to 8 hours (depending on dose). &nbsp;The 4 mg dose of Endoxifen produced a maximum serum level of Endoxifen in 4 to 8 hours at levels above the generally accepted threshold for a therapeutic effect on estrogen-dependent breast cancer.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Potential Treatment of MBD</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Legislation that has been recently enacted in approximately 35 states requiring that women be notified if they have MBD and those notifications typically state that women with MBD have a higher risk of developing breast cancer, and that mammography may not be as effective in detecting breast cancer because the MBD can &ldquo;mask&rdquo; the detection of cancers. In February 2019, Federal legislation was enacted that requires that the FDA adopt rules requiring that mammography reports include information about breast density and inform women about their breast density.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We estimate that approximately ten million women in the Unites States have MBD, for which there is no FDA-approved treatment. Although oral tamoxifen is approved to prevent breast cancer in &ldquo;high-risk&rdquo; women (usually described as having been diagnosed with estrogen receptor positive breast cancer), it is used by less than 5% of women with an increased risk of developing breast cancer because of the actual or perceived side effects and risks of tamoxifen. We believe our Endoxifen may provide an option for women to proactively reduce the density of their breasts. Moreover, our Endoxifen may improve mammography accuracy and patient care by unmasking cancerous tumors that are otherwise hidden by breast density. In two separate reports of film-screen mammography, mammographic sensitivity decreased from a level of 85.7%&ndash;88.8% in patients with almost entirely fatty tissue to 62.2%&ndash;68.1% in patients with extremely dense breast tissue.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In September 2017, we contracted Stockholm South General Hospital in Sweden to conduct a Phase 2 study of our topical Endoxifen in women with high MBD. The study&nbsp;is being led by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. The primary endpoint of this pilot study is to determine if topical Endoxifen results in an individual reduction of MBD as measured by mammography. Secondary endpoints include demonstrating safety and tolerability. The primary objective is to determine the effect size of breast density between placebo and topical Endoxifen to permit sample size calculations for statistical significance in a future Phase 3 trial. The study was fully enrolled in October 2018 with 90 participants who were equally randomized to three different groups (30 per group): placebo; lower dose topical Endoxifen; and higher dose topical Endoxifen. Participants receive the active drug or placebo for a maximum of six months. The study calls for each participant to have a baseline (pre-treatment) mammogram, and additional mammograms at month 3 and 6, or at the time of study exit. Once the study has been completed, all mammograms will be interpreted and MBD determined and any changes that occur per patient recorded. &nbsp;Some participants have chosen to exit the study before receiving a full six months of drug or placebo for a number of reasons: for example, some exit for non-compliance with the study protocol and some have exited because of skin rashes and irritation. As of the date of this annual report, approximately 72 participants have exited the study primarily because of skin rashes and irritation. Because the study is double blinded and results-to-date are not known, we do not know how or if the fact that some study participants exited the study before six months of dosing will result in sufficient data to achieve the primary objective which is to design a subsequent study. We expect that all dosing in the study will be completed in April 2019 with preliminary result to be reported in the second quarter of 2019.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Refractory Patients</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are developing oral Endoxifen for breast cancer patients who are refractory to tamoxifen, meaning for whatever reason, tamoxifen is not effectively metabolized into active metabolites. Approximately one million breast cancer patients take tamoxifen to prevent recurrent and new breast cancer; however, up to 50% of those patients are refractory to tamoxifen. We believe our oral Endoxifen may provide an effective treatment supplement or option for these refractory patients because Endoxifen, unlike tamoxifen, does not require liver metabolism.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In December 2018, we began providing our oral Endoxifen to a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient under an FDA-approved &quot;expanded access&quot; program. The purpose of this therapeutic approach was to reduce activity of the cancer cells prior to surgery. The patient received daily doses of our oral Endoxifen for approximately three weeks prior to surgery. There were no safety or tolerability issues and her surgery was completed successfully. To determine if the oral Endoxifen reduced the biological activity of the cancer cells, the test results obtained from the initial biopsy were compared with those from the specimen obtained during surgery. There were no safety or tolerability issues and her surgery was successfully completed. The cancer cell biological activity was reduced, based on the estrogen receptor activity of the tumor cells and a 50% reduction in Ki-67. Under the FDA expanded access IND program, the use of our proprietary oral Endoxifen is restricted solely to this patient.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Window of Opportunity</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are also currently conducting a Phase 2 study of our oral Endoxifen in Australia in the window of opportunity between diagnosis of breast cancer and surgery. The Pilot Phase of the study will initially enroll up to eight newly-diagnosed patients with ER+ and HER2 negative (HER2-) stage 1 or 2 invasive breast cancer, requiring mastectomy or lumpectomy. Patients will receive our proprietary oral Endoxifen for at least 21 days from the time of diagnosis up to the day of surgery. Provided tumor activity reduction is demonstrated in at least two patients, an additional 17 patients will be enrolled for a total of 25. The primary endpoint is to determine if the administration of oral Endoxifen reduces the tumor activity as measured by Ki-67&nbsp;(a measure of cellular proliferation that correlates with tumor growth). The secondary endpoints are safety and tolerability and assessment of the study drug on expression levels of both estrogen and progesterone receptors. The impact on additional markers of cellular activity will also be explored. The Phase 2 study is being conducted on behalf of Atossa by Avance Clinical (formerly CPR Pharma Services Pty Ltd.), Thebarton, SA, Australia.&nbsp;Avance&nbsp;Clinical recently completed the successful Phase 1 study of our oral and topical Endoxifen.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt -18pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Proprietary Intraductal Delivery Technology</i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We believe intraductal delivery technology may be useful in delivering CAR-T, immunotherapies and a number of drugs to the ducts in the breast, the site of the majority of early breast cancers. Doing so is intended to provide a therapeutic directly to the breast tissue while at the same time reducing delivery of the drug to healthy tissue. We must obtain FDA approval of any therapy delivered via intraductal delivery technology, which will require expensive and time-consuming studies in the current regulatory framework. For example, we must complete clinical studies to demonstrate the safety and tolerability of fulvestrant using our delivery method. We may not be successful in completing these studies or obtaining approval from the FDA or other applicable foreign regulatory authority.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Breast cancers and precancerous lesions are typically treated with systemically administered agents such as tamoxifen, Faslodex<sup>&reg;</sup>, Perjeta<sup>&reg;</sup> and Herceptin<sup>&reg;</sup>. However, these therapies can cause serious side effects which may lead to poor patient compliance with the treatment regimens. Providing therapies directly into the breast ducts targeting the site of the localized cancerous lesions could reduce the need for systemic anti-cancer therapies, and potentially reduce or eliminate the systemic side effects of the therapies and morbidity in such patients, and ultimately improve patient compliance and ultimately reduce mortality.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt -18pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Transpapillary CAR-T</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Much of the recent success in the field of chimeric antigen receptor therapy, or CAR-T, has relied on the systemic delivery (for example a needle injection into the blood stream) of the CAR-T which is intended to treat various non-solid tumor cancers, such as blood cancers. One concern with this systemic approach is that it does not target the location of the cancer and it can have adverse effects, including deadly &ldquo;cytokine storms.&rdquo; Moreover, CAR-T treatments delivered systemically can be as high as $500,000 per patient.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are developing a novel method to deliver CAR-T cells into the ducts of the breast for the potential targeted treatment of breast cancer. This approach uses our proprietary intraductal delivery technology for the potential transpapillary, or &ldquo;TRAP,&rdquo; delivery of either T-cells that have been genetically modified to attack breast cancer cells or various immune-therapies. We believe this method has several potential advantages including the reduction of toxicity by limiting systemic exposure of the T-cells or immunotherapy; improved efficacy by placing the T-cells or immunotherapy in direct contact with the target ductal epithelial cells that are undergoing malignant transformation; and, lymphatic migration of the CAR-T cells or immunotherapy potentially extending their cytotoxic actions into the regional lymph system, which could limit tumor cell dissemination. Moreover, our proprietary approach may be more cost effective if lower doses of therapy can be delivered compared to systemic CAR-T. Our approach is in the R&amp;D stage and is currently not FDA approved. We intend to commence studies that will help demonstrate safety and efficacy of this novel approach.&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The TRAP delivery of pharmaceutical therapeutics in breast cancer clinical trials have demonstrated &ldquo;that cytotoxic drugs can be safely administered into breast ducts with minimal toxicity&rdquo; (Zhang B, et al. Chin J Cancer Res. 2014 Oct;26(5):579-87;&nbsp;<u>www.ncbi.nlm.nih.gov/pubmed/25400424</u>). In our program, we plan to remove&nbsp;T cells from a patient and modify them so that they express receptors specific to the patient&#39;s particular breast cancer. The T cells, which can then recognize and kill the cancer cells, are then intended to be reintroduced into the patient via natural ducts of the breast using our intraductal delivery technology. Chimeric antigen receptors (or, &ldquo;CARs&rdquo; and also known as chimeric immunoreceptors, chimeric T cell receptors, artificial T cell receptors or CAR-T) are engineered receptors, which graft an arbitrary specificity onto an immune effector cell (&ldquo;T cell&rdquo;). Typically, these receptors are used to graft the specificity of a monoclonal antibody onto a T cell, with transfer of their coding sequence facilitated by retroviral vectors. The receptors are called chimeric because they are composed of parts from different sources.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have filed a foundational patent application with respect to the intraductal delivery of CAR-T, and we intend to continue research and development through partnership with leading investigators, institutions, and organizations around the world, bringing our technology and expertise in TRAP delivery together with experts in cancer immunology and T-cell biology.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Delivery of Drugs via our Microcatheters</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The initial drug we are studying using our microcatheters for intraductal delivery is fulvestrant. Fulvestrant is FDA-approved for metastatic breast cancer. It is administered as a monthly injection of two shots, typically into the buttocks, and costs ~$11,000 per dose.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We own several pending patent applications directed to the treatment of breast conditions, including cancer, by the intraductal administration of therapeutics including fulvestrant, and expect to file additional patent applications as and when applicable.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are currently conducting a Phase 2 study using our intraductal delivery technology using microcatheters&nbsp;to deliver fulvestrant at Montefiore Medical Center in the window of opportunity. This trial is a Phase 2 study in women with ductal carcinoma in situ (&ldquo;DCIS&rdquo;) or Stage 1 or 2 breast cancer (invasive ductal carcinoma) scheduled for mastectomy or lumpectomy within 30 to 45 days. This study is assessing the safety, tolerability, cellular activity and distribution of fulvestrant when delivered directly into breast milk ducts of these patients compared to those who receive the same drug by injection. Of the 30 patients required for full enrollment, six will receive the standard intramuscular injection of fulvestrant and 24 will receive fulvestrant with our microcatheter device.&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The primary endpoint of the clinical trial is to compare the safety, tolerability and distribution of fulvestrant between the two routes of administration (intramuscular injection or through our microcatheters). The secondary endpoint of the study is to determine if there are changes in the expression of Ki-67 as well as estrogen and progesterone receptors between a pre-fulvestrant biopsy and post-fulvestrant surgical specimens. Digital breast imaging before and after drug administration in both groups will also be performed to determine the effect of fulvestrant on any lesions as well as breast density of the participant.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Other Studies of Intraductal Administration using our Microcatheters</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">An October 2011 peer-reviewed paper published in&nbsp;<i>Science Translational Medicine</i> reported the results of a study conducted at the Johns Hopkins Medical School demonstrating the prevention of breast cancer in rats with intraductal non-systemic chemotherapy, and a proof-of-principle Phase 1 clinical trial involving 17 women with breast cancer who subsequently received surgery. An accompanying editorial commented that &ldquo;intraductal treatment could be especially useful for women with premalignant lesions or those at high risk of developing breast cancer, thus drastically improving upon their other, less attractive options of breast-removal surgery or surveillance (termed &lsquo;watch and wait&rsquo;).&rdquo;&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In a December 2012 peer-reviewed paper published in <i>Cancer Prevention Research,</i> Dr. Susan Love and her colleagues reported the results of a Phase I clinical trial of intraductal chemotherapy drugs administered into multiple ducts within one breast in women awaiting mastectomy for treatment of invasive cancer. Thirty subjects were enrolled in this dose escalation study conducted at a single center in Beijing, China. Under local anesthetic, one of two chemotherapy drugs, carboplatin or pegylated liposomal doxorubicin (PLD), was administered into five to eight ducts at three dose levels. Pharmacokinetic analysis has shown that carboplatin was rapidly absorbed into the bloodstream, whereas PLD, though more erratic, was absorbed after a delay. Pathologic analysis showed marked effects on breast duct epithelium in ducts treated with either drug compared with untreated ducts. The investigators concluded the study showed the safety and feasibility of intraductal administration of chemotherapy drugs into multiple ducts for the purpose of breast cancer prevention and that this was an important step towards implementing of this strategy as a &quot;chemical mastectomy,&quot; potentially eliminating the need for surgery.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Markets</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Potential Market Opportunities</i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We believe that, based in part on a January 2017 study by Defined Health Inc., a leading market research firm, the potential U.S. market for intraductal administration of fulvestrant or similar drugs in DCIS patients is up to $800 million annually. This estimate includes treatment of DCIS patients prior to surgery as well as patients who would use intraductal treatment as an alternative to surgery. We believe that the potential U.S. market for our Endoxifen in the treatment and prevention settings is up to $1 billion annually.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>The Breast Cancer and Related Markets</i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The American Cancer Society (&ldquo;ACS&rdquo;) estimates that in 2019, 269,000 women will be diagnosed with breast cancer in the United States. Every two minutes an American woman is diagnosed with breast cancer and 42,000 die each year. Although about 100 times less common than in women, breast cancer also affects men. The ACS estimates that the lifetime risk of men getting breast cancer is about 1 in 1,000; 2,670 new cases of invasive breast cancer will be diagnosed in 2019; and&nbsp;500 men will die from breast cancer in 2019.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We were incorporated in April of 2009 and our common stock is currently quoted on The NASDAQ Capital Market under the symbol &ldquo;ATOS.&rdquo;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Our Medical Devices </b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The use of our intraductal delivery technology is being developed for the targeted delivery of potential drugs, CAR-T and immunotherapies, as described above.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our medical devices also include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator, which collect specimens of nipple aspirate fluid (NAF) for cytological testing at a laboratory, and a universal transport kit to assist with the packaging and transport of NAF samples to a laboratory. We also own the exclusive rights to manufacture and sell various medical devices consisting primarily of tools to assist breast surgeons, which we acquired from Acueity Healthcare in 2012. We are not currently commercializing our breast aspirator devices, transportation kits, tools for breast surgeons and NAF cytology tests nor do we maintain an inventory of our medical devices.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Additionally, we, as a pharmaceutical company, are not maintaining the device patents directed to any of our medical devices due to the short patent term remaining on them.</p>

<p>&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">11</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Our Capital Resources</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have not yet established an ongoing source of revenue sufficient to cover our operating costs and allow us to continue as a going concern. Our ability to continue as a going concern is dependent on obtaining adequate capital to fund operating losses until we become profitable. We plan to obtain additional capital resources by selling our equity securities and borrowing from stockholders or others when needed. However, we cannot assure you that we will be successful in accomplishing any of these plans and, if we are unable to obtain adequate capital, we could be forced to cease operations.&nbsp;We do not anticipate any revenue until our pharmaceutical programs are developed, including receiving all necessary regulatory approvals, and until we successfully commercialize these programs.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of December 31, 2018, we had cash and cash equivalents of $10,380,493 and in March 2019 we received approximately $11.3 million from the exercise of warrants that were issued on May 30, 2018. Our capital raising activity in 2017 and 2018 consisted of the following (all share and per-share amounts in this report&nbsp;have been adjusted to reflect the 1:12 reverse stock split we effectuated on April 20, 2018):</p>

<p style="margin: 0pt 7.5pt 0pt 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<b>&nbsp;</b></p>

<p style="margin: 0pt 7.2pt; text-align: left; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>2017 Financing Activities</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On March 28, 2017, the Company entered into an underwriting agreement with Aegis Capital Corp. relating to a public offering which closed on April 3, 2017. The offering generated gross proceeds to the Company of approximately $4.4 million and net proceeds of approximately $3.9 million after deducting underwriting discounts and commissions and other offering expenses paid by the Company.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On October 26, 2017, the Company entered into an underwriting agreement with Maxim Group LLC relating to a public offering of common stock which closed on October 30, 2017. The offering generated gross proceeds to the Company of approximately $5.5 million and net proceeds of $4.9 million after deducting underwriting discounts, commissions and other offering expenses paid by the Company.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On December 20, 2017, the Company entered into a placement agent agreement with Maxim Group LLC relating to the sale of the Company&rsquo;s securities. Pursuant to the placement agent agreement, on December 20, 2017, the Company entered into a securities purchase agreement with certain purchasers named therein relating to the offering and sale of 441,667 shares of Company common stock at a public offering price of $3.24 per share. The offering generated gross proceeds to the Company of approximately $1.4 million and net proceeds of $1.2 million after deduction of underwriting discounts, commissions, and other offering expenses paid by the Company.</p>

<p style="margin: 0pt 7.5pt 0pt 18pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 7.5pt 0pt 18pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>2018 Financing Activities</b></p>

<p style="margin: 0pt 7.5pt 0pt 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On May 30, 2018, we completed a rights offering pursuant to which we sold an aggregate of 13,624 units consisting of an aggregate of 13,624 shares of Series B convertible preferred stock, convertible into 3,869,216 shares of common stock, and 3,869,216 warrants, with each warrant exercisable for one share of common stock at an exercise price of $4.048 per share, resulting in net proceeds to us of approximately $12.3 million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Research and Development Phase</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">All of our programs are in the pre-clinical or clinical research and development phase. Research and development costs are generally expensed as incurred. Our research and development expenses include, for example, manufacturing expenses for our drugs under development, expenses associated with clinical studies and associated salaries and benefits. Research and development expenses for the years ended December 31, 2018 and 2017 were $4,209,981 and $2,328,087, respectively.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Intellectual Property</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our owned and licensed patents and patent applications are directed to Endoxifen and Fulvestrant, and immunotherapies such as CAR-T therapy. We commonly seek patent claims directed to compositions of matter, including Endoxifen, Fulvestrant, and other Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Downregulators (SERDs), and Aromatase Inhibitors (AI), as well as methods of using such compositions. When appropriate, we also seek claims to related technologies, such as treatment methods via transpappillary and intraductal delivery of therapeutics to breast ducts of an individual. For each of our products, we filed and expect to file multiple patent applications&#65279;. As of February 28, 2019, and based on a recent periodic review of our patent estate, we own 13 issued patents (11 US and 2 international) and 29 pending patent applications (5 in the United States, and 24 international applications) directed to our programs on Endoxifen, Fulvestrant, CAR-T therapeutics and intraductal delivery of&nbsp;therapeutics&nbsp;using devices such as microcatheters. This list above does not identify all patents and patent applications currently in Atossa&rsquo;s patent portfolio. For example, the foregoing patent counts exclude certain applications and device patents with short patent terms remaining on them and those covering our ForeCyte, FullCyte and Acueity devices and various tests that are no longer core to our business. We continue to evaluate our patent portfolio and, as a clinical-stage pharmaceutical company, will no longer maintain our device and test patents and applications.</p>

<p>Of the 29 pending patent applications in Atossa&rsquo;s patent portfolio, 3 of the 5 United States pending applications and 16 of the 24 pending international applications include at least one claim directed to Endoxifen; 4 of the 5 United States pending applications and 16 of the 24 pending international applicatons include at least one claim directed to Fulvestrant; and 1 of the 5 United States pending application and 2 of the 24 international pending applications are directed to our intraductal program delivering CAR-T therapeutics and other immunotherapy.</p>

<p>The following table provides the patent counts<sup>4</sup> related to our programs.</p>

<p style="margin: 0pt 14.4pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 558px; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 4.2%;">

		<tr>
			<td style="width: 193px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 179px; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pending Applications<sup>1</sup><sup>, 2</sup></p>
			</td>
			<td style="width: 176px; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Approximate Expiry Date<sup>3</sup>&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 193px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 93px; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">U.S.</p>
			</td>
			<td style="width: 84px; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">International</p>
			</td>
			<td style="width: 176px; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 193px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Endoxifen Program</p>
			</td>
			<td style="width: 93px; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3</p>
			</td>
			<td style="width: 84px; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">16</p>
			</td>
			<td style="width: 176px; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2034 - 2037</p>
			</td>
		</tr>
		<tr>
			<td style="width: 193px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Fulvestrant Program</p>
			</td>
			<td style="width: 93px; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4</p>
			</td>
			<td style="width: 84px; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">16</p>
			</td>
			<td style="width: 176px; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2034 - 2037</p>
			</td>
		</tr>
		<tr>
			<td style="width: 193px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Immunotherapy/&nbsp; CAR-T Program</p>
			</td>
			<td style="width: 93px; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1</p>
			</td>
			<td style="width: 84px; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2</p>
			</td>
			<td style="width: 176px; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2037 - 2038</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt 14.4pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 14.4pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 14.4pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup>1</sup> Each patent application includes at least one claim directed to a listed therapeutic/program.</p>

<p style="margin: 0pt 14.4pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup>2</sup> The patent counts in the table above are greater than the total numbers of the patent applications in the Atossa portfolio as the patent counts in the table above reflect that a patent application may have claims directed to more than one type of therapeutic/program.</p>

<p style="margin: 0pt 14.4pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup>3 </sup>The patent counts and the approximate expiry dates disclosed herein and in our patent estate are subject to change, for example, in the event of changes in the law or legal rulings affecting our patents and applications or if we become aware of new information. The standards that the U.S. Patent and Trademark Office, or USPTO, and foreign patent offices use to grant patents are not always applied predictably or uniformly and can change. Consequently, our pending patent applications may not be allowed and, if allowed, may not contain the type and extent of patent claims that will be adequate to conduct our business as planned. Additionally, any issued patents we currently own or obtain in the future may have a shorter patent term than expected or may not contain claims that will permit us to stop competitors from using our technology or similar technology or from copying our products.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 7.2pt 0pt 16pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup>4</sup>The standards that the U.S. Patent and Trademark Office, or USPTO, and foreign patent offices use to grant patents are not always applied predictably or uniformly and can change. Consequently, our pending patent applications may not be allowed and, if allowed, may not contain the type and extent of patent claims that will be adequate to conduct our business as planned. Additionally, any issued patents we currently own or obtain in the future may have a shorter patent term than expected or may not contain claims that will permit us to stop competitors from using our technology or similar technology or from copying our product&#65279;.</p>

<p style="text-indent: 36pt;">Atossa and Atossa Genetics (stylized) are our registered trademarks.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Manufacturing, Clinical Studies and Associated Operations</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our drug development strategy utilizes third party contractors for the procurement and manufacture, as applicable, of raw materials, active pharmaceutical ingredients and finished drug products, as well as for storage, and distribution of our products and associated supply chain operations. We also plan to rely on third parties to conduct pre-clinical and clinical studies of our drugs and microcatheter technology under development. As our development programs advance, we expect that our manufacturing, pre-clinical and clinical studies, and related operational requirements will correspondingly increase. Each third-party contractor undergoes a qualification process by Atossa subject matter experts prior to signing any service agreement and initiating any third-party work.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Integral to our development strategy is our quality program, which includes standard operating procedures and specifications with the goal that our work complies with Good Clinical (GCP), Good Laboratory (GLP) and Good Manufacturing Practices (cGMP), and other applicable global regulations. We expect and confirm that selected service providers meet or exceed our expectations for compliance with these standards in providing services and products that meet our requirements.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We believe our operational strategy of utilizing qualified contractors and suppliers in the foregoing manner allows us to direct our financial and managerial resources to development and commercialization activities, rather than to the establishment and maintenance of a manufacturing and clinical infrastructure.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Government Regulation</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Drug Regulations</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies. The Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations set forth, among other things, regulations for the execution of clinical studies, and the requirements for the testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record keeping, reporting, distribution, import, export, advertising and promotion of our products. Our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the U.S., although there can be important differences. Additionally, some significant aspects of regulation in the E.U. are addressed in a centralized way through the EMA and the European Commission, but country-specific regulation by the competent authorities of the E.U. member states remains essential in many respects.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>U.S. Regulations</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In the U.S., the FDA regulates drugs under the FDCA and its implementing regulations, through review and ultimately approval of NDAs. NDAs require extensive studies and submission of a large amount of data by the applicant, which is an amalgamation of data obtained under INDs and other supporting available information.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Drug Development</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Preclinical Testing: </i>Before testing any compound in human subjects in the U.S., a company must generate extensive preclinical data. Preclinical testing generally includes laboratory evaluation of product chemistry and formulation, as well as toxicological and pharmacological studies in several animal species to assess the quality and safety of the product. Animal studies must be performed in compliance with the FDA&rsquo;s Good Laboratory Practice regulations and the U.S. Department of Agriculture&rsquo;s Animal Welfare Act.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>IND Application:</i> In most cases, human clinical trials in the U.S. cannot commence until an IND is submitted to the FDA for review and a &ldquo;Safe to Proceed&rdquo; letter has been provided to the sponsor. The sponsor must prepare a dossier of information that includes the results of preclinical studies; detailed drug manufacturing information and results; and proposed clinical studies, design and development strategy. The FDA then evaluates if there is an adequate basis for testing the drug in an initial (human) clinical study. Unless the FDA raises concerns, the IND application becomes effective 30 days following its receipt by the FDA at which time written notification is provided. Once human clinical trials have commenced, the sponsor is obligated to report serious side effects to the FDA. The FDA may suspend a clinical trial by placing it on &ldquo;clinical hold&rdquo; if the FDA has concerns about the safety of the product being tested, subject risks, investigator actions, related product information or for other reasons.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">13</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Clinical Trials:</i> Clinical trials involve the administration of the drug to healthy human volunteers or to patients, under the supervision of a qualified investigator according to a&nbsp;vetted and approved protocol.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The conduct of clinical trials is subject to extensive regulation, including compliance with the FDA&rsquo;s bioresearch monitoring regulations and Good Clinical Practice, or GCP, requirements, which establish standards for conducting, recording data from and reporting the results of, clinical trials, and are intended to assure that the data and reported results are credible and accurate, and that the rights, safety, and well-being of study participants are protected. Clinical trials must be conducted under written and approved protocols that detail the study objectives, parameters for monitoring safety, and the efficacy criteria, if any, to be evaluated. Each protocol is reviewed by the FDA as part of the IND application. In addition, each clinical trial must be reviewed, approved, and conducted under the auspices of an institutional review board, or IRB, at the institution conducting the clinical trial. Companies sponsoring the clinical trials, investigators, and IRBs also must comply with regulations and guidelines for obtaining informed consent from the study subjects, complying with the protocol and investigational plan, adequately monitoring the clinical trial and timely reporting adverse events. Foreign studies conducted under an IND application must meet the same requirements that apply to studies being conducted in the U.S. Data from a foreign study not conducted under an IND application may be submitted in support of an NDA if the study was conducted in accordance with GCP and the FDA is able to validate the data.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A study sponsor is required to submit certain details about active clinical trials and clinical trial results to the National Institutes of Health for public posting on http://clinicaltrials.gov. Human clinical trials are typically conducted in three sequential phases, although the phases may overlap with one another:</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Phase 1 clinical trials include the initial administration of the investigational drug to humans, typically to a small group of healthy human subjects, but occasionally to a group of patients with the targeted disease or disorder. Phase 1 clinical trials generally are intended to determine the metabolism and pharmacologic actions of the drug, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Phase 2 clinical trials generally are controlled studies that involve a relatively small sample of the intended patient population, and are designed to develop data regarding the product&rsquo;s effectiveness, to determine dose response and the optimal dose range and to gather additional information relating to safety and potential adverse effects.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Phase 3 clinical trials are conducted after preliminary evidence of effectiveness has been obtained, and are intended to gather the additional information about safety and effectiveness necessary to evaluate the drug&rsquo;s overall risk-benefit profile, and to provide a basis for physician labeling. Generally, Phase 3 clinical development programs consist of expanded, large-scale studies of patients with the target disease or disorder to obtain statistical evidence of the efficacy and safety of the drug, or the safety, purity, and potency of a biological product, at the proposed dosing regimen.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The sponsoring company, the FDA or the IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. Further, success in early-stage clinical trials does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be subject to alternative interpretations that could delay, limit or prevent regulatory approval.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">There are regulatory pathways that can accelerate the speed with which a product can be developed, including a Special Protocol Assessment (SPA), Break-through therapy designation, etc. The designations are obtained from the FDA on a case-by-case basis and do not guarantee the ultimate approval of a product for commercialization.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">14</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Drug Approval</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and of the clinical trials, together with other detailed information, including information on the manufacture and composition of the investigational product, are submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. The testing and approval process requires substantial time, effort and financial resources. Submission of an NDA requires payment of a review user fee to the FDA, which is $2,588,478 for fiscal year 2019. The FDA will review the application and may deem it to be inadequate to support commercial marketing, and there can be no assurance that any product approval will be granted on a timely basis, if at all. The FDA may also seek the advice of an advisory committee, typically a panel of clinicians practicing in the field for which the product is intended, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendations of the advisory committee.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The FDA has various programs, including breakthrough therapy, fast track, priority review and accelerated approval that are intended to expedite or simplify the process for reviewing drugs and/or provide for approval on the basis of surrogate endpoints. Generally, drugs that may be eligible for one or more of these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that provide meaningful benefit over existing treatments. We cannot be sure that any of our drugs will qualify for any of these programs, or that, if a drug does qualify, the review time will be reduced or the product will be approved.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Before approving an NDA, the FDA usually inspects the clinical sites with the greatest accrual to confirm the veracity of the clinical data, execution of the clinical study and protection of patient safety. The FDA will inspect the facility or the facilities where the product is manufactured, tested and distributed. Approval is not granted if these inspections raise concerns about the execution of the clinical studies or there is a lack of cGMP compliance. If the FDA evaluates the NDA and determines the clinical trial execution and manufacturing facilities as acceptable, the FDA may issue an approval letter. If the NDA is not approved, the FDA issues a complete response letter which is only issued for applications that are not approved. The approval letter authorizes commercial marketing of the drug for specific indications. As a condition of approval, the FDA may require post-marketing testing and surveillance to monitor the product&rsquo;s safety or efficacy, or impose other post-approval commitment conditions.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In some circumstances, post-marketing testing may include post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, which are used primarily to gain additional experience from the treatment of patients in the intended population, particularly for long-term safety follow-up. In addition, the FDA may require a Risk Evaluation and Mitigation Strategy, or REMS, to ensure that the benefits outweigh the risks. A REMS can include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries or other risk mitigation tools.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">After approval, certain changes to the approved product, such as adding new indications, making certain manufacturing changes or making certain additional labeling claims, are subject to further FDA review and approval. Obtaining approval for a new indication generally requires that additional clinical trials be conducted.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Post-Approval Requirements</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Holders of an approved NDA are required to: (i) report certain adverse reactions to the FDA; (ii) comply with certain requirements concerning advertising and promotional labeling for their products; and (iii) continue to have cGMP compliance and all aspects of product manufacturing in a &ldquo;state of control.&rdquo; The FDA periodically inspects the sponsor&rsquo;s records related to safety reporting and/or manufacturing and distribution facilities; this latter effort includes assessment of compliance with cGMP. Accordingly, manufacturers must continue to expend time, money and effort in the area of production, quality control and distribution to maintain cGMP compliance. Future FDA inspections may identify compliance issues at manufacturing facilities that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including withdrawal of the product from the market.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">15</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Marketing of prescription drugs is also subject to significant regulation through federal and state agencies tasked with consumer protection and prevention of medical fraud, waste and abuse. After approval in the U.S., we must comply with FDA&rsquo;s regulation of drug promotion and advertising, including restrictions on off-label promotion, and we comply with federal anti-kickback statutes, limitations on gifts and payments to physicians and reporting of payments to certain third parties, among other requirements.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Failure to comply with applicable U.S. requirements may subject us to administrative or judicial sanctions, such as clinical holds, FDA refusal to approve pending NDAs or supplemental applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Non-U.S. Regulation</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Before our products can be marketed outside of the U.S., they are subject to regulatory approval similar to that required in the U.S., although the requirements governing the conduct of clinical trials, including additional clinical trials that may be required, product licensing, pricing and reimbursement vary widely from country to country. No action can be taken to market any product in a country until an appropriate application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In the E.U., marketing authorizations for medicinal products can be obtained through several different procedures founded on the same basic regulatory process. The centralized procedure is mandatory for certain medicinal products, including orphan medicinal products, medicinal products derived from certain biotechnological processes, advanced therapy medicinal products and certain other new medicinal products containing a new active substance for the treatment of certain diseases. It is optional for certain other products, including medicinal products that are significant therapeutic, scientific or technical innovations, or whose authorization would be in the interest of public or animal health. The centralized procedure allows a company to submit a single application to the EMA which will provide a positive opinion regarding the application if it meets certain quality, safety, and efficacy requirements. Based on the opinion of the EMA, the European Commission takes a final decision to grant a centralized marketing authorization which is valid in all 28 E.U. Member States and three of the four European Free Trade Association states (Iceland, Liechtenstein and Norway). Cancer products are usually required to go through the centralized procedure.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Unlike the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of each E.U. Member State in which the product is to be marketed. One national competent authority selected by the applicant, the Reference Member State, assesses the application for marketing authorization. Following a positive opinion by the competent authority of the Reference Member State the competent authorities of the other E.U. Member States, Concerned Member States are subsequently required to grant marketing authorization for their territory on the basis of this assessment except where grounds of potential serious risk to public health require this authorization to be refused. The mutual recognition procedure is similarly based on the acceptance by the competent authorities of the Concerned Member States of the marketing authorization of a medicinal product by the competent authorities of other Reference Member States. The holder of a national marketing authorization granted by a Reference Member State may submit an application to the competent authority of a Concerned Member State requesting that this authority mutually recognize the marketing authorization delivered by the competent authority of the Reference Member State.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Similar to accelerated approval regulations in the U.S., conditional marketing authorizations can be granted in the E.U. by the European Commission in exceptional circumstances. A conditional marketing authorization can be granted for medicinal products where a number of criteria are fulfilled; i) although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, the benefit/risk balance of the product is positive, ii) it is likely that the applicant will be in a position to provide the comprehensive clinical data, iii) unmet medical needs will be fulfilled and iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization must be renewed annually.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">16</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Even if a product receives authorization in the E.U., there can be no assurance that reimbursement for such product will be secured on a timely basis or at all. Individual countries comprising the E.U. member states, rather than the E.U., have jurisdiction across the region over patient reimbursement or pricing matters. Therefore, we will need to expend significant effort and expense to establish and maintain reimbursement arrangements in the various countries comprising the E.U. and may never succeed in obtaining widespread reimbursement arrangements therein.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The national authorities of the individual E.U. Member States are free to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices and/or reimbursement of medicinal products for human use. Some E.U. Member States adopt policies according to which a specific price or level of reimbursement is approved for the medicinal product. Other E.U. Member States adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market, including volume-based arrangements and reference pricing mechanisms.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Health Technology Assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some E.U. Member States. These E.U. Member States include the U.K, France, Germany and Sweden. The HTA process, which is governed by the national laws of these countries, is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product vary between E.U. Member States.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Post-Approval Regulation</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Similarly to the U.S., both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA and the competent authorities of the individual E.U. Member States both before and after grant of the manufacturing and marketing authorizations. Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with E.U. laws and the related national laws of individual E.U. Member States governing the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of marketing authorization, may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The holder of an E.U. marketing authorization for a medicinal product must also comply with E.U. pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. These rules can impose on central marketing authorization holders for medicinal products the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies, which may be time consuming and expensive and could impact our profitability. Non-compliance with such obligations can lead to the variation, suspension or withdrawal of the marketing authorization for the product or imposition of financial penalties or other enforcement measures.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The manufacturing process for medicinal products in the E.U., is highly regulated: regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable E.U. laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with E.U. cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the E.U. with the intention to import the active pharmaceutical ingredients into the E.U. Similarly, the distribution of medicinal products into and within the E.U. is subject to compliance with the applicable E.U. laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the E.U. Member States.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">17</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We and our third-party manufacturers are subject to cGMP, which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by the EMA, the competent authorities of E.U. Member States and other regulatory authorities. The EMA reviews Periodic Safety Update Reports for medicinal products authorized in the E.U. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing marketing authorization for the product be suspended or varied and can advise that the marketing authorization holder be obliged to conduct post-authorization safety studies. The EMA opinion is submitted for approval by the European Commission. Failure by the marketing authorization holder to fulfill the obligations for which the approved opinion provides can undermine the on-going validity of the marketing authorization.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Sales and Marketing Regulations</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In the E.U., the advertising and promotion of our products are subject to E.U. Member States&rsquo; laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other legislation adopted by individual E.U. Member States may apply to the advertising and promotion of medicinal products. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&rsquo;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion. The off-label promotion of medicinal products is prohibited in the E.U. The applicable laws at E.U. level and in the individual E.U. Member States also prohibit the direct-to-consumer advertising of prescription-only medicinal products. Violations of the rules governing the promotion of medicinal products in the E.U. could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on our promotional activities with health care professionals.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Anti-Corruption Legislation</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our business activities outside of the U.S. are subject to anti-bribery or anti-corruption laws, regulations, industry self-regulation codes of conduct, and physicians&rsquo; codes of professional conduct or rules of other countries in which we operate, including the U.K. Bribery Act of 2010.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&rsquo; codes of professional conduct developed at both E.U. level and in the individual E.U. Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the E.U. Violation of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain E.U. Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&rsquo;s employer, his/her competent professional organization, and/or the competent authorities of the individual E.U. Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Data Privacy and Protection</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Data protection laws and regulations have been adopted at E.U. level with related implementing laws in individual E.U. Member States which impose significant compliance obligations. For example, the E.U. Data Protection Directive, as implemented into national laws by the E.U. Member States, imposes strict obligations and restrictions on the ability to collect, analyze, and transfer personal data, including health data from clinical trials and adverse event reporting. Furthermore, there is a growth towards the public disclosure of clinical trial data in the E.U. which also adds to the complexity of processing health data from clinical trials. Such public disclosure obligations are provided in the new E.U. Clinical Trials Regulation, EMA disclosure initiatives, and voluntary commitments by industry. Data protection authorities from the different E.U. Member States may interpret the E.U. Data Protection Directive and national laws differently, which adds to the complexity of processing personal data in the E.U., and guidance on implementation and compliance practices are often updated or otherwise revised. Apart from exceptional circumstances, the E.U. Data Protection Directive prohibits the transfer of personal data to countries outside of the European Economic Area that are not considered by the European Commission to provide an adequate level of data protection including the U.S.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Further, the EU has recently adopted a comprehensive overhaul of its data protection regime from the current national legislative approach to a single European Economic Area Privacy Regulation, the General Data Protection Regulation 2016/679/EU (&ldquo;GDPR&rdquo;), which comes into effect in May 2018. The EU data protection regime extends the scope of the EU data protection law to all foreign companies controlling, processing, and/or using data of EU residents. It imposes a strict data protection compliance regime with severe penalties of up to the greater of 4% of worldwide turnover and &euro;20 million and includes new rights such as the &ldquo;right to be forgotten&rdquo; and &ldquo;portability&rdquo; of personal data, with more onerous requirements related to pseudo-anonymization and anonymization of personal data. Further, the scope of &ldquo;personal data&rdquo; has been expanded to include genetic data, and data concerning health and adverse event reporting from clinical trials. The Company is evaluating its ability and the cost to comply with the new EU regulations. Failure to comply with these laws could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">18</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>United States Medical Device Regulation</b>&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Federal Food, Drug, and Cosmetic Act, and the FDA&rsquo;s implementing regulations, govern registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, and post-market surveillance. Medical devices and their manufacturers are also subject to inspection by the FDA. The FDCA, as supplemented by other federal and state laws, also provides civil and criminal penalties for violations of its provisions. We manufacture and market a medical device that is regulated by the FDA, comparable state agencies and regulatory bodies in other countries. The FDA classifies medical devices into one of three classes (Class I, II or III) based on the degree of risk the FDA determines to be associated with a device and the extent of control deemed necessary to ensure the device&rsquo;s safety and effectiveness. Devices requiring fewer controls because they are deemed to pose lower risk are placed in Class I or II. Class I devices are deemed to pose the least risk and are subject only to general controls applicable to all devices, such as requirements for device labeling, premarket notification, and adherence to the FDA&rsquo;s current Good Manufacturing Practice requirements, as reflected in its QSR. Class II devices are intermediate risk devices that are subject to general controls and may also be subject to special controls such as performance standards, product-specific guidance documents, special labeling requirements, patient registries or post-market surveillance.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Class III devices are those for which insufficient information exists to assure safety and effectiveness solely through general or special controls, and include life-sustaining, life-supporting, or implantable devices, and devices not &ldquo;substantially equivalent&rdquo; to a device that is already legally marketed.&nbsp;Most Class I devices, and some Class II devices are exempted by regulation from the 510(k) clearance requirement and can be marketed without prior authorization from the FDA. Class I and Class II devices that have not been so exempted are eligible for marketing through the 510(k) clearance pathway. By contrast, devices placed in Class III generally require premarket approval, or PMA, prior to commercial marketing. To obtain 510(k) clearance for a medical device, an applicant must submit a premarket notification to the FDA demonstrating that the device is &ldquo;substantially equivalent&rdquo; to a predicate device legally marketed in the United States. A device is substantially equivalent if, with respect to the predicate device, it has the same intended use and (i) the same technological characteristics, or (ii) has different technological characteristics and the information submitted demonstrates that the device is as safe and effective as a legally marketed device and does not raise different questions of safety or effectiveness. A showing of substantial equivalence sometimes, but not always, requires clinical data. Generally, the 510(k) clearance process can exceed 90 days and may extend to a year or more. After a device has received 510(k) clearance for a specific intended use, any modification that could significantly affect its safety or effectiveness, such as a significant change in the design, materials, method of manufacture or intended use, will require a new 510(k) clearance or (if the device, as modified, is not substantially equivalent to a legally marketed predicate device) PMA approval. While the determination as to whether new authorization is needed is initially left to the manufacturer, the FDA may review this determination and evaluate the regulatory status of the modified product at any time and may require the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA approval is obtained. The manufacturer may also be subject to significant regulatory fines or penalties.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">All clinical trials must be conducted in accordance with regulations and requirements collectively known as Good Clinical Practice, or GCP. GCPs include the FDA&rsquo;s Investigational Device Exemption, or IDE, regulations, which describe the conduct of clinical trials with medical devices, including the recordkeeping, reporting and monitoring responsibilities of sponsors and investigators, and labeling of investigation devices. They also prohibit promotion, test marketing, or commercialization of an investigational device, and any representation that such a device is safe or effective for the purposes being investigated. GCPs also include FDA&rsquo;s regulations for institutional review board approval and for protection of human subjects (informed consent), as well as disclosure of financial interests by clinical investigators.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">19</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Required records and reports are subject to inspection by the FDA. The results of clinical testing may be unfavorable or, even if the intended safety and effectiveness success criteria are achieved, may not be considered sufficient for the FDA to grant approval or clearance of a product.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We expect that each of our devices under development will require clinical trials to support a 510(k) or PMA submission, as the case may be. For example, we expect that our intraductal microcatheters may be considered part of a &ldquo;combination&rdquo; product along with a drug and may require a PMA prior to commercialization.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The commencement or completion of clinical trials, if any, that we may sponsor, may be delayed or halted, or be inadequate to support approval of a PMA application or clearance of a premarket notification for numerous reasons, including, but not limited to, the following:</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial (or a change to a previously approved protocol or trial that requires approval), or place a clinical trial on hold;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">patients do not enroll in clinical trials or follow up at the rate expected;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">institutional review boards and third-party clinical investigators may delay or reject the Company&rsquo;s trial protocol or changes to its trial protocol;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">third-party clinical investigators decline to participate in a trial or do not perform a trial on the Company&rsquo;s anticipated schedule or consistent with the clinical trial protocol, investigator agreements, Good Clinical Practices or other FDA requirements;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">third-party organizations do not perform data collection and analysis in a timely or accurate manner;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory inspections of clinical trials or manufacturing facilities, which may, among other things, require the Company to undertake corrective action or suspend or terminate its clinical trials;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">changes in governmental regulations or administrative actions;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the interim or final results of the clinical trial are inconclusive or unfavorable as to safety or effectiveness; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA concludes that the Company&rsquo;s trial design is inadequate to demonstrate safety and effectiveness.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">After a device is approved and placed in commercial distribution, numerous regulatory requirements apply. These include:</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">establishment registration and device listing;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the Quality System Regulations (QSR), which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">labeling regulations, which prohibit the promotion of products for unapproved or &ldquo;off-label&rdquo; uses and impose other restrictions on labeling;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">medical device reporting regulations, which require that manufacturers report to the FDA if a device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if malfunctions were to occur; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">corrections and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA caused by the device that may present a risk to health.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">20</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The FDA enforces regulatory requirements by conducting periodic, announced and unannounced inspections and market surveillance. Inspections may include the manufacturing facilities of our subcontractors. Failure to comply with applicable regulatory requirements, including those applicable to the conduct of our clinical trials, can result in enforcement action by the FDA, which may lead to any of the following sanctions:</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 7.7%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: 88.5%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">warning letters or untitled letters;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 7.7%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: 88.5%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">fines and civil penalties;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 7.7%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: 88.5%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">unanticipated expenditures;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 7.7%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: 88.5%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delays in clearing or approving or refusal to clear or approve products;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 7.7%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: 88.5%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">withdrawal or suspension of FDA clearance;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 7.7%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: 88.5%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">product recall or seizure;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 7.7%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: 88.5%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">orders for physician notification or device repair, replacement, or refund;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 7.7%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: 88.5%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">production interruptions;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 7.7%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: 88.5%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">operating restrictions; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 7.7%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: 88.5%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">criminal prosecution.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We and our contract manufacturers, specification developers and suppliers are also required to manufacture our medical devices, including our intraductal microcatheters in compliance with current Good Manufacturing Practice requirements set forth in the QSR. The QSR requires a quality system for the design, manufacture, packaging, labeling, storage, installation and servicing of marketed devices, and includes extensive requirements with respect to quality management and organization, device design, buildings, equipment, purchase and handling of components, production and process controls, packaging and labeling controls, device evaluation, distribution, installation, complaint handling, servicing and recordkeeping. The FDA enforces the QSR through periodic announced and unannounced inspections that may include the manufacturing facilities of our subcontractors. If the FDA believes we or any of our contract manufacturers or regulated suppliers is not in compliance with these requirements, it can shut down our manufacturing operations, require recall of our devices, refuse to clear or approve new marketing applications, institute legal proceedings to detain or seize products, enjoin future violations, or assess civil and criminal penalties against us or our officers or other employees. Any such action by the FDA would have a material adverse effect on our business.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Privacy and Security of Health Information and Personal Information; Standard Transactions</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are subject to state and federal laws and implementing regulations relating to the privacy and security of the medical information of the patients it treats. The principal federal legislation is part of HIPAA. Pursuant to HIPAA, the Secretary of the Department of Health and Human Services, or HHS, has issued final regulations designed to improve the efficiency and effectiveness of the healthcare system by facilitating the electronic exchange of information in certain financial and administrative transactions, while protecting the privacy and security of the patient information exchanged. International regulations (such as the current Directive 95/46/EC and from May 25, 2018, the GDPR) also provide privacy protection to clinical trial participants of their personal health care information. We take appropriate steps to protect the privacy of our clinical study participants. We are evaluating our ability and cost to comply with the new EU GDPR regulations, and as a result of that evaluation we may make changes to our business practices and may incur additional costs.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">21</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Federal and State Fraud and Abuse Laws</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The federal healthcare Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce referrals or in return for purchasing, leasing, ordering, or arranging for the purchase, lease, or order of any healthcare item or service reimbursable under a governmental payor program. The definition of &ldquo;remuneration&rdquo; has been broadly interpreted to include anything of value, including gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests, opportunity to earn income, and providing anything at less than its fair market value. The Anti-Kickback Statute is broad, and it prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Recognizing that the Anti-Kickback Statute is broad and may technically prohibit many innocuous or beneficial arrangements within the healthcare industry, HHS has issued a series of regulatory &ldquo;safe harbors.&rdquo; These safe harbor regulations set forth certain provisions that, if met, will provide healthcare providers and other parties with an affirmative defense against prosecution under the federal Anti-Kickback Statute. Although full compliance with these provisions ensures against prosecution under the federal Anti-Kickback Statute, the failure of a transaction or arrangement to fit within a specific safe harbor does not necessarily mean that the transaction or arrangement is illegal or that prosecution under the federal Anti-Kickback Statute will be pursued.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">From time to time, the Office of Inspector General, or OIG, issues alerts and other guidance on certain practices in the healthcare industry. In October 1994, the OIG issued a Special Fraud Alert on arrangements for the provision of clinical laboratory services. The Fraud Alert set forth a number of practices allegedly engaged in by some clinical laboratories and healthcare providers that raise issues under the &ldquo;fraud and abuse&rdquo; laws, including the Anti-Kickback Statute.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Regulation of Medical Devices Outside the United States</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Before we can market a medical device in the European Union and the European Free Trade Association, we must comply with the Essential Requirements set forth in Annex I to the Directive 93/42/EEC of 14 June 1993 concerning medical devices, commonly known as the Medical Devices Directive. The Essential Requirements relate to the quality, safety and performance of the medical devices. Compliance with the Essential Requirements entitles a manufacturer to affix the Conformit&eacute; Europ&eacute;enne mark, or CE mark, without which the products cannot be placed on the market in the European Union and the European Free Trade Association countries. To demonstrate compliance with the Essential Requirements and obtain the right to affix the CE mark, medical device manufacturers must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Medical Devices Directive establishes a classification system placing devices into Class I, IIa, IIb, or III, depending on the risks and characteristics of the medical device. For certain types of low risk medical devices, the manufacturer may prepare a CE Declaration of Conformity based on a self-assessment of the conformity of its products with the Essential Requirements set forth in Annex I to the Medical Devices Directive. Other devices are subject to a conformity assessment procedure requiring the intervention of a &ldquo;notified body,&rdquo; which is a private organization designated by the competent authorities of an E.U. Member State to conduct conformity assessments and verify the conformity of manufacturers and their medical devices with the Essential Requirements. The notified body issues a CE Certificate of Conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the Essential Requirements. This Certificate entitles the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related Declaration of Conformity.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Compliance Program</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Compliance with government rules and regulations is a significant concern throughout the industry, in part due to evolving interpretations of these rules and regulations. We seek to conduct our business in compliance with all statutes and regulations applicable to our operations. To this end, we have established a compliance program that reviews for regulatory compliance procedures, policies, and facilities throughout our business. Failure to comply with applicable requirements may subject us to administrative or judicial sanctions, such as clinical holds, refusal of regulatory authorities to approve or authorize pending product applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">22</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Legal Proceedings </b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">See &ldquo;Part I, ITEM 3. LEGAL PROCEEDINGS&rdquo; in this Annual Report, which is incorporated into this Part I, Item 1 by this reference.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Employees</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of the date of filing this report, we employed two executive officers, two full-time employees and two part-time employees. We expect that we will hire more employees as we expand.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Executive officers</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The names of our executive officers and their ages as of December 31, 2018 are as follows:</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 29%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Name</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 10%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Age</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 59%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Position</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 29%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Executive Officers:</i></b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 59%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 29%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Steven C. Quay, M.D., Ph.D.</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">68</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 59%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chairman of the Board, President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 29%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Kyle Guse, Esq., CPA (inactive)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">55</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 59%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chief Financial Officer, General Counsel and Secretary</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Steven C. Quay, M.D., Ph.D.</i></b>&nbsp;Dr. Quay has served as Chief Executive Officer, President and Chairman of the Board of Directors of the Company since the Company was incorporated in April 2009. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology and completed both an internship and residency in anatomic pathology at Massachusetts General Hospital, a Harvard Medical School teaching hospital. He is a former faculty member of the Department of Pathology, Stanford University School of Medicine. Dr. Quay is an inventor, with 87 U.S. patents, 133 pending patent applications and is a named inventor on patents covering five pharmaceutical products that have been approved by the U.S. Food and Drug Administration. Dr. Quay received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan Medical School. He also received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Kyle Guse, Esq., CPA (inactive).</i></b>&nbsp;&nbsp;Mr. Guse has served as Chief Financial Officer, General Counsel and Secretary since January 2013. His experience includes more than 25 years of counseling life sciences and other rapid growth companies through all aspects of finance, corporate governance, securities laws and commercialization. Mr. Guse has practiced law at several of the largest international law firms, including from January 2012 through January 2013 as a partner at Baker Botts LLP and, prior to that, from October 2007 to January 2012, as a partner at McDermott Will &amp; Emery LLP. Before working at McDermott Will &amp; Emery, Mr. Guse previously served as a partner at Heller Ehrman LLP. Mr. Guse began his career as an accountant at Deloitte &amp; Touche and he is a licensed Certified Public Accountant&nbsp;(inactive)&nbsp;and member of the Bar in the State of California. Mr. Guse earned a B.S. in business administration and an M.B.A. from California State University, Sacramento, and a J.D. from Santa Clara University School of Law.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Insurance</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We currently maintain director&rsquo;s and officer&rsquo;s insurance, key-man life insurance for our Chief Executive Officer, commercial general and office premises liability insurance, insurance on our clinical studies, and product errors and omissions liability insurance for our products and services.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Research and Development Phase</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are in the research and development phase and are not currently marketing any products or services. We do not anticipate generating revenue unless and until we develop and launch our pharmaceutical or device programs.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">23</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item1a" name="item1a"></a>ITEM 1A. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a class="rdg_comment commentapprove" name="doccmt-528">RISK FACTORS</a></b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: center; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Purchasing of our shares of common stock is an investment in our securities and involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information contained in this Annual Report, before purchasing our securities. If any of the following risks actually occur, our business, financial condition and results of operations would likely suffer. In that case, the market price of the common stock could decline, and you may lose part or all of your investment in our company. Additional risks of which we are not presently aware or that we currently believe are immaterial may also harm our business and results of operations.</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risks Relating to our Business</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We have only a limited operating history, and, as such, an investor cannot assess our profitability or performance based on past results.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We were incorporated in Delaware in April 2009. Initially, our operations were focused on establishing our CLIA-certified laboratory, commercializing our ForeCYTE and FullCYTE Breast Aspirators and manufacturing our intraductal microcatheters. In December 2015, we sold our laboratory, ceased generating revenue and refocused our business on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. Because of our limited operating history, particularly in the area of pharmaceutical development, our revenue and income potential is uncertain and cannot be based on prior results. Any evaluation of our business and prospects must be considered in light of these factors and the risks and uncertainties often encountered by companies in the development stage. Some of these risks and uncertainties include our ability to:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">commence, execute and obtain successful results from our clinical studies;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">obtain regulatory approvals in the United States and elsewhere for our pharmaceuticals and intraductal microcatheters we are developing;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">work with contract manufacturers to produce our pharmaceuticals under development and our intraductal microcatheter in clinical and commercial quantities on acceptable terms and in accordance with required standards;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">respond effectively to competition;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">manage growth in operations;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">respond to changes in applicable government regulations and legislation;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">access additional capital when required; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">attract and retain key personnel.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We may not continue as a going concern.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have not yet established an ongoing source of revenue sufficient to cover operating costs and allow us to continue as a going concern. Our ability to continue as a going concern is dependent on obtaining adequate capital to fund operating losses until we become profitable. If we are unable to obtain adequate capital, we may be unable to develop and commercialize our product offerings or geographic reach and we could be forced to cease operations.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">24</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>If we do not raise additional capital, we anticipate liquidity issues in the next twelve to&nbsp;eighteen</i></b><b><i> months.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For the year ended December 31, 2018, we incurred a net loss of $11,404,934 and we had an accumulated deficit of $76,831,263. As of the date of filing this Annual Report, we expect that our existing resources will be sufficient to fund our planned operations for at least the next twelve to eighteen months. We have not yet established an ongoing source of revenue sufficient to cover our operating costs and allow us to continue as a going concern. Our ability to continue as a going concern is dependent on obtaining adequate capital to fund operating losses until we become profitable. We currently have no other products and services approved for commercialization. We may not receive or maintain regulatory clearance for our products and other sources of capital may not be available when we need them or on acceptable terms. If we are unable to raise in a timely fashion the amount of capital we anticipate needing, we would be forced to curtail or cease operations.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We will need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">When we elect to raise additional funds or when additional funds are required, we may raise such funds from time to time through public or private equity offerings, debt financings, corporate collaboration and licensing arrangements or other financing alternatives. These financing arrangements may not be available on acceptable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from developing our device and pharmaceutical candidates, pursuing acquisition, licensing, development and commercialization efforts, and our ability to continue operations, generate revenues, and achieve or sustain profitability will be substantially harmed.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional equity, including securities convertible into or exercisable for equity securities, that we raise may contain terms, such as liquidation, conversion and other preferences, that are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, our business, operating results, financial condition and prospects could be materially and adversely affected and we may be unable to continue our operations.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Failure to raise additional capital as needed could adversely affect us and our ability to develop our products.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We expect to spend substantial amounts of capital to:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">develop our pharmaceutical and microcatheter programs under development;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">perform clinical studies for the pharmaceuticals and microcatheters we are developing;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">continue our research and development activities to advance our product pipeline; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">obtain clinical supplies of the pharmaceuticals and microcatheters we are developing.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have not identified other sources for additional funding and we cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may have to significantly delay, scale back or discontinue the commercialization of our products or our research and development activities. Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which could significantly harm the business and development of operations.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">25</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We have a history of operating losses and we expect to continue to incur losses in the future.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have a limited operating history and have incurred net losses each year. Our net loss for the year ended December 31, 2018 was $11,404,934. We will continue to incur further losses in connection with research and development costs for development of our programs, including ongoing and additional clinical studies.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Our business may be affected by legal proceedings.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have been in the past, and may become in the future, involved in legal proceedings.&nbsp;For example, on October 10, 2013, a securities class action complaint was filed against us, certain of our directors and officers and the underwriters from our initial public offering.&nbsp;This action was purportedly brought on behalf of a class of persons and entities who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount. On March 23, 2018, the parties filed a stipulation of settlement with the court to settle the matter for $3.5 million, completely funded by defendants&rsquo; insurers, and on July 20, 2018 the Court approved the settlement. This case is considered closed.&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">You should carefully review and consider the various disclosures we make in our reports filed with the SEC regarding legal matters that may affect our business. Civil and criminal litigation is inherently unpredictable and outcomes can result in excessive verdicts, fines, penalties and/or injunctive relief that affect how we operate our business. Monitoring and defending against legal actions, whether or not meritorious, and considering stockholder demands, is time-consuming for our management and detracts from our ability to fully focus our internal resources on our business activities. In addition, legal fees and costs incurred in connection with such activities may be significant. We cannot predict with certainty the outcome of any legal proceedings in which we become involved, and it is difficult to estimate the possible costs to us stemming from these matters. Settlements and decisions adverse to our interests in legal actions could result in the payment of substantial amounts and could have a material adverse effect on our cash flow, results of operations, and financial position.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Raising funds by issuing equity or debt securities could dilute the value of the Common Stock and impose restrictions on our working capital.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we raise additional capital by issuing equity securities or through the exercise of warrants currently outstanding or that we may issue in the future, the value of the then outstanding common stock may be reduced. If the additional equity securities are issued at a per share price less than the per share value of the outstanding shares, then all of the outstanding shares would suffer a dilution in value with the issuance of such additional shares. Further, the issuance of debt securities in order to obtain additional funds may impose restrictions on our operations and may impair our working capital as we service any such debt obligations.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>The products we may develop may never achieve significant commercial market acceptance.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may not succeed in achieving commercial market acceptance of any of our products. In order to gain market acceptance for the drugs and microcatheters under development, we will need to demonstrate to physicians and other healthcare professionals the benefits of these therapies including the clinical and economic application for their particular practice. Many physicians and healthcare professionals may be hesitant to introduce new services or techniques into their practice for many reasons, including lack of time and resources, the learning curve associated with the adoption of such new services or techniques into already established procedures, and the uncertainty of the applicability or reliability of the results of a new product. In addition, the availability of full or even partial payment for our products and tests, whether by third-party payors (e.g., insurance companies), or the patients themselves, will likely heavily influence physicians&rsquo; decisions to recommend or use our products.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>The loss of the services of our Chief Executive Officer could adversely affect our business.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our success is dependent in large part upon the ability to execute our business plan, manufacture our pharmaceutical drugs and medical devices, and attract and retain highly skilled professional personnel. In particular, due to the relatively early stage of our business, our future success is highly dependent on the services of Steven C. Quay, our Chief Executive Officer and founder, who provides much of the necessary experience to execute our business plan.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We may experience difficulty in locating, attracting, and retaining experienced and qualified personnel, which could adversely affect our business.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We will need to attract, retain, and motivate experienced clinical development and other personnel, particularly in the greater Seattle area as we expand our pharmaceutical development activities. These employees may not be available in this geographic region. In addition, competition for these employees is intense and recruiting and retaining skilled employees is difficult, particularly for a development-stage organization such as ours. If we are unable to attract and retain qualified personnel, our development activities may be adversely affected.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">26</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Compounds that appear promising in research and development may fail to reach later stages of development for a number of reasons, including, among others, that clinical trials may take longer to complete than expected or may not be completed at all, and top-line or preliminary clinical trial data reports may ultimately differ from actual results once data are more fully evaluated.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Successful development of anti-cancer and other pharmaceutical products is highly uncertain, and obtaining regulatory approval to market drugs to treat cancer and other breast conditions is expensive, difficult, and speculative. Compounds that appear promising in research and development may fail to reach later stages of development for several reasons, including, but not limited to:</p>

<p style="margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">an unacceptable safety profile;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">lack of efficacy;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delay or failure in obtaining necessary U.S. and international regulatory approvals, or the imposition of a partial or full regulatory hold on a clinical trial;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">difficulties in formulating a compound, scaling the manufacturing process, timely attaining process validation for particular drug products, and completing manufacturing to support clinical studies;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">pricing or reimbursement issues or other factors that may make the product uneconomical to commercialize;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">production problems, such as the inability to obtain raw materials or supplies satisfying acceptable standards for the manufacture of our products;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">equipment obsolescence, malfunctions or failures, product quality/contamination problems or changes in regulations requiring manufacturing modifications;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">inefficient cost structure of a compound, finished drug, or device compared to alternative treatments;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">obstacles resulting from proprietary rights held by others, such as patent rights for a particular compound;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">lower than anticipated rates of patient enrollment as a result of factors, such as the number of patients with the relevant conditions, the proximity of patients to clinical testing centers, perceived cost/benefit of participating in the study, eligibility criteria for tests, and competition with other clinical testing programs;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">preclinical or clinical testing requiring significantly more time than expected, resources or expertise than originally expected and inadequate financing, which could cause clinical trials to be delayed or terminated;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure of clinical testing to show potential products to be safe and efficacious, and failure to demonstrate desired safety and efficacy characteristics in human clinical trials;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">suspension of a clinical trial at any time by us, an applicable collaboration partner or a regulatory authority on the basis that the participants are being exposed to unacceptable health risks or for other reasons;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delays in reaching or failing to reach agreement on acceptable terms with manufacturers or prospective clinical research organizations, or CROs, and trial sites; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure of third-parties, such as CROs, academic institutions, collaborators, cooperative groups, and/or investigator sponsors, to conduct, oversee, and monitor clinical trials and results.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, from time to time we expect to report top-line or &ldquo;preliminary&rdquo; data for clinical trials. Such data are based on a preliminary analysis of then-available efficacy and safety data, and such findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. Top-line or preliminary data are based on important assumptions, estimations, calculations and information then available to us to the extent we have had, at the time of such reporting, an opportunity to fully and carefully evaluate such information in light of all surrounding facts, circumstances, recommendations and analyses. As a result, top-line or &ldquo;preliminary&rdquo; results may differ from future results, or different conclusions or considerations may qualify such results once existing data have been more fully evaluated. In addition, third parties, including regulatory agencies, may not accept or agree with our assumptions, estimations, calculations or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular compound and our business in general.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For example, some participants in the Phase 2 MBD study we are conducting in Stockholm, Sweden have exited the study before completing a full six months of dosing for a number of reasons including because of skin irritation and rashes and, as of the date of filing this Annual Report, approximately 72 of the 90 participants in the study have exited the study. This is a higher rate of attrition than we expected and as a result the study may not produce sufficient data to achieve the primary study objective which is to determine sample size for a subsequent Phase 3 study.</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If the development of our products is delayed or fails, or if top-line or preliminary clinical trial data reported differ from actual results, our development costs may increase and the ability to commercialize our products may be harmed, which could harm our business, financial condition, operating results or prospects.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">27</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We may not obtain or maintain the regulatory approvals required to develop or commercialize some or all of our products.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are subject to rigorous and extensive regulation by the FDA in the U.S. and by comparable agencies in other jurisdictions, including the European Medicines Agency (the &ldquo;<b><i>EMA</i></b>&rdquo;) in the E.U.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our product candidates are currently in research or development and we have not received marketing approval for our products. Our products may not be marketed in the U.S. until they have been approved by the FDA and may not be marketed in other jurisdictions until they have received approval from the appropriate foreign regulatory agencies. Each product candidate requires significant research, development and preclinical testing and extensive clinical investigation before submission of any regulatory application for marketing approval. Our products may be considered &ldquo;combination&rdquo; products in that they use both medical devices and drugs. For example, our intraductal microcatheters utilize both a medical device and the drug they are intended to deliver. As a result, the regulatory pathway for these products may be more complex and obtaining regulatory approvals may be more difficult.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Obtaining regulatory approval requires substantial time, effort and financial resources, and we may not be able to obtain approval of any of our products on a timely basis, or at all. The number, size, design, and focus of preclinical and clinical trials that will be required for approval by the FDA, the EMA, or any other foreign regulatory agency varies depending on the compound, the disease or condition that the products is designed to address and the regulations applicable to any particular products. Preclinical and clinical data can be interpreted in different ways, which could delay, limit or preclude regulatory approval. The FDA, the EMA, and other foreign regulatory agencies can delay, limit, or deny approval of a product for many reasons, including, but not limited to:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a product may not be shown to be safe or effective;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the clinical and other benefits of a product may not outweigh its safety risks;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">clinical trial results may be negative or inconclusive, or adverse medical events may occur during a clinical trial;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the results of clinical trials may not meet the level of statistical significance required by regulatory agencies for approval;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory agencies may interpret data from pre-clinical and clinical trials in different ways than we do;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory agencies may not approve the manufacturing process or determine that the manufacturing is not in accordance with current good manufacturing practices;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a product may fail to comply with regulatory requirements; or</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory agencies might change their approval policies or adopt new regulations.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If our products are not approved at all or quickly enough to provide net revenues to defray our operating expenses, our business, financial condition, operating results and prospects could be harmed.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">28</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>In the event that we seek and the FDA does not grant accelerated approval or priority review for a drug or device candidate, we would experience a longer time to commercialization in the U.S., if commercialized at all, our development costs may increase and our competitive position may be harmed.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may in the future decide to seek accelerated approval pathway for our products. The FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. A surrogate endpoint under an accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. There can be no assurance that the FDA will agree that any endpoint we suggest with respect to any of our drug candidates is an appropriate surrogate endpoint. Furthermore, there can be no assurance that any application will be accepted or that approval will be granted. Even if a product candidate is granted accelerated approval, such accelerated approval is contingent on the sponsor&rsquo;s agreement to conduct one or more post-approval confirmatory trials. Such confirmatory trial(s) must be completed with due diligence and, in some cases, the FDA may require that the trial(s) be designed and/or initiated prior to approval. Moreover, the FDA may withdraw approval of a product candidate or indication approved under the accelerated approval pathway for a variety of reasons, including if the trial(s) required to verify the predicted clinical benefit of a product candidate fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with the drug, or if the sponsor fails to conduct any required post-approval trial(s) with due diligence.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In the event of priority review, the FDA has a goal (but is not required) to take action on an application within a total of eight months (6 months to take action following a 60 day period to determine if the application is acceptable) instead of the 12- months (10 months to take action following a 60 day period to determine if the application is acceptable) allocated&nbsp;for a standard review. The FDA grants priority review only if it determines that a product treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared to a standard application. The FDA has broad discretion whether to grant priority review, and, while the FDA has granted priority review to other oncology product candidates, our drug candidates may not receive similar designation. Moreover, receiving priority review from the FDA does not guarantee completion of review or approval within the targeted eight-month cycle or thereafter.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A failure to obtain accelerated approval or priority review would result in a longer time to commercialization of the applicable product in the U.S., if commercialized at all, could increase the cost of development and could harm our competitive position in the marketplace.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Even if our products are successful in clinical trials and receive regulatory approvals, we may not be able to successfully commercialize them.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The development and ongoing clinical trials for our drug and device candidates may not be successful and, even if they are, the resulting products may never be successfully developed into commercial products. Even if we are successful in our clinical trials and in obtaining other regulatory approvals, the respective products may not reach or remain in the market for a number of reasons including:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">they may be found ineffective or cause harmful side effects;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">they may be difficult to manufacture on a scale necessary for commercialization;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">they may experience excessive product loss due to contamination, equipment failure, inadequate transportation or storage, improper installation or operation of equipment, vendor or operator error, inconsistency in yields or variability in product characteristics;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">they may be uneconomical to produce;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may fail to obtain reimbursement approvals or pricing that is cost effective for patients as compared to other available forms of treatment or that covers the cost of production and other expenses;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">they may not compete effectively with existing or future alternatives;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may be unable to develop commercial operations and to sell marketing rights;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">they may fail to achieve market acceptance; or</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may be precluded from commercialization of a product due to proprietary rights of third parties.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we fail to commercialize products or if our future products do not achieve significant market acceptance, we will not likely generate significant revenues or become profitable.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">29</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>The pharmaceutical business is subject to increasing government price controls and other restrictions on pricing, reimbursement and access to drugs, which could adversely affect our future revenues and profitability.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To the extent our products are developed, commercialized, and successfully introduced to market, they may not be considered cost-effective and third-party or government reimbursement might not be available or sufficient. Globally, governmental and other third-party payors are becoming increasingly aggressive in attempting to contain health care costs by strictly controlling, directly or indirectly, pricing and reimbursement and, in some cases, limiting or denying coverage altogether on the basis of a variety of justifications, and we expect pressures on pricing and reimbursement from both governments and private payors inside and outside the U.S. to continue.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In the U.S., we are subject to substantial pricing, reimbursement, and access pressures from state Medicaid programs, private insurance programs and pharmacy benefit managers, and implementation of U.S. health care reform legislation is increasing these pricing pressures. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the &ldquo;<b><i>PPACA</i></b>&rdquo; or the &ldquo;<b><i>Affordable Care Act</i></b>&rdquo;), instituted comprehensive health care reform, and includes provisions that, among other things, reduce and/or limit Medicare reimbursement, require all individuals to have health insurance (with limited exceptions), and impose new and/or increased taxes. The future of the Affordable Care Act and its constituent parts are uncertain at this time.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In almost all markets, pricing and choice of prescription pharmaceuticals are subject to governmental control. Therefore, the price of our products and their reimbursement in Europe and in other countries is and will be determined by national regulatory authorities. Reimbursement decisions from one or more of the European markets may impact reimbursement decisions in other European markets. A variety of factors are considered in making reimbursement decisions, including whether there is sufficient evidence to show that treatment with the product is more effective than current treatments, that the product represents good value for money for the health service it provides, and that treatment with the product works at least as well as currently available treatments.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The continuing efforts of government and insurance companies, health maintenance organizations, and other payors of health care costs to contain or reduce costs of health care may affect our future revenues and profitability or those of our potential customers, suppliers, and collaborative partners, as well as the availability of capital.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We are dependent on third-party service providers for a number of critical operational activities including, in particular, for the manufacture and testing of our products and associated supply chain operations, as well as for clinical trial activities. Any failure or delay in these undertakings by third parties could harm our business.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our business is dependent on the performance by third parties of their responsibilities under contractual relationships. In particular, we heavily rely on third parties for the manufacture and testing of our products. We do not have internal analytical laboratory or manufacturing facilities to allow the testing or production of products in compliance with cGMP. As a result, we rely on third parties to supply us in a timely manner with manufactured product candidates. We may not be able to adequately manage and oversee the manufacturers we choose, they may not perform as agreed or they may terminate their agreements with us. In particular, we depend on third-party manufacturers to conduct their operations in compliance with GLP or similar standards imposed by the U.S. and/or applicable foreign regulatory authorities, including the FDA and EMA. Any of these regulatory authorities may take action against a contract manufacturer who violates cGMP. Failure of our manufacturers to comply with FDA, EMA or other applicable regulations may cause us to curtail or stop the manufacture of such products until we obtain regulatory compliance.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may not be able to obtain sufficient quantities of our products if we are unable to secure manufacturers when needed, or if our designated manufacturers do not have the capacity or otherwise fail to manufacture compounds according to our schedule and specifications or fail to comply with cGMP regulations. Furthermore, in order to ultimately obtain and maintain applicable regulatory approvals, any manufacturers we utilize are required to consistently produce the respective products in commercial quantities and of specified quality or execute fill-finish services on a repeated basis and document their ability to do so, which is referred to as process validation. In order to obtain and maintain regulatory approval of a compound, the applicable regulatory authority must consider the result of the applicable process validation to be satisfactory and must otherwise approve of the manufacturing process. Even if our compound manufacturing processes obtain regulatory approval and sufficient supply is available to complete clinical trials necessary for regulatory approval, there are no guarantees we will be able to supply the quantities necessary to effect a commercial launch of the applicable drug, or once launched, to satisfy ongoing demand. Any product shortage could also impair our ability to deliver contractually required supply quantities to applicable collaborators, as well as to complete any additional planned clinical trials.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">30</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We also rely on third-party service providers for certain warehousing and transportation. With regard to the distribution of our drugs, we depend on third-party distributors to act in accordance with GDP, and the distribution process and facilities are subject to continuing regulation by applicable regulatory authorities with respect to the distribution and storage of products.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, we depend on medical institutions and CROs (together with their respective agents) to conduct clinical trials and associated activities in compliance with GCP and in accordance with our timelines, expectations and requirements. We are substantially dependent on Montefiore Medical Center for the clinical study they are conducting for us using our intraductal microcatheters to deliver fulvestrant and we will be substantially dependent on the organizations conducting the clinical trials of our proprietary Endoxifen. To the extent any such third parties are delayed in achieving or fail to meet our clinical trial enrollment expectations, fail to conduct our trials in accordance with GCP or study protocol or otherwise take actions outside of our control or without our consent, our business may be harmed. Furthermore, we conduct clinical trials in foreign countries, subjecting us to additional risks and challenges, including, in particular, as a result of the engagement of foreign medical institutions and foreign CROs, who may be less experienced with regard to regulatory matters applicable to us and may have different standards of medical care.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">With regard to certain of the foregoing clinical trial operations and stages in the manufacturing and distribution chain of our compounds, we rely on single vendors. In particular, our current business structure contemplates, at least in the foreseeable future, use of a single commercial supplier for Endoxifen drug substance. In addition, in the event Endoxifen is approved, we are initially preparing to have only one commercial supplier. The use of single vendors for core operational activities, such as clinical trial operations, manufacturing and distribution, and the resulting lack of diversification, expose us to the risk of a material interruption in service related to these single, outside vendors. As a result, our exposure to this concentration risk could harm our business.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Although we monitor the compliance of our third-party service providers performing the aforementioned services, we cannot be certain that such service providers will consistently comply with applicable regulatory requirements or that they will otherwise timely satisfy their obligations to us. Any such failure and/or any failure by us to monitor their services or to plan for and manage our short- and long-term requirements underlying such services could result in shortage of the compound, delays in or cessation of clinical trials, failure to obtain or revocation of product approvals or authorizations, product recalls, withdrawal or seizure of products, suspension of an applicable wholesale distribution authorization, and/or distribution of products, operating restrictions, injunctions, suspension of licenses, other administrative or judicial sanctions (including civil penalties and/or criminal prosecution), and/or unanticipated related expenditures to resolve shortcomings.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Such consequences could have a significant impact on our business, financial condition, operating results, or prospects.<b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We may encounter delays in our clinical trials, or may not be able to conduct our trials timely.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Clinical trials are expensive and subject to regulatory approvals. Potential trial delays may arise from, but are not limited to:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Failure to obtain on a timely basis, or at all, approval from the applicable institutional review board or ethics committee to open a clinical study;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">lower than anticipated patient enrollment for reasons such as existing conditions, eligibility criteria or if patients perceive a lack of benefit to enroll in the study for whatever reason;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delays in reaching agreements on acceptable terms with prospective CROs; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure of Montefiore Medical Center, CROs, or other third parties to effectively and timely monitor, oversee, and maintain the clinical trials.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Our products and services may expose us to possible litigation and product liability claims.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our business may expose us to potential product liability risks inherent in the testing, marketing, and processing personalized medical products, particularly those products and services we offered prior to shifting our focus on pharmaceutical development. Product liability risks may arise from, but are not limited to:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure of our microcatheters to inject a sufficient amount of drug, CAR-T or other immunotherapy into the desired location, which could lead to ineffective treatment; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">adverse events related to drugs and therapies we are developing.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A successful product liability claim, or the costs and time commitment involved in defending against a product liability claim, could have a material adverse effect on our business. Any successful product liability claim may prevent us from obtaining adequate product liability insurance in the future on commercially desirable or reasonable terms. An inability to obtain sufficient insurance coverage at an acceptable cost, or otherwise, to protect against potential product liability claims could prevent or inhibit the commercialization of our products.<b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">31</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>If we are not able to protect our proprietary technology, others could compete against us more directly, which would harm our business.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our commercial success will depend, in part, on our ability to obtain additional patents and licenses and protect our existing patent position, both in the United States and in other countries, for devices, therapeutics and related technologies, processes, methods, compositions, and other inventions that we believe are patentable.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our ability to preserve our trade secrets and other intellectual property is also important to our long-term success. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to establish or maintain profitability. Patents may also issue to third parties which could interfere with our ability to bring our therapeutics and devices to market.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The laws of some foreign countries do not protect our proprietary rights to the same extent as U.S. laws, and we may encounter significant problems in protecting our proprietary rights in these countries. The patent positions of diagnostic companies and pharmaceutical and biotechnology companies, including our patent position, are generally highly uncertain and particularly after the Supreme Court decisions,&nbsp;<i>Mayo Collaborative Services v. Prometheus Laboratories</i>, 132 S. Ct. 1289 (2012),&nbsp;<i>Association for Molecular Pathology v. Myriad Genetics, Inc.</i>, 133 S. Ct. 2107 (2013), and&nbsp;<i>Alice Corp. v. CLS Bank International</i>, 134 S. Ct. 2347 (2014). Our patent positions also involve complex legal and factual questions, and, therefore, any patents issued to us may be challenged, deemed unenforceable, invalidated or circumvented. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies and any future tests and products are covered by valid and enforceable patents or are effectively maintained as trade secrets. In addition, our patent applications may never issue as patents, and the claims of any issued patents may not afford meaningful protection for our products, technology or tests.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we or others were the first to make the inventions covered by each of our patent applications;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we or others were the first to file patent applications for our claimed inventions;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">others will not independently develop similar or alternative technologies or duplicate any of our technologies;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any of our patent applications will result in issued patents;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any of our patents will be valid or enforceable;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any patents issued to us and collaborators will provide a basis for commercially viable therapeutics, will provide us with any competitive advantages or will not be challenged by third parties;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the patents of others will not have an adverse effect on our business; or</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our patents or patents that we license from others will survive legal challenges, and remain valid and enforceable.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If a third-party files a patent application with claims to a drug or device we have discovered or developed, a derivation proceeding may be initiated regarding competing patent applications. If a derivation proceeding is initiated, we may not prevail in the derivation proceeding. If the other party prevails in the derivation proceeding, we may be precluded from commercializing our products, or may be required to seek a license. A license may not be available to us on commercially acceptable terms, if at all.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">32</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Any litigation proceedings relating to our proprietary technology may fail and, even if successful, may result in substantial costs and distract our management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Finally, we may not be able to prevent, alone or with the support of our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.<b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The U.S. Patent and Trademark Office (the &ldquo;<b><i>USPTO</i></b>&rdquo;) and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on any issued patents and/or applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees. While an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Changes in U.S.&nbsp;patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As is the case with other medical device and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the medical device and pharmaceutical industries involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation under the Leahy-Smith America Invents Act, or the America Invents Act, including changes from a &ldquo;first-to-invent&rdquo; system to a &ldquo;first to file&rdquo; system, changes to examination of U.S. patent applications and changes to the processes for challenging issued patents. These changes include provisions that affect the way patent applications are being filed, prosecuted and litigated. For example, the America Invents Act enacted proceedings involving post-issuance patent review procedures, such as inter partes review, or IPR, and post-grant review and covered business methods. These proceedings are conducted before the Patent Trial and Appeal Board, or PTAB, of the USPTO. Each proceeding has different eligibility criteria and different patentability challenges that can be raised. In this regard, the IPR process permits any person (except a party who has been litigating the patent for more than a year) to challenge the validity of some patents on the grounds that it was anticipated or made obvious by prior art. As a result, non-practicing entities associated with hedge funds, pharmaceutical companies who may be our competitors and others have challenged certain valuable pharmaceutical U.S. patents based on prior art through the IPR process. A decision in such a proceeding adverse to our interests could result in the loss of valuable patent rights which would have a material adverse effect on our business, financial condition, results of operations and growth prospects. In any event, the America Invents Act and any other potential future changes to the U.S. patent system could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Further, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In particular, on March 20, 2012, the U.S. Supreme Court issued the&nbsp;<i>Prometheus and Alice</i>&nbsp;decision, holding that several claims drawn to measuring drug metabolite levels from patient samples were not patentable subject matter. The full impact of the&nbsp;<i>Prometheus and Alice</i>&nbsp;decision on diagnostic claims is uncertain. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on decisions by the U.S.&nbsp;Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. The standards that courts use to interpret patents are not always applied predictably or uniformly and may evolve, particularly as new technologies develop. In addition, changes to patent laws in the United States or other countries may be applied retroactively to affect the validity, enforceability, or term of our patent. For example, the U.S. Supreme Court has modified some legal standards applied by the USPTO in examination of U.S. patent applications, which may decrease the likelihood that we will be able to obtain patents and may increase the likelihood of challenges to patents we obtain or license.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We may not be able to protect our intellectual property rights throughout the world.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Filing, prosecuting and defending patents on our products in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights in the same manner and to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection but enforcement of such patent protection is not as strong as that in the United States. These products may compete with our products and services, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing with our products.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products and services in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">33</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Our current patent portfolio may not include all patent rights needed for the full development and commercialization of our products. We cannot be sure that patent rights we may need in the future will be available for license on commercially reasonable terms, or at all.</i></b>&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may be unable to obtain any licenses or other rights to patents, technology, or know-how from third parties necessary to conduct our business and such licenses, if available at all, may not be available on commercially reasonable terms. Others may seek licenses from us for other technology we use or intend to use. Any failure to obtain such licenses could delay or prevent us from developing or commercializing our proposed products, which would harm our business. For example, we may seek to develop our intraductal treatment program by licensing pharmaceuticals, CAR-T cell technology or immunotherapy from a third-party. We may not be able to secure such a license on acceptable terms. Litigation or patent derivation proceedings need to be brought against third parties, as discussed below, to enforce any of our patents or other proprietary rights, or to determine the scope and validity or enforceability of the proprietary rights of such third parties.<b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Third-party claims alleging intellectual property infringement may prevent or delay our drug discovery and development efforts.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties, including the intellectual property rights of competitors. There is a substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the medical device and pharmaceutical fields, as well as administrative proceedings for challenging patents, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in various foreign jurisdictions. Recently, the America Invents Act (the &ldquo;<b><i>AIA</i></b>&rdquo;) introduced new procedures including inter partes review and post-grant review. The implementation of these procedures brings uncertainty to the possibility of challenges to our patents in the future, including those patents perceived by our competitors as blocking entry into the market for their products, and the outcome of such challenges. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our products. As the medical device and pharmaceutical industries expand and more patents are issued, the risk increases that our activities related to our products may give rise to claims of infringement of the patent rights of others.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We cannot assure you that our current or future products will not infringe on existing or future patents. We may not be aware of patents that have already issued that a third-party might assert are infringed by one of our current or future products.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our products. Because patent applications can take many years to issue and may be confidential for eighteen months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our products may infringe, or which such third-parties claim are infringed by our products and services.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our products. Defense of these claims, regardless of their merit, would involve substantial expenses and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us by a third-party, we may have to (i) pay substantial damages, including treble damages and attorneys&rsquo; fees if we are found to have willfully infringed the third-party&rsquo;s patents; (ii) obtain one or more licenses from the third-party; (iii) pay royalties to the third-party; or (iv) redesign any infringing products. Redesigning any infringing products may be impossible or require substantial time and monetary expenditure. Further, we cannot predict whether any required license would be available at all or whether it would be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop and commercialize our products, which could harm our business significantly. Even if we were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition to infringement claims against us, if third parties have prepared and filed patent applications in the United States that also claim technology related to our products, we may have to participate in interference proceedings in the USPTO to determine the priority of invention. Third parties may also attempt to initiate reexamination, post-grant review or inter partes review of our patents in the USPTO. We may also become involved in similar proceedings in the patent offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">34</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other diagnostic, medical device or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees&rsquo; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our products. We may also be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology, to enter into confidentiality agreements. However, we cannot be certain that all such confidentiality agreements have been duly executed, that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">35</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risks Related to Our Industry</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute our products after approval is obtained.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of future products. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be. Similar changes and revisions can also occur in foreign countries.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For example, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our products under development or impact our ability to modify our currently cleared products on a timely basis. Any change in the laws or regulations that govern the clearance and approval processes relating to our current and future products could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market and distribute existing products. Significant delays in receiving clearance or approval, or the failure to receive clearance or approval for our new products would have an adverse effect on our ability to expand our business.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Our inadvertent or unintentional failure to comply with the complex government regulations concerning privacy of medical records could subject us to fines and adversely affect our reputation.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Federal privacy regulations, among other things, restrict our ability to use or disclose protected health information in the form of patient-identifiable laboratory data, without written patient authorization, for purposes other than payment, treatment, or healthcare operations (as defined under the Health Insurance Portability and Accountability Act, or HIPAA) except for disclosures for various public policy purposes and other permitted purposes outlined in the privacy regulations. The privacy regulations provide for significant fines and other penalties for wrongful use or disclosure of protected health information, including potential civil and criminal fines and penalties. Although the HIPAA statute and regulations do not expressly provide for a private right of damages, we could incur damages under state laws to private parties for the wrongful use or disclosure of confidential health information or other private personal information.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We intend to implement policies and practices that we believe will make us compliant with the privacy regulations. However, the documentation and process requirements of the privacy regulations are complex and subject to interpretation. Failure to comply with the privacy regulations could subject us to sanctions or penalties, loss of business, and negative publicity.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The HIPAA privacy regulations establish a &ldquo;floor&rdquo; of minimum protection for patients as to their medical information and do not supersede state laws that are more stringent. Therefore, we are required to comply with both HIPAA privacy regulations and various state privacy laws. The failure to do so could subject us to regulatory actions, including significant fines or penalties, and to private actions by patients, as well as to adverse publicity and possible loss of business. In addition, federal and state laws and judicial decisions provide individuals with various rights for violation of the privacy of their medical information by healthcare providers such as us.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The collection and use of personal health data in the E.U. is governed by the provisions of Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data, commonly known as the Data Protection Directive. The Directive imposes a number of requirements including an obligation to seek the consent of individuals to whom the personal data relates, the information that must be provided to the individuals, notification of data processing obligations to the competent national data protection authorities of individual E.U. Member States, and the security and confidentiality of the personal data. The Data Protection Directive also imposes strict rules on the transfer of personal data out of the E.U. to the U.S. In April 2016, the EU adopted the new GDPR to replace the Directive 95/46/EC, which is expected to come into effect in May 2018 with no transition period, and which has enhanced penalties for noncompliance. We are evaluating our ability and cost to comply with the new EU GDPR regulations, and as a result of that evaluation we may make changes to our business practices and may incur additional costs.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Failure to comply with the requirements of the Data Protection Directive (or GDPR when it takes effect), and the related national data protection laws of the E.U. Member States may result in fines and other administrative penalties, litigation, government enforcement actions (which could include civil and/or criminal penalties), and harm our business. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information with us, may have contractual rights that may limit our ability to use this information, Claims that we have violated patient&rsquo;s or any individual&rsquo;s rights or breached our contractual obligations, even if ultimately we are not found liable, could be expensive and time-consuming to defend, and could result in adverse publicity and harm our business.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>The failure to comply with complex federal and state laws and regulations related to submission of claims for services could result in significant monetary damages and penalties and exclusion from the Medicare and Medicaid programs.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are subject to extensive federal and state laws and regulations relating to the submission of claims for payment for services, including those that relate to coverage of services under Medicare, Medicaid, and other governmental healthcare programs, the amounts that may be billed for services, and to whom claims for services may be submitted, such as billing Medicare as the secondary, rather than the primary, payor. The failure to comply with applicable laws and regulations, for example, enrollment in the Medicare Provider Enrollment, Chain and Ownership System, could result in our inability to receive payment for our services or attempts by third-party payors, such as Medicare and Medicaid, to recover payments from us that we have already received. Submission of claims in violation of certain statutory or regulatory requirements can result in penalties, including civil money penalties of up to $10,000 for each item or service billed to Medicare in violation of the legal requirement, and exclusion from participation in Medicare and Medicaid. Government authorities may also assert that violations of laws and regulations related to submission of claims violate the federal False Claims Act or other laws related to fraud and abuse, including submission of claims for services that were not medically necessary. The Company will be generally dependent on independent physicians to determine when its services are medically necessary for a particular patient. Nevertheless, we could be adversely affected if it were determined that the services we provided were not medically necessary and not reimbursable, particularly if it were asserted that we contributed to the physician&rsquo;s referrals of unnecessary services. It is also possible that the government could attempt to hold us liable under fraud and abuse laws for improper claims submitted by us if it were found that we knowingly participated in the arrangement that resulted in submission of the improper claims.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">36</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition to the PPACA, the effect of which cannot presently be quantified, various healthcare reform proposals have also emerged from federal and state governments. Changes in healthcare policy could adversely affect our business.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the United States in which we may do business, or the effect any future legislation or regulation will have on us. The taxes imposed by the new federal legislation and the expansion in government&rsquo;s effect on the United States healthcare industry may result in decreased profits to us, lower reimbursements by payors for our products or reduced medical procedure volumes, all of which may adversely affect our business, financial condition and results of operations.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<b><i>&nbsp;&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risks Related to the Securities Markets and Investment in our Securities</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><i>Our shares of common stock are listed on The NASDAQ Capital Market, but we cannot guarantee that we will be able to satisfy the continued listing standards going forward.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">Although our shares of common stock are listed on The NASDAQ Capital Market, we cannot ensure that we will be able to satisfy the continued listing standards of The NASDAQ Capital Market going forward. If we cannot satisfy the continued listing standards going forward, NASDAQ may commence delisting procedures against us, which could result in our stock being removed from listing on The NASDAQ Capital Market.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">If our stock price does not satisfy the $1.00 minimum bid price requirement or we otherwise fail to satisfy other continued listing requirements (and such other continued listing requirements may be enhanced during the period our stock price is below the $1.00 minimum bid requirement including a requirement that we maintain at least $5 million in stockholders&rsquo; equity rather than the $2.5 million that is typically required for continued listing), we may be delisted from NASDAQ, which could adversely affect our stock price, liquidity, and our ability to raise funding.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>The sale of a substantial number of shares of our common stock into the market may cause substantial dilution to our existing stockholders and the sale, actual or anticipated, of a substantial number of shares of common stock could cause the price of our common stock to decline.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Any actual or anticipated sales of shares by us, holders of our warrants to purchase common stock or other stockholders may cause the trading price of our common stock to decline. Additional issuances of shares by us may result in dilution to the interests of other holders of our common stock. The sale of a substantial number of shares of our common stock by us, our warrant holders or other stockholders or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>The trading price of our common stock has been, and is likely to continue to be volatile.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our stock price is highly volatile. During the one year prior to February 28, 2019, our stock price has ranged from $0.80 to $9.96. In addition to the factors discussed in this report, the trading price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">results of clinical studies;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory and FDA actions, including inspections and warning letters;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">actions of securities analysts who initiate or maintain coverage of us, and changes in financial estimates by any securities analysts who follow our Company, or our failure to meet these estimates or the expectations of investors;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any ongoing litigation that we are currently involved in or litigation that we may become involved in in the future;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">additional shares of our common stock being sold into the market by us or our existing stockholders or warrant holders or the anticipation of such sales; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">media coverage of our business and financial performance.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many healthcare companies. Stock prices of many healthcare companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. As a result, an investment in our common stock may decrease in value.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">37</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>If our common stock is delisted from The NASDAQ Capital Market, we may be subject to the risks relating to penny stocks.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If our common stock were to be delisted from trading on The NASDAQ Capital Market and the trading price of the common stock were below $5.00 per share on the date the common stock was delisted, trading in our common stock would also be subject to the requirements of certain rules promulgated under the Exchange Act. These rules require additional disclosure by broker-dealers in connection with any trades involving a stock defined as a &ldquo;penny stock&rdquo; (i.e., generally, any non-exchange listed equity security that has a market price of less than $5.00 per share, subject to certain exceptions) and impose various sales practice requirements on broker-dealers who sell penny stocks to persons other than established customers and accredited investors, generally institutions. These additional requirements may discourage broker-dealers from effecting transactions in securities that are classified as penny stocks, which could severely limit the market price and liquidity of such securities and the ability of purchasers to sell such securities in the secondary market.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>The ownership of our common stock is concentrated among a small number of stockholders, and if our principal stockholders, directors, and officers choose to act together, they may be able to significantly influence management and operations, which may prevent us from taking actions that may be favorable to you.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our ownership may be concentrated among a small number of stockholders. <a class="rdg_comment commentapprove" id="doccmt-556" name="doccmt-556"></a>These stockholders, acting together, will have the ability to exert substantial influence over all matters requiring approval by our stockholders, including the election and removal of directors and any proposed merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership could have the effect of delaying, deferring, or preventing a change in control of the Company or impeding a merger or consolidation, takeover or other business combination that could be favorable to you.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>If we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the trading price of our common stock may be negatively affected.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are required to maintain internal controls over financial reporting and to report any material weaknesses in such internal controls. If we&nbsp;identify material weaknesses in our internal control over financial reporting, if we&nbsp;are unable to comply with the requirements of the Sarbanes-Oxley Act in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express, if required, an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the trading price of our common stock could be negatively affected, and we could become subject to investigations by the stock exchange on which our securities is listed, the Securities and Exchange Commission, or other regulatory authorities, which could require additional financial and management resources.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>The requirements of being a public company may strain our resources and divert management&rsquo;s attention.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The NASDAQ Capital Market, and other applicable securities rules and regulations. Compliance with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming, or costly, and increase demand on our systems and resources. As a result, management&rsquo;s attention may be diverted from other business concerns, which could harm our business and operating results.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, complying with public disclosure rules makes our business more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business and operating results could be harmed, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm our business and operating results.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">38</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Our Stockholder Rights Agreement, the anti-takeover provisions in our charter documents and Delaware law could delay or prevent a change in control which could limit the market price of our common stock and could prevent or frustrate attempts by the our stockholders to replace or remove current management and the current Board of Directors.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our Stockholder Rights Agreement that we adopted in May 2014, our amended and restated certificate of incorporation, and amended and restated bylaws contain provisions that could delay or prevent a change in control or changes in our Board of Directors that our stockholders might consider favorable. These provisions include the establishment of a staggered Board of Directors, which divides the board into three classes, with directors in each class serving staggered three-year terms. The existence of a staggered board can make it more difficult for a third-party to effect a takeover of our Company if the incumbent board does not support the transaction. These and other provisions in our corporate documents, our Shareholder Rights Plan and Delaware law might discourage, delay or prevent a change in control or changes in the Board of Directors of the Company. These provisions could also discourage proxy contests and make it more difficult for an investor and other stockholders to elect directors not nominated by our Board. Furthermore, the existence of these provisions, together with certain provisions of Delaware law, might hinder or delay an attempted takeover other than through negotiations with the Board of Directors.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We do not expect to pay dividends in the future, which means that investors may not be able to realize the value of their shares except through a sale.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have never, and do not anticipate that we will, declare or pay a cash dividend. We expect to retain future earnings, if any, for our business and do not anticipate paying dividends on common stock at any time in the foreseeable future. Because we do not anticipate paying dividends in the future, the only opportunity for our stockholders to realize the creation of value in our common stock will likely be through a sale of those shares.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>We will need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms.</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may elect to raise additional funds from time to time through public or private equity offerings, debt financings, corporate collaboration, and licensing arrangements, or other financing alternatives, as well as sales of common stock through a purchase agreement. Additional equity or debt financing or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing acquisition, licensing, development and commercialization efforts and our ability to generate revenues and achieve or sustain profitability will be substantially harmed.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such as liquidation preferences, and other rights that are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, our business, operating results, financial condition, and prospects could be materially and adversely affected and we may be unable to continue our operations.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">39</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item1b" name="item1b"></a>ITEM 1B. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>UNRESOLVED STAFF COMMENTS</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Not applicable.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item2" name="item2"></a>ITEM 2. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>PROPERTIES</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of December 31, 2018, we leased a total of approximately 202 square feet of office space in one location in Seattle, Washington, from WW 107 Spring Street LLC. We believe that our current facilities will be adequate to meet our needs for the next 24 months. This information is incorporated in this report under &ldquo;PART II, ITEM 7. MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS &ndash; Commercial Lease Arrangements.&rdquo;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item3" name="item3"></a>ITEM 3. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>LEGAL PROCEEDINGS</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On October 10, 2013, a putative securities class action complaint, captioned <i>Cook v. Atossa Genetics, Inc., et al.</i>, No. 2:13-cv-01836-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering. The complaint alleged that all defendants violated Sections 11 and 12(a)(2), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering&rsquo;s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. The complaint sought, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount. On March 23, 2018, the parties filed a stipulation of settlement with the court to settle the matter for $3.5 million, completely funded by defendants&rsquo; insurers, and on July 20, 2018 the Court approved the settlement. This case is considered closed.&nbsp;</p>

<p style="margin: 0pt 14.4pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">40</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item4" name="item4"></a>ITEM 4. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>MINE SAFETY DISCLOSURE</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Not applicable.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="partii" name="partii"></a>PART II</b></p>

<p style="margin: 0pt; text-align: center; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item5" name="item5"></a>ITEM 5. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>MARKET FOR THE REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Market Information</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our common stock, par value $0.18 per share, began trading on the NASDAQ Capital Market under the symbol &ldquo;ATOS&rdquo; on November 8, 2012.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Stockholders</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of&nbsp;March 25, 2019, there were approximately <a class="rdg_comment commentapprove" id="doccmt-610" name="doccmt-610">33&nbsp;stockholders </a>of record of our common stock, one of which is Cede&nbsp;&amp;&nbsp;Co., a nominee for Depository Trust Company, or DTC and approximately <a class="rdg_comment commentapprove" id="doccmt-676" name="doccmt-676">15,000 </a>beneficial holders. All of the shares of common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC, and are therefore considered to be held of record by Cede&nbsp;&amp;&nbsp;Co. as one stockholder.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>Dividends</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has never declared or paid any cash dividends on our common stock. We currently intend to retain any future earnings to finance the growth and development of our business.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>Issuer Purchases of Securities</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We did not repurchase any of our equity securities during the fourth quarter of the year ended December 31, 2018.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Use of Proceeds</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Not applicable.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item6" name="item6"></a>ITEM 6.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>SELECTED FINANCIAL DATA</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Not applicable.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">41</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item7" name="item7"></a>ITEM 7. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Overview</b></p>

<p style="margin: 0pt; text-align: justify; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>The following discussion of the financial condition and results of operations should be read in conjunction with the financial statements and the related notes included elsewhere in this Annual Report. This discussion contains forward-looking statements, which are based on assumptions about the future of the Company&#39;s business. The actual results could differ materially from those contained in the forward-looking statements. Please read &ldquo;Forward-Looking Statements&rdquo; included elsewhere in this report for additional information regarding forward-looking statements.</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Company Overview</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are a clinical-stage biopharmaceutical company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. Our lead program is the development of Endoxifen, which is an active metabolite of tamoxifen, an FDA-approved drug to treat and prevent breast cancer. We are developing an oral and topical form of Endoxifen. Our Endoxifen is being developed to potentially treat a number of conditions, including: mammographic breast density (or, MBD); breast cancer in the &ldquo;window of opportunity&rdquo; between diagnosis of breast cancer and surgery; gynecomastia, which is male breast enlargement; and the recurrence of breast cancer in patients who do not benefit from taking tamoxifen meaning that they are &ldquo;refractory&rdquo; to tamoxifen. We are also developing our patented intraductal microcatheter technology to potentially target the delivery of therapies, including fulvestrant, immunotherapies and Chimeric Antigen Receptor T-cell therapies (CAR-T therapies), directly to the site of breast cancer.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In 2017, we completed a Phase 1 placebo-controlled clinical study of our proprietary oral and topical formulations of Endoxifen in 48 healthy women. All objectives were met: there were no clinically significant safety signals and no clinically significant adverse events, and both the oral and topical Endoxifen were well tolerated. In the topical arm of the study, low but measurable Endoxifen levels were detected in the blood in a dose-dependent fashion. In the oral arm of the study, participants exhibited dose-dependent Endoxifen levels that met or exceeded the published therapeutic level. The median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of oral Endoxifen was 7 days. Published literature indicates that it takes approximately 50-200 days for patients to reach steady-state Endoxifen levels from daily doses of oral tamoxifen. In September 2018, we completed a Phase 1 placebo-controlled clinical study of our proprietary topical Endoxifen in 24 healthy men. All of our objectives of safety, tolerability and pharmacokinetics were successfully met.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are currently conducting two Phase 2 studies of our proprietary Endoxifen: one in Stockholm, Sweden using our topical Endoxifen for reduction of MBD and another in Australia using our oral Endoxifen for patients in the window of opportunity between diagnosis of breast cancer and surgery. In October 2018, the MBD study in Sweden was fully-enrolled with all 90 participants:&nbsp; 60 participants on two different dose levels and 30 participants on placebo. We expect dosing in this study to be completed in April 2019 and to report preliminary results in the second quarter 2019.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In December 2018, we began providing our oral Endoxifen to a pre-menopausal, estrogen-receptor positive (ER+), lacking CYP2D6 function, breast cancer patient under an FDA-approved &quot;expanded access&quot; program. The purpose of this therapeutic approach was to reduce activity of the cancer cells prior to surgery. The patient received daily doses of our oral Endoxifen for approximately three weeks prior to surgery. There were no safety or tolerability issues and her surgery was successfully completed. The cancer cell biological activity was reduced, based on the estrogen receptor activity of the tumor cells and a 50% reduction in Ki-67. Under the FDA expanded access IND program, the use of our proprietary oral Endoxifen is restricted solely to this patient.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are currently conducting a Phase 2 study at Montefiore Medical Center, Bronx, New York, using our intraductal microcatheter technology to deliver fulvestrant directly to the site of the tumor via the breast ducts. Our program to use our intraductal microcatheters to deliver CAR-T and other immunotherapies is in the pre-clinical phase.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">42</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Research and Development Phase</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are in the research and development phase and are not currently marketing any products or services. We do not anticipate generating revenue unless and until we develop and launch our pharmaceutical programs.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Commercial Lease Agreements&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On November 1, 2018, the Company entered into an operating lease to pay $3,660 monthly&nbsp;rent for a term of 22 months with WW 107 Spring Street LLC to lease office space at 107 Spring Street, Seattle, Washington.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Critical Accounting Policies and Estimates</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our management&rsquo;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we evaluate these estimates and judgments, including those described below. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">While our significant accounting policies are more fully described in Note 3 to our financial statements, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">43</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Financial Instruments with Characteristics of Both Liabilities and Equity</i></b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the year ended December 31, 2017, the Company issued certain financial instruments, consisting of warrants to purchase common stock, which have characteristics of both liability and equity. Financial instruments such as warrants that are classified as liabilities are fair valued upon issuance and are re-measured at fair value at subsequent reporting periods with the resulting change in fair value recorded in &ldquo;change in fair value of common stock warrants&rdquo; in the consolidated statements of operations. The fair value of warrants is estimated using valuation models that require the input of subjective assumptions including stock price volatility, expected life, and the probability of future equity issuances and their impact to the price protection feature. No warrants that are classified as liabilities were outstanding at December 31, 2017 and 2018.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Share-Based Payments</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We follow the provisions of ASC 718, <i>Compensation &ndash; Stock Compensation</i>, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date&rsquo;s fair value was estimated in accordance with the provisions of ASC 718 and is recognized as an expense over the requisite service period with forfeitures recognized when they occur.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of our stock options, the expected life of the options, an expectation regarding future dividends on our common stock, and estimation of an appropriate risk-free interest rate. Our expected common stock price volatility assumption is based upon the volatility of our stock price. The expected life assumption for stock option grants was based upon the simplified method provided for under ASC 718-10, which averages the contractual term of the options of ten years with the average vesting term of one to four years. The dividend yield assumption of zero is based upon the fact that we have never paid cash dividends and presently have no intention of paying cash dividends in the future. The risk-free interest rate used for each grant was based upon prevailing short-term interest rates over the expected life of the options.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">44</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Results of Operations</b></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Comparison of Years Ended December 31, 201</b><b>8</b><b> and 201</b><b>7</b></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Revenue and Cost of Revenue: </i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For the years ended December 31, 2018 and 2017, we have no source of sustainable revenue and no associated cost of revenue.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Operating Expenses</i>: Total operating expenses were $11,434,000 for the year ended December 31, 2018, which is an increase of $3,785,000 or 49%, from the year ended December 31, 2017. Operating expenses for 2018 consisted of research and development (R&amp;D) expenses of $4,210,000 and general and administrative (G&amp;A) expenses of $7,224,000. Operating expenses for 2017 consisted of R&amp;D expenses of $2,328,000, G&amp;A expenses of $4,859,000 and impairment of our Acueity intangible assets of $462,000.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Research and Development Expenses</i>: R&amp;D expenses for the year ended December 31, 2018, were $4,210,000, an increase of $1,882,000 or 81% from total R&amp;D expenses in 2017 of $2,328,000. The increase in R&amp;D expense is attributed to salaries, stock-based compensation, manufacturing and clinical trial expenses associated with our Endoxifen program. Our R&amp;D expenses have increased because we commenced two Phase 2 studies of our proprietary Endoxifen during the year ended December 31, 2018. There were no Phase 2 studies of Endoxifen in 2017. Stock-based compensation expense also increased approximately $627,000 in 2018 as compared to 2017. We expect our R&amp;D expenses to increase throughout 2019 as we commence additional Phase 2 clinical studies of Endoxifen, continue the clinical trial of Fulvestrant administered via our microcatheters and continue the development of other indications and therapeutics, including CAR-T and immunotherapies administered via our intraductal microcatheters.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>General and Administrative Expenses</i>: G&amp;A expenses were $7,224,000 for the year ended December 31, 2018, an increase of $2,365,000, or 49% from the total G&amp;A expenses for the year ended December 31, 2017, of $4,859,000. G&amp;A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The increase in G&amp;A expenses for year ended&nbsp;December 31, 2018,&nbsp;is mainly attributed to an increase in stock-based compensation expense of approximately $1,049,000, payroll expenses resulting from salary increases, one-time bonus payments of $350,000 and increased legal and professional consulting expenses&nbsp;of approximately $600,000 over the prior year.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Impairment of Intangible Assets:</i> During the years ended December 31, 2017, we evaluated our Acueity intangible assets for impairment and concluded that the fair values as of December 31, 2017, were below the carrying values of $462,000. Therefore, we reduced the carrying value of these assets to zero as of December 31, 2017. There were no write downs of intangible assets during the year ended December 31, 2018.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Warrant Financing Costs and Change in Fair Value of Common Stock Warrants:</i> The Company&#39;s April 2017 financing included the issuance of common stock liability warrants, which were exercised during 2017 and were no longer outstanding as December 31, 2017. The Company incurred financing costs associated with these common stock liability warrants of $192,817 upon issuance. The Company also recorded changes in the fair value of the liability warrants during the year ended December 31, 2017, of $280,747. There were no common stock liability warrants issued during the year ended December 31, 2018.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;&nbsp;</i>&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Income taxes:</i> We have incurred net operating losses from inception; we did not record an income tax benefit for our incurred losses for the years ended December 31, 2018 and 2017, due to uncertainty regarding utilization of our net operating carryforwards and due to our history of losses.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">45</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Liquidity and Capital Resources</b></p>

<p style="margin: 0pt; text-align: justify; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has incurred net losses and negative operating cash flows since inception. For the year ended December 31, 2018, the Company recorded a net loss of approximately $11.4 million and used approximately $9.0 million of cash in operating activities. As of December 31, 2018, the Company had approximately $10.4 million in cash and cash equivalents and working capital of approximately $8.6 million. However, in March 2019, the Company received $11.3 million in cash upon exercises of certain of the Company&rsquo;s previously outstanding warrants to purchase its common stock. As of March 25, 2019, the Company had approximately $19.3 million in cash and cash equivalents. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and is currently expending funds in research and development activities that are expected to continue to require funding. Management believes its currently available funding, including the funds received from warrant exercises in March 2019, will be sufficient to finance the Company&rsquo;s operations for at least one year from the date these consolidated financial statements are issued. However, the Company will likely require additional funding to continue its activities beyond that date. If adequate funds are not available, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned commercial activities. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company&rsquo;s ability to continue as a going concern.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Cash Flows</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of December 31, 2018, we had cash, cash equivalents and restricted cash of $10.5 million.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Net Cash Flows from Operating Activities</i>: Net cash used in operating activities was $8,962,000 for the year ended December 31, 2018, an increase of $2,368,000, or 36%, compared to net cash used in operating activities for the year ended December 31, 2017 of $6,594,000. The increase in the 2018 period as compared to 2017 resulted primarily from increased spending on R&amp;D activities. We spent approximately $4.2 million on research and development for the year ended December 31, 2018, compared to $2.3 million in 2017. Increases in compensation expense also contributed to the increase in cash used in operations over 2017.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Net Cash Flows from Investing Activities</i>: Net cash used in investing activities for the year ended December 31, 2018 was $111,000. There was no comparable spending for the year ended December 31, 2017. The increase was attributable to the purchase of fixed asset equipment and the replacement of our website during 2018.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Net Cash Flows from Financing Activities: </i>Net cash provided by financing activities was $12,291,000 for the year ended December 31, 2018, an increase of $1,508,000, or 14%, compared to net cash provided by financing activities of $10,783,000, for the year ended December 31, 2017. The increase was attributable to higher financing proceeds received in 2018 as compared to proceeds received from 2017 financings.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">46</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Funding Requirements</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We&nbsp;expect to incur ongoing operating losses for the foreseeable future as we continue to develop our planned therapeutic programs including related clinical studies and other programs in the pipeline. We expect that our existing resources combined with the $11.3 million proceeds from the March 2019 warrant exercise will be sufficient to fund our planned&nbsp;operations for at least&nbsp;the next 12 to 18&nbsp;months from the date of this report. <a class="rdg_comment commentapprove" id="doccmt-682" name="doccmt-682"></a> If we meet certain requirements, we may sell securities that are registered on our Form S-3 registration statement<a class="rdg_comment commentapprove" name="doccmt-529"> (File No. 333-220572),</a> and by raising capital through sales of securities to third parties and existing stockholders. If we are unable to raise additional capital when needed, however, we could be forced to curtail or cease operations. Our future capital uses and requirements will depend on the time and expenses needed to begin and continue clinical trials for our new drug developments.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Additional funding may not be available to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities or by selling debt securities, if convertible, further dilution to our existing stockholders would result. To the extent our capital resources are insufficient to meet our future capital requirements, we will need to finance our future cash needs through public or private equity offerings, collaboration agreements, debt financings or licensing arrangements.</p>

<p style="margin: 0pt; text-align: left; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If adequate funds are not available, we may be required to terminate, significantly modify or delay our development programs, reduce our planned commercialization efforts, or obtain funds through collaborators that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. Further, we may elect to raise additional funds even before we need them if we believe the conditions for raising capital are favorable.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">47</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Off-Balance Sheet Arrangements</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Recent Accounting Pronouncements</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In February 2016, Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2016-02, <i>Lease Accounting Topic 842.</i> The new standard is effective for reporting periods beginning after December 15, 2018 and early adoption is permitted. The standard will require lessees to report most leases as assets or liabilities on the balance sheet, while lessor accounting will remain substantially unchanged. The standard permits two approaches, one requiring retrospective application of the new guidance with restatement of prior years, and one requiring prospective application of the new guidance. We plan to adopt the new lease standard effective January 1, 2019 and apply it prospectively. We do not expect the new lease standard to have a material effect on our financial position, results of operations or cash flows.&nbsp;Upon adoption of ASU 2016-02, we will be required to recognize an operating lease liability and right-of-use asset of approximately $100,000, based on the lease composition disclosed in <a class="rdg_comment commentapprove" name="doccmt-695">footnote 13.</a></p>

<p style="text-indent: 36pt;">In November 2016, the FASB issued ASU No. 2016-18, <i>Statement of Cash Flows</i>, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016-18 as of January 1, 2018 on a retrospective basis. For the years ended December 31, 2018 and 2017, we included $110,000 and $55,000, respectively, of restricted cash within cash, cash equivalents, and restricted cash&nbsp;on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In July 2017, the FASB issued ASU 2017-11, <i>Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</i>. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&rsquo;s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017-11 as of January 1, 2018. As the Company does not have any financial instruments with down round features, this ASU did not have a material impact on the financial statements upon adoption.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In June 2018, the FASB issued ASU 2018-07, <i>Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. </i>This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, <i>Revenue from Contracts with Customers</i>. This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2018-07 as of April 1, 2018, and it did not have a material impact on the financial statements upon adoption.</p>

<p style="margin: 0pt 14.4pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In June 2018, the FASB issued&nbsp;ASU 2018-08, <i>Not-for-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.</i> This ASU affects not-for-profit entities and business entities that receive or make contributions of cash.&nbsp;The&nbsp;ASU&nbsp;clarifies and improves the scope and accounting guidance to assist entities in evaluating if those transactions should be accounted for as contributions under the scope of Topic 958 or as an exchange transaction subject to other guidance.&nbsp;This update is effective for public entities for fiscal years beginning after December 15, 2018. The Company is currently evaluating the impact that adoption will have on its financial statements.</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">48</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item7a" name="item7a"></a>ITEM 7A. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Not applicable.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item8" name="item8"></a>ITEM 8. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The financial statements required by this item are set forth beginning on page&nbsp;53 <a class="rdg_comment commentapprove" id="doccmt-608" name="doccmt-608">of </a>this report and are incorporated herein by reference.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item9" name="item9"></a>ITEM 9. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">None.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item9a" name="item9a"></a>ITEM 9A. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONTROLS AND PROCEDURES</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as&nbsp;of December 31, 2018. The term &ldquo;disclosure controls and procedures,&rdquo; as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (&ldquo;Exchange Act&rdquo;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&rsquo;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&rsquo;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer concluded that, as of December 31, 2018, the Company&rsquo;s disclosure controls and procedures were not effective at the reasonable assurance level for the reasons described below.</p>

<p style="margin: 0pt 15pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended December 31, 2018, that has materially affected, or is reasonably likely to materially affect, our disclosure controls and procedures.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the quarter ended June 30, 2018, we identified a material weakness in our internal controls over the calculation of the deemed dividend on Series B convertible preferred stock (the &ldquo;deemed dividend&rdquo;) for the three and six months ended June 30, 2018, due to a lack of appropriately detailed knowledge of the technical accounting guidance with respect to complex financial instruments. Because of this error, an incorrect deemed dividend was included in net loss applicable to common stockholders which caused an incorrect calculation of loss per common share, basic and diluted, as presented in our originally filed Form 10-Q for the three months ended June 30, 2018. The error resulted in a restatement of our originally filed Form 10-Q for the three months ended June 30, 2018. Management misinterpreted the technical guidance contained in <i>ASC 470- Debt</i> in calculating the deemed dividend. An appropriately detailed knowledge of <i>ASC 470 -Debt</i> was not present to prevent or detect this error. We incorrectly stated the amount of the deemed dividend as $4,782,100, rather than $11,479,308, for the three and six months ended June 30, 2018. We also incorrectly stated the loss per common share - basic and diluted, for the three and six months ended June 30, 2018 as $(2.90) and $(3.77) respectively, rather than the correct amount of $(5.08) and $(6.11), respectively.</p>

<p style="margin: 0pt 15pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Management&rsquo;s remediation plan is discussed in Management&#39;s Report on Internal Control Over Financial Reporting.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Management&#39;s Report on Internal Control Over Financial Reporting</b></p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules&nbsp;13a-15(f). Under the supervision and with the participation of our management, including our principal executive officer and principal accounting and financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in&nbsp;<i>Internal Control&mdash;Integrated Framework (2013)&nbsp;</i>issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in&nbsp;Internal <i>Control&mdash;Integrated Framework</i>, our management concluded that our internal control over financial reporting was ineffective as of December 31, 2018. Because we are a smaller reporting company, BDO USA LLP, our independent registered public accounting firm, is not required to attest to or issue a report on the effectiveness of our internal control over financial reporting.</p>

<p style="margin: 0pt 15pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the quarter ended June 30, 2018, we identified a material weakness in our internal controls over the calculation of the deemed dividend on Series B convertible preferred stock (the &ldquo;deemed dividend&rdquo;) for the three and six months June 30, 2018, due to a lack of appropriately detailed knowledge of the technical accounting guidance with respect to complex financial instruments. Because of this error, an incorrect deemed dividend was included in net loss applicable to common stockholders which caused an incorrect calculation of loss per common share, basic and diluted, as presented in our originally filed Form 10-Q for the three months ended June 30, 2018. The error resulted in a restatement of our originally filed Form 10-Q for the three months ended June 30, 2018. Management misinterpreted the technical guidance contained in <i>ASC 470- Debt</i> in calculating the deemed dividend. An appropriately detailed knowledge of <i>ASC 470 -Debt</i> was not present to prevent or detect this error. We incorrectly stated the amount of the deemed dividend as $4,782,100, rather than $11,479,308, for the three and six months ended June 30, 2018. We also incorrectly stated the loss per common share - basic and diluted, for the three and six months ended June 30, 2018 as $(2.90) and $(3.77) respectively, rather than the correct amount of $(5.08) and $(6.11), respectively.</p>

<p style="margin: 0pt 15pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Management&rsquo;s remediation plan is to enhance the procedures performed to independently review technical accounting memorandums for accuracy and completeness including when appropriate with an outside independent accounting firm in future periods.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item9b" name="item9b"></a>ITEM 9B. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>OTHER INFORMATION</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">None.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">49</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="partiii" name="partiii"></a>PART III</b></p>

<p style="margin: 0pt; text-align: center; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item10" name="item10"></a>ITEM 10. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Information regarding our executive officers is set forth in Item&nbsp;1 of Part&nbsp;I of this Report under the caption &ldquo;Executive Officers.&rdquo;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The information required by this item is incorporated herein by reference to the sections entitled &ldquo;Proposal&nbsp;No. 1&nbsp;&mdash; Election of Directors,&rdquo; &ldquo;Beneficial Owners and Management,&rdquo;&nbsp; &ldquo;Section&nbsp;16(a) Beneficial Ownership Reporting Compliance,&rdquo; &ldquo;Director Compensation,&rdquo; &ldquo;Corporate Governance&rdquo; and &ldquo;Board of Directors and Committees&rdquo; in our definitive Proxy Statement for the Annual Meeting of Shareholders to be held on May 9, 2019 (the &ldquo;Proxy Statement&rdquo;).</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item11" name="item11"></a>ITEM 11. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>EXECUTIVE COMPENSATION</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The information required by this item is incorporated by reference to the sections entitled &ldquo;Executive Compensation,&rdquo; &ldquo;Director Compensation,&rdquo; &ldquo;Proposal No. 3 &mdash; To&nbsp;approve the 2019 Amendments to the Atossa&nbsp;Genetics Inc. 2010 Stock Option and Incentive Plan and to&nbsp;increase the number of shares authorized for issuance under the Plan by 3,600,000,&rdquo; and &ldquo;Corporate Governance&rdquo;, in the Proxy Statement.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item12" name="item12"></a>ITEM 12. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The information required by this item is incorporated by reference to the sections entitled &ldquo;Executive Compensation- Equity Compensation Plan Information,&rdquo; &quot;Proposal No. 3 - To approve the 2019 Amendments to the Atossa Genetics Inc. 2010 Stock&nbsp;Option and Incentive Plan and to increase the number of shares authorized for issuance under the plan by 3,600,000,&quot;&nbsp;and &ldquo;Beneficial Owners and Management&rdquo; in the Proxy Statement.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item13" name="item13"></a>ITEM 13. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The information required by this item is incorporated by reference to the section entitled &ldquo;Certain Relationships and Related Party Transactions&rdquo; and &ldquo;Corporate Governance&rdquo; in the Proxy Statement.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item14" name="item14"></a>ITEM 14. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>PRINCIPAL ACCOUNTING FEES AND SERVICES</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The information required by this item is incorporated by reference to the sections entitled &ldquo;Proposal No. 2 &mdash; Ratification of Selection of Independent Registered Public Accounting Firm&rdquo; in the Proxy Statement.<b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><a id="partiv" name="partiv"></a>PART IV</b></p>

<p style="margin: 0pt; text-align: center; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item15" name="item15"></a>ITEM 15. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>(a)</b> The following documents are filed as a part of this 10-K:</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>1.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Financial Statements</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">The following financial statements are included in Part&nbsp;II, Item&nbsp;8 of this 10-K:</p>

<table cellpadding="0" cellspacing="0" style="margin: 0pt auto 0pt 36pt; width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Report of Independent Registered Public Accounting Firm</p>
			</td>
			<td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">52</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Balance Sheets</p>
			</td>
			<td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">53</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Statements of Operations</p>
			</td>
			<td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">54</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Statements of Stockholders&#39; Equity</p>
			</td>
			<td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">55</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Statements of Cash Flows</p>
			</td>
			<td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">56</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Notes to Consolidated Financial Statements</p>
			</td>
			<td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">57</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>2.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Financial Statement Schedules</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">All financial statement schedules are omitted because they are not required or the required information is included in the financial statements or notes thereto. &nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>3.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Exhibits</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">See the Exhibit Index set forth on page<a class="rdg_comment commentapprove" name="doccmt-609">&nbsp;75 of </a>this report.</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="item16" name="item16"></a>ITEM 16. </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>FORM 10-K SUMMARY</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">Not applicable.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">50</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ATOSSA GENETICS INC.</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Audited Consolidated Financial Statements:</p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#report" style="-sec-extract: exhibit;">Report of Independent Registered Public Accounting Firm</a></p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a class="rdg_comment commentapprove" name="doccmt-530">52</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#balance" style="-sec-extract: exhibit;">Consolidated Balance Sheets</a></p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">53</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#income" style="-sec-extract: exhibit;">Consolidated Statements of Operations</a></p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">54</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#equity" style="-sec-extract: exhibit;">Consolidated Statements of Stockholders&rsquo; Equity</a></p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">55</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#cashflow" style="-sec-extract: exhibit;">Consolidated Statements of Cash Flows</a></p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">56</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#notes" style="-sec-extract: exhibit;">Notes to Consolidated Financial Statements</a></p>
			</td>
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">57</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">51</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="report" name="report"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Board of Directors and Stockholders</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Atossa Genetics Inc.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Seattle, Washington</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Opinion on the Consolidated Financial Statements </b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have audited the accompanying consolidated balance sheets of Atossa Genetics Inc. (the &ldquo;Company&rdquo;) and subsidiaries as of December 31, 2018 and 2017, the related consolidated statements of operations, stockholders&rsquo; equity, and cash flows for each of the two years in the period ended December 31, 2018, and the related notes (collectively referred to as the &ldquo;consolidated financial statements&rdquo;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company and&nbsp;subsidiaries at December 31, 2018 and 2017, and the results of their operations and their cash flows for each of the two years in the period ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="margin: 0pt 0pt 0pt 45pt; text-align: justify; text-indent: -45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Basis for Opinion</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">These consolidated financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ BDO USA, LLP</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have served as the Company&#39;s auditor since 2014.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 45pt; text-align: justify; text-indent: -45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Seattle, Washington</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 28, 2019</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">52</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div contenteditable="false" docsect="4" id="49382" sectdesc="Balance Sheet">&nbsp;</div>

<p style="margin: 0pt 0pt 0pt 5.4pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="balance" name="balance"></a>ATOSSA GENETICS INC.</b></p>

<p style="margin: 0pt 0pt 0pt 5.4pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="margin: 0pt 0pt 0pt 5.4pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-statement-type="balance-sheet" data-td-taggable-table="" data-td-v2v-id="1551720507429">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tblname="5819" data-tblv="24" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="6" id=".amt.D3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>As of December 31, </b></p>
			</td>
			<td id=".trail.D4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><u><b>Assets</b></u></td>
			<td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><b>2018</b></td>
			<td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><b>2017</b></td>
			<td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Current assets</p>
			</td>
			<td id=".lead.B3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,380,493</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,217,469</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Restricted cash</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">110,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,000</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Prepaid expenses</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">509,833</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250,944</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research and development tax rebate receivable</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">518,098</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">358,277</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Other current assets</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">30,942</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">16,344</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total current assets</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">11,549,366</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">7,898,034</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%;">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
			<td id=".lead.B4">&nbsp;</td>
			<td id=".symb.B4">&nbsp;</td>
			<td id=".amt.B4">&nbsp;</td>
			<td id=".trail.B4">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Furniture and equipment, net</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">54,487</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,467</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Intangible assets, net</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">99,375</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75,686</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Other assets</p>
			</td>
			<td id=".lead.3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">17,218</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">178,907</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total Assets</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">11,720,446</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">8,164,094</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%;">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
			<td id=".lead.B4">&nbsp;</td>
			<td id=".symb.B4">&nbsp;</td>
			<td id=".amt.B4">&nbsp;</td>
			<td id=".trail.B4">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><u>Liabilities and Stockholders&#39; Equity</u></b></p>
			</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Current liabilities</p>
			</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Accounts payable</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">353,328</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">334,901</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Accrued expenses</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">177,074</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90,105</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Payroll liabilities</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">935,070</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">784,867</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stock-based compensation liability</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,410,025</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Other current liabilities</p>
			</td>
			<td id=".lead.3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">39,939</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">15,534</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total Current Liabilities</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">2,915,436</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,225,407</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%;">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
			<td id=".lead.B4">&nbsp;</td>
			<td id=".symb.B4">&nbsp;</td>
			<td id=".amt.B4">&nbsp;</td>
			<td id=".trail.B4">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Commitments and contingencies (<a class="rdg_comment commentapprove" name="doccmt-696">note 13)</a></p>
			</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="margin: 0px; padding: 0px; width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stockholders&#39; equity</td>
			<td id=".lead.B3" style="margin: 0px; padding: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="margin: 0px; padding: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="margin: 0px; padding: 0px; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="margin: 0px; padding: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="margin: 0px; padding: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="margin: 0px; padding: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="margin: 0px; padding: 0px; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="margin: 0px; padding: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of Series A convertible preferred stock- $0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of December 31, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 2,379 and 0 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Additional paid-in capital- Series B convertible preferred stock</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,378,997</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Common stock - $0.18 par value; 175,000,000 shares authorized, and 5,846,552 and 2,651,952 shares issued and outstanding, as of December 31, 2018 and December 31, 2017, respectively</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,052,372</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">477,342</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Additional paid-in capital</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">82,204,902</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">71,887,674</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Accumulated deficit</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(76,831,263</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(65,426,329</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total Stockholders&#39; Equity</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">8,805,010</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">6,938,687</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 70%;">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
			<td id=".lead.B4">&nbsp;</td>
			<td id=".symb.B4">&nbsp;</td>
			<td id=".amt.B4">&nbsp;</td>
			<td id=".trail.B4">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 70%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total Liabilities and Stockholders&#39; Equity</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">11,720,446</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">8,164,094</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>The accompanying notes are an integral part of these consolidated financial statements.</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">53</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div contenteditable="false" docsect="5" id="49383" sectdesc="Income Statement">&nbsp;</div>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="income" name="income"></a>ATOSSA GENETICS INC.</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-statement-type="income" data-td-taggable-table="" data-td-v2v-id="1551720515179">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tblname="5818" data-tblv="24" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>For the Years Ended December 31, </b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating Expenses</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="margin: 0px; padding: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research and development</td>
			<td id=".lead.2" style="margin: 0px; padding: 0px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="margin: 0px; padding: 0px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td id=".amt.2" style="margin: 0px; padding: 0px; width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4,209,981</td>
			<td id=".trail.2" nowrap="true" style="margin: 0px; padding: 0px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="margin: 0px; padding: 0px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="margin: 0px; padding: 0px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td id=".amt.3" style="margin: 0px; padding: 0px; width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2,328,087</td>
			<td id=".trail.3" nowrap="true" style="margin: 0px; padding: 0px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="margin: 0px; padding: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">General and administrative</td>
			<td id=".lead.2" style="margin: 0px; padding: 0px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="margin: 0px; padding: 0px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="margin: 0px; padding: 0px; width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7,224,252</td>
			<td id=".trail.2" nowrap="true" style="margin: 0px; padding: 0px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="margin: 0px; padding: 0px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="margin: 0px; padding: 0px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="margin: 0px; padding: 0px; width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4,859,369</td>
			<td id=".trail.3" nowrap="true" style="margin: 0px; padding: 0px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="margin: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Impairment of intangible assets</td>
			<td id=".lead.B2" style="margin: 0px; padding: 0px 0px 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="margin: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B2" style="margin: 0px; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B2" style="margin: 0px; padding: 0px 0px 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="margin: 0px; padding: 0px 0px 1px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="margin: 0px; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="margin: 0px; width: 12%; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">461,715</td>
			<td id=".trail.3" nowrap="true" style="margin: 0px; padding: 0px 0px 1px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="padding-left: 27pt;">Total operating expenses</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">11,434,233</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">7,649,171</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11,434,233</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(7,649,171</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value of common stock warrants</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(280,747</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrant financing expense</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(192,817</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other income</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">29,299</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">154</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss before income taxes</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11,404,934</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,122,581</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income taxes</p>
			</td>
			<td id=".lead.B2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(11,404,934</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(8,122,581</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deemed dividend attributable to preferred stock</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(11,479,308</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(2,568,132</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss applicable to common shareholders</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(22,884,242</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(10,690,713</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss per common share - basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(5.50</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(10.97</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding - basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">4,157,746</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">974,773</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>The accompanying notes are an integral part of these consolidated financial statements.</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">54</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div contenteditable="false" docsect="7" id="49384" sectdesc="Stockholders' Equity">&nbsp;</div>

<p style="margin: 0pt 0pt 0pt 5.4pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="equity" name="equity"></a>ATOSSA GENETICS INC.</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONSOLIDATED STATEMENTS OF <a class="rdg_comment commentapprove" name="doccmt-533">STOCKHOLDERS&#39; EQUITY</a></b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-statement-type="stockholders-equity" data-td-taggable-table="" data-td-v2v-id="1551720522390">
<table cellpadding="0" cellspacing="0" class="finTable" data-tblname="5874" data-tblv="24" style="margin: 0pt; width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">

		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="width: 14111%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b>Series A Convertible Preferred Stock </b></p>
			</td>
			<td id=".trail.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".amt.B4" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".lead.D6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="6" id=".amt.D6" style="width: 14111%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b>Series B Convertible Preferred Stock </b></p>
			</td>
			<td id=".trail.D6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".lead.D9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="6" id=".amt.D9" style="width: 14111%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b>Common Stock </b></p>
			</td>
			<td id=".trail.D9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".symb.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".amt.B10" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".trail.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".amt.B11" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".lead.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".symb.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".amt.B12" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
			<td id=".trail.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b><b>Shares </b></b></p>
			</td>
			<td id=".trail.D2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b><b>Amount </b></b></p>
			</td>
			<td id=".trail.D3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b><b>Additional Paid-in Capital </b></b></p>
			</td>
			<td id=".trail.D4" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b><b>Shares </b></b></p>
			</td>
			<td id=".trail.D5" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b><b>Amount </b></b></p>
			</td>
			<td id=".trail.D6" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D7" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b><b>Additional Paid-in Capital </b></b></p>
			</td>
			<td id=".trail.D7" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D8" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b><b>Shares </b></b></p>
			</td>
			<td id=".trail.D8" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D9" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b><b>Amount </b></b></p>
			</td>
			<td id=".trail.D9" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D10" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b><b>Additional Paid-in Capital </b></b></p>
			</td>
			<td id=".trail.D10" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D11" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b><b>Accumulated Deficit </b></b></p>
			</td>
			<td id=".trail.D11" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D12" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);"><b><b>Total Stockholders&#39; Equity </b></b></p>
			</td>
			<td id=".trail.D12" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at December 31, 2016</b></p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">315,576</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td>
			<td id=".amt.9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">56,804</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">60,344,050</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td>
			<td id=".amt.11" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(57,303,748</td>
			<td id=".trail.11" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">3,097,106</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B10" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B12" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Issuance of common stock and warrants net of issuance costs of $768,412</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,483,333</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">267,001</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">5,895,587</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">6,162,588</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Issuance of common stock in Class A units, net of issuance costs of $65,816</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">99,500</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">17,910</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">811,774</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">829,684</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Allocation of Class A unit proceeds to warrant liability</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(328,350</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(328,350</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">292</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">4</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">3,234,769</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B10" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">3,234,773</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Allocation of Series A convertible preferred stock to warrants and beneficial conversion feature</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(2,568,132</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,284,066</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(1,284,066</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Deemed dividend on Series A convertible preferred stock</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">2,568,132</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(2,568,132</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B12" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Conversion of Series A convertible preferred stock to common stock</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(292</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(4</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(3,234,769</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">389,111</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">70,040</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">3,164,733</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B12" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Reclassification of warrant liability upon exercise of common stock warrants</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">124,236</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">22,362</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,870,798</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,893,160</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Issuance of common stock upon warrant exercise for cash on liability warrant exercise</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">240,196</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">43,225</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">706,008</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">749,233</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Amortization of commitment shares</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(79,410</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(79,410</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Compensation cost for stock options granted</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">786,550</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">786,550</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B10" style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.11" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(8,122,581</td>
			<td id=".trail.11" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(8,122,581</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at December 31, 2017 </b></p>
			</td>
			<td id=".lead.B2" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">2,651,952</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.9" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">477,342</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">71,887,674</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.11" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.11" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(65,426,329</td>
			<td id=".trail.11" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.12" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">6,938,687</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B10" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B12" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Issuance of Series B convertible preferred stock and warrants, net of issuance costs of $1,333,449</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">13,624</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">14</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">6,926,778</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">5,363,759</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">12,290,551</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Allocation of Series B convertible preferred stock proceeds to beneficial conversion feature</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(4,782,100</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">4,782,100</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Deemed dividend on Series B convertible preferred stock</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">11,479,308</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(11,479,308</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Conversion of Series B convertible preferred stock to common stock</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(11,245</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(12</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(11,244,989</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">3,194,600</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">575,030</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">10,669,971</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Amortization of commitment shares</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(72,790</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">(72,790</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Compensation cost for stock options granted</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,053,496</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.B11" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".trail.B11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,053,496</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.B2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B5" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B5" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B5" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B6" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B6" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B7" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B7" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B7" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B8" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B8" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B9" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B9" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B10" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B10" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.11" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.11" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(11,404,934</td>
			<td id=".trail.11" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.12" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(11,404,934</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at December 31, 2018 </b></p>
			</td>
			<td id=".lead.B2" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.B3" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.B4" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.B4" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B4" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.5" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">2,379</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.6" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">2</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.7" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">2,378,997</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.8" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">5,846,552</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.9" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.9" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">1,052,372</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.10" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.10" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">82,204,902</td>
			<td id=".trail.10" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.11" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.11" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.11" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(76,831,263</td>
			<td id=".trail.11" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">)</td>
			<td id=".lead.12" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&nbsp;</td>
			<td id=".symb.12" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.12" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">8,805,010</td>
			<td id=".trail.12" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>The accompanying notes are an integral part of these consolidated financial statements.</i></p>

<p style="margin: 0pt; text-align: center; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">55</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div contenteditable="false" docsect="8" id="49385" sectdesc="Cash Flows">&nbsp;</div>

<p style="margin: 0pt 0pt 0pt 3.9pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="cashflow" name="cashflow"></a>ATOSSA GENETICS INC.</b></p>

<p style="margin: 0pt 0pt 0pt 3.9pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<div data-td-statement-type="cash-flows" data-td-taggable-table="" data-td-v2v-id="1551720529395">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tblname="5823" data-tblv="24" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>For the Years Ended December 31, </b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>CASH FLOWS FROM OPERATING ACTIVITIES</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11,404,934</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,122,581</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Adjustments to reconcile net loss to net cash used in operating activities</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Compensation cost for stock options granted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,053,496</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">786,550</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Loss on disposal of assets</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,695</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Impairment of intangible assets</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">461,715</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Depreciation and amortization</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,197</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">128,994</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Change in fair value of common stock warrants</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">280,747</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Warrant financing expense</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">192,817</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Change in stock-based compensation liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,410,025</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Changes in operating assets and liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Prepaid expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(258,889</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(79,343</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Research and development tax rebate receivable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(159,821</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(358,277</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Other assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">74,301</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(80,408</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accounts payable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,427</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80,581</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Payroll liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">150,203</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,968</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accrued expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86,969</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,141</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Other current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">24,405</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">9,451</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net cash used in operating activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(8,961,621</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(6,593,950</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>CASH FLOWS FROM INVESTING ACTIVITIES </b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Purchase of furniture and equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(110,906</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net cash used in investing activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(110,906</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>CASH FLOWS FROM FINANCING ACTIVITIES </b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from issuance of Series B convertible preferred stock and warrants, net of issuance costs</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,290,551</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from issuance of Class A and Class B Units, net of issuance costs</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,871,636</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from exercise of warrants</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">749,233</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from issuance of common stock and warrants, net of issuance costs</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">6,162,588</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net cash provided by financing activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">12,290,551</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">10,783,457</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH </b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,218,024</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,189,507</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE </b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">7,272,469</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">3,082,962</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE </b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">10,490,493</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">7,272,469</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>SUPPLEMENTAL DISCLOSURES </b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Interest Paid</p>
			</td>
			<td id=".lead.2" style="width: 1%;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">330</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>NONCASH INVESTING AND FINANCING ACTIVITIES </b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amortization of commitment shares</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">72,790</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">79,410</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="margin: 0px; padding: 0px;">&nbsp;</td>
			<td id=".lead.B2" style="margin: 0px; padding: 0px;">&nbsp;</td>
			<td id=".symb.B2" style="margin: 0px; padding: 0px;">&nbsp;</td>
			<td id=".amt.B2" style="margin: 0px; padding: 0px;">&nbsp;</td>
			<td id=".trail.B2" style="margin: 0px; padding: 0px;">&nbsp;</td>
			<td id=".lead.B3" style="margin: 0px; padding: 0px;">&nbsp;</td>
			<td id=".symb.B3" style="margin: 0px; padding: 0px;">&nbsp;</td>
			<td id=".amt.B3" style="margin: 0px; padding: 0px;">&nbsp;</td>
			<td id=".trail.B3" style="margin: 0px; padding: 0px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>The accompanying notes are an integral part of these consolidated financial statements.</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">56</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="49386" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720538188">
<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="notes" name="notes"></a>NOTE 1: NATURE OF OPERATIONS</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Atossa Genetics Inc. (the &ldquo;Company&rdquo;) was incorporated on April 30, 2009, in the State of Delaware. The Company was initially formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company&rsquo;s fiscal year ends on December 31.&nbsp;The Company is currently focused on development of its pharmaceutical and drug delivery programs for the treatment of breast cancer and other breast conditions.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="49387" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720545641">
<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE 2: <a class="rdg_comment commentapprove" id="doccmt-692" name="doccmt-692">LIQUIDITY</a>&nbsp; AND CAPITAL RESOURCES</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has incurred net losses and negative operating cash flows since inception. For the year ended December 31, 2018, the Company recorded a net loss of approximately $11.4 million and used approximately $9.0 million of cash in operating activities. As of December 31, 2018, the Company had approximately $10.4 million in cash and cash equivalents and working capital of approximately $8.6 million. However, in March 2019, the Company received $11.3 million in cash upon exercises of certain of the Company&rsquo;s previously outstanding warrants to purchase its common stock. As of March 25, 2019, the Company had approximately $19.3 million in cash and cash equivalents. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and is currently expending funds in research and development activities that are expected to continue to require funding. Management believes its currently available funding, including the funds received from warrant exercises in March 2019, will be sufficient to finance the Company&rsquo;s operations for at least one year from the date these consolidated financial statements are issued. However, the Company will likely require additional funding to continue its activities beyond that date. If adequate funds are not available, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned commercial activities. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company&rsquo;s ability to continue as a going concern.</p>

<p style="margin: 0pt; text-align: left; text-indent: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">57</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="49388" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720558240">
<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE 3: SUMMARY OF ACCOUNTING POLICIES</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Basis of Presentation:</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The accompanying consolidated financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission (&ldquo;SEC&rdquo;) and in accordance with accounting principles generally accepted in the United States of America&nbsp;(&ldquo;GAAP&rdquo;). The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiaries. All significant intercompany account balances and transactions have been eliminated in consolidation.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;On April 20, 2018, the Company completed a 1-for-12 reverse stock&nbsp;split&nbsp;of the shares of the Company&rsquo;s common stock (the &ldquo;Reverse Stock&nbsp;Split&rdquo;). As a result of the Reverse Stock Split, every 12 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, and the par value per share was changed to $0.18 per share. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company&rsquo;s common stock began trading on a reverse stock&nbsp;split-adjusted basis on April 20, 2018. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock&nbsp;Split.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Use of Estimates:</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Recently Issued Accounting Pronouncements:</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In February 2016, Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2016-02, <i>Lease Accounting Topic 842.</i> The new standard is effective for reporting periods beginning after December 15, 2018 and early adoption is permitted. The standard will require lessees to report most leases as assets or liabilities on the balance sheet, while lessor accounting will remain substantially unchanged. The standard permits two approaches, one requiring retrospective application of the new guidance with restatement of prior years, and one requiring prospective application of the new guidance. We plan to adopt the new lease standard effective January 1, 2019 and apply it prospectively. We do not expect the new lease standard to have a material effect on our financial position, results of operations or cash flows. Upon adoption of ASU 2016-02, we will be required to recognize an operating lease liability and right-of-use asset of approximately $100,000, based on the lease composition disclosed in <a class="rdg_comment commentapprove" name="doccmt-697">footnote 13.</a></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p>&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">58</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In November 2016, the FASB issued ASU No. 2016-18, <i>Statement of Cash Flows</i>, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016-18 as of January 1, 2018 on a retrospective basis. For years ended December 31, 2018 and 2017, we included $110,000 and $55,000, respectively, of restricted cash within cash, cash equivalents, and restricted cash&nbsp;on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In July 2017, the FASB issued ASU 2017-11, <i>Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</i>. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&rsquo;s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017-11 as of January 1, 2018. As the Company does not have any financial instruments with down round features, this ASU did not have a material impact on the financial statements upon adoption.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In June 2018, the FASB issued ASU 2018-07, <i>Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. </i>This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, <i>Revenue from Contracts with Customers</i>. This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2018-17 as of April 1, 2018 and it did not have a material impact on the financial statements upon adoption.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In June 2018, the FASB issued ASU 2018-08, <i>Not-for-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.</i> This ASU affects not-for-profit entities and business entities that receive or make contributions of cash.&nbsp;The ASU&#65279; clarifies and improves the scope and accounting guidance to assist entities in evaluating if those transactions should be accounted for as contributions under the scope of Topic 958 or as an exchange transaction subject to other guidance.&nbsp;This update is effective for public entities for fiscal years beginning after December 15, 2018. The Company is currently evaluating the impact that adoption will have on its financial statements.</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">59</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Research and Development</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">All research and development costs are expensed as incurred.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Income Taxes</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized based on the weight of available evidence, including expected future earnings. The Company recognizes an uncertain tax position in its financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. The Company elects to accrue any interest or penalties related to income taxes as part of its income tax expense.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<b><i>&nbsp;</i></b></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Furniture and Equipment</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Furniture and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When furniture and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Depreciation is computed using the straight-line method over the estimated useful lives ranging from three to&nbsp;five years.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 7.2pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Furniture and equipment amounted to $216,000 and $171,000 at December 31, 2018 and 2017, respectively. Accumulated depreciation was $162,000 and $160,000 at December 31, 2018 and 2017, respectively. Depreciation expense for the years ended December 31, 2018 and 2017 was $14,386 and $25,956, respectively.&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company periodically evaluates the carrying value of long-lived assets to be held and used and, if necessary, records impairment losses when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#39; carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-loved assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.&nbsp; For the years ended December 31, 2018 and 2017, no impairment of furniture and equipment was recorded.</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">60</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Fair Value Measurements</i></b></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company records financial assets&nbsp;and liabilities measured on a recurring and non-recurring basis&nbsp;as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. These fair value principles prioritize valuation inputs across three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.&nbsp;Level 3&nbsp;inputs are unobservable inputs based on the Company&#39;s assumptions used to measure assets and liabilities at fair value. An asset or liability&#39;s classification within the various levels is determined based on the lowest level input that is significant to the fair value measurement.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Intangible Assets</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Intangible assets consist of intellectual property and software acquired. Intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. Impairment losses must be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&rsquo; carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the assets. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are not correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;During the year ended December 31, 2017, we determined certain intangible assets acquired from Acueity Healthcare, Inc. (&quot;Acueity&quot;) were impaired and&nbsp;recorded an asset impairment charge of $461,715 for the year ended December 31, 2017, to adjust the carrying value of these intangible assets to zero as of December 31, 2017. &nbsp;No impairment charges were recorded during the year ended December 31, 2018.</p>

<p style="margin: 0pt; text-align: center; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We determined the fair values of the Acueity intangibles using an income approach (Level 3 of the fair value hierarchy). For purposes of the income approach, fair value was determined based on the present value of estimated future cash flows that a market participant could expect to generate from the development of products using the patented technology acquired in the Acueity transaction, discounted at an appropriate risk-adjusted rate reflecting the weighted average cost of capital for a potential market participant. The discount rate used in valuation for these intangible assets was 48.50%. The estimated future cash flows, including an estimate of long-term future growth rates, reflect our own assumptions of what market participants would utilize to price the assets pursuant to ASC 820, <i>Fair Value Measurements</i>.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Amortization of intangible assets&nbsp;is computed using the straight-line method over the estimated useful lives ranging from three to ten years.</p>

<p style="margin: 0pt 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 7.2pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Intangible assets amounted to $192,000 and $234,000 for at December 31, 2018 and 2017, respectively. Accumulated amortization was $93,000 and $158,000 at December 31, 2018 and 2017, respectively. Amortization expense for the years ended December 31, 2018 and 2017 was $29,811 and $103,038, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">61</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Financial Instruments with Characteristics of Both Liabilities and Equity</i></b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the year ended December 31, 2017, the Company issued certain financial instruments, consisting of warrants to purchase common stock, which have characteristics of both liability and equity. Financial instruments such as warrants that are classified as liabilities are fair valued upon issuance and are re-measured at fair value at subsequent reporting periods with the resulting change in fair value recorded in &ldquo;change in fair value of common stock warrants&rdquo; in the consolidated statement of operations. The fair value of warrants is estimated using valuation models that require the input of subjective assumptions including stock price volatility, expected life, and the probability of future equity issuances and their impact to the price protection feature. There were no outstanding warrants accounted for as liabilities as of December 31, 2018 or 2017.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Share-Based Payments</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company follows the provisions of ASC Topic 718, <i>Compensation - Stock Compensation</i> (&ldquo;ASC 718&rdquo;), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period and the Company made a policy election to recognize forfeitures when they occur.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company&rsquo;s common stock, and estimation of an appropriate risk-free interest rate. The Company&rsquo;s expected common stock price volatility assumption is based upon the historical volatility of our stock price. The expected life assumption for stock options grants was based upon the simplified method provided for under ASC 718-10, which averages the contractual term of the options of ten years with the vesting term, typically one to four years. The dividend yield assumption of zero is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends in the future. The risk-free interest rate used for each grant was based upon prevailing short-term interest rates over the expected life of the options.</p>
</div>

<div contenteditable="false" docsect="9" id="49389" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720565121">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE 4: RESTRICTED CASH</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our restricted cash balance of $110,000 and $55,000 as of December 31, 2018 and 2017, consists entirely of cash pledged as security for the Company&rsquo;s issued commercial credit cards.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="49390" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720575363">
<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE 5: PREPAID EXPENSES</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Prepaid expenses consisted of the following:</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552247762407">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tblname="5826" data-tblv="3" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">160,576</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">125,056</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">218,090</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Professional services</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">110,094</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">97,788</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Retainer and security deposits</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,718</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,218</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">4,355</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">13,882</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="margin: 0px; width: 70%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total prepaid expenses</td>
			<td id=".lead.2" style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="margin: 0px; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="margin: 0px; width: 12%; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">509,833</td>
			<td id=".trail.2" nowrap="true" style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="margin: 0px; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="margin: 0px; width: 12%; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">250,944</td>
			<td id=".trail.3" nowrap="true" style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">62</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="49391" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720581699">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE 6: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On May 23, 2017, Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (&ldquo;R&amp;D&rdquo;) including our Phase 1 and Phase 2 Endoxifen clinical trials. Australia offers an R&amp;D cash rebate of $0.435 per dollar spent on qualified R&amp;D activities incurred in the country. For the years ended December 31, 2018 and 2017, the Company incurred qualified R&amp;D expenses in Australia of approximately $851,000 and $824,000, respectively. The Company recorded a rebate receivable of approximately $370,000 and $358,000 at December 31, 2018 and 2017, respectively, and a corresponding credit to R&amp;D expenses for the years then ended. At December 31, 2018, we had a total R&amp;D rebate receivable of approximately $518,000 that included approximately $148,000 receivable remaining from the year ended December 31, 2017.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="49392" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720587601">
<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE </b><b>7</b><b>: PAYROLL LIABILITIES</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Payroll liabilities consisted of the following:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1553033211344">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tblname="5871" data-tblv="24" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>December 31, 2018</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>December 31, 2017</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued bonus payable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">697,995</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">566,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued vacation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">160,740</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">147,861</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">76,335</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">71,006</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total payroll liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">935,070</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">784,867</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="49393" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720594600">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE </b><b>8</b><b>: FAIR VALUE OF FINANCIAL INSTRUMENTS</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">There were no financial assets outstanding that were required to be measured at fair value on a recurring basis at December 31, 2018 or December 31, 2017.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Warrants issued in the April 3, 2017, offering, which are discussed further in Note 9, contained provisions that could have required the Company to settle the warrants in cash in an event outside the Company&rsquo;s control or had price protection rights and were therefore accounted for as liabilities while they were outstanding, with changes in the fair values included in net loss for the respective periods. Because some of the inputs to the valuation model were either not observable or were not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability was classified as Level 3 in the fair value hierarchy.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table summarizes the changes in the Company&rsquo;s Level 3 warrant liability for the year ended December 31, 2017:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720594599">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrant liability</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Beginning balance</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Issuances of warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,612,413</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrant exercises</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,893,160</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">280,747</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Ending balance</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company&rsquo;s intangible assets are classified within Level 3 of the fair value hierarchy, measured at fair value on a nonrecurring basis. Refer to Note 3 for further discussion.&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">There were no transfers between Level 1, Level 2 or Level 3 for the years ended December 31, 2018 or December 31, 2017.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">63</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="49394" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720606249">
<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE </b><b>9</b><b>: STOCKHOLDERS&rsquo; EQUITY</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company is authorized to issue a total of 185,000,000 shares of stock consisting of 175,000,000 shares of common stock, par value $0.18 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. The Company has designated 750,000 shares of Series A junior participating preferred stock, par value $0.001 per share, 4,000 shares of Series A convertible preferred stock, par value $0.001 per share, and 25,000 shares of Series B convertible preferred stock, par value $0.001 per share,&nbsp;through the filings of certificates of designation with the Delaware Secretary of State. No shares of Series A junior participating preferred stock or Series A convertible preferred stock are issued or outstanding as of December 31, 2018.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On May 19, 2014, the Company adopted a stockholder rights agreement which provides that all stockholders of record on May 26, 2014, received a non-taxable distribution of one preferred stock purchase right for each share of the Company&rsquo;s common stock held by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable only if one of the following occurs: (1)&nbsp;a person becomes an &ldquo;Acquiring Person&rdquo; by acquiring beneficial ownership of 15% or more of the Company&rsquo;s common stock (or, in the case of a person who beneficially owned 15% or more of the Company&rsquo;s common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing 2.0% of the Company&rsquo;s common stock then outstanding (excluding compensatory arrangements)), or (2)&nbsp;a person commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of the Company&rsquo;s common stock with a market value that equals twice the exercise price of the right. The initial exercise price of each right is $15.00, so each holder (other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive $30.00 worth of the Company&rsquo;s common stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring entity.&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>2017 Public Offering of Class A and Class B Units Consisting of Common Stock, Series A Convertible Preferred Stock and Warrants</u></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On March 28, 2017, the Company entered into an underwriting agreement with Aegis Capital Corp. relating to a public offering which closed on April 3, 2017. The offering generated gross proceeds to the Company of approximately $4.4 million and net proceeds of approximately $3.9 million after deducting underwriting discounts and commissions and other offering expenses paid by the Company.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The offering included 55,333 Class A Units at a public offering price of $9.00 per Class A Unit, which consisted of 55,333 shares of common stock and warrants to purchase 55,333 shares of common stock. The offering also included 292 Class B Units at a public offering price of $12,000 per Class B Unit, which consisted of 292 shares of Series A convertible preferred stock convertible into a total of 389,111 shares of common stock and warrants to purchase 389,111 shares of common stock. In addition, the underwriter exercised the over-allotment option to purchase an additional 44,167 shares of common stock and warrants to purchase 44,167 shares of common stock, which are included in the gross proceeds of $4.4 million. The warrants had a per share exercise price of $11.25, were exercisable immediately and were scheduled to expire five years from the date of issuance.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of December 31, 2017, all of the warrants issued in the April 3, 2017 offering have been exercised and are no longer outstanding and all of the shares of Series A convertible preferred stock have been converted into shares of common stock.</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Accounting Treatment</i></b></p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company allocated the proceeds from the sale of the Class A and Class B units to the separate securities issued. The Company determined that, on the date of issuance, the warrants were not indexed to its stock because they did not meet the &ldquo;fixed-for-fixed&rdquo; criterion&nbsp;due to the price protection and fundamental transaction provisions and, therefore, the warrants were accounted for as liabilities with changes in fair value recorded in non-operating income (expense) in the consolidated statement of operations.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company allocated the amount representing the fair value of the warrants at the date of issuance separately to the warrant liability and recorded the remaining proceeds as common stock, in the case of the Class A units, or as Series A convertible preferred stock, in the case of the Class B units. Due to the allocation of a portion of the proceeds to the warrants, the Series A convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of $1,284,066 based on the intrinsic value of the beneficial conversion feature. The discount on the Series A convertible preferred stock of $1,284,066 caused by allocation of the proceeds to the warrant was recorded as a deemed dividend upon issuance of the Series A convertible preferred stock. As a result, total deemed dividends of $2,568,132 were recorded upon issuance of the Series A convertible preferred stock, which is reflected as an addition to net loss in the consolidated statement of operations to arrive at net loss applicable to common shareholders.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">64</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Exercise of 2017 Warrants</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On June 29, 2017, the Company offered to modify the rights of the holders of the warrants issued in the public offering the Company completed on April 3, 2017. The temporary modification included (a) lowering the exercise price of the warrants to $3.12 per share, (b) setting the applicable volume-weighted average price (VWAP) at $6.24 per share, and (c) allowing for temporary cashless exercise of the warrants for all holders that accepted the temporary modification before 8:00 a.m. Eastern daylight time on June 30, 2017. Holders of warrants to purchase a total of approximately <a class="rdg_comment commentapprove" name="doccmt-603">250,000 shares of common stock accepted the offer resulting in the cancellation of those warrants and the issuance by the Company of a total of approximately 125,000 shares </a>of common stock (including shares held in abeyance). The shares of common stock are registered under the Securities Act of 1933, as amended. In connection with the temporary modification, the Company agreed to extend the &ldquo;Lock-up Period&rdquo; of the underwriting agreement between the Company and Aegis Capital Corp., dated March 28, 2017, by 45 days and the Company agreed not to enter into any further amendments to the warrants during such extended Lock-up Period without the prior written consent of each holder. During the third quarter of 2017, all remaining warrants were exercised for cash so that no warrants issued in the April 3, 2017, financing remained outstanding. Upon exercise of these warrants, the amount of the warrant liability at the date of exercise was reclassified from warrant liability to additional paid-in capital.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table summarizes the 2017 liability warrant activity:&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720606245">
<table cellpadding="0" cellspacing="0" class="finTable" style="margin: 0pt auto 0pt 36pt; width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Shares</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Weighted<br>
			Average<br>
			Exercise<br>
			Price</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 74%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of January 1, 2017</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants granted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">488,611</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11.25</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants exercised</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(488,611</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">3.12</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2017</p>
			</td>
			<td id=".lead.B2" style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company estimated the fair value of the warrants using the Monte Carlo simulation (MCS) model, which is a type of income approach, where the current value of an asset is expressed as the sum of probable future cash flows across various scenarios and time frames discounted for risk and time. The significant assumptions included timing of future rounds of financing, timing and success rates of oncology clinical trials, and the probability of a merger and acquisition adjusted for a lack of marketability discount. The MCS model also included a full term and an early conversion scenario that were each weighted at 50% in the final concluded fair value.&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Inputs used in the valuation of the warrants at the issuance date of April 3, 2017 and June 30, 2017, are set forth below. All of&nbsp;the warrants issued in the April 2017 financing&nbsp;were exercised during&nbsp;2017 and none remained outstanding at December 31, 2017.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720606246">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Initial valuation</b></p>
			</td>
			<td id=".lead.B2" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td style="width: 4%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock price</p>
			</td>
			<td id=".lead.2" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$9.00</td>
			<td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercise price</p>
			</td>
			<td id=".lead.2" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$11.25</td>
			<td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p>
			</td>
			<td id=".lead.2" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50%</td>
			<td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p>
			</td>
			<td id=".lead.2" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0%</td>
			<td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p>
			</td>
			<td id=".lead.2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">0.79%</td>
			<td id=".amt.2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.88%</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</p>
			</td>
			<td id=".lead.2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;0.24</td>
			<td id=".amt.2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 87%;">&nbsp;</td>
			<td id=".lead.B2" style="width: 4%;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%;">&nbsp;</td>
			<td style="width: 4%;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>June 30, 2017 valuation</b></p>
			</td>
			<td id=".lead.B2" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 4%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td style="width: 4%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock price</p>
			</td>
			<td id=".lead.2" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$6.00</td>
			<td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercise price</p>
			</td>
			<td id=".lead.2" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$3.12</td>
			<td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p>
			</td>
			<td id=".lead.2" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50%</td>
			<td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p>
			</td>
			<td id=".lead.2" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0%</td>
			<td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p>
			</td>
			<td id=".lead.2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;0.79</td>
			<td id=".amt.2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.88%</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</p>
			</td>
			<td id=".lead.2" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;0.08</td>
			<td id=".amt.2" style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.76</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">65</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Conversion of Series A Convertible Preferred Stock</i></b></p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the year ended December 31, 2017, certain holders of the Series A convertible preferred stock exercised their conversion option and converted an aggregate of 292 shares of Series A convertible preferred stock into 389,111 shares of the Company&rsquo;s common stock based on the conversion ratio of 111 shares of common stock for each share of Series A convertible preferred stock. As of December 31, 2017 and 2018, no shares of Series A convertible preferred stock were outstanding.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>October 2017 Public Offering</u></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On October 26, 2017, the Company entered into an underwriting agreement with Maxim Group LLC relating to a public offering of common stock which closed on October 30, 2017. The offering generated gross proceeds to the Company of approximately $5.5 million and net proceeds of $4.9 million after deducting underwriting discounts, commissions and other offering expenses paid by the Company.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The offering included 958,333 shares of common stock at a public offering price of $5.28 per share. In addition, the underwriter exercised the over-allotment option to purchase an additional 83,333 shares of common stock at the offering price of $5.28 per share, which are included in the gross proceeds of $5.5 million.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>December 2017 Public Offering and Private Placement</u></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On December 20, 2017, the Company entered into a placement agent agreement with Maxim Group LLC relating to the sale of the Company&rsquo;s securities. Pursuant to the placement agent agreement, on December 20, 2017, the Company entered into a securities purchase agreement with certain purchasers named therein relating to the offering and sale of 441,667 shares of Company common stock at a public offering price of $3.24 per share. The offering generated gross proceeds to the Company of approximately $1.4 million and net proceeds of $1.2 million after deduction of underwriting discounts, commissions, and other offering expenses paid by the Company.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Concurrently with the public offering the Company also commenced a private placement whereby it issued and sold Class A and Class B Warrants, exercisable for an aggregate of 883,333 shares of common stock, at an exercise price of $3.78 per share. The public offering and the private placement involved the same purchasers. The Class A and Class B Warrants exercise price&nbsp;was fixed at $3.78 per warrant, and the warrants&nbsp;became&nbsp;exercisable commencing six months from issuance. The Class A Warrants and&nbsp;Class B Warrants&nbsp;expired on the first anniversary of the date of issuance. None of the Class A Warrants, the Class B Warrants nor the shares issuable upon exercise of such Warrants were&nbsp;registered with the Securities and Exchange Commission. The Warrants could not be exercised on a cashless basis. There&nbsp;were no redemption features embodied in the Warrants and they met the conditions for equity classification. On December 22, 2018, the Class A and Class B warrants expired unexercised.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>2018 Subscription Rights Offering of Units Consisting of Series B Convertible Preferred Stock and Warrants</u></p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On May 9, 2018, the Company&rsquo;s Registration Statement on Form S-1 with the Securities and Exchange Commission was declared effective to offer subscription rights to purchase up to 25,000 units at $1,000 per unit with each unit consisting of one share of Series B convertible preferred stock and warrants to purchase 284 shares of common stock.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On May 29, 2018, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B convertible preferred stock with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value $0.001 per share, designated as the Series B convertible preferred stock. The number of shares initially constituting the Series B preferred stock was set at 25,000 shares.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On May 30, 2018, the Company completed its previously announced rights offering pursuant to which the Company sold an aggregate of 13,624 units consisting of an aggregate of 13,624 shares of Series B convertible preferred stock and 3,869,216 warrants, with each warrant exercisable for one share of common stock at an exercise price of $4.048 per share (the &ldquo;2018 Warrants&rdquo;), resulting in net proceeds to the Company of approximately $12.3 million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">66</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Series B Convertible Preferred Stock</i></b>.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The terms and provisions of our Series B convertible preferred stock are:</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Conversion.</i> Each share of Series B convertible preferred stock is convertible at our option at any time on or after the first anniversary of the closing of the rights offering or at the option of the holder at any time, into the number of shares of our common stock determined by dividing the $1,000 stated value per share of the Series B convertible preferred stock by a conversion price of $3.52 per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series B convertible preferred stock will not have the right to convert any portion of the Series B convertible preferred stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to its conversion.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Fundamental Transactions.</i> In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a business combination in which another person acquires 50% of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of 50% of the aggregate ordinary voting power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series B convertible preferred stock, the holders of the Series B convertible preferred stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of common stock then issuable upon conversion in full of the Series B convertible preferred stock.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Dividends.</i> Holders of Series B convertible preferred stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Voting Rights.</i> Except as otherwise provided in the certificate of designation or as otherwise required by law, the Series B convertible preferred stock has no voting rights.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Liquidation Preference</i><b><i>. </i></b>Upon our liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series B convertible preferred stock will be entitled to receive out of our assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series B convertible preferred stock were fully converted (disregarding for such purpose any conversion limitations under the certificate of designation) to common stock, which amounts shall be paid pari passu with all holders of common stock.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Redemption Rights. </i>We are not obligated to redeem or repurchase any shares of Series B convertible preferred stock. Shares of Series B convertible preferred stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous provisions.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>2018 Warrants</i></b><i>&nbsp;</i></p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The terms and conditions of the warrants included in the 2018 rights offering are as follows:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Exercisability</i>. Each warrant is exercisable at any time and will expire four years from the date of issuance. The warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment in full for the number of shares of our common stock purchased upon such exercise, except in the case of a cashless exercise as discussed below.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The number of shares of common stock issuable upon exercise of the warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. Upon the merger, consolidation, sale of substantially all of our assets, or other similar transaction, the holders of warrants shall, at the option of the company, be required to exercise the warrants immediately prior to the closing of the transaction, or such warrants shall automatically expire. Upon such exercise, the holders of warrants shall participate on the same basis as the holders of common stock in connection with the transaction.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Cashless Exercise</i>. If at any time there is no effective registration statement registering, or the prospectus contained therein is not available for issuance of, the shares issuable upon exercise of the warrant, the holder may exercise the warrant on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of shares of our common stock purchasable upon such exercise.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">67</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Exercise Price</i>. Each warrant represents the right to purchase one share of common stock at an exercise price of $4.048 per share. In addition, the exercise price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations, or reclassifications, and for certain dilutive issuances. Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of the warrant to the extent that, after giving effect to the exercise, the holder, together with its affiliates, and any other person acting as a group together with the holder or any of its affiliates, would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to its exercise. The holder, upon notice to the Company, may increase or decrease the beneficial ownership limitation provisions of the warrant, provided that in no event shall the limitation exceed 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise of the warrant.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Transferability</i>. Subject to applicable laws and restrictions, a holder may transfer a warrant upon surrender of the warrant to us with a completed and signed assignment in the form attached to the warrant. The transferring holder will be responsible for any tax that liability that may arise as a result of the transfer.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Exchange Listing</i>. We do not intend to apply to list the warrants on any securities exchange or recognized trading system.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Rights as Stockholder</i>. Except as set forth in the warrant, the holder of a warrant, solely in such holder&rsquo;s capacity as a holder of a warrant, will not be entitled to vote, to receive dividends, or to any of the other rights of our stockholders.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Redemption Rights</i>. We may redeem the warrants for $0.18 per warrant if the volume-weighted-average-price of our common stock equals or exceeds $10.56 per share for ten consecutive trading days, provided that we may not do so prior to the first anniversary of closing of the rights offering.</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Accounting Treatment</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company allocated the proceeds from the sale of the Series B convertible preferred stock and the warrants to purchase common stock to the separate securities issued. The Company allocated the amount representing the fair value of the warrants at the date of issuance to common stock based on the relative warrant fair value in the amount of $5,363,759, which is net of issuance costs allocated to the warrants. Due to the allocation of a portion of the proceeds to the warrants, the convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of $4,782,100 based on the relative fair value of the beneficial conversion feature. The discount on the convertible preferred stock was $11,479,308, which consists of the beneficial conversion feature of $4,782,100, the allocation of a portion of the proceeds to the warrants in the amount of $5,363,759, and the total issuance costs related to the financing of $1,333,449. The discount on the convertible preferred stock of $11,479,308 was recorded as a deemed dividend upon issuance of the convertible preferred stock. The deemed dividend is reflected as an addition to net loss in the consolidated statements of operations to arrive at net loss applicable to common shareholders. The Company has made an accounting policy election to record the deemed dividend related to discounts on convertible instruments at the time of issuance of the convertible instruments.</p>

<p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Outstanding Warrants</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of December 31, 2018, warrants to purchase 3,875,699 shares of common stock were outstanding including:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720606246">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tblname="5827" data-tblv="1" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b>Outstanding </b></b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b>Warrants to </b></b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b>Purchase </b></b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b>Shares</b></b></b></p>
			</td>
			<td id=".trail.D2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b>Exercise Price</b></b></b></p>
			</td>
			<td id=".trail.D3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td style="width: 25%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>Expiration Date</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="width: 45%;">&nbsp;</td>
			<td id=".lead.B2" style="width: 1%;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%;">&nbsp;</td>
			<td id=".amt.B2" style="width: 12%;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%;">&nbsp;</td>
			<td id=".amt.B3" style="width: 12%;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%;">&nbsp;</td>
			<td style="width: 25%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2014 public offering</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,483</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">540.00</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="width: 25%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">January 29, 2019</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2018 warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">3,869,216</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.05</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="width: 25%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">May 30, 2022</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">3,875,699</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Conversion of Series B Convertible Preferred Stock</i></b></p>

<p style="margin: 0pt 7.5pt 0pt 43.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the year ended December 31, 2018, certain holders of the Series B convertible preferred stock exercised their conversion option and converted an aggregate of 11,245 shares into 3,194,600 shares of the Company&#39;s common stock based on the conversion ratio of approximately 284 shares of common stock for each share of Series B convertible preferred stock.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">68</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="49395" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720612929">
<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE 1</b><b>0</b><b>: NET LOSS PER SHARE&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company accounts for and discloses net income (loss) per common share in accordance with Accounting Standards Codification (&quot;ASC&quot;) Topic 260, <i>Earnings Per Share</i>. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented they have been excluded from the calculation.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table summarizes the Company&rsquo;s calculation of net loss per common share:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720612928">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tblname="5829" data-tblv="2" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%; margin-left: 45pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b>Year Ended December 31,</b></b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b>2018</b></b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b>2017</b></b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Numerator</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11,404,934</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,122,581</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deemed dividend attributable to preferred stock</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(11,479,308</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(2,568,132</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common shareholders</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(22,884,242</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(10,690,713</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Denominator</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding used to compute net loss per share, basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">4,157,746</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">974,773</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Net loss per share of common stock, basic and diluted: </b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5.50</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10.97</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>

</table>
</div>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share, because including them would be anti-dilutive:&nbsp;</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720612929">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tblname="5828" data-tblv="2" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%; margin-left: 45pt;">

		<tr style="vertical-align: bottom;">
			<td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="width: 111111%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>Year Ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options to purchase common stock</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">487,941</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">117,301</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series A convertible preferred stock</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,835</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series B convertible preferred stock</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">774,983</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants to purchase common stock</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">3,054,481</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">202,063</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">4,317,405</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">375,199</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="49396" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720621758">
<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE 1</b><b>1</b><b>: INCOME TAXES</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company accounts for income taxes using the asset and liability method, under which deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On December 22, 2017, the President signed into law the Tax Cut and Jobs Act of 2017 (the &ldquo;2017 Tax Act&rdquo;). The 2017 Tax Act provisions applicable to the Company include a permanent reduction to the U.S. federal corporate income tax rate from 35% to 21%, the capitalization and amortization of research and development related expenses, and placing additional limits on the use of net operating losses. Under ASC Topic 740, <i>Accounting for Income Taxes</i>, companies are required to recognize the changes in the period of enactment.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the year ended December 31, 2017, the Company recorded a reduction in the amount of&nbsp;$1.9 million in the carrying value of the Company&rsquo;s U.S. deferred tax assets resulting from the 2017 Tax Act&rsquo;s reduction in the U.S. federal corporate income tax rate from 35% to 21%, which is fully offset by the valuation allowance.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">69</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company did not record an income tax benefit for its losses incurred for the years ending December 31, 2018 or 2017, due to uncertainty regarding utilization of its net operating loss carryforwards and due to its history of losses. The benefit for income taxes differs from the benefit computed by applying the federal statutory rate to loss before income taxes as follows:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1553438777808">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tblname="5830" data-tblv="6" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b>As of December 31,</b></b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b>2018</b></b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b>2017</b></b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected federal income tax benefit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,395,036</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,761,678</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">169,957</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">197,336</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other permanent items</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,616</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,668</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of change in valuation allowance</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,223,463</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,344,015</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prior year true-up</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(126,031</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tax rate change</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,912,427</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of NOL limitation</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">16,119,293</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Actual federal income tax benefit</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The components of net deferred tax assets and liabilities are as follows:</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720621757">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tblname="5831" data-tblv="6" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>Year Ended December 31, </b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b><b>2018</b></b></b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b><b><b><b>2017</b></b></b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 74%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Obsolete inventory</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,881</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,881</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accrued vacation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,755</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,051</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accrued bonuses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">99,666</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Stock-based compensation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">968,170</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">620,789</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Basis difference in fixed assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,241</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,241</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Intangible assets, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">572,687</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">634,521</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Contribution, carryforward</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">707</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">677</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net operating loss carryforwards</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,588,401</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">747,589</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Capital loss carryforward</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,027,111</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,027,111</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Valuation allowance</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(5,312,769</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(3,089,306</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax asset</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">32,850</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">27,554</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Other</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(32,850</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(27,554</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax asset</p>
			</td>
			<td id=".lead.2" style="width: 1%;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 10%; text-align: right; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 10%; text-align: right; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Based on an assessment of all available evidence including, but not limited to the Company&rsquo;s limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, the Company has concluded that it is more likely than not that these net operating loss carryforwards and credits will not be realized and, as a result, a full valuation allowance has been recorded against the Company&rsquo;s deferred income tax assets. Utilization of the net operating loss carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by the Internal Revenue Code Section 382. In general, an &ldquo;ownership change,&rdquo; as defined by the code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Any limitation may result in expiration of all or a portion of the net operating loss carryforwards before utilization. Since the Company&rsquo;s initial public offering, ownership changes have triggered a Section 382 limitation, which limits the ability to utilize net operating loss carryforwards.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has incurred net operating losses from inception. At December 31, 2018, the Company had domestic federal net operating loss carryforwards of approximately $58.2 million. In May of 2018 and October 2017, the Company completed public offerings, which triggered ownership changes under section 382. We believe that as of December 31, 2018, the gross net operating loss carryforwards have been limited to approximately $<a class="rdg_comment commentapprove" name="doccmt-684">12.3</a> million, which are available to reduce future taxable income. Federal net operating loss carryforwards generated through December 31, 2017 expire at various dates beginning in 2029 through 2038, while federal net operating loss carryforwards generated in 2018 do not expire. The Company recorded a valuation allowance against all of its net deferred tax assets of approximately $5.3 million and $3.1 million as of December 31, 2018 and 2017, respectively, for a net increase of $2.2 million from 2017 to 2018 and a net decrease of <a class="rdg_comment commentapprove" name="doccmt-604">$15.5 </a>million from 2016 to 2017.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company files income tax returns in the U.S. The Company is subject to tax examinations for the 2012 tax year and beyond. The Company has no unrecognized tax positions and does not believe there will be any material changes in its unrecognized tax positions over the next 12 months. The Company has not incurred any interest or penalties related to unrecognized tax positions. In the event that the Company is assessed interest or penalties at some point in the future, they will be classified in the financial statements as general and administrative expense.</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">70</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="49397" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720628108">
<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE 1</b><b>2</b><b>: CONCENTRATION OF CREDIT RISK</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (&ldquo;FDIC&rdquo;) up to $250,000. As of December 31, 2018 and 2017, the Company had $10,052,914 and $6,967,469 in excess of the FDIC insured limit, respectively.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="49398" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720635220">
<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE 1</b><b>3</b><b>: COMMITMENTS AND CONTINGENCIES</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Lease Commitments</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On November 1, 2018, the Company entered into an operating lease to pay $3,660 monthly&nbsp;rent for a term of 22 months.&nbsp;The&nbsp;total future minimum lease payments due under this lease&nbsp;<a class="rdg_comment commentapprove" name="doccmt-605">are $73,200</a>, of which $43,920 and $29,280 are due in 2019 and 2020, respectively.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The total rent expense for the years ended December 31, 2018 and 2017, was $31,457 and $33,285, respectively. Rent expense was included in general and administrative expenses for both years.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;On October 30, 2018, the Company entered into an operating lease for a copier system for a term of 36 months. The total future minimum lease payments due under this lease&nbsp;are $42,228, of which $14,904, $14,904 and $12,420 are due in 2019, 2020 and 2021, respectively.</p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Litigation and Contingencies</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On October 10, 2013, a putative securities class action complaint, captioned <i>Cook v. Atossa Genetics, Inc., et al.</i>, No. 2:13-cv-01836-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering. The complaint alleged that all defendants violated Sections 11 and 12(a)(2), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering&rsquo;s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. The complaint sought, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an <a class="rdg_comment commentapprove" id="doccmt-524" name="doccmt-524">unspecific amount.</a>&nbsp;On March 23, 2018, the parties filed a stipulation of settlement with the court to settle the matter for $3.5 million, completely funded by defendants&rsquo; insurers, and on July 20, 2018 the Court approved the settlement. This case is considered closed.&nbsp;&nbsp;</p>

<p style="margin: 0pt 21.9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are subject to other legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">71</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="49399" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1551720644284">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE 1</b><b>4</b><b>: STOCK BASED COMPENSATION</b></p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Stock Option and Incentive Plan</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On September 28, 2010, the Board of Directors approved the adoption of the 2010 Stock Option and Incentive Plan the (&ldquo;2010 Plan&rdquo;) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options may be granted under the 2010 Plan until September 2020. No other awards may be granted under the 2010 Plan after the date that is 10 years from the date of stockholder approval. An aggregate of 5,556 shares were initially reserved for issuance in connection with awards granted under the 2010 Plan and on May 18, 2016, an additional 11,111 shares were reserved for issuance under the 2010 Plan. On May 9, 2017, the stockholders approved an additional 125,000 shares for issuance under the 2010 Plan. On April 12, 2018, the stockholders approved an additional 500,000 shares for issuance under the 2010 Plan.</p>

<p style="margin: 0pt 7.5pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table presents the automatic additions to the 2010 Plan since inception pursuant to the &ldquo;evergreen&rdquo; terms of the 2010 Plan:</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720644279">
<table cellpadding="0" cellspacing="0" class="finTable" style="margin: 0pt auto 0pt 36pt; width: 92%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>January 1,</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Number of<br>
			shares</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2012</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,502</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2013</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,871</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2014</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,128</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2015</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,463</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2016</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,257</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2017</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,623</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2018</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">106,076</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total additional shares</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">140,920</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company granted options to purchase 611,668&nbsp;and&nbsp;143,027 shares of common stock to employees and directors during the year ended December 31, 2018 and 2017, respectively.&nbsp;The weighted average grant date fair value of options granted during 2018 and 2017 was $2.02 and $4.80, respectively. There are 3,575 options available for grant under the 2010 Plan as of December 31, 2018, and as a result of the evergreen provision contained in the 2010 Plan, an additional 233,862 shares were added to the 2010 Plan on January 1, 2019.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Compensation costs associated with the Company&rsquo;s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $1,053,496 and $786,550 for the years ended December 31, 2018 and 2017, respectively, which was included in the following captions in the consolidated statements of operations.</p>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720644280">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt;">

		<tr style="vertical-align: bottom;">
			<td colspan="1" style="width: 68%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Year Ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td colspan="1" style="width: 68%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>201</b><b>8</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>201</b><b>7</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td colspan="1" style="width: 68%;">&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 68%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">809,110</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">621,668</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 68%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">244,386</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">164,882</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 68%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total stock compensation expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">1,053,496</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">786,550</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The fair value of stock options granted for the years ended December 31, 2018 and 2017, was calculated using the Black-Scholes option-pricing model applying the following assumptions:</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720644280">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt;">

		<tr style="vertical-align: bottom;">
			<td colspan="1" style="width: 67%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="7" id=".amt.D3" rowspan="1" style="width: 636163%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Year ended December 31,</b></b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td colspan="1" style="width: 67%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="3" id=".amt.D2" rowspan="1" style="width: 63%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>201</b><b>8</b></b></p>
			</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="3" id=".amt.D3" rowspan="1" style="width: 63%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>201</b><b>7</b></b></p>
			</td>
			<td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td colspan="1" style="width: 67%;">&nbsp;</td>
			<td id=".lead.B2" style="width: 1%;">&nbsp;</td>
			<td id=".symb.B2" style="width: 6%;">&nbsp;</td>
			<td id=".amt.B2" style="width: 3%;">&nbsp;</td>
			<td id=".trail.B2" style="width: 6%;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%;">&nbsp;</td>
			<td id=".symb.B3" style="width: 6%;">&nbsp;</td>
			<td id=".amt.B3" style="width: 3%;">&nbsp;</td>
			<td id=".trail.B3" style="width: 6%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 67%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Risk free interest rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;2.47%</td>
			<td id=".amt.2" style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.2" nowrap="true" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.71%</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;1.86%</td>
			<td id=".amt.3" style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.04%</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 67%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected term (in years)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;5.24</td>
			<td id=".amt.2" style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.2" nowrap="true" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.57&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;5.32</td>
			<td id=".amt.3" style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.36</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 67%;">&nbsp;</td>
			<td id=".lead.B2" style="width: 1%;">&nbsp;</td>
			<td id=".symb.B2" style="width: 6%;">&nbsp;</td>
			<td id=".amt.B2" style="width: 3%;">&nbsp;</td>
			<td id=".trail.B2" style="width: 6%;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%;">&nbsp;</td>
			<td id=".symb.B3" style="width: 6%;">&nbsp;</td>
			<td id=".amt.B3" style="width: 3%;">&nbsp;</td>
			<td id=".trail.B3" style="width: 6%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 67%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Dividend yield</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-%</td>
			<td id=".trail.2" nowrap="true" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-%</td>
			<td id=".trail.3" nowrap="true" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 67%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected volatility</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;108.81%</td>
			<td id=".amt.2" style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.2" nowrap="true" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">126.43%</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;112.86%</td>
			<td id=".amt.3" style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;-</td>
			<td id=".trail.3" nowrap="true" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">114.19</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">72</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Options issued and outstanding as of December 31, 2018, and their activities during the year then ended are as follows:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720644281">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 51.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 10.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Number of<br>
			Underlying<br>
			Shares</b></p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 9.9%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Weighted-<br>
			Average<br>
			Exercise Price<br>
			Per Share</b></p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Weighted-<br>
			Average<br>
			Contractual<br>
			Life Remaining<br>
			in Years</b></p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 9.9%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Aggregate<br>
			Intrinsic Value</b></p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 51.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Outstanding as of January 1, 2018</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">172,510</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 8.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">49.27</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 8.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 51.8%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Granted</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">611,668</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.39</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 51.8%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Forfeited</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(795</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">562.55<a class="rdg_comment commentapprove" name="doccmt-534"></a></p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 51.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Outstanding as of December 31, 2018</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">783,383</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12.14</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9.17</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 51.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Exercisable as of December 31, 2018</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">317,042</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">24.39</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8.97</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 51.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Vested and expected to vest</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">783,383</p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12.14</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 9.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9.17</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 0.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>
</div>

<p style="margin: 0pt 7.5pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">At December 31, 2018, there were 466,341 unvested options outstanding and the related unrecognized total compensation cost associated with these options was $1,152,367. This expense is expected to be recognized over a weighted-average period of 1.45 years.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Executive Option Grants Classified as Liabilities (&quot;2018 Liability Grants&quot;)</i></b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On June 27, 2018, the Company granted 2,300,000 options to the Chief Executive Officer and 700,000 to the Chief Financial Officer. Each option is exercisable for an equivalent number of shares of Company&#39;s common stock. The options were granted pursuant to an option award agreement and were granted outside the Company&rsquo;s 2010 Plan; however, they are subject to the terms and conditions of the 2010 Plan. On January 13, 2019, the 2018 liability options were canceled.</p>

<p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Liability Grants were exercisable for shares of common stock at an exercise price of $2.38 per share, which was the fair value on the date of grant. The options had an exercise period of ten years from their date of issuance. If at the time the options were exercised the Company cannot deliver shares of common stock to the optionee including, for example, if there were insufficient shares available under the Plan at the time of exercise, then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option only would be exercised on a cash &ldquo;net basis&rdquo; so that the Company would pay cash in an amount equal to the excess of the fair value of the common stock over the option exercise price. There were not sufficient shares available under the Plan. Therefore the&nbsp;Company&nbsp;would have been obligated to settle these options in cash if they were exercised. Because these options contained provisions that would require the Company to settle the options in cash in an event outside the Company&rsquo;s control, they were accounted for as liabilities.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Liability Grants were subject to vesting requirements. Twenty-five percent of the options were vested as of the grant date, 50% of the options would have vested quarterly over two years, and the remaining 25% would have vested upon achievement of certain milestones related to clinical trial progress. As of December 31, 2018, all of the options that vested upon achievement of clinical trial&nbsp;milestones&nbsp;were vested.&nbsp;At December 31, 2018, there were&nbsp;1,125,000 unvested options outstanding and the related unrecognized total compensation cost associated with these options was $857,673. This expense was expected to be recognized over a weighted-average period of 1.5 years.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div style="display: none;">&nbsp;</div>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Compensation costs associated with the Liability Grants were initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria were achieved for options that vest based on performance. Compensation cost was remeasured each period based on the market value of our underlying stock until award vesting or settlement.</p>

<p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For the year ended December 31, 2018, the Company&nbsp;recognized compensation expense related to these options of $1,410,025, which was included in the following captions in the consolidated statements of operations.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720644282">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt;">

		<tr style="vertical-align: bottom;">
			<td colspan="1" style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b><b>Year Ended </b></b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b><b>December 31, 2018</b></b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td colspan="1" style="width: 85%;">&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 85%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">869,515</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="width: 85%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">540,510</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="width: 85%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total stock compensation expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">1,410,025</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The fair value of liability options granted for the year ended December 31, 2018, was calculated using the Black-Scholes option-pricing model applying the following assumptions:</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1551720692058">
<table cellpadding="0" cellspacing="0" style="margin: 0pt auto 0pt 27pt; width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="3" rowspan="1" style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Year Ended</b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>December 31</b><b>, 2018</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Risk free interest rate</p>
			</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.51</p>
			</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</p>
			</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.94%</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected term (in years)</p>
			</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.5</p>
			</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</p>
			</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5.0</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stock price</p>
			</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$1.02</p>
			</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</p>
			</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$2.38</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Dividend yield</p>
			</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected volatility</p>
			</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">122.0</p>
			</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</p>
			</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">125.0%</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Refer to footnote <a class="rdg_comment commentapprove" name="doccmt-698">16 </a>for&nbsp;further description.</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="52820" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1553033163886">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>NOTE 15:&nbsp; RESTATEMENT TO PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></b></p>

<p style="margin: 0pt 22.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>&nbsp;</b></b></p>

<p style="margin: 0pt 14.7pt 0pt 6pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has corrected an inadvertent error in the calculation of the deemed dividend on Series B convertible preferred stock in the financial statements for the three and six months ended June 30, 2018 that were included in the Company&rsquo;s Form 10-Q filed on August 13, 2018 (the &ldquo;Original Form 10-Q&rdquo;). Accounting principles generally accepted in the United States of America require that we allocate the proceeds from the May 2018 financing to the warrants and preferred stock issued in the financing and that we estimate and record any discount on the securities as a deemed dividend. In the financial statements included in the Original Form 10-Q, we did not properly allocate the proceeds to the warrants, and we did not properly record the deemed dividend related to the warrant discount as additional paid in capital to common stock. The Company incorrectly stated the deemed dividend for the three and six months ended June 30, 2018 as $4,782,100, rather than $11,479,308. The corrections result from application of technical accounting rules and do not impact cash or operations.</p>

<p style="margin: 0pt 22.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 14.7pt 0pt 6pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In accordance with applicable generally accepted accounting principles, the Company has calculated and recognized adjustments accordingly. The following table shows the effect of the restatement on certain line items within the Company&rsquo;s Condensed Consolidated Statement of Operations for the three months and six months ended June 30, 2018: &nbsp;</p>

<p style="margin: 0pt 22.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1553033180711">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>For the Three Months Ended<br>
			June 30, 2018</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>For the Six Months Ended<br>
			June 30, 2018</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 12%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Previously</b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Reported</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 12%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Restated</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 12%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Previously</b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Reported</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 12%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Restated</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deemed dividend attributable to preferred stock</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(4,782,100</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(11,479,308</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(4,782,100</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(11,479,308</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Net loss applicable to common stockholders</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(8,924,677</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(15,621,885</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(10,799,059</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(17,496,267</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Loss per common share -basic and diluted</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2.90</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(5.08</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3.77</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(6.11</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>

</table>
</div>

<p style="margin: 0pt 22.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 14.7pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table shows the effect of the restatement on certain line items within the Company&rsquo;s Condensed Consolidated Statement of Stockholders&rsquo; Equity for the six months ended June 30, 2018: &nbsp;</p>

<p style="margin: 0pt 22.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1553033183299">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Preferred Stock Additional Paid-in Capital</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Common Stock Additional Paid-in Capital</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 12%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Previously</b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Reported</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 12%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Restated</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 12%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Previously</b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Reported</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 12%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Restated</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Issuance of Series B convertible preferred stock, net of issuance costs</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12,290,537</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6,926,778</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">0</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5,363,759</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deemed Dividend on Series B convertible preferred stock</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4,782,100</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">11,479,308</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(4,782,100</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(11,479,308</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Conversion of Series B convertible preferred stock to common stock</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(7,056,421</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(7,821,992</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6,656,442</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</p>
			</td>
			<td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7,422,013</p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="52821" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1553033173637">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE 16</b><b>: SUBSEQUENT EVENTS</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i><b>Stock Option and Incentive Plan</b></i></b></p>

<p style="margin: 0pt 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">June 27, 2018, the Company granted 2,300,000 options to the Chief Executive Officer and 700,000 to the Chief Financial Officer (collectively, the &ldquo;2018&nbsp;Liability Options&rdquo;). Each option was exercisable for an equivalent number of shares of Company common stock.&nbsp;The 2018 Liability Options contained a &ldquo;Net Cash Exercise Provision&rdquo; so that if at the time the 2018 Liability&nbsp;Options were exercised the Company could not deliver shares of Common Stock to the optionee (including, for example, if there were insufficient shares available under the Plan at the time of exercise), then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option would only be exercised on a cash &ldquo;net basis&rdquo; requiring that the Company pay cash in an amount equal to the excess of the fair market value of the Common Stock over the option exercise price.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On January 13, 2019, the Company,&nbsp;CEO and CFO&nbsp;agreed to cancel and terminate the&nbsp;2018 Liability&nbsp;Options so they are no longer outstanding and of no further force and effect. On January 13, 2019, the Company granted a new option to the CEO to purchase 2,300,000 shares of Common Stock and a new option to&nbsp;the&nbsp;CFO&nbsp;to purchase 800,000 shares of Common Stock (the &ldquo;2019 Options&rdquo;). The 2019 Options: (i) have an exercise price equal to the fair market value of Common Stock on the date of grant which was $1.36 per share, (ii) do not contain a Net Cash Exercise provision, (iii) are granted pursuant to the terms and conditions of the Plan as amended by the Board of Directors on January 13, 2019, to include shares issuable upon exercise of the 2019 Options and other changes to the Plan so that the 2019 Options do not conflict with the Plan (the &ldquo;Amended Plan&rdquo;), (iv) vest and are exercisable in accordance with the vesting schedule related to the&nbsp;2018 Liability&nbsp;Options; provided, however, that the 2019 Options are not exercisable unless and until the Company&rsquo;s stockholders approve the Amended Plan to increase the authorized number of shares available for grant under the Plan as only 3,575 options were available for grant as of December 31, 2018, and&nbsp;(vi) are subject to and conditioned the 2019 Option Agreements with the optionees and the employment agreements with the optionees.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The above actions were unanimously approved by the disinterested members&nbsp;of the Board of Directors. The above actions are intended to eliminate the Company&rsquo;s potential liability associated with the Net Cash Exercise Provision of the liability options, and to allow the stockholders of the Company the opportunity to vote on the Amended Plan, which includes shares issuable upon exercise of the 2019 Options.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;<a class="rdg_comment commentapprove" id="doccmt-675" name="doccmt-675"><i>Warrant Exercises</i></a></b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In&nbsp;March 2019, the Company received approximately $11.3 million from exercises of warrants issued on May 30, 2018. As a result of the warrant exercises, the Company retired approximately 2.8 million warrants and issued approximately 2.8 million shares of common stock.</p>

<p style="margin: 0pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">74</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="12" id="49402" sectdesc="Other">&nbsp;</div>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">EXHIBIT INDEX&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="3" style="width: 301%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a class="rdg_comment commentapprove" name="doccmt-535"><b>Incorporated by Reference Herein</b></a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Exhibit&nbsp;No.</b></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Description</b></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Form</b></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex1-1.htm" style="-sec-extract: exhibit;">1.1</a></td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex1-1.htm" style="-sec-extract: exhibit;">Form of Dealer-Manager Agreement</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex1-1.htm" style="-sec-extract: exhibit;">Amendment No. 1 to Registration Statement on Form S-1, as Exhibit 1.1</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex1-1.htm" style="-sec-extract: exhibit;">April 23, 2018</a></td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex3-2.htm" style="-sec-extract: exhibit;">3.1</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex3-2.htm" style="-sec-extract: exhibit;">Amended and Restated Certificate of Incorporation of Atossa Genetics Inc.</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex3-2.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 3.2</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex3-2.htm" style="-sec-extract: exhibit;">June 11, 2012</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416121498/v447714_ex4-1.htm" style="-sec-extract: exhibit;">3.2</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416121498/v447714_ex4-1.htm" style="-sec-extract: exhibit;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Atossa Genetics Inc.</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416121498/v447714_ex4-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 4.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416121498/v447714_ex4-1.htm" style="-sec-extract: exhibit;">August 26, 2016</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex3-4.htm" style="-sec-extract: exhibit;">3.3</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex3-4.htm" style="-sec-extract: exhibit;">Bylaws of Atossa Genetics Inc.</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex3-4.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 3.4</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex3-4.htm" style="-sec-extract: exhibit;">June 11, 2012</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412069016/v330725_ex3-1.htm" style="-sec-extract: exhibit;">3.4</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412069016/v330725_ex3-1.htm" style="-sec-extract: exhibit;">Amendment to Bylaws of Atossa Genetics Inc.</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412069016/v330725_ex3-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 3.1</a></td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412069016/v330725_ex3-1.htm" style="-sec-extract: exhibit;">December 20, 2012</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414032964/v379431_ex3-1.htm" style="-sec-extract: exhibit;">3.5</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414032964/v379431_ex3-1.htm" style="-sec-extract: exhibit;">Certificate of Designation, Preferences, and Rights of Series A Junior Participating Preferred Stock of Atossa Genetics, Inc.</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414032964/v379431_ex3-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 3.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414032964/v379431_ex3-1.htm" style="-sec-extract: exhibit;">May 22, 2014</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417002259/s105962_ex3-1.htm" style="-sec-extract: exhibit;">3.6</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417002259/s105962_ex3-1.htm" style="-sec-extract: exhibit;">Certificate of Designation of Preference, Rights and Limitations of Series A Convertible Preferred Stock</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417002259/s105962_ex3-1.htm" style="-sec-extract: exhibit;">Current Report on Form 10Q, as Exhibit 3.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417002259/s105962_ex3-1.htm" style="-sec-extract: exhibit;">May 11, 2017</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-1.htm" style="-sec-extract: exhibit;">3.7</a></td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-1.htm" style="-sec-extract: exhibit;">Form of Certificate of Designation of Preference, Rights and Limitations of Series B Convertible Preferred Stock</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-1.htm" style="-sec-extract: exhibit;">Amendment No. 1 to Registration Statement on Form S-1, as Exhibit 4.1</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-1.htm" style="-sec-extract: exhibit;">April 23, 2018</a></td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412030728/v310463_ex4-1.htm" style="-sec-extract: exhibit;">4.1</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412030728/v310463_ex4-1.htm" style="-sec-extract: exhibit;">Specimen common stock certificate</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412030728/v310463_ex4-1.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 4.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412030728/v310463_ex4-1.htm" style="-sec-extract: exhibit;">May 21, 2012</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412054574/v324416_ex4-2.htm" style="-sec-extract: exhibit;">4.2</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412054574/v324416_ex4-2.htm" style="-sec-extract: exhibit;">Form of Warrant from 2011 private placement</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412054574/v324416_ex4-2.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 4.2</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412054574/v324416_ex4-2.htm" style="-sec-extract: exhibit;">October 4, 2012</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412054574/v324416_ex4-3.htm" style="-sec-extract: exhibit;">4.3</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412054574/v324416_ex4-3.htm" style="-sec-extract: exhibit;">Form of Placement Agent Warrant from 2011 private placement</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412054574/v324416_ex4-3.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 4.3</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412054574/v324416_ex4-3.htm" style="-sec-extract: exhibit;">October 4, 2012</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412054574/v324416_ex4-4.htm" style="-sec-extract: exhibit;">4.4</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412054574/v324416_ex4-4.htm" style="-sec-extract: exhibit;">Form of Warrant dated September 30, 2012</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412054574/v324416_ex4-4.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 4.4</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412054574/v324416_ex4-4.htm" style="-sec-extract: exhibit;">October 4, 2012</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416105300/v441040_ex4-1.htm" style="-sec-extract: exhibit;">4.5</a></td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416105300/v441040_ex4-1.htm" style="-sec-extract: exhibit;">Registration Rights Agreement&nbsp;, dated as of May 25, 2016&nbsp;by and between the Company and&nbsp;Aspire&nbsp;Capital Fund, LLC.</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416105300/v441040_ex4-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 4.1</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416105300/v441040_ex4-1.htm" style="-sec-extract: exhibit;">May 27, 2016</a></td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414003982/v366184_ex4-1.htm" style="-sec-extract: exhibit;">4.6</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414003982/v366184_ex4-1.htm" style="-sec-extract: exhibit;">Form of Warrant Agreement from January 2014 Public Offering</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414003982/v366184_ex4-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 4.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414003982/v366184_ex4-1.htm" style="-sec-extract: exhibit;">January 24, 2014</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414003982/v366184_ex4-2.htm" style="-sec-extract: exhibit;">4.7</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414003982/v366184_ex4-2.htm" style="-sec-extract: exhibit;">Form of Warrant issued to Dawson James Securities Inc. in January 2014</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414003982/v366184_ex4-2.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 4.2</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414003982/v366184_ex4-2.htm" style="-sec-extract: exhibit;">January 24, 2014</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414032964/v379431_ex4-1.htm" style="-sec-extract: exhibit;">4.8</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414032964/v379431_ex4-1.htm" style="-sec-extract: exhibit;">Rights Agreement dated as of May 19, 2014, by and between the Company and VStock Transfer LLC, as rights agent, which includes as Exhibit B the Form of Rights Certificate</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414032964/v379431_ex4-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 4.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420414032964/v379431_ex4-1.htm" style="-sec-extract: exhibit;">May 22, 2014</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex4-1.htm" style="-sec-extract: exhibit;">4.9</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex4-1.htm" style="-sec-extract: exhibit;">Form of Common Stock Purchase Warrant A</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex4-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 4.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex4-1.htm" style="-sec-extract: exhibit;">December 22, 2017</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex4-2.htm" style="-sec-extract: exhibit;">4.10</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex4-2.htm" style="-sec-extract: exhibit;">Form of Commons Stock Purchase Warrant B</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex4-2.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 4.2</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex4-2.htm" style="-sec-extract: exhibit;">December 22, 2017</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002808/s109743_ex4-1.htm" style="-sec-extract: exhibit;">4.11</a></td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002808/s109743_ex4-1.htm" style="-sec-extract: exhibit;">Certificate of Amendment to Amended&nbsp;and Restated Certificate of Incorporation of Atossa Genetics Inc.</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002808/s109743_ex4-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 4.1</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002808/s109743_ex4-1.htm" style="-sec-extract: exhibit;">April 23, 2018</a></td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-2.htm" style="-sec-extract: exhibit;">4.12</a></td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-2.htm" style="-sec-extract: exhibit;">Form of Warrant Agreement</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-2.htm" style="-sec-extract: exhibit;">Amendment No.1 to Registration Statement on Form S-1, as Exhibit 4.2</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-2.htm" style="-sec-extract: exhibit;">April 23, 2018</a></td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-3.htm" style="-sec-extract: exhibit;">4.13</a></td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-3.htm" style="-sec-extract: exhibit;">Form of Warrant Certificate</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-3.htm" style="-sec-extract: exhibit;">Amendment No. 1 to Registration Statement on Form S-1, as Exhibit 4.3</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-3.htm" style="-sec-extract: exhibit;">April 23, 2018</a></td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-4.htm" style="-sec-extract: exhibit;">4.14</a></td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-4.htm" style="-sec-extract: exhibit;">Form of Non-Transferable Subscription Rights Certificate</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-4.htm" style="-sec-extract: exhibit;">Amendment No. 1 to Registration Statement on Form S-1, as Exhibit 4.4</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/s109744_ex4-4.htm" style="-sec-extract: exhibit;">April 23, 2018</a></td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; text-align: center; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000143774919000870/ex_132964.htm" style="-sec-extract: exhibit;">4.15</a></td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000143774919000870/ex_132964.htm" style="-sec-extract: exhibit;">Form of 2019 Option Award Agreement</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000143774919000870/ex_132964.htm" style="-sec-extract: exhibit;">Current Report on Form 8K, as Exhibit 4.1</a></td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; text-align: center; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000143774919000870/ex_132964.htm" style="-sec-extract: exhibit;">January 13, 2019</a></td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8px; vertical-align: top;">&nbsp;</td>
			<td style="width: 494px; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; text-align: center; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; text-align: center; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412007893/v301800_ex10-3.htm" style="-sec-extract: exhibit;">10.1</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412007893/v301800_ex10-3.htm" style="-sec-extract: exhibit;">Restated and Amended Employment Agreement with Steven Quay</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412007893/v301800_ex10-3.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 10.3</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412007893/v301800_ex10-3.htm" style="-sec-extract: exhibit;">February 14, 2012</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412030728/v310463_ex10-5.htm" style="-sec-extract: exhibit;">10.2</a></p>
			</td>
			<td style="width: 8px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 494px; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412030728/v310463_ex10-5.htm" style="-sec-extract: exhibit;">Form of Indemnification Agreement</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412030728/v310463_ex10-5.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 10.5</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412030728/v310463_ex10-5.htm" style="-sec-extract: exhibit;">May 21, 2012</a></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">75</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-7.htm" style="-sec-extract: exhibit;">10.3</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-7.htm" style="-sec-extract: exhibit;">Form of Incentive Stock Option Agreement</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-7.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 10.7</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-7.htm" style="-sec-extract: exhibit;">June 11, 2012</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-8.htm" style="-sec-extract: exhibit;">10.4</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-8.htm" style="-sec-extract: exhibit;">Form of Non-Qualified Stock Option Agreement for Employees</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-8.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 10.8</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-8.htm" style="-sec-extract: exhibit;">June 11, 2012</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-9.htm" style="-sec-extract: exhibit;">10.5</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-9.htm" style="-sec-extract: exhibit;">Form of Non-Qualified Stock Option Agreement for Non-Employee Directors</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-9.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 10.9</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-9.htm" style="-sec-extract: exhibit;">June 11, 2012</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412020447/v306694_ex10-12.htm" style="-sec-extract: exhibit;">10.6</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412020447/v306694_ex10-12.htm" style="-sec-extract: exhibit;">Patent Assignment Agreement by and between the Company and Ensisheim Partners, LLC</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412020447/v306694_ex10-12.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 10.12</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412020447/v306694_ex10-12.htm" style="-sec-extract: exhibit;">April 6, 2012&nbsp;</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-13.htm" style="-sec-extract: exhibit;">10.7</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-13.htm" style="-sec-extract: exhibit;">Form of Restricted Stock Award Agreement</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-13.htm" style="-sec-extract: exhibit;">Registration Statement on Form S-1, as Exhibit 10.13</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420412034079/v315460_ex10-13.htm" style="-sec-extract: exhibit;">June 11, 2012</a></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416103985/v440599_ex99-1.htm" style="-sec-extract: exhibit;">10.8</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416103985/v440599_ex99-1.htm" style="-sec-extract: exhibit;">Amended and Restated Employment Agreement between the Company and Kyle Guse dated May 18, 2016</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416103985/v440599_ex99-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 10.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416103985/v440599_ex99-1.htm" style="-sec-extract: exhibit;">May 20, 2016</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420415064686/v422970_ex10-1.htm" style="-sec-extract: exhibit;">10.9</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420415064686/v422970_ex10-1.htm" style="-sec-extract: exhibit;">Common Stock Purchase Agreement, between the Company and Aspire Capital Fund, LLC, dated as of November 11, 2015.</a></td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420415064686/v422970_ex10-1.htm" style="-sec-extract: exhibit;">Quarterly Report on Form 10-Q, as Exhibit 10.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420415064686/v422970_ex10-1.htm" style="-sec-extract: exhibit;">November 12, 2015</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 41%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 18%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416105300/v441040_ex10-1.htm" style="-sec-extract: exhibit;">10.10</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416105300/v441040_ex10-1.htm" style="-sec-extract: exhibit;">Common Stock Purchase Agreement, between the Company and Aspire Capital Fund, LLC, dated as of May 25, 2016.</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416105300/v441040_ex10-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 10.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416105300/v441040_ex10-1.htm" style="-sec-extract: exhibit;">May 27, 2016</a></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">76</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;"><a href="#toc">Table of Contents</a></div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420415031846/v410987_ex10-1.htm" style="-sec-extract: exhibit;">10.11</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420415031846/v410987_ex10-1.htm" style="-sec-extract: exhibit;">Intellectual Property License Agreement between Atossa Genetics Inc. and Besins Healthcare Luxembourg SARL, dated May 14, 2015.</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420415031846/v410987_ex10-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 10.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420415031846/v410987_ex10-1.htm" style="-sec-extract: exhibit;">May 18, 2015</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416116738/v446144_ex10-1.htm" style="-sec-extract: exhibit;">10.12</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416116738/v446144_ex10-1.htm" style="-sec-extract: exhibit;">Settlement and Termination of License Agreement between Besins Healthcare Luxembourg SARL and its Affiliates and Atossa Genetics, Inc. dated August 4, 2016.</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416116738/v446144_ex10-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 10.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420416116738/v446144_ex10-1.htm" style="-sec-extract: exhibit;">&nbsp;August 5, 2016</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420415071223/v426801_ex10-1.htm" style="-sec-extract: exhibit;">10.13</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420415071223/v426801_ex10-1.htm" style="-sec-extract: exhibit;">Stock Purchase Agreement by and among the Company, the National Reference Laboratory for Breast Health, Inc. and NRL Investment Group, LLC, dated December 16, 2015.</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420415071223/v426801_ex10-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 10.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000114420415071223/v426801_ex10-1.htm" style="-sec-extract: exhibit;">December 16, 2015</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000143774919000870/ex_132965.htm" style="-sec-extract: exhibit;">10.14</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000143774919000870/ex_132965.htm" style="-sec-extract: exhibit;">2010 Stock Option and Incentive Plan, as amended January 13, 2019</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000143774919000870/ex_132965.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 4.2</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000143774919000870/ex_132965.htm" style="-sec-extract: exhibit;">January&nbsp;15, 2019</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex10-1.htm" style="-sec-extract: exhibit;">10.15</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex10-1.htm" style="-sec-extract: exhibit;">Placement agreement between Atossa Genetics Inc. and Maxim Corp. as representative of the Purchasers, dated December 20, 2017&nbsp;</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex10-1.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 10.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex10-1.htm" style="-sec-extract: exhibit;">December 22, 2017</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex10-2.htm" style="-sec-extract: exhibit;">10.16</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex10-2.htm" style="-sec-extract: exhibit;">Securities Purchase agreement between Atossa Genetics Inc. and each purchaser</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex10-2.htm" style="-sec-extract: exhibit;">Current Report on Form 8-K, as Exhibit 10.2</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/s108519_ex10-2.htm" style="-sec-extract: exhibit;">December 22, 2017</a></p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135719.htm" style="-sec-extract: exhibit;">22.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135719.htm" style="-sec-extract: exhibit;">List of Subsidiaries</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135719.htm" style="-sec-extract: exhibit;">Filed herewith</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135720.htm" style="-sec-extract: exhibit;">23.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135720.htm" style="-sec-extract: exhibit;">Consent of BDO USA LLP</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135720.htm" style="-sec-extract: exhibit;">Filed herewith</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#poa" style="-sec-extract: exhibit;">24.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#poa" style="-sec-extract: exhibit;">Powers of Attorney</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="#poa" style="-sec-extract: exhibit;">Filed Herewith on the signature page</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135721.htm" style="-sec-extract: exhibit;">31.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135721.htm" style="-sec-extract: exhibit;">Certification pursuant to Rule&nbsp;13a-14(a) under the Securities Exchange Act of 1934 of Steven C. Quay</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135721.htm" style="-sec-extract: exhibit;">Filed herewith</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135722.htm" style="-sec-extract: exhibit;">31.2</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135722.htm" style="-sec-extract: exhibit;">Certification pursuant to Rule&nbsp;13a-14(a) under the Securities Exchange Act of Kyle Guse</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135722.htm" style="-sec-extract: exhibit;">Filed herewith</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135723.htm" style="-sec-extract: exhibit;">32.1</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135723.htm" style="-sec-extract: exhibit;">Certification pursuant to 18 U.S.C. Section&nbsp;1350 of Steven C. Quay</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135723.htm" style="-sec-extract: exhibit;">Filed herewith</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135724.htm" style="-sec-extract: exhibit;">32.2</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135724.htm" style="-sec-extract: exhibit;">Certification pursuant to 18 U.S.C. Section&nbsp;1350 of Kyle Guse</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_135724.htm" style="-sec-extract: exhibit;">Filed herewith</a></p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.INS</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">XBRL Instance Document</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.SCH</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">XBRL Taxonomy Extension Schema Document</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.CAL</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.DEF</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">XBRL Taxonomy Extension Definition Linkbase Document</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.LAB</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">XBRL Taxonomy Extension Labels Linkbase Document</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101.PRE</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 41%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 30%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 1%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 18%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">#</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Indicates management contract or compensatory plan, contract or agreement.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&dagger;&dagger;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Schedules and exhibits omitted pursuant to Item 601 of Regulation S-K.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt 7.2pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">77</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 7.2pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a id="signatures" name="signatures"></a><b>SIGNATURES</b></p>

<p style="margin: 0pt 7.2pt; text-align: justify; text-indent: 24.5pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pursuant to the requirements Section 13 or 15(d) of the Securities Exchange Act of 1934, the issuer, a corporation organized and existing under the laws of the State of Delaware, has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized in the City of Seattle, State of Washington, on the&nbsp;28th day of March, 2019.</p>

<p style="margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 50%; vertical-align: top;">&nbsp;</td>
			<td colspan="2" style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Atossa Genetics Inc.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="width: 46%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By:&nbsp;</p>
			</td>
			<td style="width: 46%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Steven C. Quay</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="width: 46%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Steven C. Quay, M.D., Ph.D.</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="width: 46%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Chairman, Chief Executive Officer and President</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt 7.2pt; text-align: center; text-indent: 24.5pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt 7.2pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><a id="poa" name="poa"></a>POWER OF ATTORNEY</b></p>

<p style="margin: 0pt 7.2pt; text-align: justify; text-indent: 24.5pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Steven C. Quay and Kyle Guse and each of them acting individually, as his true and lawful attorneys-in-fact and agents, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this report on Form&nbsp;10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>

<p style="margin: 0pt 7.2pt; text-align: justify; text-indent: 24.5pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form&nbsp;10-K has been signed by the following persons in the capacities and on the dates indicated</b></p>

<p style="margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 28%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Signature</b></p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Office(s)</b></p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Steven C. Quay</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chairman, Chief Executive</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 28, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Steven C. Quay, M.D., Ph.D.</b></p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Officer and President</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Principal Executive Officer)</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Kyle Guse</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chief Financial Officer, General Counsel and Secretary</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 28, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Kyle Guse</b></p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Principal Financial and</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Accounting Officer)</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Richard I. Steinhart</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 28, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Richard I. Steinhart</b></p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Shu-Chi Chen</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 28, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Shu-Chih Chen, Ph.D.</b></p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Gregory Weaver</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 28, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Gregory Weaver</b></p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Stephen J. Galli</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 28, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Stephen J. Galli, M.D.</b></p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ H. Lawrence Remmel</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 15%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 28, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="width: 28%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>H. Lawrence Remmel</b></p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 55%; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%; vertical-align: middle;">&nbsp;</td>
			<td style="width: 15%; vertical-align: middle;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">78</p>

<p>&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-22.1
<SEQUENCE>2
<FILENAME>ex_135719.htm
<DESCRIPTION>EXHIBIT 22.1
<TEXT>
<html>
<head>
	<title>ex_135719.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 2/25/2019 6:45:34 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;"><b>Exhibit&nbsp;22.1</b></p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:92.3%;margin-right:0pt;margin-top:0pt;text-align:right;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>LIST OF SUBSIDIARIES</b></p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Atossa Genetics UK Ltd.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Atossa Genetics AUS Pty Ltd.</b></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex_135720.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
<head>
	<title>ex_135720.htm</title>
	<!-- Created by RDG HTML Converter v1.1.0.0 2/25/2019 6:45:44 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="padding: 0in 0.1in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; cursor: auto;">
<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Exhibit 23.1</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Atossa Genetics Inc.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Seattle, Washington</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-1<a class="rdg_comment commentapprove" id="doccmt-674" name="doccmt-674"> (333-223949), Form S-3 (333-192390 and 333-220572), and Form S-8 (No. 333-185625 and 333-193952) </a>of Atossa Genetics Inc. of our report dated March 28, 2019, relating to the consolidated financial statements, which appears in this Form 10-K.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ BDO USA, LLP</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Seattle, Washington</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 28, 2019</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex_135721.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
	<title>ex_135721.htm</title>
	<!-- Created by RDG HTML Converter v1.1.0.0 2/25/2019 6:46:15 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="padding: 0in 0.1in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Exhibit&nbsp;31.1</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>CERTIFICATION PURSUANT TO RULE 13a-14(a)</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934, AS AMENDED</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF&nbsp;2002</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">I, Steven C. Quay, certify that:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Annual Report of Atossa Genetics&nbsp;Inc.;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#39;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(a)&nbsp;&nbsp;&nbsp;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(b)&nbsp;&nbsp;&nbsp;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(c)&nbsp;&nbsp;&nbsp;evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(d)&nbsp;&nbsp;&nbsp;disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#39;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent function):</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(a)&nbsp;&nbsp;&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(b)&nbsp;&nbsp;&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Date: March 28, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/Steven C. Quay</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Steven C. Quay</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Chief Executive Officer and President</i></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>(Principal executive officer)</i></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex_135722.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
	<title>ex_135722.htm</title>
	<!-- Created by RDG HTML Converter v1.1.0.0 2/25/2019 6:46:36 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="padding: 0in 0.1in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Exhibit&nbsp;31.2</b></p>

<p style="margin: 0pt; text-align: center; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>CERTIFICATION PURSUANT TO RULE 13a-14(a)</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934, AS AMENDED</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF&nbsp;2002</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">I, Kyle Guse, certify that:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Annual Report of Atossa Genetics&nbsp;Inc.;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#39;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(a)&nbsp;&nbsp;&nbsp;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(b)&nbsp;&nbsp;&nbsp;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(c)&nbsp;&nbsp;&nbsp;evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(d)&nbsp;&nbsp;&nbsp;disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#39;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent function):</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(a)&nbsp;&nbsp;&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(b)&nbsp;&nbsp;&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Date: March 28, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/Kyle Guse</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Kyle Guse</p>

			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Chief Financial Officer, General Counsel and Secretary</i></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>(Principal financial and accounting officer)</i></p>
			</td>
		</tr>

</table>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex_135723.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
	<title>ex_135723.htm</title>
	<!-- Created by RDG HTML Converter v1.1.0.0 2/25/2019 6:46:46 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="padding: 0in 0.1in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;<b>Exhibit&nbsp;32.1</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>18 U.S.C. SECTION&nbsp;1350,</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF&nbsp;2002</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">In connection with the Annual Report of Atossa Genetics Inc. (the &quot;Company&quot;) on Form&nbsp;10-K for the period ending December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &quot;Report&quot;), I, Steven C. Quay, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(1)&nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(2)&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Date: March 28, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/&nbsp;Steven C. Quay</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Steven C. Quay</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Chief Executive Officer and President</i></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>(Principal executive officer)</i></p>
			</td>
		</tr>

</table>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex_135724.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
<head>
	<title>ex_135724.htm</title>
	<!-- Created by RDG HTML Converter v1.1.0.0 2/25/2019 6:46:55 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="padding: 0in 0.1in; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; cursor: auto;">
<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Exhibit&nbsp;32.2</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>18 U.S.C. SECTION&nbsp;1350,</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><b>SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF&nbsp;2002</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">In connection with the Annual Report of Atossa Genetics Inc. (the &quot;Company&quot;) on Form&nbsp;10-K for the period ending December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &quot;Report&quot;), I, Kyle Guse, Chief Financial Officer, General Counsel and Secretary of the Company, certify, pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(1)&nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">(2)&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Date: March 28, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Kyle Guse</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Kyle Guse</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Chief Financial Officer, General Counsel and Secretary</i></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 50%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>(Principal financial and accounting officer)</i></p>
			</td>
		</tr>

</table>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>atos-20181231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:01PM UTC 2019-03-28--><xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.xbrl.org/2003/instance" xmlns:atos="http://www.atossagenetics.com/20181231" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="atos-20181231.xsd" xlink:type="simple"/>
  <atos:AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310898" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310899" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310901" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310902" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45310904" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310905" unitRef="iso4217-usd">328350</atos:AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability>
  <atos:AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45310906" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310907" unitRef="iso4217-usd">328350</atos:AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability>
  <atos:AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock contextRef="d_2017-04-03_2017-04-03_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember" decimals="INF" id="c45311487" unitRef="iso4217-usd">1284066</atos:AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock>
  <atos:AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock contextRef="d_2018-01-01_2018-12-31_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311576" unitRef="iso4217-usd">4782100</atos:AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310942" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310943" unitRef="iso4217-usd">2568132</atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310945" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310946" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45310948" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310949" unitRef="iso4217-usd">-2568132</atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45310950" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2017-01-01_2017-12-31" id="c45310951" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311063" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311064" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311066" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311067" unitRef="iso4217-usd">11479308</atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45311069" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311070" unitRef="iso4217-usd">-11479308</atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45311071" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend contextRef="d_2018-01-01_2018-12-31" id="c45311072" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310874" unitRef="iso4217-usd">768412</atos:AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts>
  <atos:AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311050" unitRef="iso4217-usd">1333449</atos:AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts>
  <atos:AmortizationOfCommitmentShares contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311195" unitRef="iso4217-usd">72790</atos:AmortizationOfCommitmentShares>
  <atos:AmortizationOfCommitmentShares contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311196" unitRef="iso4217-usd">79410</atos:AmortizationOfCommitmentShares>
  <atos:AmortizationOfCommitmentShares contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310986" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AmortizationOfCommitmentShares contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310987" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AmortizationOfCommitmentShares contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310989" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AmortizationOfCommitmentShares contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310990" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AmortizationOfCommitmentShares contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45310992" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AmortizationOfCommitmentShares contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310993" unitRef="iso4217-usd">79410</atos:AmortizationOfCommitmentShares>
  <atos:AmortizationOfCommitmentShares contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45310994" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AmortizationOfCommitmentShares contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311085" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AmortizationOfCommitmentShares contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311086" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AmortizationOfCommitmentShares contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311088" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AmortizationOfCommitmentShares contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311089" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AmortizationOfCommitmentShares contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45311091" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:AmortizationOfCommitmentShares contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311092" unitRef="iso4217-usd">72790</atos:AmortizationOfCommitmentShares>
  <atos:AmortizationOfCommitmentShares contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45311093" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:ChangeInStockBasedCompensationLiability contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311150" unitRef="iso4217-usd">1410025</atos:ChangeInStockBasedCompensationLiability>
  <atos:ChangeInStockBasedCompensationLiability contextRef="d_2017-01-01_2017-12-31" id="c45311151" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:ClassOfWarrantOrRightCancelled contextRef="d_2017-06-29_2017-06-29_ClassOfWarrantOrRightAxis-The2017PublicOfferingWarrantsMember" decimals="INF" id="c45311494" unitRef="xbrli-shares">250000</atos:ClassOfWarrantOrRightCancelled>
  <atos:ClassOfWarrantOrRightExercisablePeriod contextRef="d_2017-12-20_2017-12-20_ClassOfWarrantOrRightAxis-ClassAAndClassBWarrantsMember_SubsidiarySaleOfStockAxis-December2017PublicOfferingAndPrivatePlacementMember" id="c45311527">P180D</atos:ClassOfWarrantOrRightExercisablePeriod>
  <atos:ClassOfWarrantOrRightExercised contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311595" unitRef="xbrli-shares">488611</atos:ClassOfWarrantOrRightExercised>
  <atos:ClassOfWarrantOrRightExercisedExercisePrice contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311596" unitRef="iso4217-usd-per-xbrli-shares">3.12</atos:ClassOfWarrantOrRightExercisedExercisePrice>
  <atos:ClassOfWarrantOrRightGranted contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311593" unitRef="xbrli-shares">488611</atos:ClassOfWarrantOrRightGranted>
  <atos:ClassOfWarrantOrRightGrantedExercisePrice contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311594" unitRef="iso4217-usd-per-xbrli-shares">11.25</atos:ClassOfWarrantOrRightGrantedExercisePrice>
  <atos:ClassOfWarrantOrRightRetired contextRef="d_2019-03-01_2019-03-24_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c45312037" unitRef="xbrli-shares">2800000</atos:ClassOfWarrantOrRightRetired>
  <atos:CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed contextRef="i_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember" decimals="INF" id="c45311567" unitRef="xbrli-pure">0.0999</atos:CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed>
  <atos:ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares contextRef="i_2018-12-31" decimals="INF" id="c45311552" unitRef="xbrli-pure">0.5</atos:ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares>
  <atos:ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower contextRef="i_2018-12-31" decimals="INF" id="c45311553" unitRef="xbrli-pure">0.5</atos:ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower>
  <atos:ConvertiblePreferredStockSharesIssuable contextRef="i_2017-04-03_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember" decimals="INF" id="c45311477" unitRef="xbrli-shares">389111</atos:ConvertiblePreferredStockSharesIssuable>
  <atos:DeemedDividendOnSeriesBConvertiblePreferredStock contextRef="d_2018-04-01_2018-06-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45311981" unitRef="iso4217-usd">11479308</atos:DeemedDividendOnSeriesBConvertiblePreferredStock>
  <atos:DividendOnSeriesConvertiblePreferredStock contextRef="d_2018-04-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalConvertiblePreferredStockMember" decimals="INF" id="c45312002" unitRef="iso4217-usd">4782100</atos:DividendOnSeriesConvertiblePreferredStock>
  <atos:DividendOnSeriesConvertiblePreferredStock contextRef="d_2018-04-01_2018-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalConvertiblePreferredStockMember" decimals="INF" id="c45312003" unitRef="iso4217-usd">11479308</atos:DividendOnSeriesConvertiblePreferredStock>
  <atos:DividendOnSeriesConvertiblePreferredStock contextRef="d_2018-01-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalCommonStockMember" decimals="INF" id="c45312004" unitRef="iso4217-usd">-4782100</atos:DividendOnSeriesConvertiblePreferredStock>
  <atos:DividendOnSeriesConvertiblePreferredStock contextRef="d_2018-01-01_2018-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalCommonStockMember" decimals="INF" id="c45312005" unitRef="iso4217-usd">-11479308</atos:DividendOnSeriesConvertiblePreferredStock>
  <atos:EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation contextRef="d_2018-01-01_2018-12-31" id="c45311755" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311756" unitRef="iso4217-usd">16119293</atos:EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation>
  <atos:ExpirationDatesOfClassOfWarrantOrRight contextRef="d_2018-01-01_2018-12-31_ClassOfWarrantOrRightAxis-The2014PublicOfferingMember" id="c45311643">January 29, 2019</atos:ExpirationDatesOfClassOfWarrantOrRight>
  <atos:ExpirationDatesOfClassOfWarrantOrRight contextRef="d_2018-01-01_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember" id="c45311647">May 30, 2022</atos:ExpirationDatesOfClassOfWarrantOrRight>
  <atos:ExpirationDatesOfClassOfWarrantOrRight contextRef="d_2018-01-01_2018-12-31" id="c45311651" xs:nil="true"/>
  <atos:FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c45311242">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Financial Instruments with Characteristics of Both Liabilities and Equity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;During the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;the Company issued certain financial instruments, consisting of warrants to purchase common stock, which have characteristics of both liability and equity. Financial instruments such as warrants that are classified as liabilities are fair valued upon issuance and are re-measured at fair value at subsequent reporting periods with the resulting change in fair value recorded in &amp;#x201c;change in fair value of common stock warrants&amp;#x201d; in the consolidated statement of operations. The fair value of warrants is estimated using valuation models that require the input of subjective assumptions including stock price volatility, expected life, and the probability of future equity issuances and their impact to the price protection feature. There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; outstanding warrants accounted for as liabilities as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</atos:FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock>
  <atos:IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable contextRef="d_2018-01-01_2018-12-31_ConsolidatedEntitiesAxis-AtossaGeneticsAUSPtyLtdMember" decimals="INF" id="c45311406" unitRef="iso4217-usd">370000</atos:IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable>
  <atos:IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable contextRef="d_2017-01-01_2017-12-31_ConsolidatedEntitiesAxis-AtossaGeneticsAUSPtyLtdMember" decimals="INF" id="c45311407" unitRef="iso4217-usd">358000</atos:IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable>
  <atos:IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311155" unitRef="iso4217-usd">159821</atos:IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable>
  <atos:IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311156" unitRef="iso4217-usd">358277</atos:IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable>
  <atos:IntangibleAssetMeasurementInput contextRef="i_2018-12-31" decimals="INF" id="c45311343" unitRef="xbrli-pure">0.485</atos:IntangibleAssetMeasurementInput>
  <atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310975" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310976" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310978" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310979" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45310981" unitRef="iso4217-usd">43225</atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise>
  <atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310982" unitRef="iso4217-usd">706008</atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise>
  <atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45310983" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310984" unitRef="iso4217-usd">749233</atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise>
  <atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310974" unitRef="xbrli-shares" xs:nil="true"/>
  <atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310977" unitRef="xbrli-shares" xs:nil="true"/>
  <atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45310980" unitRef="xbrli-shares">240196</atos:IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares>
  <atos:LockupPeriodExtension contextRef="d_2017-06-29_2017-06-29" id="c45311497">P45D</atos:LockupPeriodExtension>
  <atos:NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit contextRef="i_2018-05-09_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311536" unitRef="xbrli-shares">1</atos:NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit>
  <atos:NumberOfSharesAuthorizedToIssue contextRef="i_2018-12-31" decimals="INF" id="c45311446" unitRef="xbrli-shares">185000000</atos:NumberOfSharesAuthorizedToIssue>
  <atos:NumberOfUnitsAuthorizedToPurchaseMaximum contextRef="i_2018-05-09_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311534" unitRef="xbrli-shares">25000</atos:NumberOfUnitsAuthorizedToPurchaseMaximum>
  <atos:NumberOfUnitsSold contextRef="d_2017-04-03_2017-04-03_StatementClassOfStockAxis-ClassAUnitsMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember" decimals="INF" id="c45311470" unitRef="xbrli-shares">55333</atos:NumberOfUnitsSold>
  <atos:NumberOfUnitsSold contextRef="d_2017-04-03_2017-04-03_StatementClassOfStockAxis-ClassBUnitsMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember" decimals="INF" id="c45311474" unitRef="xbrli-shares">292</atos:NumberOfUnitsSold>
  <atos:NumberOfUnitsSold contextRef="d_2018-05-30_2018-05-30_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311540" unitRef="xbrli-shares">13624</atos:NumberOfUnitsSold>
  <atos:OperatingLeaseLesseeMonthlyRentExpense contextRef="d_2018-11-01_2018-11-01" decimals="INF" id="c45311803" unitRef="iso4217-usd">3660</atos:OperatingLeaseLesseeMonthlyRentExpense>
  <atos:OperatingLossCarryforwardsExpirationYear contextRef="d_2018-01-01_2018-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-EarliestTaxYearMember" id="c45311715">2029</atos:OperatingLossCarryforwardsExpirationYear>
  <atos:OperatingLossCarryforwardsExpirationYear contextRef="d_2018-01-01_2018-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-LatestTaxYearMember" id="c45311716">2038</atos:OperatingLossCarryforwardsExpirationYear>
  <atos:PreferredStockConvertibleConversionPrice contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45311549" unitRef="iso4217-usd-per-xbrli-shares">3.52</atos:PreferredStockConvertibleConversionPrice>
  <atos:PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45311551" unitRef="xbrli-pure">0.0999</atos:PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed>
  <atos:PreferredStockDeemedDividend contextRef="d_2017-04-03_2017-04-03_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" decimals="INF" id="c45311489" unitRef="iso4217-usd">2568132</atos:PreferredStockDeemedDividend>
  <atos:PreferredStockDeemedDividend contextRef="d_2018-01-01_2018-12-31_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311577" unitRef="iso4217-usd">11479308</atos:PreferredStockDeemedDividend>
  <atos:PreferredStockDeemedDividend contextRef="d_2018-04-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45311980" unitRef="iso4217-usd">4782100</atos:PreferredStockDeemedDividend>
  <atos:PreferredStockDeemedDividend contextRef="d_2018-04-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" decimals="INF" id="c45311986" unitRef="iso4217-usd">4782100</atos:PreferredStockDeemedDividend>
  <atos:PreferredStockDeemedDividend contextRef="d_2018-04-01_2018-06-30" decimals="INF" id="c45311987" unitRef="iso4217-usd">11479308</atos:PreferredStockDeemedDividend>
  <atos:PreferredStockDeemedDividend contextRef="d_2018-01-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" decimals="INF" id="c45311988" unitRef="iso4217-usd">4782100</atos:PreferredStockDeemedDividend>
  <atos:PreferredStockDeemedDividend contextRef="d_2018-01-01_2018-06-30" decimals="INF" id="c45311989" unitRef="iso4217-usd">11479308</atos:PreferredStockDeemedDividend>
  <atos:PreferredStockDeemedDividend contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45310833" unitRef="iso4217-usd">11479308</atos:PreferredStockDeemedDividend>
  <atos:PreferredStockDeemedDividend contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310834" unitRef="iso4217-usd">2568132</atos:PreferredStockDeemedDividend>
  <atos:PrepaidExpensesTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154326">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5:&lt;/div&gt; PREPAID EXPENSES&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Prepaid expenses consisted of the following:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid insurance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;160,576&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125,056&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;218,090&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Professional services&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;110,094&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;97,788&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Retainer and security deposits&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,718&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,218&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,355&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,882&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="margin: 0px; width: 70%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Total prepaid expenses&lt;/td&gt; &lt;td style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="margin: 0px; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="margin: 0px; width: 12%; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;509,833&lt;/div&gt;&lt;/td&gt; &lt;td style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="margin: 0px; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="margin: 0px; width: 12%; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;250,944&lt;/div&gt;&lt;/td&gt; &lt;td style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</atos:PrepaidExpensesTextBlock>
  <atos:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="d_2018-01-01_2018-12-31" id="c45311181" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311182" unitRef="iso4217-usd">6162588</atos:ProceedsFromIssuanceOfCommonStockAndWarrants>
  <atos:ProceedsFromIssuanceOfStockUnits contextRef="d_2018-05-30_2018-05-30_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311546" unitRef="iso4217-usd">12300000</atos:ProceedsFromIssuanceOfStockUnits>
  <atos:ProceedsFromIssuanceOfStockUnits contextRef="d_2018-01-01_2018-12-31" id="c45311177" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:ProceedsFromIssuanceOfStockUnits contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311178" unitRef="iso4217-usd">3871636</atos:ProceedsFromIssuanceOfStockUnits>
  <atos:ProceedsFromIssuanceOrSaleOfEquityNet contextRef="d_2017-04-03_2017-04-03_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember" decimals="INF" id="c45311469" unitRef="iso4217-usd">3900000</atos:ProceedsFromIssuanceOrSaleOfEquityNet>
  <atos:ProceedsFromIssuanceOrSaleOfEquityNet contextRef="d_2017-10-26_2017-10-26_SubsidiarySaleOfStockAxis-October2017PublicOfferingMember" decimals="INF" id="c45311514" unitRef="iso4217-usd">4900000</atos:ProceedsFromIssuanceOrSaleOfEquityNet>
  <atos:ProceedsFromIssuanceOrSaleOfEquityNet contextRef="d_2017-12-20_2017-12-20_SubsidiarySaleOfStockAxis-December2017PublicOfferingAndPrivatePlacementMember" decimals="INF" id="c45311523" unitRef="iso4217-usd">1200000</atos:ProceedsFromIssuanceOrSaleOfEquityNet>
  <atos:ProfessionalServicesCurrent contextRef="i_2018-12-31" decimals="INF" id="c45311390" unitRef="iso4217-usd">110094</atos:ProfessionalServicesCurrent>
  <atos:ProfessionalServicesCurrent contextRef="i_2017-12-31" decimals="INF" id="c45311392" unitRef="iso4217-usd">97788</atos:ProfessionalServicesCurrent>
  <atos:PurchasePriceOfUnit contextRef="i_2017-04-03_StatementClassOfStockAxis-ClassAUnitsMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember" decimals="INF" id="c45311471" unitRef="iso4217-usd-per-thunderdome-item">9</atos:PurchasePriceOfUnit>
  <atos:PurchasePriceOfUnit contextRef="i_2017-04-03_StatementClassOfStockAxis-ClassBUnitsMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember" decimals="INF" id="c45311475" unitRef="iso4217-usd-per-thunderdome-item">12000</atos:PurchasePriceOfUnit>
  <atos:PurchasePriceOfUnit contextRef="i_2018-05-09_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311535" unitRef="iso4217-usd-per-thunderdome-item">1000</atos:PurchasePriceOfUnit>
  <atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310964" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310965" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310967" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310968" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45310970" unitRef="iso4217-usd">22362</atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants>
  <atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310971" unitRef="iso4217-usd">1870798</atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants>
  <atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45310972" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310973" unitRef="iso4217-usd">1893160</atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants>
  <atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310963" unitRef="xbrli-shares" xs:nil="true"/>
  <atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310966" unitRef="xbrli-shares" xs:nil="true"/>
  <atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45310969" unitRef="xbrli-shares">124236</atos:ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares>
  <atos:ReductionInDeferredTaxAssets contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c45311698" unitRef="iso4217-usd">1900000</atos:ReductionInDeferredTaxAssets>
  <atos:ResearchAndDevelopmentCashRebatePerDollar contextRef="i_2017-05-23_ConsolidatedEntitiesAxis-AtossaGeneticsAUSPtyLtdMember" decimals="INF" id="c45311402" unitRef="iso4217-usd">0.435</atos:ResearchAndDevelopmentCashRebatePerDollar>
  <atos:ResearchAndDevelopmentCurrent contextRef="i_2018-12-31" decimals="INF" id="c45311387" unitRef="iso4217-usd">218090</atos:ResearchAndDevelopmentCurrent>
  <atos:ResearchAndDevelopmentCurrent contextRef="i_2017-12-31" id="c45311389" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:ResearchAndDevelopmentTaxRebateReceivable contextRef="i_2018-12-31_ConsolidatedEntitiesAxis-AtossaGeneticsAUSPtyLtdMember" decimals="INF" id="c45311409" unitRef="iso4217-usd">518000</atos:ResearchAndDevelopmentTaxRebateReceivable>
  <atos:ResearchAndDevelopmentTaxRebateReceivable contextRef="i_2017-12-31_ConsolidatedEntitiesAxis-AtossaGeneticsAUSPtyLtdMember" decimals="INF" id="c45311410" unitRef="iso4217-usd">148000</atos:ResearchAndDevelopmentTaxRebateReceivable>
  <atos:ResearchAndDevelopmentTaxRebateReceivable contextRef="i_2018-12-31" decimals="INF" id="c45310732" unitRef="iso4217-usd">518098</atos:ResearchAndDevelopmentTaxRebateReceivable>
  <atos:ResearchAndDevelopmentTaxRebateReceivable contextRef="i_2017-12-31" decimals="INF" id="c45310733" unitRef="iso4217-usd">358277</atos:ResearchAndDevelopmentTaxRebateReceivable>
  <atos:ResearchAndDevelopmentTaxRebateReceivableTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154328">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6:&lt;/div&gt; RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 23, 2017, &lt;/div&gt;Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (&amp;#x201c;R&amp;amp;D&amp;#x201d;) including our Phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; and Phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; Endoxifen clinical trials. Australia offers an R&amp;amp;D cash rebate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.435&lt;/div&gt; per dollar spent on qualified R&amp;amp;D activities incurred in the country. For the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the Company incurred qualified R&amp;amp;D expenses in Australia of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$851,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$824,000,&lt;/div&gt; respectively. The Company recorded a rebate receivable of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$370,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$358,000&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively, and a corresponding credit to R&amp;amp;D expenses for the years then ended. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;we had a total R&amp;amp;D rebate receivable of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$518,000&lt;/div&gt; that included approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$148,000&lt;/div&gt; receivable remaining from the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</atos:ResearchAndDevelopmentTaxRebateReceivableTextBlock>
  <atos:ScheduleOfWarrantsActivityTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-23">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="margin: 0pt auto 0pt 36pt; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 74%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding as of January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrants granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;488,611&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.25&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrants exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(488,611&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.12&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding as of December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</atos:ScheduleOfWarrantsActivityTableTextBlock>
  <atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized contextRef="d_2012-01-01_2012-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311895" unitRef="xbrli-shares">2502</atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized>
  <atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized contextRef="d_2013-01-01_2013-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311896" unitRef="xbrli-shares">2871</atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized>
  <atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311897" unitRef="xbrli-shares">4128</atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized>
  <atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311898" unitRef="xbrli-shares">5463</atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized>
  <atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized contextRef="d_2016-01-01_2016-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311899" unitRef="xbrli-shares">7257</atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized>
  <atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized contextRef="d_2017-01-01_2017-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311900" unitRef="xbrli-shares">12623</atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized>
  <atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311901" unitRef="xbrli-shares">106076</atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized>
  <atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized contextRef="d_2012-01-01_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311902" unitRef="xbrli-shares">140920</atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized>
  <atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares contextRef="d_2010-09-28_2010-09-28_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" id="c45311841">P10Y</atos:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares>
  <atos:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm contextRef="d_2018-01-01_2018-12-31_RangeAxis-MinimumMember" id="c45311369">P1Y</atos:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm>
  <atos:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm contextRef="d_2018-01-01_2018-12-31_RangeAxis-MaximumMember" id="c45311370">P4Y</atos:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm>
  <atos:StatedValuePerShare contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45311548" unitRef="iso4217-usd-per-xbrli-shares">1000</atos:StatedValuePerShare>
  <atos:StockAndWarrantsIssuedDuringPeriodShares contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310853" unitRef="xbrli-shares" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodShares contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310856" unitRef="xbrli-shares" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodShares contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45310859" unitRef="xbrli-shares">1483333</atos:StockAndWarrantsIssuedDuringPeriodShares>
  <atos:StockAndWarrantsIssuedDuringPeriodShares contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311029" unitRef="xbrli-shares" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodShares contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c45311032" unitRef="xbrli-shares">13624</atos:StockAndWarrantsIssuedDuringPeriodShares>
  <atos:StockAndWarrantsIssuedDuringPeriodShares contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45311035" unitRef="xbrli-shares" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310854" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310855" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310857" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310858" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45310860" unitRef="iso4217-usd">267001</atos:StockAndWarrantsIssuedDuringPeriodValue>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310861" unitRef="iso4217-usd">5895587</atos:StockAndWarrantsIssuedDuringPeriodValue>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45310862" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310863" unitRef="iso4217-usd">6162588</atos:StockAndWarrantsIssuedDuringPeriodValue>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311030" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311031" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c45311033" unitRef="iso4217-usd">14</atos:StockAndWarrantsIssuedDuringPeriodValue>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311034" unitRef="iso4217-usd">6926778</atos:StockAndWarrantsIssuedDuringPeriodValue>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45311036" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311037" unitRef="iso4217-usd">5363759</atos:StockAndWarrantsIssuedDuringPeriodValue>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45311038" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:StockAndWarrantsIssuedDuringPeriodValue contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311039" unitRef="iso4217-usd">12290551</atos:StockAndWarrantsIssuedDuringPeriodValue>
  <atos:StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership contextRef="i_2014-05-19" decimals="INF" id="c45311463" unitRef="xbrli-pure">0.02</atos:StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership>
  <atos:StockholderRightsAgreementAcquiringPersonPercentageOfOwnership contextRef="i_2014-05-19" decimals="INF" id="c45311461" unitRef="xbrli-pure">0.15</atos:StockholderRightsAgreementAcquiringPersonPercentageOfOwnership>
  <atos:StockholderRightsAgreementInitialExercisePriceOfEachRight contextRef="i_2014-05-19" decimals="INF" id="c45311465" unitRef="iso4217-usd-per-xbrli-shares">15</atos:StockholderRightsAgreementInitialExercisePriceOfEachRight>
  <atos:StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock contextRef="i_2014-05-19" decimals="INF" id="c45311458" unitRef="xbrli-shares">1</atos:StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock>
  <atos:StockholderRightsAgreementSharePrice contextRef="i_2014-05-19" decimals="INF" id="c45311466" unitRef="iso4217-usd-per-xbrli-shares">30</atos:StockholderRightsAgreementSharePrice>
  <atos:WarrantFinancingExpense contextRef="d_2018-01-01_2018-12-31" id="c45311148" unitRef="iso4217-usd" xs:nil="true"/>
  <atos:WarrantFinancingExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311149" unitRef="iso4217-usd">192817</atos:WarrantFinancingExpense>
  <atos:WarrantLiabilities contextRef="i_2018-12-31" decimals="INF" id="c45311360" unitRef="iso4217-usd">0</atos:WarrantLiabilities>
  <atos:WarrantLiabilities contextRef="i_2017-12-31" decimals="INF" id="c45311374" unitRef="iso4217-usd">0</atos:WarrantLiabilities>
  <atos:WarrantsAllocatedToCommonStockNetOfIssuanceCost contextRef="i_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311575" unitRef="iso4217-usd">5363759</atos:WarrantsAllocatedToCommonStockNetOfIssuanceCost>
  <atos:WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock contextRef="i_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember" decimals="INF" id="c45311571" unitRef="iso4217-usd-per-xbrli-shares">10.56</atos:WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock>
  <atos:WarrantsAndRightsOutstandingRedemptionPrice contextRef="i_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember" decimals="INF" id="c45311570" unitRef="iso4217-usd-per-xbrli-shares">0.18</atos:WarrantsAndRightsOutstandingRedemptionPrice>
  <atos:WarrantsAndRightsRedemptionRightsConsecutiveTradingDays contextRef="d_2018-01-01_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember" decimals="INF" id="c45311572" unitRef="xbrli-pure">10</atos:WarrantsAndRightsRedemptionRightsConsecutiveTradingDays>
  <atos:WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed contextRef="i_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember" decimals="INF" id="c45311565" unitRef="xbrli-pure">0.0499</atos:WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed>
  <atos:WorkingCapital contextRef="i_2018-12-31" decimals="-5" id="c45311202" unitRef="iso4217-usd">8600000</atos:WorkingCapital>
  <dei:AmendmentFlag contextRef="d_2018-01-01_2018-12-31" id="c-18">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2018-01-01_2018-12-31" id="c-4">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2018-01-01_2018-12-31" id="c-17">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2018-01-01_2018-12-31" id="c-16">2018</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2018-01-01_2018-12-31" id="c-15">2018-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2018-01-01_2018-12-31" id="c-14">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2018-01-01_2018-12-31" id="c-2">0001488039</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2019-03-25" decimals="INF" id="c-11" unitRef="xbrli-shares">9116490</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2018-01-01_2018-12-31" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="d_2018-01-01_2018-12-31" id="c-9">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityFilerCategory contextRef="d_2018-01-01_2018-12-31" id="c-5">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="i_2018-06-30" decimals="0" id="c-12" unitRef="iso4217-usd">4874099</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="d_2018-01-01_2018-12-31" id="c-1">ATOSSA GENETICS INC</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="d_2018-01-01_2018-12-31" id="c-13">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="d_2018-01-01_2018-12-31" id="c-10">true</dei:EntitySmallBusiness>
  <dei:EntityVoluntaryFilers contextRef="d_2018-01-01_2018-12-31" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2018-01-01_2018-12-31" id="c-8">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2018-01-01_2018-12-31" id="c-3">atos</dei:TradingSymbol>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154329">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;: PAYROLL LIABILITIES&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Payroll liabilities consisted of the following:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued bonus payable&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;697,995&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;566,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued vacation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;160,740&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;147,861&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued payroll liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;76,335&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;71,006&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total payroll liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;935,070&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;784,867&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:AccountsPayableCurrent contextRef="i_2018-12-31" decimals="INF" id="c45310748" unitRef="iso4217-usd">353328</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2017-12-31" decimals="INF" id="c45310749" unitRef="iso4217-usd">334901</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedBonusesCurrent contextRef="i_2018-12-31" decimals="INF" id="c45311414" unitRef="iso4217-usd">697995</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedBonusesCurrent contextRef="i_2017-12-31" decimals="INF" id="c45311416" unitRef="iso4217-usd">566000</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2018-12-31" decimals="INF" id="c45310750" unitRef="iso4217-usd">177074</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2017-12-31" decimals="INF" id="c45310751" unitRef="iso4217-usd">90105</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="i_2018-12-31" decimals="INF" id="c45311419" unitRef="iso4217-usd">76335</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="i_2017-12-31" decimals="INF" id="c45311420" unitRef="iso4217-usd">71006</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedVacationCurrent contextRef="i_2018-12-31" decimals="INF" id="c45311417" unitRef="iso4217-usd">160740</us-gaap:AccruedVacationCurrent>
  <us-gaap:AccruedVacationCurrent contextRef="i_2017-12-31" decimals="INF" id="c45311418" unitRef="iso4217-usd">147861</us-gaap:AccruedVacationCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2018-12-31" decimals="INF" id="c45311317" unitRef="iso4217-usd">162000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2017-12-31" decimals="INF" id="c45311318" unitRef="iso4217-usd">160000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="i_2018-12-31" decimals="INF" id="c45310796" unitRef="iso4217-usd">82204902</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="i_2017-12-31" decimals="INF" id="c45310797" unitRef="iso4217-usd">71887674</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalPreferredStock contextRef="i_2018-12-31" decimals="INF" id="c45310784" unitRef="iso4217-usd">2378997</us-gaap:AdditionalPaidInCapitalPreferredStock>
  <us-gaap:AdditionalPaidInCapitalPreferredStock contextRef="i_2017-12-31" id="c45310785" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310931" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310932" unitRef="iso4217-usd">-2568132</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310934" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310935" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45310937" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310938" unitRef="iso4217-usd">1284066</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45310939" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310940" unitRef="iso4217-usd">-1284066</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311052" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311053" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311055" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311056" unitRef="iso4217-usd">-4782100</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45311058" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311059" unitRef="iso4217-usd">4782100</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45311060" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2018-01-01_2018-12-31" id="c45311061" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310997" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310998" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311000" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311001" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45311003" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311004" unitRef="iso4217-usd">786550</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45311005" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311006" unitRef="iso4217-usd">786550</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311096" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311097" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311099" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311100" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45311102" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311103" unitRef="iso4217-usd">1053496</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45311104" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311105" unitRef="iso4217-usd">1053496</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="d_2017-01-01_2017-12-31_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember" decimals="INF" id="c45310896" unitRef="iso4217-usd">65816</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310929" unitRef="iso4217-usd">267231</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311864" unitRef="iso4217-usd">1053496</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311865" unitRef="iso4217-usd">786550</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember" decimals="INF" id="c45311887" unitRef="iso4217-usd">1410025</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="INF" id="c45311951" unitRef="iso4217-usd">869515</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="INF" id="c45311952" unitRef="iso4217-usd">540510</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="INF" id="c45311903" unitRef="iso4217-usd">809110</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="INF" id="c45311904" unitRef="iso4217-usd">621668</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="INF" id="c45311905" unitRef="iso4217-usd">244386</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="INF" id="c45311906" unitRef="iso4217-usd">164882</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311907" unitRef="iso4217-usd">1053496</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311908" unitRef="iso4217-usd">786550</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311358" unitRef="iso4217-usd">29811</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311359" unitRef="iso4217-usd">103038</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2018-01-01_2018-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" decimals="INF" id="c45311677" unitRef="xbrli-shares">487941</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" decimals="INF" id="c45311678" unitRef="xbrli-shares">117301</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2018-01-01_2018-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAConvertiblePreferredStockMember" id="c45311679" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAConvertiblePreferredStockMember" decimals="INF" id="c45311681" unitRef="xbrli-shares">55835</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2018-01-01_2018-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45311682" unitRef="xbrli-shares">774983</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesBConvertiblePreferredStockMember" id="c45311684" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2018-01-01_2018-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" decimals="INF" id="c45311685" unitRef="xbrli-shares">3054481</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" decimals="INF" id="c45311686" unitRef="xbrli-shares">202063</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311687" unitRef="xbrli-shares">4317405</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311688" unitRef="xbrli-shares">375199</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2018-12-31" decimals="INF" id="c45310744" unitRef="iso4217-usd">11720446</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2017-12-31" decimals="INF" id="c45310745" unitRef="iso4217-usd">8164094</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2018-12-31" decimals="INF" id="c45310736" unitRef="iso4217-usd">11549366</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2017-12-31" decimals="INF" id="c45310737" unitRef="iso4217-usd">7898034</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosure contextRef="i_2018-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" decimals="-3" id="c45311424" unitRef="iso4217-usd">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="i_2017-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" decimals="-3" id="c45311436" unitRef="iso4217-usd">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c45311211">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Basis of Presentation:&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The accompanying consolidated financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) and in accordance with accounting principles generally accepted in the United States of America&amp;nbsp;(&amp;#x201c;GAAP&amp;#x201d;). The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiaries. All significant intercompany account balances and transactions have been eliminated in consolidation.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 20, 2018, &lt;/div&gt;the Company completed a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;-for-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; reverse stock&amp;nbsp;split&amp;nbsp;of the shares of the Company&amp;#x2019;s common stock (the &amp;#x201c;Reverse Stock&amp;nbsp;Split&amp;#x201d;). As a result of the Reverse Stock Split, every &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; shares of issued and outstanding common stock were combined into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; issued and outstanding share of common stock, and the par value per share was changed to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.18&lt;/div&gt; per share. The number of authorized shares of common stock was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; reduced as a result of the Reverse Stock Split. The Company&amp;#x2019;s common stock began trading on a reverse stock&amp;nbsp;split-adjusted basis on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 20, 2018. &lt;/div&gt;All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock&amp;nbsp;Split.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154324">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3:&lt;/div&gt; SUMMARY OF ACCOUNTING POLICIES&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Basis of Presentation:&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The accompanying consolidated financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) and in accordance with accounting principles generally accepted in the United States of America&amp;nbsp;(&amp;#x201c;GAAP&amp;#x201d;). The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiaries. All significant intercompany account balances and transactions have been eliminated in consolidation.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 20, 2018, &lt;/div&gt;the Company completed a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;-for-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; reverse stock&amp;nbsp;split&amp;nbsp;of the shares of the Company&amp;#x2019;s common stock (the &amp;#x201c;Reverse Stock&amp;nbsp;Split&amp;#x201d;). As a result of the Reverse Stock Split, every &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; shares of issued and outstanding common stock were combined into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; issued and outstanding share of common stock, and the par value per share was changed to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.18&lt;/div&gt; per share. The number of authorized shares of common stock was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; reduced as a result of the Reverse Stock Split. The Company&amp;#x2019;s common stock began trading on a reverse stock&amp;nbsp;split-adjusted basis on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 20, 2018. &lt;/div&gt;All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock&amp;nbsp;Split.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Use of Estimates:&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recently Issued Accounting Pronouncements:&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2016, &lt;/div&gt;Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Lease Accounting Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842.&lt;/div&gt;&lt;/div&gt; The new standard is effective for reporting periods beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018 &lt;/div&gt;and early adoption is permitted. The standard will require lessees to report most leases as assets or liabilities on the balance sheet, while lessor accounting will remain substantially unchanged. The standard permits &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; approaches, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; requiring retrospective application of the new guidance with restatement of prior years, and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; requiring prospective application of the new guidance. We plan to adopt the new lease standard effective &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019 &lt;/div&gt;and apply it prospectively. We do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect the new lease standard to have a material effect on our financial position, results of operations or cash flows. Upon adoption of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; we will be required to recognize an operating lease liability and right-of-use asset of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$100,000,&lt;/div&gt; based on the lease composition disclosed in &lt;div style="display: inline;"&gt;footnote &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 2016, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Statement of Cash Flows&lt;/div&gt;, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2018 &lt;/div&gt;on a retrospective basis. For years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; we included &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$110,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$55,000,&lt;/div&gt; respectively, of restricted cash within cash, cash equivalents, and restricted cash&amp;nbsp;on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer has the credit card or the limit changes on the credit card.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2017, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception&lt;/div&gt;. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer precludes equity classification when assessing whether the instrument is indexed to an entity&amp;#x2019;s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;260&lt;/div&gt; to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This update is effective for public entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018. &lt;/div&gt;Early adoption is permitted. The Company early adopted the provisions of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2018. &lt;/div&gt;As the Company does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have any financial instruments with down round features, this ASU did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a material impact on the financial statements upon adoption.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2018, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;07,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. &lt;/div&gt;This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt; to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt; to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt; does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;606,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Revenue from Contracts with Customers&lt;/div&gt;. This update is effective for public entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018, &lt;/div&gt;including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 1, 2018 &lt;/div&gt;and it did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a material impact on the financial statements upon adoption.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2018, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;08,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Not&lt;/div&gt;-for-Profit Entities (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;958&lt;/div&gt;): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.&lt;/div&gt; This ASU affects &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;-for-profit entities and business entities that receive or make contributions of cash.&amp;nbsp;The ASU&amp;#xfeff; clarifies and improves the scope and accounting guidance to assist entities in evaluating if those transactions should be accounted for as contributions under the scope of Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;958&lt;/div&gt; or as an exchange transaction subject to other guidance.&amp;nbsp;This update is effective for public entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018. &lt;/div&gt;The Company is currently evaluating the impact that adoption will have on its financial statements.&lt;/div&gt;  &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;All research and development costs are expensed as incurred.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; that some portion or all of a deferred tax asset will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be realized based on the weight of available evidence, including expected future earnings. The Company recognizes an uncertain tax position in its financial statements when it concludes that a tax position is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to be sustained upon examination based solely on its technical merits. Only after a tax position passes the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit that is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. The Company elects to accrue any interest or penalties related to income taxes as part of its income tax expense.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Cash and cash equivalents include cash and all highly liquid instruments with original maturities of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months or less.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Furniture and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Furniture and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When furniture and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Depreciation is computed using the straight-line method over the estimated useful lives ranging from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; to&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt 7.2pt; text-align: left; text-indent: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Furniture and equipment amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$216,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$171,000&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively. Accumulated depreciation was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$162,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$160,000&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively. Depreciation expense for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$14,386&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$25,956,&lt;/div&gt; respectively.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Company periodically evaluates the carrying value of long-lived assets to be held and used and, if necessary, records impairment losses when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-loved assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.&amp;nbsp; For the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; impairment of furniture and equipment was recorded.&lt;/div&gt;  &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company records financial assets&amp;nbsp;and liabilities measured on a recurring and non-recurring basis&amp;nbsp;as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. These fair value principles prioritize valuation inputs across &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; broad levels. Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.&amp;nbsp;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&amp;nbsp;inputs are unobservable inputs based on the Company's assumptions used to measure assets and liabilities at fair value. An asset or liability's classification within the various levels is determined based on the lowest level input that is significant to the fair value measurement.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Intangible Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Intangible assets consist of intellectual property and software acquired. Intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the assets might &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be recoverable. Impairment losses must be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&amp;#x2019; carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the assets. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;During the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;we determined certain intangible assets acquired from Acueity Healthcare, Inc. ("Acueity") were impaired and&amp;nbsp;recorded an asset impairment charge of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$461,715&lt;/div&gt; for the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;to adjust the carrying value of these intangible assets to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;zero&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017. &amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; impairment charges were recorded during the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;We determined the fair values of the Acueity intangibles using an income approach (Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; of the fair value hierarchy). For purposes of the income approach, fair value was determined based on the present value of estimated future cash flows that a market participant could expect to generate from the development of products using the patented technology acquired in the Acueity transaction, discounted at an appropriate risk-adjusted rate reflecting the weighted average cost of capital for a potential market participant. The discount rate used in valuation for these intangible assets was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48.50%.&lt;/div&gt; The estimated future cash flows, including an estimate of long-term future growth rates, reflect our own assumptions of what market participants would utilize to price the assets pursuant to ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;820,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Fair Value Measurements&lt;/div&gt;.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Amortization of intangible assets&amp;nbsp;is computed using the straight-line method over the estimated useful lives ranging from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; years.&lt;/div&gt; &lt;div style=" margin: 0pt 7.2pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt 7.2pt; text-align: left; text-indent: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Intangible assets amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$192,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$234,000&lt;/div&gt; for at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively. Accumulated amortization was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$93,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$158,000&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively. Amortization expense for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$29,811&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$103,038,&lt;/div&gt; respectively.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Financial Instruments with Characteristics of Both Liabilities and Equity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;During the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;the Company issued certain financial instruments, consisting of warrants to purchase common stock, which have characteristics of both liability and equity. Financial instruments such as warrants that are classified as liabilities are fair valued upon issuance and are re-measured at fair value at subsequent reporting periods with the resulting change in fair value recorded in &amp;#x201c;change in fair value of common stock warrants&amp;#x201d; in the consolidated statement of operations. The fair value of warrants is estimated using valuation models that require the input of subjective assumptions including stock price volatility, expected life, and the probability of future equity issuances and their impact to the price protection feature. There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; outstanding warrants accounted for as liabilities as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Share-Based Payments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 15pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company follows the provisions of ASC Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Compensation - Stock Compensation&lt;/div&gt; (&amp;#x201c;ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&amp;#x201d;&lt;/div&gt;), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt; is recognized as an expense over the requisite service period and the Company made a policy election to recognize forfeitures when they occur.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company&amp;#x2019;s common stock, and estimation of an appropriate risk-free interest rate. The Company&amp;#x2019;s expected common stock price volatility assumption is based upon the historical volatility of our stock price. The expected life assumption for stock options grants was based upon the simplified method provided for under ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,&lt;/div&gt; which averages the contractual term of the options of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; years with the vesting term, typically &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;four&lt;/div&gt; years. The dividend yield assumption of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;zero&lt;/div&gt; is based upon the fact that the Company has never paid cash dividends and presently has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; intention of paying cash dividends in the future. The risk-free interest rate used for each grant was based upon prevailing short-term interest rates over the expected life of the options.&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2018-12-31" decimals="INF" id="c45311201" unitRef="iso4217-usd">10380493</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2019-03-25_SubsequentEventTypeAxis-SubsequentEventMember" decimals="-5" id="c45312740" unitRef="iso4217-usd">19300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2017-12-31" decimals="INF" id="c45310725" unitRef="iso4217-usd">7217469</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c45311228">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Cash and cash equivalents include cash and all highly liquid instruments with original maturities of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months or less.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="i_2017-12-31" decimals="INF" id="c45311187" unitRef="iso4217-usd">7272469</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="i_2016-12-31" decimals="INF" id="c45311188" unitRef="iso4217-usd">3082962</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="i_2018-12-31" decimals="INF" id="c45311189" unitRef="iso4217-usd">10490493</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311185" unitRef="iso4217-usd">3218024</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311186" unitRef="iso4217-usd">4189507</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashUninsuredAmount contextRef="i_2018-12-31" decimals="INF" id="c45311799" unitRef="iso4217-usd">10052914</us-gaap:CashUninsuredAmount>
  <us-gaap:CashUninsuredAmount contextRef="i_2017-12-31" decimals="INF" id="c45311800" unitRef="iso4217-usd">6967469</us-gaap:CashUninsuredAmount>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2017-04-03_ClassOfWarrantOrRightAxis-The2017PublicOfferingOverallotmentWarrantsMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" decimals="INF" id="c45311482" unitRef="iso4217-usd-per-xbrli-shares">11.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2017-06-29_ClassOfWarrantOrRightAxis-The2017PublicOfferingWarrantsMember" decimals="INF" id="c45311491" unitRef="iso4217-usd-per-xbrli-shares">3.12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2017-12-20_ClassOfWarrantOrRightAxis-ClassAAndClassBWarrantsMember_SubsidiarySaleOfStockAxis-December2017PublicOfferingAndPrivatePlacementMember" decimals="INF" id="c45311525" unitRef="iso4217-usd-per-xbrli-shares">3.78</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2018-05-30_ClassOfWarrantOrRightAxis-The2018WarrantsMember_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311544" unitRef="iso4217-usd-per-xbrli-shares">4.048</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember" decimals="INF" id="c45311563" unitRef="iso4217-usd-per-xbrli-shares">4.048</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2016-12-31" decimals="INF" id="c45311592" unitRef="iso4217-usd-per-xbrli-shares">0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2017-12-31" decimals="INF" id="c45311598" unitRef="iso4217-usd-per-xbrli-shares">0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2018-12-31_ClassOfWarrantOrRightAxis-The2014PublicOfferingMember" decimals="INF" id="c45311641" unitRef="iso4217-usd-per-xbrli-shares">540</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2018-12-31" id="c45311650" unitRef="iso4217-usd-per-xbrli-shares" xs:nil="true"/>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2018-05-09_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311537" unitRef="xbrli-shares">284</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2018-05-30_ClassOfWarrantOrRightAxis-The2018WarrantsMember_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311543" unitRef="xbrli-shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember" decimals="INF" id="c45311562" unitRef="xbrli-shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2017-04-03_ClassOfWarrantOrRightAxis-The2017PublicOfferingClassAUnitsWarrantsMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember" decimals="INF" id="c45311473" unitRef="xbrli-shares">55333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2017-04-03_ClassOfWarrantOrRightAxis-The2017PublicOfferingWarrantsMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember" decimals="INF" id="c45311478" unitRef="xbrli-shares">389111</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2017-04-03_ClassOfWarrantOrRightAxis-The2017PublicOfferingOverallotmentWarrantsMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" decimals="INF" id="c45311480" unitRef="xbrli-shares">44167</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2017-12-20_ClassOfWarrantOrRightAxis-ClassAAndClassBWarrantsMember_SubsidiarySaleOfStockAxis-December2017PublicOfferingAndPrivatePlacementMember" decimals="INF" id="c45311524" unitRef="xbrli-shares">883333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2017-09-30_ClassOfWarrantOrRightAxis-The2017PublicOfferingWarrantsMember" decimals="INF" id="c45311502" unitRef="xbrli-shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2017-12-31_ClassOfWarrantOrRightAxis-The2017PublicOfferingWarrantsMember" decimals="INF" id="c45311507" unitRef="xbrli-shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2018-05-30_ClassOfWarrantOrRightAxis-The2018WarrantsMember_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311542" unitRef="xbrli-shares">3869216</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2018-12-31" decimals="INF" id="c45311582" unitRef="xbrli-shares">3875699</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2016-12-31" decimals="INF" id="c45311591" unitRef="xbrli-shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2017-12-31" decimals="INF" id="c45311597" unitRef="xbrli-shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2018-12-31_ClassOfWarrantOrRightAxis-The2014PublicOfferingMember" decimals="INF" id="c45311640" unitRef="xbrli-shares">6483</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember" decimals="INF" id="c45311644" unitRef="xbrli-shares">3869216</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2018-12-31" id="c45310760" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2017-12-31" id="c45310761" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154344">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;: COMMITMENTS AND CONTINGENCIES&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Lease Commitments&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 1, 2018, &lt;/div&gt;the Company entered into an operating lease to pay &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,660&lt;/div&gt; monthly&amp;nbsp;rent for a term of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22&lt;/div&gt; months.&amp;nbsp;The&amp;nbsp;total future minimum lease payments due under this lease&amp;nbsp;&lt;div style="display: inline;"&gt;are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$73,200&lt;/div&gt;&lt;/div&gt;, of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$43,920&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$29,280&lt;/div&gt; are due in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2020,&lt;/div&gt; respectively.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The total rent expense for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$31,457&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$33,285,&lt;/div&gt; respectively. Rent expense was included in general and administrative expenses for both years.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 30, 2018, &lt;/div&gt;the Company entered into an operating lease for a copier system for a term of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;36&lt;/div&gt; months. The total future minimum lease payments due under this lease&amp;nbsp;are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$42,228,&lt;/div&gt; of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$14,904,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$14,904&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12,420&lt;/div&gt; are due in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2020&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2021,&lt;/div&gt; respectively.&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Litigation and Contingencies&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 10, 2013, &lt;/div&gt;a putative securities class action complaint, captioned &lt;div style="display: inline; font-style: italic;"&gt;Cook v. Atossa Genetics, Inc., et al.&lt;/div&gt;, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2:13&lt;/div&gt;-cv-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;01836&lt;/div&gt;-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 2012 &lt;/div&gt;initial public offering. The complaint alleged that all defendants violated Sections &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;(a)(&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;), and that we and certain of our directors and officers violated Section &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,&lt;/div&gt; of the Securities Act by making material false and misleading statements and omissions in the offering&amp;#x2019;s registration statement, and that we and certain of our directors and officers violated Sections &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;(b) and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20A&lt;/div&gt; of the Exchange Act and SEC Rule &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10b&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt; promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. The complaint sought, on behalf of persons who purchased our common stock between &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 8, 2012 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 4, 2013, &lt;/div&gt;inclusive, damages of an &lt;div style="display: inline;"&gt;unspecific amount.&lt;/div&gt;&amp;nbsp;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 23, 2018, &lt;/div&gt;the parties filed a stipulation of settlement with the court to settle the matter for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.5&lt;/div&gt; million, completely funded by defendants&amp;#x2019; insurers, and on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 20, 2018 &lt;/div&gt;the Court approved the settlement. This case is considered closed.&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt 21.9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;We are subject to other legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2018-12-31" decimals="INF" id="c45310788" unitRef="iso4217-usd-per-xbrli-shares">0.18</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2017-12-31" decimals="INF" id="c45310789" unitRef="iso4217-usd-per-xbrli-shares">0.18</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2018-12-31" decimals="INF" id="c45310790" unitRef="xbrli-shares">175000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2017-12-31" decimals="INF" id="c45310791" unitRef="xbrli-shares">175000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2018-12-31" decimals="INF" id="c45310792" unitRef="xbrli-shares">5846552</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2017-12-31" decimals="INF" id="c45310793" unitRef="xbrli-shares">2651952</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2018-12-31" decimals="INF" id="c45310794" unitRef="xbrli-shares">5846552</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2017-12-31" decimals="INF" id="c45310795" unitRef="xbrli-shares">2651952</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2018-12-31" decimals="INF" id="c45310786" unitRef="iso4217-usd">1052372</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2017-12-31" decimals="INF" id="c45310787" unitRef="iso4217-usd">477342</us-gaap:CommonStockValue>
  <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154343">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;: CONCENTRATION OF CREDIT RISK&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (&amp;#x201c;FDIC&amp;#x201d;) up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$250,000.&lt;/div&gt; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the Company had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10,052,914&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6,967,469&lt;/div&gt; in excess of the FDIC insured limit, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c45310909" unitRef="iso4217-usd">4</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310910" unitRef="iso4217-usd">3234769</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310912" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310913" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45310915" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" id="c45310916" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45310917" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310918" unitRef="iso4217-usd">3234773</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="d_2017-01-01_2017-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" decimals="INF" id="c45311508" unitRef="xbrli-shares">292</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="d_2018-01-01_2018-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" decimals="INF" id="c45311583" unitRef="xbrli-shares">11245</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c45310908" unitRef="xbrli-shares">292</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310911" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45310914" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="d_2018-01-01_2018-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" decimals="INF" id="c45311584" unitRef="xbrli-shares">3194600</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="i_2017-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" decimals="INF" id="c45311510" unitRef="xbrli-shares">111</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="i_2018-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" decimals="INF" id="c45311585" unitRef="xbrli-shares">284</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent contextRef="i_2018-12-31" decimals="INF" id="c45310754" unitRef="iso4217-usd">1410025</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
  <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent contextRef="i_2017-12-31" id="c45310755" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid insurance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;160,576&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125,056&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;218,090&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Professional services&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;110,094&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;97,788&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Retainer and security deposits&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,718&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,218&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,355&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,882&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="margin: 0px; width: 70%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Total prepaid expenses&lt;/td&gt; &lt;td style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="margin: 0px; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="margin: 0px; width: 12%; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;509,833&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="margin: 0px; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="margin: 0px; width: 12%; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;250,944&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="i_2018-12-31" decimals="INF" id="c45311783" unitRef="iso4217-usd">1027111</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
  <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="i_2017-12-31" decimals="INF" id="c45311784" unitRef="iso4217-usd">1027111</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="i_2018-12-31" decimals="INF" id="c45311779" unitRef="iso4217-usd">707</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="i_2017-12-31" decimals="INF" id="c45311780" unitRef="iso4217-usd">677</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="i_2018-12-31" decimals="INF" id="c45311777" unitRef="iso4217-usd">572687</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="i_2017-12-31" decimals="INF" id="c45311778" unitRef="iso4217-usd">634521</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsInventory contextRef="i_2018-12-31" decimals="INF" id="c45311765" unitRef="iso4217-usd">21881</us-gaap:DeferredTaxAssetsInventory>
  <us-gaap:DeferredTaxAssetsInventory contextRef="i_2017-12-31" decimals="INF" id="c45311766" unitRef="iso4217-usd">21881</us-gaap:DeferredTaxAssetsInventory>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="i_2018-12-31" decimals="INF" id="c45311792" unitRef="iso4217-usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="i_2017-12-31" decimals="INF" id="c45311793" unitRef="iso4217-usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="i_2018-12-31" decimals="INF" id="c45311787" unitRef="iso4217-usd">32850</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="i_2017-12-31" decimals="INF" id="c45311788" unitRef="iso4217-usd">27554</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="i_2018-12-31" decimals="INF" id="c45311781" unitRef="iso4217-usd">2588401</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="i_2017-12-31" decimals="INF" id="c45311782" unitRef="iso4217-usd">747589</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="i_2018-12-31" decimals="-3" id="c45311714" unitRef="iso4217-usd">12300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences contextRef="i_2018-12-31" decimals="INF" id="c45311768" unitRef="iso4217-usd">33755</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences contextRef="i_2017-12-31" decimals="INF" id="c45311769" unitRef="iso4217-usd">31051</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses contextRef="i_2018-12-31" decimals="INF" id="c45311771" unitRef="iso4217-usd">99666</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses contextRef="i_2017-12-31" id="c45311772" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="i_2018-12-31" decimals="INF" id="c45311773" unitRef="iso4217-usd">968170</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="i_2017-12-31" decimals="INF" id="c45311774" unitRef="iso4217-usd">620789</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="i_2018-12-31" decimals="INF" id="c45311775" unitRef="iso4217-usd">33241</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="i_2017-12-31" decimals="INF" id="c45311776" unitRef="iso4217-usd">33241</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2018-12-31" decimals="INF" id="c45311719" unitRef="iso4217-usd">5312769</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2017-12-31" decimals="INF" id="c45311720" unitRef="iso4217-usd">3089306</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilitiesOther contextRef="i_2018-12-31" decimals="INF" id="c45311790" unitRef="iso4217-usd">32850</us-gaap:DeferredTaxLiabilitiesOther>
  <us-gaap:DeferredTaxLiabilitiesOther contextRef="i_2017-12-31" decimals="INF" id="c45311791" unitRef="iso4217-usd">27554</us-gaap:DeferredTaxLiabilitiesOther>
  <us-gaap:DepositAssets contextRef="i_2018-12-31" decimals="INF" id="c45311393" unitRef="iso4217-usd">16718</us-gaap:DepositAssets>
  <us-gaap:DepositAssets contextRef="i_2017-12-31" decimals="INF" id="c45311394" unitRef="iso4217-usd">14218</us-gaap:DepositAssets>
  <us-gaap:Depreciation contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311322" unitRef="iso4217-usd">14386</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311324" unitRef="iso4217-usd">25956</us-gaap:Depreciation>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311144" unitRef="iso4217-usd">44197</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311145" unitRef="iso4217-usd">128994</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154345">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;: STOCK BASED COMPENSATION&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock Option and Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 28, 2010, &lt;/div&gt;the Board of Directors approved the adoption of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Stock Option and Incentive Plan the (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x201c;2010&lt;/div&gt; Plan&amp;#x201d;) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be granted under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan until &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 2020. &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; other awards &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be granted under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan after the date that is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt; years from the date of stockholder approval. An aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,556&lt;/div&gt; shares were initially reserved for issuance in connection with awards granted under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan and on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 18, 2016, &lt;/div&gt;an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,111&lt;/div&gt; shares were reserved for issuance under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan. On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 9, 2017, &lt;/div&gt;the stockholders approved an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125,000&lt;/div&gt; shares for issuance under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan. On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 12, 2018, &lt;/div&gt;the stockholders approved an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;500,000&lt;/div&gt; shares for issuance under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: justify; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The following table presents the automatic additions to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan since inception pursuant to the &amp;#x201c;evergreen&amp;#x201d; terms of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan:&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="margin: 0pt auto 0pt 36pt; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;January 1,&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number of&lt;br /&gt; shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,502&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,871&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,128&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,463&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,257&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,623&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;106,076&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Total additional shares&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;140,920&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company granted options to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;611,668&lt;/div&gt;&amp;nbsp;and&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;143,027&lt;/div&gt; shares of common stock to employees and directors during the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively.&amp;nbsp;The weighted average grant date fair value of options granted during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.02&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.80,&lt;/div&gt; respectively. There are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,575&lt;/div&gt; options available for grant under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;and as a result of the evergreen provision contained in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan, an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;233,862&lt;/div&gt; shares were added to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Compensation costs associated with the Company&amp;#x2019;s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,053,496&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$786,550&lt;/div&gt; for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively, which was included in the following captions in the consolidated statements of operations.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;201&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;201&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 68%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 68%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;809,110&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;621,668&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 68%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;244,386&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;164,882&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 68%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Total stock compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,053,496&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;786,550&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The fair value of stock options granted for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; was calculated using the Black-Scholes option-pricing model applying the following assumptions:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 67%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" rowspan="1" style="width: 636163%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 67%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 63%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;201&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 63%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;201&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 67%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 3%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 3%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 67%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;2.47%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.71%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;1.86%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.04%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 67%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;5.24&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.57&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;5.32&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.36&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 67%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 3%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 3%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 67%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 67%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;108.81%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;126.43%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;112.86%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;114.19&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Options issued and outstanding as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;and their activities during the year then ended are as follows:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 10.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number of&lt;br /&gt; Underlying&lt;br /&gt; Shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 9.9%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted-&lt;br /&gt; Average&lt;br /&gt; Exercise Price&lt;br /&gt; Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted-&lt;br /&gt; Average&lt;br /&gt; Contractual&lt;br /&gt; Life Remaining&lt;br /&gt; in Years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 9.9%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Aggregate&lt;br /&gt; Intrinsic Value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Outstanding as of January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.3%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;172,510&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;49.27&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.9%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.3%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;611,668&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2.39&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.9%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(795&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;562.55&lt;div style="display: inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.9%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Outstanding as of December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;783,383&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;12.14&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.9%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;9.17&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Exercisable as of December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;317,042&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;24.39&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.9%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;8.97&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Vested and expected to vest&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;783,383&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;12.14&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.9%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;9.17&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: justify; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;there were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;466,341&lt;/div&gt; unvested options outstanding and the related unrecognized total compensation cost associated with these options was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,152,367.&lt;/div&gt; This expense is expected to be recognized over a weighted-average period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.45&lt;/div&gt; years.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Executive Option Grants Classified as Liabilities (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;"2018&lt;/div&gt; Liability Grants")&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 27, 2018, &lt;/div&gt;the Company granted &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,300,000&lt;/div&gt; options to the Chief Executive Officer and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;700,000&lt;/div&gt; to the Chief Financial Officer. Each option is exercisable for an equivalent number of shares of Company's common stock. The options were granted pursuant to an option award agreement and were granted outside the Company&amp;#x2019;s &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan; however, they are subject to the terms and conditions of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2010&lt;/div&gt; Plan. On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 13, 2019, &lt;/div&gt;the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; liability options were canceled.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Liability Grants were exercisable for shares of common stock at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.38&lt;/div&gt; per share, which was the fair value on the date of grant. The options had an exercise period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; years from their date of issuance. If at the time the options were exercised the Company cannot deliver shares of common stock to the optionee including, for example, if there were insufficient shares available under the Plan at the time of exercise, then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option only would be exercised on a cash &amp;#x201c;net basis&amp;#x201d; so that the Company would pay cash in an amount equal to the excess of the fair value of the common stock over the option exercise price. There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; sufficient shares available under the Plan. Therefore the&amp;nbsp;Company&amp;nbsp;would have been obligated to settle these options in cash if they were exercised. Because these options contained provisions that would require the Company to settle the options in cash in an event outside the Company&amp;#x2019;s control, they were accounted for as liabilities.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Liability Grants were subject to vesting requirements. Twenty-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; percent of the options were vested as of the grant date, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt; of the options would have vested quarterly over &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; years, and the remaining &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25%&lt;/div&gt; would have vested upon achievement of certain milestones related to clinical trial progress. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;all of the options that vested upon achievement of clinical trial&amp;nbsp;milestones&amp;nbsp;were vested.&amp;nbsp;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;there were&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,125,000&lt;/div&gt; unvested options outstanding and the related unrecognized total compensation cost associated with these options was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$857,673.&lt;/div&gt; This expense was expected to be recognized over a weighted-average period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.5&lt;/div&gt; years.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style="display: none;"&gt;  &amp;nbsp; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Compensation costs associated with the Liability Grants were initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria were achieved for options that vest based on performance. Compensation cost was remeasured each period based on the market value of our underlying stock until award vesting or settlement.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;For the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;the Company&amp;nbsp;recognized compensation expense related to these options of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,410,025,&lt;/div&gt; which was included in the following captions in the consolidated statements of operations.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 85%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 85%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;869,515&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 85%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;540,510&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 85%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Total stock compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,410,025&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The fair value of liability options granted for the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;was calculated using the Black-Scholes option-pricing model applying the following assumptions:&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="margin: 0pt auto 0pt 27pt; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 53%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2.51&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2.94%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;4.5&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;5.0&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Stock price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$1.02&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$2.38&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;122.0&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;125.0%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Refer to footnote &lt;div style="display: inline;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt; &lt;/div&gt;for&amp;nbsp;further description.&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="margin: 0pt auto 0pt 36pt; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;January 1,&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number of&lt;br /&gt; shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,502&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,871&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,128&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,463&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,257&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,623&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;106,076&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 87%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Total additional shares&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;140,920&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="d_2018-01-01_2018-12-31" id="c45311140" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311141" unitRef="iso4217-usd">-17695</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2018-04-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" decimals="INF" id="c45311994" unitRef="iso4217-usd-per-xbrli-shares">-2.90</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2018-04-01_2018-06-30" decimals="INF" id="c45311995" unitRef="iso4217-usd-per-xbrli-shares">-5.08</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2018-01-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" decimals="INF" id="c45311996" unitRef="iso4217-usd-per-xbrli-shares">-3.77</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2018-01-01_2018-06-30" decimals="INF" id="c45311997" unitRef="iso4217-usd-per-xbrli-shares">-6.11</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45310838" unitRef="iso4217-usd-per-xbrli-shares">-5.50</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310839" unitRef="iso4217-usd-per-xbrli-shares">-10.97</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154337">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;: NET LOSS PER SHARE&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company accounts for and discloses net income (loss) per common share in accordance with Accounting Standards Codification ("ASC") Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;260,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Earnings Per Share&lt;/div&gt;. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented they have been excluded from the calculation.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The following table summarizes the Company&amp;#x2019;s calculation of net loss per common share:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-right: 10%; margin-left: 45pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Numerator&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11,404,934&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8,122,581&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deemed dividend attributable to preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11,479,308&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,568,132&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss attributable to common shareholders&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22,884,242&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(10,690,713&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Denominator&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average common shares outstanding used to compute net loss per share, basic and diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,157,746&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;974,773&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Net loss per share of common stock, basic and diluted: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5.50&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(10.97&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share, because including them would be anti-dilutive:&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-right: 10%; margin-left: 45pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="width: 111111%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Options to purchase common stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;487,941&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;117,301&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series A convertible preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;55,835&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series B convertible preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;774,983&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrants to purchase common stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,054,481&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;202,063&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,317,405&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;375,199&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2017-01-01_2017-12-31" decimals="2" id="c45311700" unitRef="xbrli-pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2018-01-01_2018-12-31" decimals="2" id="c45311701" unitRef="xbrli-pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2018-12-31" decimals="INF" id="c45311421" unitRef="iso4217-usd">935070</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2017-12-31" decimals="INF" id="c45311422" unitRef="iso4217-usd">784867</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" id="c45311870">P1Y164D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember" id="c45311886">P1Y182D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="i_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311869" unitRef="iso4217-usd">1152367</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="i_2018-12-31_AwardTypeAxis-LiabilityOptionsMember" decimals="INF" id="c45311885" unitRef="iso4217-usd">857673</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="d_2018-01-01_2018-12-31" id="c45311146" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311147" unitRef="iso4217-usd">280747</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="d_2018-01-01_2018-12-31_FinancialInstrumentAxis-WarrantMember" id="c-24">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Initial valuation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$9.00&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercise price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11.25&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.79%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.88%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;0.24&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;June 30, 2017 valuation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6.00&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercise price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.12&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;0.79&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.88%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;0.08&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.76&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154331">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;: FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; financial assets outstanding that were required to be measured at fair value on a recurring basis at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Warrants issued in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 3, 2017, &lt;/div&gt;offering, which are discussed further in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; contained provisions that could have required the Company to settle the warrants in cash in an event outside the Company&amp;#x2019;s control or had price protection rights and were therefore accounted for as liabilities while they were outstanding, with changes in the fair values included in net loss for the respective periods. Because some of the inputs to the valuation model were either &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; observable or were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; derived principally from or corroborated by observable market data by correlation or other means, the warrant liability was classified as Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; in the fair value hierarchy.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The following table summarizes the changes in the Company&amp;#x2019;s Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; warrant liability for the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017:&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Beginning balance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Issuances of warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612,413&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrant exercises&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,893,160&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in fair value&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;280,747&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Ending balance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company&amp;#x2019;s intangible assets are classified within Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; of the fair value hierarchy, measured at fair value on a nonrecurring basis. Refer to Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; for further discussion.&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; transfers between Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,&lt;/div&gt; Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; or Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Beginning balance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Issuances of warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612,413&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrant exercises&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,893,160&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in fair value&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;280,747&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Ending balance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c45311236">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company records financial assets&amp;nbsp;and liabilities measured on a recurring and non-recurring basis&amp;nbsp;as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. These fair value principles prioritize valuation inputs across &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; broad levels. Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.&amp;nbsp;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&amp;nbsp;inputs are unobservable inputs based on the Company's assumptions used to measure assets and liabilities at fair value. An asset or liability's classification within the various levels is determined based on the lowest level input that is significant to the fair value measurement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="d_2017-01-01_2017-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityMember" decimals="INF" id="c45311442" unitRef="iso4217-usd">-280747</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="d_2017-01-01_2017-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityMember" decimals="INF" id="c45311440" unitRef="iso4217-usd">1612413</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="d_2017-01-01_2017-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityMember" decimals="INF" id="c45311441" unitRef="iso4217-usd">1893160</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="i_2016-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityMember" id="c45311439" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="i_2017-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityMember" id="c45311443" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2018-01-01_2018-12-31_RangeAxis-MinimumMember" id="c45311346">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2018-01-01_2018-12-31_RangeAxis-MaximumMember" id="c45311347">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2018-12-31" decimals="INF" id="c45311351" unitRef="iso4217-usd">93000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2017-12-31" decimals="INF" id="c45311353" unitRef="iso4217-usd">158000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="i_2018-12-31" decimals="INF" id="c45310740" unitRef="iso4217-usd">99375</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="i_2017-12-31" decimals="INF" id="c45310741" unitRef="iso4217-usd">75686</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45310812" unitRef="iso4217-usd">7224252</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310813" unitRef="iso4217-usd">4859369</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="d_2017-01-01_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-AcueityIntangibleAssetsMember" decimals="INF" id="c45311337" unitRef="iso4217-usd">461715</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311340" unitRef="iso4217-usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311143" unitRef="iso4217-usd">461715</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311326" unitRef="iso4217-usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311373" unitRef="iso4217-usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45310827" unitRef="iso4217-usd">-11404934</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310828" unitRef="iso4217-usd">-8122581</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154340">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;: INCOME TAXES&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company accounts for income taxes using the asset and liability method, under which deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expected to be realized.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 22, 2017, &lt;/div&gt;the President signed into law the Tax Cut and Jobs Act of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; (the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x201c;2017&lt;/div&gt; Tax Act&amp;#x201d;). The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; Tax Act provisions applicable to the Company include a permanent reduction to the U.S. federal corporate income tax rate from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;35%&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21%,&lt;/div&gt; the capitalization and amortization of research and development related expenses, and placing additional limits on the use of net operating losses. Under ASC Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;740,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Accounting for Income Taxes&lt;/div&gt;, companies are required to recognize the changes in the period of enactment.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;During the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;the Company recorded a reduction in the amount of&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.9&lt;/div&gt; million in the carrying value of the Company&amp;#x2019;s U.S. deferred tax assets resulting from the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; Tax Act&amp;#x2019;s reduction in the U.S. federal corporate income tax rate from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;35%&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21%,&lt;/div&gt; which is fully offset by the valuation allowance.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; record an income tax benefit for its losses incurred for the years ending &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; due to uncertainty regarding utilization of its net operating loss carryforwards and due to its history of losses. The benefit for income taxes differs from the benefit computed by applying the federal statutory rate to loss before income taxes as follows:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;As of December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected federal income tax benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,395,036&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,761,678&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;169,957&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;197,336&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other permanent items&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,616&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,668&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Effect of change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,223,463&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(15,344,015&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prior year true-up&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(126,031&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Tax rate change&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,912,427&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Effect of NOL limitation&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,119,293&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Actual federal income tax benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The components of net deferred tax assets and liabilities are as follows:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended December 31, &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 74%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Obsolete inventory&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,881&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,881&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Accrued vacation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33,755&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,051&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Accrued bonuses&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;99,666&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;968,170&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;620,789&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Basis difference in fixed assets&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33,241&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33,241&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Intangible assets, net&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;572,687&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;634,521&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Contribution, carryforward&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;707&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;677&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,588,401&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;747,589&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Capital loss carryforward&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,027,111&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,027,111&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,312,769&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,089,306&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax asset&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,850&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27,554&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(32,850&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(27,554&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax asset&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Based on an assessment of all available evidence including, but &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; limited to the Company&amp;#x2019;s limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, the Company has concluded that it is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; that these net operating loss carryforwards and credits will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be realized and, as a result, a full valuation allowance has been recorded against the Company&amp;#x2019;s deferred income tax assets. Utilization of the net operating loss carryforwards &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be subject to a substantial annual limitation due to ownership change limitations that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;have occurred or that could occur in the future, as required by the Internal Revenue Code Section &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;382.&lt;/div&gt; In general, an &amp;#x201c;ownership change,&amp;#x201d; as defined by the code, results from a transaction or series of transactions over a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-year period resulting in an ownership change of more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50&lt;/div&gt; percentage points of the outstanding stock of a company by certain stockholders or public groups. Any limitation &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;result in expiration of all or a portion of the net operating loss carryforwards before utilization. Since the Company&amp;#x2019;s initial public offering, ownership changes have triggered a Section &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;382&lt;/div&gt; limitation, which limits the ability to utilize net operating loss carryforwards.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company has incurred net operating losses from inception. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;the Company had domestic federal net operating loss carryforwards of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$58.2&lt;/div&gt; million. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May &lt;/div&gt;of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 2017, &lt;/div&gt;the Company completed public offerings, which triggered ownership changes under section &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;382.&lt;/div&gt; We believe that as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;the gross net operating loss carryforwards have been limited to approximately $&lt;div style="display: inline;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12.3&lt;/div&gt;&lt;/div&gt; million, which are available to reduce future taxable income. Federal net operating loss carryforwards generated through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;expire at various dates beginning in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2029&lt;/div&gt; through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2038,&lt;/div&gt; while federal net operating loss carryforwards generated in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expire. The Company recorded a valuation allowance against all of its net deferred tax assets of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.3&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.1&lt;/div&gt; million as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively, for a net increase of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.2&lt;/div&gt; million from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; and a net decrease of &lt;div style="display: inline;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$15.5&lt;/div&gt; &lt;/div&gt;million from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company files income tax returns in the U.S. The Company is subject to tax examinations for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2012&lt;/div&gt; tax year and beyond. The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; unrecognized tax positions and does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; believe there will be any material changes in its unrecognized tax positions over the next &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months. The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; incurred any interest or penalties related to unrecognized tax positions. In the event that the Company is assessed interest or penalties at some point in the future, they will be classified in the financial statements as general and administrative expense.&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c45311702" unitRef="iso4217-usd">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c45311733" unitRef="iso4217-usd">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c45311225">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; that some portion or all of a deferred tax asset will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be realized based on the weight of available evidence, including expected future earnings. The Company recognizes an uncertain tax position in its financial statements when it concludes that a tax position is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to be sustained upon examination based solely on its technical merits. Only after a tax position passes the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit that is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. The Company elects to accrue any interest or penalties related to income taxes as part of its income tax expense.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311749" unitRef="iso4217-usd">2223463</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311750" unitRef="iso4217-usd">-15344015</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="d_2018-01-01_2018-12-31" id="c45311753" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311754" unitRef="iso4217-usd">1912427</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311741" unitRef="iso4217-usd">-2395036</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311742" unitRef="iso4217-usd">-2761678</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311746" unitRef="iso4217-usd">1616</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311748" unitRef="iso4217-usd">2668</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311743" unitRef="iso4217-usd">169957</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311745" unitRef="iso4217-usd">197336</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="d_2018-01-01_2018-12-31" id="c45311751" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311752" unitRef="iso4217-usd">-126031</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311159" unitRef="iso4217-usd">18427</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311160" unitRef="iso4217-usd">80581</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311163" unitRef="iso4217-usd">86969</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311164" unitRef="iso4217-usd">73141</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311161" unitRef="iso4217-usd">150203</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311162" unitRef="iso4217-usd">14968</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311157" unitRef="iso4217-usd">-74301</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311158" unitRef="iso4217-usd">80408</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311165" unitRef="iso4217-usd">24405</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311166" unitRef="iso4217-usd">9451</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311153" unitRef="iso4217-usd">258889</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311154" unitRef="iso4217-usd">79343</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2018-01-01_2018-12-31" id="c45311239">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Intangible Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Intangible assets consist of intellectual property and software acquired. Intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the assets might &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be recoverable. Impairment losses must be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&amp;#x2019; carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the assets. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;During the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;we determined certain intangible assets acquired from Acueity Healthcare, Inc. ("Acueity") were impaired and&amp;nbsp;recorded an asset impairment charge of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$461,715&lt;/div&gt; for the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;to adjust the carrying value of these intangible assets to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;zero&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017. &amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; impairment charges were recorded during the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;We determined the fair values of the Acueity intangibles using an income approach (Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; of the fair value hierarchy). For purposes of the income approach, fair value was determined based on the present value of estimated future cash flows that a market participant could expect to generate from the development of products using the patented technology acquired in the Acueity transaction, discounted at an appropriate risk-adjusted rate reflecting the weighted average cost of capital for a potential market participant. The discount rate used in valuation for these intangible assets was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;48.50%.&lt;/div&gt; The estimated future cash flows, including an estimate of long-term future growth rates, reflect our own assumptions of what market participants would utilize to price the assets pursuant to ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;820,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Fair Value Measurements&lt;/div&gt;.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Amortization of intangible assets&amp;nbsp;is computed using the straight-line method over the estimated useful lives ranging from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; years.&lt;/div&gt; &lt;div style=" margin: 0pt 7.2pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt 7.2pt; text-align: left; text-indent: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Intangible assets amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$192,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$234,000&lt;/div&gt; for at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively. Accumulated amortization was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$93,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$158,000&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively. Amortization expense for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$29,811&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$103,038,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-AcueityIntangibleAssetsMember" decimals="INF" id="c45311338" unitRef="iso4217-usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2018-12-31" decimals="INF" id="c45311348" unitRef="iso4217-usd">192000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2017-12-31" decimals="INF" id="c45311349" unitRef="iso4217-usd">234000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InterestPaidNet contextRef="d_2018-01-01_2018-12-31" id="c45311192" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InterestPaidNet contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311193" unitRef="iso4217-usd">330</us-gaap:InterestPaidNet>
  <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="i_2018-11-01" id="c45311804">P1Y300D</us-gaap:LesseeOperatingLeaseTermOfContract>
  <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="i_2018-10-30_LeaseArrangementTypeAxis-LeaseForCopierSystemMember" id="c45311813">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2018-12-31" decimals="INF" id="c45310802" unitRef="iso4217-usd">11720446</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2017-12-31" decimals="INF" id="c45310803" unitRef="iso4217-usd">8164094</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2018-12-31" decimals="INF" id="c45310758" unitRef="iso4217-usd">2915436</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2017-12-31" decimals="INF" id="c45310759" unitRef="iso4217-usd">1225407</us-gaap:LiabilitiesCurrent>
  <us-gaap:LossContingencyDamagesPaidValue contextRef="d_2018-03-23_2018-03-23" decimals="INF" id="c45311832" unitRef="iso4217-usd">3500000</us-gaap:LossContingencyDamagesPaidValue>
  <us-gaap:NatureOfOperations contextRef="d_2018-01-01_2018-12-31" id="s1154322">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline;"&gt;&lt;/div&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1:&lt;/div&gt; NATURE OF OPERATIONS&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Atossa Genetics Inc. (the &amp;#x201c;Company&amp;#x201d;) was incorporated on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 30, 2009, &lt;/div&gt;in the State of Delaware. The Company was initially formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company&amp;#x2019;s fiscal year ends on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31.&amp;nbsp;&lt;/div&gt;The Company is currently focused on development of its pharmaceutical and drug delivery programs for the treatment of breast cancer and other breast conditions.&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311183" unitRef="iso4217-usd">12290551</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311184" unitRef="iso4217-usd">10783457</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311172" unitRef="iso4217-usd">-110906</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2017-01-01_2017-12-31" id="c45311173" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311200" unitRef="iso4217-usd">-8961621</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311168" unitRef="iso4217-usd">-6593950</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311199" unitRef="iso4217-usd">-11404934</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311134" unitRef="iso4217-usd">-8122581</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311008" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311009" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311011" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311012" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45311014" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" id="c45311015" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c45311016" unitRef="iso4217-usd">-8122581</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311107" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311108" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311110" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311111" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c45311113" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" id="c45311114" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c45311115" unitRef="iso4217-usd">-11404934</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="d_2018-04-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" decimals="INF" id="c45311990" unitRef="iso4217-usd">-8924677</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="d_2018-04-01_2018-06-30" decimals="INF" id="c45311991" unitRef="iso4217-usd">-15621885</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="d_2018-01-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" decimals="INF" id="c45311992" unitRef="iso4217-usd">-10799059</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="d_2018-01-01_2018-06-30" decimals="INF" id="c45311993" unitRef="iso4217-usd">-17496267</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45310835" unitRef="iso4217-usd">-22884242</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310836" unitRef="iso4217-usd">-10690713</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c45311218">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recently Issued Accounting Pronouncements:&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2016, &lt;/div&gt;Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Lease Accounting Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842.&lt;/div&gt;&lt;/div&gt; The new standard is effective for reporting periods beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018 &lt;/div&gt;and early adoption is permitted. The standard will require lessees to report most leases as assets or liabilities on the balance sheet, while lessor accounting will remain substantially unchanged. The standard permits &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; approaches, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; requiring retrospective application of the new guidance with restatement of prior years, and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; requiring prospective application of the new guidance. We plan to adopt the new lease standard effective &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019 &lt;/div&gt;and apply it prospectively. We do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect the new lease standard to have a material effect on our financial position, results of operations or cash flows. Upon adoption of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; we will be required to recognize an operating lease liability and right-of-use asset of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$100,000,&lt;/div&gt; based on the lease composition disclosed in &lt;div style="display: inline;"&gt;footnote &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 2016, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Statement of Cash Flows&lt;/div&gt;, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2018 &lt;/div&gt;on a retrospective basis. For years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; we included &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$110,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$55,000,&lt;/div&gt; respectively, of restricted cash within cash, cash equivalents, and restricted cash&amp;nbsp;on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer has the credit card or the limit changes on the credit card.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2017, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception&lt;/div&gt;. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer precludes equity classification when assessing whether the instrument is indexed to an entity&amp;#x2019;s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;260&lt;/div&gt; to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This update is effective for public entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018. &lt;/div&gt;Early adoption is permitted. The Company early adopted the provisions of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2018. &lt;/div&gt;As the Company does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have any financial instruments with down round features, this ASU did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a material impact on the financial statements upon adoption.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2018, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;07,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. &lt;/div&gt;This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt; to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt; to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt; does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;606,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Revenue from Contracts with Customers&lt;/div&gt;. This update is effective for public entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018, &lt;/div&gt;including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 1, 2018 &lt;/div&gt;and it did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a material impact on the financial statements upon adoption.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2018, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;08,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Not&lt;/div&gt;-for-Profit Entities (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;958&lt;/div&gt;): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.&lt;/div&gt; This ASU affects &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;-for-profit entities and business entities that receive or make contributions of cash.&amp;nbsp;The ASU&amp;#xfeff; clarifies and improves the scope and accounting guidance to assist entities in evaluating if those transactions should be accounted for as contributions under the scope of Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;958&lt;/div&gt; or as an exchange transaction subject to other guidance.&amp;nbsp;This update is effective for public entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018. &lt;/div&gt;The Company is currently evaluating the impact that adoption will have on its financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:OpenTaxYear contextRef="d_2018-01-01_2018-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" id="c45311728">2012 2013 2014 2015 2016 2017 2018</us-gaap:OpenTaxYear>
  <us-gaap:OperatingExpenses contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45310817" unitRef="iso4217-usd">11434233</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310818" unitRef="iso4217-usd">7649171</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45310819" unitRef="iso4217-usd">-11434233</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310820" unitRef="iso4217-usd">-7649171</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="i_2018-12-31" decimals="INF" id="c45311805" unitRef="iso4217-usd">73200</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="i_2018-12-31_LeaseArrangementTypeAxis-LeaseForCopierSystemMember" decimals="INF" id="c45311814" unitRef="iso4217-usd">42228</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="i_2018-12-31" decimals="INF" id="c45311806" unitRef="iso4217-usd">43920</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="i_2018-12-31_LeaseArrangementTypeAxis-LeaseForCopierSystemMember" decimals="INF" id="c45311815" unitRef="iso4217-usd">14904</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="i_2018-12-31_LeaseArrangementTypeAxis-LeaseForCopierSystemMember" decimals="INF" id="c45311817" unitRef="iso4217-usd">12420</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="i_2018-12-31" decimals="INF" id="c45311807" unitRef="iso4217-usd">29280</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="i_2018-12-31_LeaseArrangementTypeAxis-LeaseForCopierSystemMember" decimals="INF" id="c45311816" unitRef="iso4217-usd">14904</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311811" unitRef="iso4217-usd">31457</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311812" unitRef="iso4217-usd">33285</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2018-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" decimals="-3" id="c45311711" unitRef="iso4217-usd">58200000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OtherAssetsCurrent contextRef="i_2018-12-31" decimals="INF" id="c45310734" unitRef="iso4217-usd">30942</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="i_2017-12-31" decimals="INF" id="c45310735" unitRef="iso4217-usd">16344</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2018-12-31" decimals="INF" id="c45310742" unitRef="iso4217-usd">17218</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2017-12-31" decimals="INF" id="c45310743" unitRef="iso4217-usd">178907</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="i_2018-12-31" decimals="INF" id="c45310756" unitRef="iso4217-usd">39939</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="i_2017-12-31" decimals="INF" id="c45310757" unitRef="iso4217-usd">15534</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45310825" unitRef="iso4217-usd">29299</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310826" unitRef="iso4217-usd">154</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherPrepaidExpenseCurrent contextRef="i_2018-12-31" decimals="INF" id="c45311395" unitRef="iso4217-usd">4355</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:OtherPrepaidExpenseCurrent contextRef="i_2017-12-31" decimals="INF" id="c45311396" unitRef="iso4217-usd">13882</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="d_2018-01-01_2018-12-31_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311580" unitRef="iso4217-usd">1333449</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311170" unitRef="iso4217-usd">110906</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2017-01-01_2017-12-31" id="c45311171" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2018-12-31" decimals="INF" id="c45310765" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2017-12-31" decimals="INF" id="c45310766" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" decimals="INF" id="c45310770" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" decimals="INF" id="c45310771" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45310776" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45310777" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesAJuniorParticipatingPreferredStockMember" decimals="INF" id="c45311452" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2018-05-29_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45311538" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2018-12-31" decimals="INF" id="c45310767" unitRef="xbrli-shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2017-12-31" decimals="INF" id="c45310769" unitRef="xbrli-shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" decimals="INF" id="c45310772" unitRef="xbrli-shares">4000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" decimals="INF" id="c45310773" unitRef="xbrli-shares">4000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45310778" unitRef="xbrli-shares">25000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45310779" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesAJuniorParticipatingPreferredStockMember" decimals="INF" id="c45311451" unitRef="xbrli-shares">750000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2018-05-29_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45311539" unitRef="xbrli-shares">25000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45310780" unitRef="xbrli-shares">2379</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45310781" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesAJuniorParticipatingPreferredStockMember" decimals="INF" id="c45311457" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" decimals="INF" id="c45311588" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" decimals="INF" id="c45310774" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember" decimals="INF" id="c45310775" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45310782" unitRef="xbrli-shares">2379</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" decimals="INF" id="c45310783" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesAJuniorParticipatingPreferredStockMember" decimals="INF" id="c45311587" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="i_2018-12-31" decimals="INF" id="c45310763" unitRef="iso4217-usd">2</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="i_2017-12-31" id="c45310764" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PrepaidExpenseCurrent contextRef="i_2018-12-31" decimals="INF" id="c45310730" unitRef="iso4217-usd">509833</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="i_2017-12-31" decimals="INF" id="c45310731" unitRef="iso4217-usd">250944</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidInsurance contextRef="i_2018-12-31" decimals="INF" id="c45311385" unitRef="iso4217-usd">160576</us-gaap:PrepaidInsurance>
  <us-gaap:PrepaidInsurance contextRef="i_2017-12-31" decimals="INF" id="c45311386" unitRef="iso4217-usd">125056</us-gaap:PrepaidInsurance>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2017-10-26_2017-10-26_SubsidiarySaleOfStockAxis-October2017PublicOfferingMember" decimals="INF" id="c45311513" unitRef="iso4217-usd">5500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2017-12-20_2017-12-20_SubsidiarySaleOfStockAxis-December2017PublicOfferingAndPrivatePlacementMember" decimals="INF" id="c45311522" unitRef="iso4217-usd">1400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311175" unitRef="iso4217-usd">12290551</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="d_2017-01-01_2017-12-31" id="c45311176" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="d_2017-04-03_2017-04-03_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember" decimals="INF" id="c45311468" unitRef="iso4217-usd">4400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2019-03-01_2019-03-25_SubsequentEventTypeAxis-SubsequentEventMember" decimals="-5" id="c45312739" unitRef="iso4217-usd">11300000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2019-03-01_2019-03-24_SubsequentEventTypeAxis-SubsequentEventMember" decimals="-5" id="c45312036" unitRef="iso4217-usd">11300000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2018-01-01_2018-12-31" id="c45311179" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311180" unitRef="iso4217-usd">749233</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2018-12-31" decimals="INF" id="c45311314" unitRef="iso4217-usd">216000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31" decimals="INF" id="c45311315" unitRef="iso4217-usd">171000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2018-12-31" decimals="INF" id="c45310738" unitRef="iso4217-usd">54487</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2017-12-31" decimals="INF" id="c45310739" unitRef="iso4217-usd">11467</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c45311232">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Furniture and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Furniture and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When furniture and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Depreciation is computed using the straight-line method over the estimated useful lives ranging from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; to&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt 7.2pt; text-align: left; text-indent: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Furniture and equipment amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$216,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$171,000&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively. Accumulated depreciation was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$162,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$160,000&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively. Depreciation expense for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$14,386&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$25,956,&lt;/div&gt; respectively.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Company periodically evaluates the carrying value of long-lived assets to be held and used and, if necessary, records impairment losses when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-loved assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.&amp;nbsp; For the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; impairment of furniture and equipment was recorded.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2018-01-01_2018-12-31_RangeAxis-MinimumMember" id="c45311311">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2018-01-01_2018-12-31_RangeAxis-MaximumMember" id="c45311313">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:Reclassifications contextRef="d_2018-01-01_2018-12-31" id="s1154352">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15:&lt;/div&gt;&amp;nbsp; RESTATEMENT TO PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 22.2pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 14.7pt 0pt 6pt; text-align: left; text-indent: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company has corrected an inadvertent error in the calculation of the deemed dividend on Series B convertible preferred stock in the financial statements for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;six&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 30, 2018 &lt;/div&gt;that were included in the Company&amp;#x2019;s Form &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-Q filed on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 13, 2018 (&lt;/div&gt;the &amp;#x201c;Original Form &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-Q&amp;#x201d;). Accounting principles generally accepted in the United States of America require that we allocate the proceeds from the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2018 &lt;/div&gt;financing to the warrants and preferred stock issued in the financing and that we estimate and record any discount on the securities as a deemed dividend. In the financial statements included in the Original Form &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-Q, we did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; properly allocate the proceeds to the warrants, and we did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; properly record the deemed dividend related to the warrant discount as additional paid in capital to common stock. The Company incorrectly stated the deemed dividend for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;six&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 30, 2018 &lt;/div&gt;as &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,782,100,&lt;/div&gt; rather than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11,479,308.&lt;/div&gt; The corrections result from application of technical accounting rules and do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; impact cash or operations.&lt;/div&gt; &lt;div style=" margin: 0pt 22.2pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt 14.7pt 0pt 6pt; text-align: left; text-indent: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In accordance with applicable generally accepted accounting principles, the Company has calculated and recognized adjustments accordingly. The following table shows the effect of the restatement on certain line items within the Company&amp;#x2019;s Condensed Consolidated Statement of Operations for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;six&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 30, 2018: &amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 22.2pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;For the Three Months Ended&lt;br /&gt; June 30, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;For the Six Months Ended&lt;br /&gt; June 30, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Previously&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reported&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Restated&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Previously&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reported&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Restated&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Deemed dividend attributable to preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(4,782,100&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(11,479,308&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(4,782,100&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(11,479,308&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Net loss applicable to common stockholders&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(8,924,677&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(15,621,885&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(10,799,059&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(17,496,267&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Loss per common share -basic and diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(2.90&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(5.08&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(3.77&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(6.11&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt 22.2pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt 14.7pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The following table shows the effect of the restatement on certain line items within the Company&amp;#x2019;s Condensed Consolidated Statement of Stockholders&amp;#x2019; Equity for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;six&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 30, 2018: &amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 22.2pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Preferred Stock Additional Paid-in Capital&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Common Stock Additional Paid-in Capital&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Previously&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reported&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Restated&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Previously&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reported&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Restated&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Issuance of Series B convertible preferred stock, net of issuance costs&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;12,290,537&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;6,926,778&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;5,363,759&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Deemed Dividend on Series B convertible preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;4,782,100&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;11,479,308&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(4,782,100&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(11,479,308&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Conversion of Series B convertible preferred stock to common stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(7,056,421&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(7,821,992&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;6,656,442&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;7,422,013&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:Reclassifications>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2018-01-01_2018-12-31_ConsolidatedEntitiesAxis-AtossaGeneticsAUSPtyLtdMember" decimals="INF" id="c45311404" unitRef="iso4217-usd">851000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2017-01-01_2017-12-31_ConsolidatedEntitiesAxis-AtossaGeneticsAUSPtyLtdMember" decimals="INF" id="c45311405" unitRef="iso4217-usd">824000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45310809" unitRef="iso4217-usd">4209981</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310810" unitRef="iso4217-usd">2328087</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2018-01-01_2018-12-31" id="c45311222">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;All research and development costs are expensed as incurred.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RestrictedAssetsDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154325">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4:&lt;/div&gt; RESTRICTED CASH&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Our restricted cash balance of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$110,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$55,000&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; consists entirely of cash pledged as security for the Company&amp;#x2019;s issued commercial credit cards.&lt;/div&gt;&lt;/div&gt;</us-gaap:RestrictedAssetsDisclosureTextBlock>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="i_2018-12-31" decimals="INF" id="c45311267" unitRef="iso4217-usd">110000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="i_2017-12-31" decimals="INF" id="c45311268" unitRef="iso4217-usd">55000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2018-12-31" decimals="INF" id="c45310727" unitRef="iso4217-usd">110000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="i_2017-12-31" decimals="INF" id="c45310728" unitRef="iso4217-usd">55000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2018-12-31" decimals="INF" id="c45310798" unitRef="iso4217-usd">-76831263</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2017-12-31" decimals="INF" id="c45310799" unitRef="iso4217-usd">-65426329</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued bonus payable&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;697,995&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;566,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued vacation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;160,740&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;147,861&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued payroll liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;76,335&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;71,006&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total payroll liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;935,070&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;784,867&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-27">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-right: 10%; margin-left: 45pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="width: 111111%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Options to purchase common stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;487,941&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;117,301&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series A convertible preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;55,835&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Series B convertible preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;774,983&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrants to purchase common stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,054,481&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;202,063&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,317,405&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;375,199&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-29">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended December 31, &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 74%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Obsolete inventory&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,881&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,881&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Accrued vacation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33,755&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,051&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Accrued bonuses&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;99,666&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;968,170&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;620,789&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Basis difference in fixed assets&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33,241&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33,241&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Intangible assets, net&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;572,687&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;634,521&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Contribution, carryforward&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;707&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;677&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,588,401&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;747,589&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Capital loss carryforward&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,027,111&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,027,111&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,312,769&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,089,306&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax asset&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,850&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27,554&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(32,850&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(27,554&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax asset&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-26">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-right: 10%; margin-left: 45pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Numerator&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11,404,934&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8,122,581&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deemed dividend attributable to preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11,479,308&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,568,132&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss attributable to common shareholders&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22,884,242&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(10,690,713&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Denominator&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average common shares outstanding used to compute net loss per share, basic and diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,157,746&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;974,773&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Net loss per share of common stock, basic and diluted: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5.50&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(10.97&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-28">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;As of December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected federal income tax benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,395,036&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,761,678&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;169,957&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;197,336&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other permanent items&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,616&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,668&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Effect of change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,223,463&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(15,344,015&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prior year true-up&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(126,031&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Tax rate change&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,912,427&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Effect of NOL limitation&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,119,293&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Actual federal income tax benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c-31">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;201&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;201&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 68%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 68%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;809,110&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;621,668&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 68%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;244,386&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;164,882&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 68%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Total stock compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,053,496&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;786,550&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember" id="c-34">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 85%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 85%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;869,515&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 85%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;540,510&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 85%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Total stock compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,410,025&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-36">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;For the Three Months Ended&lt;br /&gt; June 30, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;For the Six Months Ended&lt;br /&gt; June 30, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Previously&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reported&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Restated&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Previously&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reported&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Restated&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Deemed dividend attributable to preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(4,782,100&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(11,479,308&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(4,782,100&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(11,479,308&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Net loss applicable to common stockholders&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(8,924,677&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(15,621,885&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(10,799,059&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(17,496,267&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Loss per common share -basic and diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(2.90&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(5.08&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(3.77&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(6.11&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Preferred Stock Additional Paid-in Capital&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Common Stock Additional Paid-in Capital&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Previously&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reported&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Restated&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Previously&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reported&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 12%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Restated&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Issuance of Series B convertible preferred stock, net of issuance costs&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;12,290,537&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;6,926,778&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;5,363,759&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Deemed Dividend on Series B convertible preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;4,782,100&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;11,479,308&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(4,782,100&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(11,479,308&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 44%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Conversion of Series B convertible preferred stock to common stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(7,056,421&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(7,821,992&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;6,656,442&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;7,422,013&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-33">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 10.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number of&lt;br /&gt; Underlying&lt;br /&gt; Shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 9.9%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted-&lt;br /&gt; Average&lt;br /&gt; Exercise Price&lt;br /&gt; Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted-&lt;br /&gt; Average&lt;br /&gt; Contractual&lt;br /&gt; Life Remaining&lt;br /&gt; in Years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="width: 9.9%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Aggregate&lt;br /&gt; Intrinsic Value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Outstanding as of January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.3%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;172,510&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;49.27&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.9%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.3%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;611,668&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2.39&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.9%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(795&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;562.55&lt;div style="display: inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.9%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Outstanding as of December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;783,383&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;12.14&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.9%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;9.17&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Exercisable as of December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;317,042&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;24.39&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.9%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;8.97&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 51.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Vested and expected to vest&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;783,383&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.8%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;12.14&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 9.9%; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;9.17&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 0.9%; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-32">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 67%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" rowspan="1" style="width: 636163%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 67%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 63%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;201&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 63%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;201&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="1" style="width: 67%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 3%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 3%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 67%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;2.47%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.71%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;1.86%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.04%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 67%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;5.24&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.57&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;5.32&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.36&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 67%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 3%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 3%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="width: 67%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="width: 67%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;108.81%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;126.43%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;112.86%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;114.19&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember" id="c-35">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="margin: 0pt auto 0pt 27pt; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 53%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2.51&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;2.94%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;4.5&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;5.0&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Stock price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$1.02&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$2.38&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;122.0&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;125.0%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-25">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 45%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Outstanding &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Warrants to &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Purchase &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 25%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Expiration Date&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 45%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 25%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 45%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2014 public offering&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,483&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;540.00&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 25%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;January 29, 2019&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 45%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2018 warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,869,216&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.05&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 25%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;May 30, 2022&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 45%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,875,699&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 25%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" id="c45311882">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311371" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember" id="c45311965" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_RangeAxis-MinimumMember" decimals="4" id="c45311967" unitRef="xbrli-pure">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_RangeAxis-MaximumMember" decimals="4" id="c45311969" unitRef="xbrli-pure">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_RangeAxis-MinimumMember" decimals="4" id="c45311954" unitRef="xbrli-pure">0.0251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_RangeAxis-MaximumMember" decimals="4" id="c45311956" unitRef="xbrli-pure">0.0294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" decimals="4" id="c45311909" unitRef="xbrli-pure">0.0247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" decimals="4" id="c45311911" unitRef="xbrli-pure">0.0271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" decimals="4" id="c45311912" unitRef="xbrli-pure">0.0186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" decimals="4" id="c45311914" unitRef="xbrli-pure">0.0204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" decimals="4" id="c45311927" unitRef="xbrli-pure">1.0881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" decimals="4" id="c45311929" unitRef="xbrli-pure">1.2643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" decimals="4" id="c45311930" unitRef="xbrli-pure">1.1286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" decimals="4" id="c45311932" unitRef="xbrli-pure">1.1419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="d_2016-05-18_2016-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311844" unitRef="xbrli-shares">11111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="d_2017-05-09_2017-05-09_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311846" unitRef="xbrli-shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="d_2018-04-12_2018-04-12_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311848" unitRef="xbrli-shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="d_2019-01-01_2019-01-01_PlanNameAxis-The2010StockOptionAndIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c45311862" unitRef="xbrli-shares">233862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2010-09-28_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311842" unitRef="xbrli-shares">5556</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311859" unitRef="xbrli-shares">3575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2018-12-31_AwardTypeAxis-The2019OptionsMember" decimals="INF" id="c45312032" unitRef="xbrli-shares">3575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="i_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311945" unitRef="xbrli-shares">317042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311946" unitRef="iso4217-usd-per-xbrli-shares">24.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311939" unitRef="xbrli-shares">795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311852" unitRef="xbrli-shares">611668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311853" unitRef="xbrli-shares">143027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="INF" id="c45311872" unitRef="xbrli-shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember" decimals="INF" id="c45311873" unitRef="xbrli-shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2019-01-13_2019-01-13_AwardTypeAxis-The2019OptionsMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="INF" id="c45312020" unitRef="xbrli-shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2019-01-13_2019-01-13_AwardTypeAxis-The2019OptionsMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember" decimals="INF" id="c45312021" unitRef="xbrli-shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311936" unitRef="xbrli-shares">611668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311857" unitRef="iso4217-usd-per-xbrli-shares">2.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311858" unitRef="iso4217-usd-per-xbrli-shares">4.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2019-01-13_AwardTypeAxis-LiabilityOptionsMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="INF" id="c45312018" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2019-01-13_AwardTypeAxis-LiabilityOptionsMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember" decimals="INF" id="c45312040" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2017-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311933" unitRef="xbrli-shares">172510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311942" unitRef="xbrli-shares">783383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2017-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311934" unitRef="iso4217-usd-per-xbrli-shares">49.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311943" unitRef="iso4217-usd-per-xbrli-shares">12.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="i_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311948" unitRef="xbrli-shares">783383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="i_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311949" unitRef="iso4217-usd-per-xbrli-shares">12.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311940" unitRef="iso4217-usd-per-xbrli-shares">562.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember" decimals="INF" id="c45311877" unitRef="iso4217-usd-per-xbrli-shares">2.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2019-01-13_2019-01-13_AwardTypeAxis-The2019OptionsMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c45312024" unitRef="iso4217-usd-per-xbrli-shares">1.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311937" unitRef="iso4217-usd-per-xbrli-shares">2.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2018-01-01_2018-12-31" id="c45311246">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Share-Based Payments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 15pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company follows the provisions of ASC Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Compensation - Stock Compensation&lt;/div&gt; (&amp;#x201c;ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&amp;#x201d;&lt;/div&gt;), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt; is recognized as an expense over the requisite service period and the Company made a policy election to recognize forfeitures when they occur.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company&amp;#x2019;s common stock, and estimation of an appropriate risk-free interest rate. The Company&amp;#x2019;s expected common stock price volatility assumption is based upon the historical volatility of our stock price. The expected life assumption for stock options grants was based upon the simplified method provided for under ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,&lt;/div&gt; which averages the contractual term of the options of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; years with the vesting term, typically &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;four&lt;/div&gt; years. The dividend yield assumption of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;zero&lt;/div&gt; is based upon the fact that the Company has never paid cash dividends and presently has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; intention of paying cash dividends in the future. The risk-free interest rate used for each grant was based upon prevailing short-term interest rates over the expected life of the options.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharePrice contextRef="i_2017-06-29_ClassOfWarrantOrRightAxis-The2017PublicOfferingWarrantsMember_RangeAxis-WeightedAverageMember" decimals="INF" id="c45311492" unitRef="iso4217-usd-per-xbrli-shares">6.24</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="i_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_RangeAxis-MinimumMember" decimals="INF" id="c45311960" unitRef="iso4217-usd-per-xbrli-shares">1.02</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="i_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_RangeAxis-MaximumMember" decimals="INF" id="c45311962" unitRef="iso4217-usd-per-xbrli-shares">2.38</us-gaap:SharePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" decimals="2" id="c45311880" unitRef="xbrli-pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember" decimals="2" id="c45311881" unitRef="xbrli-pure">0.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember_VestingAxis-ShareBasedCompensationAwardTrancheThreeMember" decimals="2" id="c45311883" unitRef="xbrli-pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember" id="c45311878">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2018-01-01_2018-12-31" id="c45311368">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_RangeAxis-MinimumMember" id="c45311957">P4Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_RangeAxis-MaximumMember" id="c45311959">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" id="c45311915">P5Y87D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" id="c45311917">P5Y208D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" id="c45311918">P5Y116D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" id="c45311920">P6Y131D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" id="c45311947">P8Y354D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" decimals="INF" id="c45311868" unitRef="xbrli-shares">466341</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2018-12-31_AwardTypeAxis-LiabilityOptionsMember" decimals="INF" id="c45311884" unitRef="xbrli-shares">1125000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" id="c45311944">P9Y62D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember" id="c45311950">P9Y62D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2017-10-26_SubsidiarySaleOfStockAxis-October2017PublicOfferingMember" decimals="INF" id="c45311516" unitRef="iso4217-usd-per-xbrli-shares">5.28</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2017-10-26_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" decimals="INF" id="c45311518" unitRef="iso4217-usd-per-xbrli-shares">5.28</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2017-12-20_SubsidiarySaleOfStockAxis-December2017PublicOfferingAndPrivatePlacementMember" decimals="INF" id="c45311521" unitRef="iso4217-usd-per-xbrli-shares">3.24</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesOutstanding contextRef="i_2016-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310842" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:SharesOutstanding contextRef="i_2016-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310845" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:SharesOutstanding contextRef="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45310848" unitRef="xbrli-shares">315576</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311018" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:SharesOutstanding contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311021" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:SharesOutstanding contextRef="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45311024" unitRef="xbrli-shares">2651952</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311117" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:SharesOutstanding contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c45311120" unitRef="xbrli-shares">2379</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45311123" unitRef="xbrli-shares">5846552</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" decimals="INF" id="c45311509" unitRef="xbrli-shares">389111</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c45310952" unitRef="xbrli-shares">292</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310955" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45310958" unitRef="xbrli-shares">389111</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311073" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c45311076" unitRef="xbrli-shares">11245</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45311079" unitRef="xbrli-shares">3194600</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-04-03_2017-04-03_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember" decimals="INF" id="c45311472" unitRef="xbrli-shares">55333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-04-03_2017-04-03_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember" decimals="INF" id="c45311476" unitRef="xbrli-shares">292</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-04-03_2017-04-03_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" decimals="INF" id="c45311479" unitRef="xbrli-shares">44167</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-06-29_2017-06-29" decimals="INF" id="c45311495" unitRef="xbrli-shares">125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-10-26_2017-10-26_SubsidiarySaleOfStockAxis-October2017PublicOfferingMember" decimals="INF" id="c45311515" unitRef="xbrli-shares">958333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-10-26_2017-10-26_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" decimals="INF" id="c45311517" unitRef="xbrli-shares">83333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-12-20_2017-12-20_SubsidiarySaleOfStockAxis-December2017PublicOfferingAndPrivatePlacementMember" decimals="INF" id="c45311520" unitRef="xbrli-shares">441667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2018-05-30_2018-05-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember" decimals="INF" id="c45311541" unitRef="xbrli-shares">13624</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2019-03-01_2019-03-24_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c45312038" unitRef="xbrli-shares">2800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember" id="c45310875" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember" id="c45310878" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember" decimals="INF" id="c45310881" unitRef="xbrli-shares">99500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c45310953" unitRef="iso4217-usd">4</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310954" unitRef="iso4217-usd">3234769</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310956" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310957" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45310959" unitRef="iso4217-usd">70040</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310960" unitRef="iso4217-usd">3164733</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45310961" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31" id="c45310962" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311074" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311075" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c45311077" unitRef="iso4217-usd">12</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311078" unitRef="iso4217-usd">11244989</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45311080" unitRef="iso4217-usd">575030</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311081" unitRef="iso4217-usd">10669971</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c45311082" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-12-31" id="c45311083" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2018-04-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalConvertiblePreferredStockMember" decimals="INF" id="c45312006" unitRef="iso4217-usd">-7056421</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2018-04-01_2018-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalConvertiblePreferredStockMember" decimals="INF" id="c45312007" unitRef="iso4217-usd">-7821992</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalCommonStockMember" decimals="INF" id="c45312008" unitRef="iso4217-usd">6656442</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2018-01-01_2018-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalCommonStockMember" decimals="INF" id="c45312009" unitRef="iso4217-usd">7422013</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember" id="c45310876" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember" id="c45310877" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember" id="c45310879" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember" id="c45310880" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember" decimals="INF" id="c45310882" unitRef="iso4217-usd">17910</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember" decimals="INF" id="c45310883" unitRef="iso4217-usd">811774</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember" id="c45310884" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember" decimals="INF" id="c45310885" unitRef="iso4217-usd">829684</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2018-04-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalConvertiblePreferredStockMember" decimals="INF" id="c45311998" unitRef="iso4217-usd">12290537</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2018-04-01_2018-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalConvertiblePreferredStockMember" decimals="INF" id="c45311999" unitRef="iso4217-usd">6926778</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2018-01-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalCommonStockMember" decimals="INF" id="c45312000" unitRef="iso4217-usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2018-01-01_2018-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalCommonStockMember" decimals="INF" id="c45312001" unitRef="iso4217-usd">5363759</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockOptionPlanExpense contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45311137" unitRef="iso4217-usd">1053496</us-gaap:StockOptionPlanExpense>
  <us-gaap:StockOptionPlanExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45311139" unitRef="iso4217-usd">786550</us-gaap:StockOptionPlanExpense>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31" decimals="INF" id="c45310800" unitRef="iso4217-usd">8805010</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31" decimals="INF" id="c45310801" unitRef="iso4217-usd">6938687</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310843" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310844" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45310846" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45310847" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45310849" unitRef="iso4217-usd">56804</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45310850" unitRef="iso4217-usd">60344050</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c45310851" unitRef="iso4217-usd">-57303748</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31" decimals="INF" id="c45310852" unitRef="iso4217-usd">3097106</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311019" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311020" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311022" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311023" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45311025" unitRef="iso4217-usd">477342</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311026" unitRef="iso4217-usd">71887674</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c45311027" unitRef="iso4217-usd">-65426329</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" id="c45311118" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" id="c45311119" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c45311121" unitRef="iso4217-usd">2</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311122" unitRef="iso4217-usd">2378997</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c45311124" unitRef="iso4217-usd">1052372</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember" decimals="INF" id="c45311125" unitRef="iso4217-usd">82204902</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c45311126" unitRef="iso4217-usd">-76831263</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154333">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;: STOCKHOLDERS&amp;#x2019; EQUITY&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company is authorized to issue a total of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;185,000,000&lt;/div&gt; shares of stock consisting of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;175,000,000&lt;/div&gt; shares of common stock, par value &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.18&lt;/div&gt; per share, and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,000,000&lt;/div&gt; shares of preferred stock, par value &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.001&lt;/div&gt; per share. The Company has designated &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;750,000&lt;/div&gt; shares of Series A junior participating preferred stock, par value &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.001&lt;/div&gt; per share, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,000&lt;/div&gt; shares of Series A convertible preferred stock, par value &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.001&lt;/div&gt; per share, and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,000&lt;/div&gt; shares of Series B convertible preferred stock, par value &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.001&lt;/div&gt; per share,&amp;nbsp;through the filings of certificates of designation with the Delaware Secretary of State. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; shares of Series A junior participating preferred stock or Series A convertible preferred stock are issued or outstanding as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 19, 2014, &lt;/div&gt;the Company adopted a stockholder rights agreement which provides that all stockholders of record on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 26, 2014, &lt;/div&gt;received a non-taxable distribution of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; preferred stock purchase right for each share of the Company&amp;#x2019;s common stock held by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable only if &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; of the following occurs: (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;)&amp;nbsp;a person becomes an &amp;#x201c;Acquiring Person&amp;#x201d; by acquiring beneficial ownership of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15%&lt;/div&gt; or more of the Company&amp;#x2019;s common stock (or, in the case of a person who beneficially owned &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15%&lt;/div&gt; or more of the Company&amp;#x2019;s common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.0%&lt;/div&gt; of the Company&amp;#x2019;s common stock then outstanding (excluding compensatory arrangements)), or (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;)&amp;nbsp;a person commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of the Company&amp;#x2019;s common stock with a market value that equals twice the exercise price of the right. The initial exercise price of each right is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$15.00,&lt;/div&gt; so each holder (other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30.00&lt;/div&gt; worth of the Company&amp;#x2019;s common stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring entity.&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; text-decoration: underline;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; Public Offering of Class A and Class B Units Consisting of Common Stock, Series A Convertible Preferred Stock and Warrants&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 28, 2017, &lt;/div&gt;the Company entered into an underwriting agreement with Aegis Capital Corp. relating to a public offering which closed on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 3, 2017. &lt;/div&gt;The offering generated gross proceeds to the Company of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.4&lt;/div&gt; million and net proceeds of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.9&lt;/div&gt; million after deducting underwriting discounts and commissions and other offering expenses paid by the Company.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The offering included &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;55,333&lt;/div&gt; Class A Units at a public offering price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$9.00&lt;/div&gt; per Class A Unit, which consisted of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;55,333&lt;/div&gt; shares of common stock and warrants to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;55,333&lt;/div&gt; shares of common stock. The offering also included &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;292&lt;/div&gt; Class B Units at a public offering price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12,000&lt;/div&gt; per Class B Unit, which consisted of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;292&lt;/div&gt; shares of Series A convertible preferred stock convertible into a total of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;389,111&lt;/div&gt; shares of common stock and warrants to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;389,111&lt;/div&gt; shares of common stock. In addition, the underwriter exercised the over-allotment option to purchase an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;44,167&lt;/div&gt; shares of common stock and warrants to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;44,167&lt;/div&gt; shares of common stock, which are included in the gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.4&lt;/div&gt; million. The warrants had a per share exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11.25,&lt;/div&gt; were exercisable immediately and were scheduled to expire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years from the date of issuance.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;all of the warrants issued in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 3, 2017 &lt;/div&gt;offering have been exercised and are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer outstanding and all of the shares of Series A convertible preferred stock have been converted into shares of common stock.&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accounting Treatment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company allocated the proceeds from the sale of the Class A and Class B units to the separate securities issued. The Company determined that, on the date of issuance, the warrants were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; indexed to its stock because they did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; meet the &amp;#x201c;fixed-for-fixed&amp;#x201d; criterion&amp;nbsp;due to the price protection and fundamental transaction provisions and, therefore, the warrants were accounted for as liabilities with changes in fair value recorded in non-operating income (expense) in the consolidated statement of operations.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company allocated the amount representing the fair value of the warrants at the date of issuance separately to the warrant liability and recorded the remaining proceeds as common stock, in the case of the Class A units, or as Series A convertible preferred stock, in the case of the Class B units. Due to the allocation of a portion of the proceeds to the warrants, the Series A convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,284,066&lt;/div&gt; based on the intrinsic value of the beneficial conversion feature. The discount on the Series A convertible preferred stock of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,284,066&lt;/div&gt; caused by allocation of the proceeds to the warrant was recorded as a deemed dividend upon issuance of the Series A convertible preferred stock. As a result, total deemed dividends of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,568,132&lt;/div&gt; were recorded upon issuance of the Series A convertible preferred stock, which is reflected as an addition to net loss in the consolidated statement of operations to arrive at net loss applicable to common shareholders.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Exercise of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 29, 2017, &lt;/div&gt;the Company offered to modify the rights of the holders of the warrants issued in the public offering the Company completed on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 3, 2017. &lt;/div&gt;The temporary modification included (a) lowering the exercise price of the warrants to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.12&lt;/div&gt; per share, (b) setting the applicable volume-weighted average price (VWAP) at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6.24&lt;/div&gt; per share, and (c) allowing for temporary cashless exercise of the warrants for all holders that accepted the temporary modification before &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8:00&lt;/div&gt; a.m. Eastern daylight time on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 30, 2017. &lt;/div&gt;Holders of warrants to purchase a total of approximately &lt;div style="display: inline;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;250,000&lt;/div&gt; shares of common stock accepted the offer resulting in the cancellation of those warrants and the issuance by the Company of a total of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125,000&lt;/div&gt; shares &lt;/div&gt;of common stock (including shares held in abeyance). The shares of common stock are registered under the Securities Act of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1933,&lt;/div&gt; as amended. In connection with the temporary modification, the Company agreed to extend the &amp;#x201c;Lock-up Period&amp;#x201d; of the underwriting agreement between the Company and Aegis Capital Corp., dated &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 28, 2017, &lt;/div&gt;by &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;45&lt;/div&gt; days and the Company agreed &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to enter into any further amendments to the warrants during such extended Lock-up Period without the prior written consent of each holder. During the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; all remaining warrants were exercised for cash so that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; warrants issued in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 3, 2017, &lt;/div&gt;financing remained outstanding. Upon exercise of these warrants, the amount of the warrant liability at the date of exercise was reclassified from warrant liability to additional paid-in capital.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The following table summarizes the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; liability warrant activity:&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="margin: 0pt auto 0pt 36pt; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 74%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding as of January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrants granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;488,611&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.25&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrants exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(488,611&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.12&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding as of December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company estimated the fair value of the warrants using the Monte Carlo simulation (MCS) model, which is a type of income approach, where the current value of an asset is expressed as the sum of probable future cash flows across various scenarios and time frames discounted for risk and time. The significant assumptions included timing of future rounds of financing, timing and success rates of oncology clinical trials, and the probability of a merger and acquisition adjusted for a lack of marketability discount. The MCS model also included a full term and an early conversion scenario that were each weighted at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt; in the final concluded fair value.&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Inputs used in the valuation of the warrants at the issuance date of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 3, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 30, 2017, &lt;/div&gt;are set forth below. All of&amp;nbsp;the warrants issued in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 2017 &lt;/div&gt;financing&amp;nbsp;were exercised during&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;none&lt;/div&gt; remained outstanding at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Initial valuation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$9.00&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercise price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11.25&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.79%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.88%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;0.24&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;June 30, 2017 valuation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6.00&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercise price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.12&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;0.79&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.88%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;0.08&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.76&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Conversion of Series A Convertible Preferred Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;During the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;certain holders of the Series A convertible preferred stock exercised their conversion option and converted an aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;292&lt;/div&gt; shares of Series A convertible preferred stock into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;389,111&lt;/div&gt; shares of the Company&amp;#x2019;s common stock based on the conversion ratio of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;111&lt;/div&gt; shares of common stock for each share of Series A convertible preferred stock. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; shares of Series A convertible preferred stock were outstanding.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; text-decoration: underline;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 2017 &lt;/div&gt;Public Offering&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 26, 2017, &lt;/div&gt;the Company entered into an underwriting agreement with Maxim Group LLC relating to a public offering of common stock which closed on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 30, 2017. &lt;/div&gt;The offering generated gross proceeds to the Company of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.5&lt;/div&gt; million and net proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.9&lt;/div&gt; million after deducting underwriting discounts, commissions and other offering expenses paid by the Company.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The offering included &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;958,333&lt;/div&gt; shares of common stock at a public offering price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.28&lt;/div&gt; per share. In addition, the underwriter exercised the over-allotment option to purchase an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;83,333&lt;/div&gt; shares of common stock at the offering price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.28&lt;/div&gt; per share, which are included in the gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.5&lt;/div&gt; million.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; text-decoration: underline;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2017 &lt;/div&gt;Public Offering and Private Placement&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 20, 2017, &lt;/div&gt;the Company entered into a placement agent agreement with Maxim Group LLC relating to the sale of the Company&amp;#x2019;s securities. Pursuant to the placement agent agreement, on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 20, 2017, &lt;/div&gt;the Company entered into a securities purchase agreement with certain purchasers named therein relating to the offering and sale of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;441,667&lt;/div&gt; shares of Company common stock at a public offering price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.24&lt;/div&gt; per share. The offering generated gross proceeds to the Company of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.4&lt;/div&gt; million and net proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.2&lt;/div&gt; million after deduction of underwriting discounts, commissions, and other offering expenses paid by the Company.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Concurrently with the public offering the Company also commenced a private placement whereby it issued and sold Class A and Class B Warrants, exercisable for an aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;883,333&lt;/div&gt; shares of common stock, at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.78&lt;/div&gt; per share. The public offering and the private placement involved the same purchasers. The Class A and Class B Warrants exercise price&amp;nbsp;was fixed at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.78&lt;/div&gt; per warrant, and the warrants&amp;nbsp;became&amp;nbsp;exercisable commencing &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;six&lt;/div&gt; months from issuance. The Class A Warrants and&amp;nbsp;Class B Warrants&amp;nbsp;expired on the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; anniversary of the date of issuance. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;None&lt;/div&gt; of the Class A Warrants, the Class B Warrants nor the shares issuable upon exercise of such Warrants were&amp;nbsp;registered with the Securities and Exchange Commission. The Warrants could &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be exercised on a cashless basis. There&amp;nbsp;were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; redemption features embodied in the Warrants and they met the conditions for equity classification. On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 22, 2018, &lt;/div&gt;the Class A and Class B warrants expired unexercised.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; text-decoration: underline;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; Subscription Rights Offering of Units Consisting of Series B Convertible Preferred Stock and Warrants&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 9, 2018, &lt;/div&gt;the Company&amp;#x2019;s Registration Statement on Form S-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; with the Securities and Exchange Commission was declared effective to offer subscription rights to purchase up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,000&lt;/div&gt; units at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,000&lt;/div&gt; per unit with each unit consisting of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; share of Series B convertible preferred stock and warrants to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;284&lt;/div&gt; shares of common stock.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 29, 2018, &lt;/div&gt;the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B convertible preferred stock with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.001&lt;/div&gt; per share, designated as the Series B convertible preferred stock. The number of shares initially constituting the Series B preferred stock was set at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,000&lt;/div&gt; shares.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 30, 2018, &lt;/div&gt;the Company completed its previously announced rights offering pursuant to which the Company sold an aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,624&lt;/div&gt; units consisting of an aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,624&lt;/div&gt; shares of Series B convertible preferred stock and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,869,216&lt;/div&gt; warrants, with each warrant exercisable for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; share of common stock at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.048&lt;/div&gt; per share (the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x201c;2018&lt;/div&gt; Warrants&amp;#x201d;), resulting in net proceeds to the Company of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12.3&lt;/div&gt; million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Series B Convertible Preferred Stock&lt;/div&gt;&lt;/div&gt;.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The terms and provisions of our Series B convertible preferred stock are:&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Conversion.&lt;/div&gt; Each share of Series B convertible preferred stock is convertible at our option at any time on or after the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; anniversary of the closing of the rights offering or at the option of the holder at any time, into the number of shares of our common stock determined by dividing the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,000&lt;/div&gt; stated value per share of the Series B convertible preferred stock by a conversion price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.52&lt;/div&gt; per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series B convertible preferred stock will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have the right to convert any portion of the Series B convertible preferred stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.99%&lt;/div&gt; of the number of shares of our common stock outstanding immediately after giving effect to its conversion.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fundamental Transactions.&lt;/div&gt; In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a business combination in which another person acquires &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt; of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt; of the aggregate ordinary voting power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series B convertible preferred stock, the holders of the Series B convertible preferred stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of common stock then issuable upon conversion in full of the Series B convertible preferred stock.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Dividends.&lt;/div&gt; Holders of Series B convertible preferred stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Voting Rights.&lt;/div&gt; Except as otherwise provided in the certificate of designation or as otherwise required by law, the Series B convertible preferred stock has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; voting rights.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Liquidation Preference&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;. &lt;/div&gt;&lt;/div&gt;Upon our liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series B convertible preferred stock will be entitled to receive out of our assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series B convertible preferred stock were fully converted (disregarding for such purpose any conversion limitations under the certificate of designation) to common stock, which amounts shall be paid pari passu with all holders of common stock.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Redemption Rights. &lt;/div&gt;We are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; obligated to redeem or repurchase any shares of Series B convertible preferred stock. Shares of Series B convertible preferred stock are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; otherwise entitled to any redemption rights, or mandatory sinking fund or analogous provisions.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The terms and conditions of the warrants included in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; rights offering are as follows:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Exercisability&lt;/div&gt;. Each warrant is exercisable at any time and will expire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;four&lt;/div&gt; years from the date of issuance. The warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment in full for the number of shares of our common stock purchased upon such exercise, except in the case of a cashless exercise as discussed below.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The number of shares of common stock issuable upon exercise of the warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. Upon the merger, consolidation, sale of substantially all of our assets, or other similar transaction, the holders of warrants shall, at the option of the company, be required to exercise the warrants immediately prior to the closing of the transaction, or such warrants shall automatically expire. Upon such exercise, the holders of warrants shall participate on the same basis as the holders of common stock in connection with the transaction.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cashless Exercise&lt;/div&gt;. If at any time there is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; effective registration statement registering, or the prospectus contained therein is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; available for issuance of, the shares issuable upon exercise of the warrant, the holder &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;exercise the warrant on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of shares of our common stock purchasable upon such exercise.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Exercise Price&lt;/div&gt;. Each warrant represents the right to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; share of common stock at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.048&lt;/div&gt; per share. In addition, the exercise price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations, or reclassifications, and for certain dilutive issuances. Subject to limited exceptions, a holder of warrants will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have the right to exercise any portion of the warrant to the extent that, after giving effect to the exercise, the holder, together with its affiliates, and any other person acting as a group together with the holder or any of its affiliates, would beneficially own in excess of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.99%&lt;/div&gt; of the number of shares of our common stock outstanding immediately after giving effect to its exercise. The holder, upon notice to the Company, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;increase or decrease the beneficial ownership limitation provisions of the warrant, provided that in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; event shall the limitation exceed &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.99%&lt;/div&gt; of the number of shares of our common stock outstanding immediately after giving effect to the exercise of the warrant.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Transferability&lt;/div&gt;. Subject to applicable laws and restrictions, a holder &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;transfer a warrant upon surrender of the warrant to us with a completed and signed assignment in the form attached to the warrant. The transferring holder will be responsible for any tax that liability that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;arise as a result of the transfer.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Exchange Listing&lt;/div&gt;. We do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; intend to apply to list the warrants on any securities exchange or recognized trading system.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Rights as Stockholder&lt;/div&gt;. Except as set forth in the warrant, the holder of a warrant, solely in such holder&amp;#x2019;s capacity as a holder of a warrant, will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be entitled to vote, to receive dividends, or to any of the other rights of our stockholders.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Redemption Rights&lt;/div&gt;. We &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;redeem the warrants for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.18&lt;/div&gt; per warrant if the volume-weighted-average-price of our common stock equals or exceeds &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10.56&lt;/div&gt; per share for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; consecutive trading days, provided that we &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; do so prior to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; anniversary of closing of the rights offering.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Accounting Treatment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company allocated the proceeds from the sale of the Series B convertible preferred stock and the warrants to purchase common stock to the separate securities issued. The Company allocated the amount representing the fair value of the warrants at the date of issuance to common stock based on the relative warrant fair value in the amount of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,363,759,&lt;/div&gt; which is net of issuance costs allocated to the warrants. Due to the allocation of a portion of the proceeds to the warrants, the convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,782,100&lt;/div&gt; based on the relative fair value of the beneficial conversion feature. The discount on the convertible preferred stock was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11,479,308,&lt;/div&gt; which consists of the beneficial conversion feature of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,782,100,&lt;/div&gt; the allocation of a portion of the proceeds to the warrants in the amount of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,363,759,&lt;/div&gt; and the total issuance costs related to the financing of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,333,449.&lt;/div&gt; The discount on the convertible preferred stock of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11,479,308&lt;/div&gt; was recorded as a deemed dividend upon issuance of the convertible preferred stock. The deemed dividend is reflected as an addition to net loss in the consolidated statements of operations to arrive at net loss applicable to common shareholders. The Company has made an accounting policy election to record the deemed dividend related to discounts on convertible instruments at the time of issuance of the convertible instruments.&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Outstanding Warrants&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;warrants to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,875,699&lt;/div&gt; shares of common stock were outstanding including:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 45%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Outstanding &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Warrants to &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Purchase &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 25%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Expiration Date&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 45%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 25%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 45%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2014 public offering&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,483&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;540.00&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 25%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;January 29, 2019&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 45%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2018 warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,869,216&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.05&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 25%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;May 30, 2022&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 45%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,875,699&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 25%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Conversion of Series B Convertible Preferred Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 7.5pt 0pt 43.5pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;During the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;certain holders of the Series B convertible preferred stock exercised their conversion option and converted an aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,245&lt;/div&gt; shares into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,194,600&lt;/div&gt; shares of the Company's common stock based on the conversion ratio of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;284&lt;/div&gt; shares of common stock for each share of Series B convertible preferred stock.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="d_2018-04-20_2018-04-20_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" decimals="INF" id="c45311216" unitRef="xbrli-pure">12</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:SubsequentEventsTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154355">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;: SUBSEQUENT EVENTS&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt 7.2pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Stock Option and Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 7.2pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 27, 2018, &lt;/div&gt;the Company granted &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,300,000&lt;/div&gt; options to the Chief Executive Officer and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;700,000&lt;/div&gt; to the Chief Financial Officer (collectively, the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x201c;2018&lt;/div&gt;&amp;nbsp;Liability Options&amp;#x201d;). Each option was exercisable for an equivalent number of shares of Company common stock.&amp;nbsp;The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; Liability Options contained a &amp;#x201c;Net Cash Exercise Provision&amp;#x201d; so that if at the time the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; Liability&amp;nbsp;Options were exercised the Company could &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; deliver shares of Common Stock to the optionee (including, for example, if there were insufficient shares available under the Plan at the time of exercise), then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option would only be exercised on a cash &amp;#x201c;net basis&amp;#x201d; requiring that the Company pay cash in an amount equal to the excess of the fair market value of the Common Stock over the option exercise price.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 13, 2019, &lt;/div&gt;the Company,&amp;nbsp;CEO and CFO&amp;nbsp;agreed to cancel and terminate the&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; Liability&amp;nbsp;Options so they are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer outstanding and of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; further force and effect. On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 13, 2019, &lt;/div&gt;the Company granted a new option to the CEO to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,300,000&lt;/div&gt; shares of Common Stock and a new option to&amp;nbsp;the&amp;nbsp;CFO&amp;nbsp;to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;800,000&lt;/div&gt; shares of Common Stock (the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x201c;2019&lt;/div&gt; Options&amp;#x201d;). The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019&lt;/div&gt; Options: (i) have an exercise price equal to the fair market value of Common Stock on the date of grant which was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.36&lt;/div&gt; per share, (ii) do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; contain a Net Cash Exercise provision, (iii) are granted pursuant to the terms and conditions of the Plan as amended by the Board of Directors on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 13, 2019, &lt;/div&gt;to include shares issuable upon exercise of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019&lt;/div&gt; Options and other changes to the Plan so that the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019&lt;/div&gt; Options do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; conflict with the Plan (the &amp;#x201c;Amended Plan&amp;#x201d;), (iv) vest and are exercisable in accordance with the vesting schedule related to the&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; Liability&amp;nbsp;Options; provided, however, that the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019&lt;/div&gt; Options are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; exercisable unless and until the Company&amp;#x2019;s stockholders approve the Amended Plan to increase the authorized number of shares available for grant under the Plan as only &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,575&lt;/div&gt; options were available for grant as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;and&amp;nbsp;(vi) are subject to and conditioned the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019&lt;/div&gt; Option Agreements with the optionees and the employment agreements with the optionees.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The above actions were unanimously approved by the disinterested members&amp;nbsp;of the Board of Directors. The above actions are intended to eliminate the Company&amp;#x2019;s potential liability associated with the Net Cash Exercise Provision of the liability options, and to allow the stockholders of the Company the opportunity to vote on the Amended Plan, which includes shares issuable upon exercise of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019&lt;/div&gt; Options.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;div style="display: inline;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Warrant Exercises&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2019, &lt;/div&gt;the Company received approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11.3&lt;/div&gt; million from exercises of warrants issued on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 30, 2018. &lt;/div&gt;As a result of the warrant exercises, the Company retired approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.8&lt;/div&gt; million warrants and issued approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.8&lt;/div&gt; million shares of common stock.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1154323">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2:&lt;/div&gt; &lt;div style="display: inline;"&gt;LIQUIDITY&lt;/div&gt;&amp;nbsp; AND CAPITAL RESOURCES&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company has incurred net losses and negative operating cash flows since inception. For the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;the Company recorded a net loss of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11.4&lt;/div&gt; million and used approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$9.0&lt;/div&gt; million of cash in operating activities. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;the Company had approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10.4&lt;/div&gt; million in cash and cash equivalents and working capital of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8.6&lt;/div&gt; million. However, in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2019, &lt;/div&gt;the Company received &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11.3&lt;/div&gt; million in cash upon exercises of certain of the Company&amp;#x2019;s previously outstanding warrants to purchase its common stock. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 25, 2019, &lt;/div&gt;the Company had approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$19.3&lt;/div&gt; million in cash and cash equivalents. The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; yet established an ongoing source of revenue sufficient to cover its operating costs and is currently expending funds in research and development activities that are expected to continue to require funding. Management believes its currently available funding, including the funds received from warrant exercises in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2019, &lt;/div&gt;will be sufficient to finance the Company&amp;#x2019;s operations for at least &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; year from the date these consolidated financial statements are issued. However, the Company will likely require additional funding to continue its activities beyond that date. If adequate funds are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; available, the Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be required to reduce the scope, delay, or eliminate some or all of its planned commercial activities. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The consolidated financial statements do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;result from uncertainty related to the Company&amp;#x2019;s ability to continue as a going concern.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 45pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2018-12-31" decimals="-3" id="c45311729" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2017-12-31" decimals="-3" id="c45311734" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="i_2018-12-31" decimals="-3" id="c45311732" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="i_2017-12-31" decimals="-3" id="c45311735" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UseOfEstimates contextRef="d_2018-01-01_2018-12-31" id="c45311215">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Use of Estimates:&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c45311722" unitRef="iso4217-usd">2200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c45311725" unitRef="iso4217-usd">-15500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" decimals="INF" id="c45311602" unitRef="xbrli-pure">9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" decimals="INF" id="c45311605" unitRef="xbrli-pure">11.25</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" decimals="INF" id="c45311608" unitRef="xbrli-pure">0.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" decimals="INF" id="c45311611" unitRef="xbrli-pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember" decimals="INF" id="c45311613" unitRef="xbrli-pure">0.0079</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MaximumMember" decimals="INF" id="c45311615" unitRef="xbrli-pure">0.0188</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember" decimals="INF" id="c45311616" unitRef="xbrli-pure">0.24</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember" decimals="INF" id="c45311618" unitRef="xbrli-pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" decimals="INF" id="c45311621" unitRef="xbrli-pure">6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" decimals="INF" id="c45311624" unitRef="xbrli-pure">3.12</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" decimals="INF" id="c45311627" unitRef="xbrli-pure">0.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" decimals="INF" id="c45311630" unitRef="xbrli-pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember" decimals="INF" id="c45311632" unitRef="xbrli-pure">0.0079</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MaximumMember" decimals="INF" id="c45311634" unitRef="xbrli-pure">0.0188</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember" decimals="INF" id="c45311635" unitRef="xbrli-pure">0.08</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember" decimals="INF" id="c45311637" unitRef="xbrli-pure">4.76</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2017-04-03_ClassOfWarrantOrRightAxis-The2017PublicOfferingOverallotmentWarrantsMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" id="c45311483">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2017-12-20_ClassOfWarrantOrRightAxis-ClassAAndClassBWarrantsMember_SubsidiarySaleOfStockAxis-December2017PublicOfferingAndPrivatePlacementMember" id="c45311528">P1Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember" id="c45311559">P4Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c45310840" unitRef="xbrli-shares">4157746</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c45310841" unitRef="xbrli-shares">974773</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-thunderdome-item">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>thunderdome:item</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="d_2010-09-28_2010-09-28_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-09-28</xbrli:startDate>
      <xbrli:endDate>2010-09-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2012-01-01_2012-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2012-01-01_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-01-01_2013-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-05-18_2016-05-18_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-05-18</xbrli:startDate>
      <xbrli:endDate>2016-05-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ConsolidatedEntitiesAxis-AtossaGeneticsAUSPtyLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">atos:AtossaGeneticsAUSPtyLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">atos:ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">atos:WarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-AcueityIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">atos:AcueityIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:PreferredStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:PreferredStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:SaleOfCommonStockInClassAUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:SaleOfCommonStockInClassAUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:PreferredStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:PreferredStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:SaleOfCommonStockInClassAUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:SaleOfCommonStockInClassAUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:CommonStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:CommonStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:SaleOfCommonStockInClassAUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:SaleOfCommonStockInClassAUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:SaleOfCommonStockInClassAUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_SubsidiarySaleOfStockAxis-SaleOfCommonStockInClassAUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:SaleOfCommonStockInClassAUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-03_2017-04-03_StatementClassOfStockAxis-ClassAUnitsMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:ClassAUnitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-03</xbrli:startDate>
      <xbrli:endDate>2017-04-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-03_2017-04-03_StatementClassOfStockAxis-ClassBUnitsMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:ClassBUnitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-03</xbrli:startDate>
      <xbrli:endDate>2017-04-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-03_2017-04-03_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-03</xbrli:startDate>
      <xbrli:endDate>2017-04-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-03_2017-04-03_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-03</xbrli:startDate>
      <xbrli:endDate>2017-04-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-03_2017-04-03_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-03</xbrli:startDate>
      <xbrli:endDate>2017-04-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-03_2017-04-03_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-03</xbrli:startDate>
      <xbrli:endDate>2017-04-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-05-09_2017-05-09_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-05-09</xbrli:startDate>
      <xbrli:endDate>2017-05-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-06-29_2017-06-29">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-06-29</xbrli:startDate>
      <xbrli:endDate>2017-06-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-06-29_2017-06-29_ClassOfWarrantOrRightAxis-The2017PublicOfferingWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2017PublicOfferingWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-06-29</xbrli:startDate>
      <xbrli:endDate>2017-06-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-10-26_2017-10-26_SubsidiarySaleOfStockAxis-October2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:October2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-10-26</xbrli:startDate>
      <xbrli:endDate>2017-10-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-10-26_2017-10-26_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-10-26</xbrli:startDate>
      <xbrli:endDate>2017-10-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-12-20_2017-12-20_ClassOfWarrantOrRightAxis-ClassAAndClassBWarrantsMember_SubsidiarySaleOfStockAxis-December2017PublicOfferingAndPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:ClassAAndClassBWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:December2017PublicOfferingAndPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-20</xbrli:startDate>
      <xbrli:endDate>2017-12-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-12-20_2017-12-20_SubsidiarySaleOfStockAxis-December2017PublicOfferingAndPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:December2017PublicOfferingAndPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-20</xbrli:startDate>
      <xbrli:endDate>2017-12-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalCommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalCommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_ClassOfWarrantOrRightAxis-The2014PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2014PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2018WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_ConsolidatedEntitiesAxis-AtossaGeneticsAUSPtyLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">atos:AtossaGeneticsAUSPtyLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">atos:ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_FinancialInstrumentAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-EarliestTaxYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-LatestTaxYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:PreferredStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:PreferredStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:CommonStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2018SubscriptionRightsOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-03-23_2018-03-23">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-23</xbrli:startDate>
      <xbrli:endDate>2018-03-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2018-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2018-06-30_RestatementAxis-ScenarioPreviouslyReportedMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:AdditionalPaidInCapitalConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2018-06-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2018-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:AdditionalPaidInCapitalConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-12_2018-04-12_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-12</xbrli:startDate>
      <xbrli:endDate>2018-04-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-20_2018-04-20_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">atos:ReverseStockSplitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-20</xbrli:startDate>
      <xbrli:endDate>2018-04-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-05-30_2018-05-30_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2018SubscriptionRightsOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-30</xbrli:startDate>
      <xbrli:endDate>2018-05-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-05-30_2018-05-30_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2018SubscriptionRightsOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-30</xbrli:startDate>
      <xbrli:endDate>2018-05-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-27</xbrli:startDate>
      <xbrli:endDate>2018-06-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-27</xbrli:startDate>
      <xbrli:endDate>2018-06-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-27</xbrli:startDate>
      <xbrli:endDate>2018-06-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-27</xbrli:startDate>
      <xbrli:endDate>2018-06-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember_VestingAxis-ShareBasedCompensationAwardTrancheThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-27</xbrli:startDate>
      <xbrli:endDate>2018-06-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-06-27_2018-06-27_AwardTypeAxis-LiabilityOptionsMember_VestingAxis-ShareBasedCompensationAwardTrancheTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-27</xbrli:startDate>
      <xbrli:endDate>2018-06-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-11-01_2018-11-01">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2018-11-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-01_2019-01-01_PlanNameAxis-The2010StockOptionAndIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-13_2019-01-13_AwardTypeAxis-The2019OptionsMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:The2019OptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-13</xbrli:startDate>
      <xbrli:endDate>2019-01-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-13_2019-01-13_AwardTypeAxis-The2019OptionsMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:The2019OptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-13</xbrli:startDate>
      <xbrli:endDate>2019-01-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-01-13_2019-01-13_AwardTypeAxis-The2019OptionsMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:The2019OptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-13</xbrli:startDate>
      <xbrli:endDate>2019-01-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-03-01_2019-03-24_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-03-01</xbrli:startDate>
      <xbrli:endDate>2019-03-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-03-01_2019-03-25_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-03-01</xbrli:startDate>
      <xbrli:endDate>2019-03-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2010-09-28_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-09-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-05-19">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-05-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">atos:WarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:PreferredStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:PreferredStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:CommonStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_ClassOfWarrantOrRightAxis-The2017PublicOfferingClassAUnitsWarrantsMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2017PublicOfferingClassAUnitsWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_ClassOfWarrantOrRightAxis-The2017PublicOfferingOverallotmentWarrantsMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2017PublicOfferingOverallotmentWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_ClassOfWarrantOrRightAxis-The2017PublicOfferingWarrantsMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2017PublicOfferingWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_StatementClassOfStockAxis-ClassAUnitsMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:ClassAUnitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_StatementClassOfStockAxis-ClassBUnitsMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:ClassBUnitsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-03_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-The2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-05-23_ConsolidatedEntitiesAxis-AtossaGeneticsAUSPtyLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">atos:AtossaGeneticsAUSPtyLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-05-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-29_ClassOfWarrantOrRightAxis-The2017PublicOfferingWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2017PublicOfferingWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-29_ClassOfWarrantOrRightAxis-The2017PublicOfferingWarrantsMember_RangeAxis-WeightedAverageMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2017PublicOfferingWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-30_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-09-30_ClassOfWarrantOrRightAxis-The2017PublicOfferingWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2017PublicOfferingWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-10-26_SubsidiarySaleOfStockAxis-October2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:October2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-10-26_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-20_ClassOfWarrantOrRightAxis-ClassAAndClassBWarrantsMember_SubsidiarySaleOfStockAxis-December2017PublicOfferingAndPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:ClassAAndClassBWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:December2017PublicOfferingAndPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-20_SubsidiarySaleOfStockAxis-December2017PublicOfferingAndPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:December2017PublicOfferingAndPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ClassOfWarrantOrRightAxis-The2017PublicOfferingWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2017PublicOfferingWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ConsolidatedEntitiesAxis-AtossaGeneticsAUSPtyLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">atos:AtossaGeneticsAUSPtyLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">atos:ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">atos:WarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-AcueityIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">atos:AcueityIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:PreferredStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:PreferredStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:CommonStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-05-09_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2018SubscriptionRightsOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-05-29_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-05-30_ClassOfWarrantOrRightAxis-The2018WarrantsMember_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2018WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2018SubscriptionRightsOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-10-30_LeaseArrangementTypeAxis-LeaseForCopierSystemMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">atos:LeaseForCopierSystemMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-11-01">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-11-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_AwardTypeAxis-LiabilityOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_AwardTypeAxis-LiabilityOptionsMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_AwardTypeAxis-The2019OptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:The2019OptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_ClassOfWarrantOrRightAxis-The2014PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2014PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2018WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_ClassOfWarrantOrRightAxis-The2018WarrantsMember_SubsidiarySaleOfStockAxis-The2018SubscriptionRightsOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atos:The2018WarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atos:The2018SubscriptionRightsOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_ConsolidatedEntitiesAxis-AtossaGeneticsAUSPtyLtdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">atos:AtossaGeneticsAUSPtyLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">atos:ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_LeaseArrangementTypeAxis-LeaseForCopierSystemMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">atos:LeaseForCopierSystemMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_PlanNameAxis-The2010StockOptionAndIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atos:The2010StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:PreferredStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementClassOfStockAxis-SeriesAJuniorParticipatingPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:PreferredStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atos:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-CommonStockAdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">atos:CommonStockAdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-01-13_AwardTypeAxis-LiabilityOptionsMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-01-13_AwardTypeAxis-LiabilityOptionsMember_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atos:LiabilityOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-25">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-25_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001488039</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>atos-20181231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:01PM UTC 2019-03-28--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:atos="http://www.atossagenetics.com/20181231" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.atossagenetics.com/20181231">
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atos-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atos-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atos-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atos-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.atossagenetics.com/20181231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-" roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations-" roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-operations-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity" roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity-parentheticals" roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-" roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-cash-flows-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-operations-" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-1-nature-of-operations-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 1 - Nature of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity-and-capital-resources" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 2 - Liquidity and Capital Resources</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-accounting-policies-" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 3 - Summary of Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-restricted-cash" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 4 - Restricted Cash</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-prepaid-expenses-" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 5 - Prepaid Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-research-and-development-tax-rebate-receivable-" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 6 - Research and Development Tax Rebate Receivable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-payroll-liabilities-" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 7 - Payroll Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-fair-value-of-financial-instruments" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 8 - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 9 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-net-loss-per-share-" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 10 - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-income-taxes" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 11 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-concentration-of-credit-risk-" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 12 - Concentration of Credit Risk</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-commitments-and-contingencies-" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 13 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 14 - Stock Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-subsequent-events" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 16 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.atossagenetics.com/20181231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-prepaid-expenses-tables" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 5 - Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-payroll-liabilities-tables" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 7 - Payroll Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-fair-value-of-financial-instruments-tables" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 8 - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity-tables" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 9 - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-net-loss-per-share-tables" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 10 - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-income-taxes-tables" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 11 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-tables" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 14 - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity-and-capital-resources-details-textual" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 2 - Liquidity and Capital Resources (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-accounting-policies-details-textual" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 3 - Summary of Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-restricted-cash-details-textual" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 4 - Restricted Cash (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 5 - Prepaid Expenses - Schedule of Prepaid Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-research-and-development-tax-rebate-receivable-details-textual" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 6 - Research and Development Tax Rebate Receivable (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 7 - Payroll Liabilities - Schedule of Payroll Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-fair-value-of-financial-instruments-details-textual" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 8 - Fair Value of Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 8 - Fair Value of Financial Instruments - Changes in Level 3 Warrant Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity-details-textual" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-2017-liability-warrant-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 9 - Stockholders' Equity - 2017 Liability Warrant Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 9 - Stockholders' Equity - Inputs Used in Valuation of Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 9 - Stockholders' Equity - Schedule of Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 10 - Net Loss Per Share - Schedule of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 10 - Net Loss Per Share - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-income-taxes-details-textual" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note 11 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 11 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 11 - Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-concentration-of-credit-risk-details-textual" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 12 - Concentration of Credit Risk (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-commitments-and-contingencies-details-textual" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-details-textual" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note 14 - Stock Based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-additional-shares-authorized-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-additional-shares-authorized-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note 14 - Stock Based Compensation - Additional Shares Authorized (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-valuation-assumptions-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-valuation-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">054 - Disclosure - Note 14 - Stock Based Compensation - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-stock-option-activity-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">055 - Disclosure - Note 14 - Stock Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">056 - Disclosure - Note 14 - Stock Based Compensation - Compensation Expense Related to Liability Grants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">057 - Disclosure - Note 14 - Stock Based Compensation - Valuation Assumptions for Liability Options (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-details-textual" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">058 - Disclosure - Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">059 - Disclosure - Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-subsequent-events-details-textual" roleURI="http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">060 - Disclosure - Note 16 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="atos_AcueityIntangibleAssetsMember" name="AcueityIntangibleAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability" name="AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_AdditionalPaidInCapitalCommonStockMember" name="AdditionalPaidInCapitalCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_AdditionalPaidInCapitalConvertiblePreferredStockMember" name="AdditionalPaidInCapitalConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock" name="AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend" name="AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts" name="AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atos_AmortizationOfCommitmentShares" name="AmortizationOfCommitmentShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_AtossaGeneticsAUSPtyLtdMember" name="AtossaGeneticsAUSPtyLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ChangeInStockBasedCompensationLiability" name="ChangeInStockBasedCompensationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_ClassAAndClassBWarrantsMember" name="ClassAAndClassBWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_ClassAUnitsMember" name="ClassAUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_ClassBUnitsMember" name="ClassBUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ClassOfWarrantOrRightCancelled" name="ClassOfWarrantOrRightCancelled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ClassOfWarrantOrRightExercisablePeriod" name="ClassOfWarrantOrRightExercisablePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ClassOfWarrantOrRightExercisedExercisePrice" name="ClassOfWarrantOrRightExercisedExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ClassOfWarrantOrRightGranted" name="ClassOfWarrantOrRightGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ClassOfWarrantOrRightGrantedExercisePrice" name="ClassOfWarrantOrRightGrantedExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ClassOfWarrantOrRightRetired" name="ClassOfWarrantOrRightRetired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_CommonStockAdditionalPaidinCapitalMember" name="CommonStockAdditionalPaidinCapitalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" name="CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares" name="ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower" name="ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" name="ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" name="ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ConvertiblePreferredStockSharesIssuable" name="ConvertiblePreferredStockSharesIssuable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="atos_December2017PublicOfferingAndPrivatePlacementMember" name="December2017PublicOfferingAndPrivatePlacementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_DeemedDividendOnSeriesBConvertiblePreferredStock" name="DeemedDividendOnSeriesBConvertiblePreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atos_DividendOnSeriesConvertiblePreferredStock" name="DividendOnSeriesConvertiblePreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" name="EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atos_ExpirationDatesOfClassOfWarrantOrRight" name="ExpirationDatesOfClassOfWarrantOrRight" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock" name="FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" name="IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="atos_IntangibleAssetMeasurementInput" name="IntangibleAssetMeasurementInput" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise" name="IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares" name="IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_LeaseForCopierSystemMember" name="LeaseForCopierSystemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_LiabilityOptionsMember" name="LiabilityOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_LockupPeriodExtension" name="LockupPeriodExtension" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit" name="NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_NumberOfSharesAuthorizedToIssue" name="NumberOfSharesAuthorizedToIssue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_NumberOfUnitsAuthorizedToPurchaseMaximum" name="NumberOfUnitsAuthorizedToPurchaseMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_NumberOfUnitsSold" name="NumberOfUnitsSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_October2017PublicOfferingMember" name="October2017PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_OperatingLeaseLesseeMonthlyRentExpense" name="OperatingLeaseLesseeMonthlyRentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atos_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:gYearItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_PreferredStockAdditionalPaidinCapitalMember" name="PreferredStockAdditionalPaidinCapitalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_PreferredStockConvertibleConversionPrice" name="PreferredStockConvertibleConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" name="PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_PreferredStockDeemedDividend" name="PreferredStockDeemedDividend" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atos_PrepaidExpensesTextBlock" name="PrepaidExpensesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ProceedsFromIssuanceOfCommonStockAndWarrants" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atos_ProceedsFromIssuanceOfStockUnits" name="ProceedsFromIssuanceOfStockUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atos_ProceedsFromIssuanceOrSaleOfEquityNet" name="ProceedsFromIssuanceOrSaleOfEquityNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atos_ProfessionalServicesCurrent" name="ProfessionalServicesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="atos_PurchasePriceOfUnit" name="PurchasePriceOfUnit" nillable="true" substitutionGroup="xbrli:item" type="us-types:perUnitItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants" name="ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares" name="ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ReductionInDeferredTaxAssets" name="ReductionInDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="atos_ResearchAndDevelopmentCashRebatePerDollar" name="ResearchAndDevelopmentCashRebatePerDollar" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_ResearchAndDevelopmentCurrent" name="ResearchAndDevelopmentCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="atos_ResearchAndDevelopmentTaxRebateReceivable" name="ResearchAndDevelopmentTaxRebateReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock" name="ResearchAndDevelopmentTaxRebateReceivableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_ReverseStockSplitMember" name="ReverseStockSplitMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_SaleOfCommonStockInClassAUnitsMember" name="SaleOfCommonStockInClassAUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ScheduleOfWarrantsActivityTableTextBlock" name="ScheduleOfWarrantsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_SeriesAJuniorParticipatingPreferredStockMember" name="SeriesAJuniorParticipatingPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_StatedValuePerShare" name="StatedValuePerShare" nillable="true" substitutionGroup="xbrli:item" type="us-types:perUnitItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_StockAndWarrantsIssuedDuringPeriodShares" name="StockAndWarrantsIssuedDuringPeriodShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_StockAndWarrantsIssuedDuringPeriodValue" name="StockAndWarrantsIssuedDuringPeriodValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership" name="StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership" name="StockholderRightsAgreementAcquiringPersonPercentageOfOwnership" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_StockholderRightsAgreementInitialExercisePriceOfEachRight" name="StockholderRightsAgreementInitialExercisePriceOfEachRight" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock" name="StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_StockholderRightsAgreementSharePrice" name="StockholderRightsAgreementSharePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="atos_The2010StockOptionAndIncentivePlanMember" name="The2010StockOptionAndIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_The2014PublicOfferingMember" name="The2014PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_The2017PublicOfferingClassAUnitsWarrantsMember" name="The2017PublicOfferingClassAUnitsWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_The2017PublicOfferingMember" name="The2017PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_The2017PublicOfferingOverallotmentWarrantsMember" name="The2017PublicOfferingOverallotmentWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_The2017PublicOfferingWarrantsMember" name="The2017PublicOfferingWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_The2018SubscriptionRightsOfferingMember" name="The2018SubscriptionRightsOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_The2018WarrantsMember" name="The2018WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_The2019OptionsMember" name="The2019OptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_WarrantFinancingExpense" name="WarrantFinancingExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atos_WarrantLiabilities" name="WarrantLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="atos_WarrantLiabilityMember" name="WarrantLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost" name="WarrantsAllocatedToCommonStockNetOfIssuanceCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock" name="WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_WarrantsAndRightsOutstandingRedemptionPrice" name="WarrantsAndRightsOutstandingRedemptionPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays" name="WarrantsAndRightsRedemptionRightsConsecutiveTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed" name="WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="atos_WorkingCapital" name="WorkingCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" name="statement-statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" name="statement-statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-10-net-loss-per-share-tables" name="statement-statement-note-10-net-loss-per-share-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" name="statement-statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-11-income-taxes-tables" name="statement-statement-note-11-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-14-stock-based-compensation-additional-shares-authorized-details" name="statement-statement-note-14-stock-based-compensation-additional-shares-authorized-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" name="statement-statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-14-stock-based-compensation-stock-option-activity-details" name="statement-statement-note-14-stock-based-compensation-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" name="statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-14-stock-based-compensation-tables" name="statement-statement-note-14-stock-based-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-details" name="statement-statement-note-14-stock-based-compensation-valuation-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" name="statement-statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" name="statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" name="statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" name="statement-statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-5-prepaid-expenses-tables" name="statement-statement-note-5-prepaid-expenses-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" name="statement-statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-7-payroll-liabilities-tables" name="statement-statement-note-7-payroll-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" name="statement-statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-8-fair-value-of-financial-instruments-tables" name="statement-statement-note-8-fair-value-of-financial-instruments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" name="statement-statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" name="statement-statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" name="statement-statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-note-9-stockholders-equity-tables" name="statement-statement-note-9-stockholders-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atos_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>atos-20181231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:03PM UTC 2019-03-28--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:href="atos-20181231.xsd#statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedVacationCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-" xlink:href="atos-20181231.xsd#statement-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:label="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-cash-flows-" xlink:href="atos-20181231.xsd#statement-consolidated-statements-of-cash-flows-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-cash-flows-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ChangeInStockBasedCompensationLiability" xlink:label="atos_ChangeInStockBasedCompensationLiability" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:label="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="atos_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOfStockUnits" xlink:label="atos_ProceedsFromIssuanceOfStockUnits" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantFinancingExpense" xlink:label="atos_WarrantFinancingExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StockOptionPlanExpense" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atos_ChangeInStockBasedCompensationLiability" xlink:type="arc"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atos_WarrantFinancingExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="atos_ProceedsFromIssuanceOfStockUnits" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="atos_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:href="atos-20181231.xsd#statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ProfessionalServicesCurrent" xlink:label="atos_ProfessionalServicesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentCurrent" xlink:label="atos_ResearchAndDevelopmentCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_DepositAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="atos_ResearchAndDevelopmentCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="atos_ProfessionalServicesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:href="atos-20181231.xsd#statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" xlink:label="atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-operations-" xlink:href="atos-20181231.xsd#statement-consolidated-statements-of-operations-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-operations-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockDeemedDividend" xlink:label="atos_PreferredStockDeemedDividend" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantFinancingExpense" xlink:label="atos_WarrantFinancingExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="atos_WarrantFinancingExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="atos_PreferredStockDeemedDividend" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:href="atos-20181231.xsd#statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInventory" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>atos-20181231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:02PM UTC 2019-03-28--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-" xlink:href="atos-20181231.xsd#statement-note-10-net-loss-per-share-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-" xlink:href="atos-20181231.xsd#statement-note-7-payroll-liabilities-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-" xlink:href="atos-20181231.xsd#statement-note-5-prepaid-expenses-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_PrepaidExpensesTextBlock" xlink:label="atos_PrepaidExpensesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="atos_PrepaidExpensesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-1-nature-of-operations-" xlink:href="atos-20181231.xsd#statement-note-1-nature-of-operations-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-1-nature-of-operations-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-document-and-entity-information" xlink:href="atos-20181231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="atos-20181231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAConvertiblePreferredStockMember" xlink:label="atos_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:href="atos-20181231.xsd#statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts" xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SaleOfCommonStockInClassAUnitsMember" xlink:label="atos_SaleOfCommonStockInClassAUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atos_SaleOfCommonStockInClassAUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources" xlink:href="atos-20181231.xsd#statement-note-2-liquidity-and-capital-resources" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-" xlink:href="atos-20181231.xsd#statement-note-3-summary-of-accounting-policies-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AcueityIntangibleAssetsMember" xlink:label="atos_AcueityIntangibleAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReverseStockSplitMember" xlink:label="atos_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="atos_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="atos_AcueityIntangibleAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash" xlink:href="atos-20181231.xsd#statement-note-4-restricted-cash" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-" xlink:href="atos-20181231.xsd#statement-note-6-research-and-development-tax-rebate-receivable-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AtossaGeneticsAUSPtyLtdMember" xlink:label="atos_AtossaGeneticsAUSPtyLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock" xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="atos_AtossaGeneticsAUSPtyLtdMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments" xlink:href="atos-20181231.xsd#statement-note-8-fair-value-of-financial-instruments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity" xlink:href="atos-20181231.xsd#statement-note-9-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassAAndClassBWarrantsMember" xlink:label="atos_ClassAAndClassBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassAUnitsMember" xlink:label="atos_ClassAUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassBUnitsMember" xlink:label="atos_ClassBUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:label="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:label="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:label="atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_October2017PublicOfferingMember" xlink:label="atos_October2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAConvertiblePreferredStockMember" xlink:label="atos_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:label="atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingMember" xlink:label="atos_The2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:label="atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingWarrantsMember" xlink:label="atos_The2017PublicOfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2018SubscriptionRightsOfferingMember" xlink:label="atos_The2018SubscriptionRightsOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2018WarrantsMember" xlink:label="atos_The2018WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atos_The2017PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_ClassAUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_ClassBUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atos_The2017PublicOfferingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atos_October2017PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atos_ClassAAndClassBWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atos_The2018SubscriptionRightsOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atos_The2018WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes" xlink:href="atos-20181231.xsd#statement-note-11-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-" xlink:href="atos-20181231.xsd#statement-note-12-concentration-of-credit-risk-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-" xlink:href="atos-20181231.xsd#statement-note-13-commitments-and-contingencies-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LeaseForCopierSystemMember" xlink:label="atos_LeaseForCopierSystemMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="atos_LeaseForCopierSystemMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2010StockOptionAndIncentivePlanMember" xlink:label="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements" xlink:href="atos-20181231.xsd#statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Reclassifications" xlink:label="us-gaap_Reclassifications" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_Reclassifications" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events" xlink:href="atos-20181231.xsd#statement-note-16-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2019OptionsMember" xlink:label="atos_The2019OptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atos_The2019OptionsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-significant-accounting-policies-policies" xlink:href="atos-20181231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock" xlink:label="atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-tables" xlink:href="atos-20181231.xsd#statement-note-5-prepaid-expenses-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-tables" xlink:href="atos-20181231.xsd#statement-note-7-payroll-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-tables" xlink:href="atos-20181231.xsd#statement-note-8-fair-value-of-financial-instruments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-tables" xlink:href="atos-20181231.xsd#statement-note-9-stockholders-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ScheduleOfWarrantsActivityTableTextBlock" xlink:label="atos_ScheduleOfWarrantsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="atos_ScheduleOfWarrantsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-tables" xlink:href="atos-20181231.xsd#statement-note-10-net-loss-per-share-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-tables" xlink:href="atos-20181231.xsd#statement-note-11-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-tables" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" xlink:href="atos-20181231.xsd#statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources-details-textual" xlink:href="atos-20181231.xsd#statement-note-2-liquidity-and-capital-resources-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_WorkingCapital" xlink:label="atos_WorkingCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WorkingCapital" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-details-textual" xlink:href="atos-20181231.xsd#statement-note-3-summary-of-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AcueityIntangibleAssetsMember" xlink:label="atos_AcueityIntangibleAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IntangibleAssetMeasurementInput" xlink:label="atos_IntangibleAssetMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReverseStockSplitMember" xlink:label="atos_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm" xlink:label="atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantLiabilities" xlink:label="atos_WarrantLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="atos_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="atos_AcueityIntangibleAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_IntangibleAssetMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WarrantLiabilities" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash-details-textual" xlink:href="atos-20181231.xsd#statement-note-4-restricted-cash-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-details-textual" xlink:href="atos-20181231.xsd#statement-note-6-research-and-development-tax-rebate-receivable-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AtossaGeneticsAUSPtyLtdMember" xlink:label="atos_AtossaGeneticsAUSPtyLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:label="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentCashRebatePerDollar" xlink:label="atos_ResearchAndDevelopmentCashRebatePerDollar" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="atos_AtossaGeneticsAUSPtyLtdMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ResearchAndDevelopmentCashRebatePerDollar" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-details-textual" xlink:href="atos-20181231.xsd#statement-note-8-fair-value-of-financial-instruments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-details-textual" xlink:href="atos-20181231.xsd#statement-note-9-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock" xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassAAndClassBWarrantsMember" xlink:label="atos_ClassAAndClassBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassAUnitsMember" xlink:label="atos_ClassAUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassBUnitsMember" xlink:label="atos_ClassBUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightCancelled" xlink:label="atos_ClassOfWarrantOrRightCancelled" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightExercisablePeriod" xlink:label="atos_ClassOfWarrantOrRightExercisablePeriod" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:label="atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares" xlink:label="atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower" xlink:label="atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:label="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:label="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConvertiblePreferredStockSharesIssuable" xlink:label="atos_ConvertiblePreferredStockSharesIssuable" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:label="atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_LockupPeriodExtension" xlink:label="atos_LockupPeriodExtension" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit" xlink:label="atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NumberOfSharesAuthorizedToIssue" xlink:label="atos_NumberOfSharesAuthorizedToIssue" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NumberOfUnitsAuthorizedToPurchaseMaximum" xlink:label="atos_NumberOfUnitsAuthorizedToPurchaseMaximum" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NumberOfUnitsSold" xlink:label="atos_NumberOfUnitsSold" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_October2017PublicOfferingMember" xlink:label="atos_October2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockConvertibleConversionPrice" xlink:label="atos_PreferredStockConvertibleConversionPrice" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:label="atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockDeemedDividend" xlink:label="atos_PreferredStockDeemedDividend" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOfStockUnits" xlink:label="atos_ProceedsFromIssuanceOfStockUnits" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="atos_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PurchasePriceOfUnit" xlink:label="atos_PurchasePriceOfUnit" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAConvertiblePreferredStockMember" xlink:label="atos_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StatedValuePerShare" xlink:label="atos_StatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership" xlink:label="atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership" xlink:label="atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementInitialExercisePriceOfEachRight" xlink:label="atos_StockholderRightsAgreementInitialExercisePriceOfEachRight" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock" xlink:label="atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementSharePrice" xlink:label="atos_StockholderRightsAgreementSharePrice" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:label="atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingMember" xlink:label="atos_The2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:label="atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingWarrantsMember" xlink:label="atos_The2017PublicOfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2018SubscriptionRightsOfferingMember" xlink:label="atos_The2018SubscriptionRightsOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2018WarrantsMember" xlink:label="atos_The2018WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost" xlink:label="atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock" xlink:label="atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsAndRightsOutstandingRedemptionPrice" xlink:label="atos_WarrantsAndRightsOutstandingRedemptionPrice" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays" xlink:label="atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed" xlink:label="atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atos_The2017PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_ClassAUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_ClassBUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atos_The2017PublicOfferingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atos_October2017PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atos_ClassAAndClassBWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atos_The2018SubscriptionRightsOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atos_The2018WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_NumberOfSharesAuthorizedToIssue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockholderRightsAgreementInitialExercisePriceOfEachRight" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockholderRightsAgreementSharePrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_NumberOfUnitsSold" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PurchasePriceOfUnit" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ConvertiblePreferredStockSharesIssuable" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PreferredStockDeemedDividend" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightCancelled" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_LockupPeriodExtension" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightExercisablePeriod" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_NumberOfUnitsAuthorizedToPurchaseMaximum" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ProceedsFromIssuanceOfStockUnits" xlink:type="arc"/>
    <link:definitionArc order="38" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="39" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PreferredStockConvertibleConversionPrice" xlink:type="arc"/>
    <link:definitionArc order="40" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:type="arc"/>
    <link:definitionArc order="41" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares" xlink:type="arc"/>
    <link:definitionArc order="42" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower" xlink:type="arc"/>
    <link:definitionArc order="43" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed" xlink:type="arc"/>
    <link:definitionArc order="44" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:type="arc"/>
    <link:definitionArc order="45" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WarrantsAndRightsOutstandingRedemptionPrice" xlink:type="arc"/>
    <link:definitionArc order="46" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock" xlink:type="arc"/>
    <link:definitionArc order="47" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays" xlink:type="arc"/>
    <link:definitionArc order="48" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost" xlink:type="arc"/>
    <link:definitionArc order="49" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="50" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-details-textual" xlink:href="atos-20181231.xsd#statement-note-11-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_OperatingLossCarryforwardsExpirationYear" xlink:label="atos_OperatingLossCarryforwardsExpirationYear" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReductionInDeferredTaxAssets" xlink:label="atos_ReductionInDeferredTaxAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ReductionInDeferredTaxAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_OperatingLossCarryforwardsExpirationYear" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-details-textual" xlink:href="atos-20181231.xsd#statement-note-12-concentration-of-credit-risk-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashUninsuredAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-details-textual" xlink:href="atos-20181231.xsd#statement-note-13-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LeaseForCopierSystemMember" xlink:label="atos_LeaseForCopierSystemMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_OperatingLeaseLesseeMonthlyRentExpense" xlink:label="atos_OperatingLeaseLesseeMonthlyRentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="atos_LeaseForCopierSystemMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_OperatingLeaseLesseeMonthlyRentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyDamagesPaidValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-details-textual" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares" xlink:label="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2010StockOptionAndIncentivePlanMember" xlink:label="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-details-textual" xlink:href="atos-20181231.xsd#statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_DeemedDividendOnSeriesBConvertiblePreferredStock" xlink:label="atos_DeemedDividendOnSeriesBConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockDeemedDividend" xlink:label="atos_PreferredStockDeemedDividend" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PreferredStockDeemedDividend" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_DeemedDividendOnSeriesBConvertiblePreferredStock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events-details-textual" xlink:href="atos-20181231.xsd#statement-note-16-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightRetired" xlink:label="atos_ClassOfWarrantOrRightRetired" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2019OptionsMember" xlink:label="atos_The2019OptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atos_The2019OptionsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightRetired" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" xlink:href="atos-20181231.xsd#statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:href="atos-20181231.xsd#statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedBonusesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedVacationCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" xlink:href="atos-20181231.xsd#statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantLiabilityMember" xlink:label="atos_WarrantLiabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="atos_WarrantLiabilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" xlink:href="atos-20181231.xsd#statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightExercised" xlink:label="atos_ClassOfWarrantOrRightExercised" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightExercisedExercisePrice" xlink:label="atos_ClassOfWarrantOrRightExercisedExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightGranted" xlink:label="atos_ClassOfWarrantOrRightGranted" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightGrantedExercisePrice" xlink:label="atos_ClassOfWarrantOrRightGrantedExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightGranted" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightGrantedExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightExercisedExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-additional-shares-authorized-details" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-additional-shares-authorized-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-additional-shares-authorized-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized" xlink:label="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2010StockOptionAndIncentivePlanMember" xlink:label="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-stock-option-activity-details" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_The2010StockOptionAndIncentivePlanMember" xlink:label="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-" xlink:href="atos-20181231.xsd#statement-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:label="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-cash-flows-" xlink:href="atos-20181231.xsd#statement-consolidated-statements-of-cash-flows-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-cash-flows-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AmortizationOfCommitmentShares" xlink:label="atos_AmortizationOfCommitmentShares" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ChangeInStockBasedCompensationLiability" xlink:label="atos_ChangeInStockBasedCompensationLiability" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:label="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="atos_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOfStockUnits" xlink:label="atos_ProceedsFromIssuanceOfStockUnits" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantFinancingExpense" xlink:label="atos_WarrantFinancingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="atos_WarrantFinancingExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="atos_ChangeInStockBasedCompensationLiability" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="atos_ProceedsFromIssuanceOfStockUnits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="atos_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="atos_AmortizationOfCommitmentShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="atos-20181231.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability" xlink:label="atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend" xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AmortizationOfCommitmentShares" xlink:label="atos_AmortizationOfCommitmentShares" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_CommonStockAdditionalPaidinCapitalMember" xlink:label="atos_CommonStockAdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise" xlink:label="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares" xlink:label="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockAdditionalPaidinCapitalMember" xlink:label="atos_PreferredStockAdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants" xlink:label="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares" xlink:label="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SaleOfCommonStockInClassAUnitsMember" xlink:label="atos_SaleOfCommonStockInClassAUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAConvertiblePreferredStockMember" xlink:label="atos_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockAndWarrantsIssuedDuringPeriodShares" xlink:label="atos_StockAndWarrantsIssuedDuringPeriodShares" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockAndWarrantsIssuedDuringPeriodValue" xlink:label="atos_StockAndWarrantsIssuedDuringPeriodValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atos_SaleOfCommonStockInClassAUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="atos_PreferredStockAdditionalPaidinCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="atos_CommonStockAdditionalPaidinCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockAndWarrantsIssuedDuringPeriodShares" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockAndWarrantsIssuedDuringPeriodValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_AmortizationOfCommitmentShares" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:href="atos-20181231.xsd#statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ProfessionalServicesCurrent" xlink:label="atos_ProfessionalServicesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentCurrent" xlink:label="atos_ResearchAndDevelopmentCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ResearchAndDevelopmentCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ProfessionalServicesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositAssets" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" xlink:href="atos-20181231.xsd#statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ExpirationDatesOfClassOfWarrantOrRight" xlink:label="atos_ExpirationDatesOfClassOfWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2014PublicOfferingMember" xlink:label="atos_The2014PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2018WarrantsMember" xlink:label="atos_The2018WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atos_The2014PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atos_The2018WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ExpirationDatesOfClassOfWarrantOrRight" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" xlink:href="atos-20181231.xsd#statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAConvertiblePreferredStockMember" xlink:label="atos_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atos_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:href="atos-20181231.xsd#statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" xlink:label="atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" xlink:href="atos-20181231.xsd#statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AdditionalPaidInCapitalCommonStockMember" xlink:label="atos_AdditionalPaidInCapitalCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AdditionalPaidInCapitalConvertiblePreferredStockMember" xlink:label="atos_AdditionalPaidInCapitalConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_DividendOnSeriesConvertiblePreferredStock" xlink:label="atos_DividendOnSeriesConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockDeemedDividend" xlink:label="atos_PreferredStockDeemedDividend" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="atos_AdditionalPaidInCapitalConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="atos_AdditionalPaidInCapitalCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PreferredStockDeemedDividend" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_DividendOnSeriesConvertiblePreferredStock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-operations-" xlink:href="atos-20181231.xsd#statement-consolidated-statements-of-operations-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-operations-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockDeemedDividend" xlink:label="atos_PreferredStockDeemedDividend" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantFinancingExpense" xlink:label="atos_WarrantFinancingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atos_WarrantFinancingExpense" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atos_PreferredStockDeemedDividend" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-valuation-assumptions-details" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-valuation-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" xlink:href="atos-20181231.xsd#statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockDeemedDividend" xlink:label="atos_PreferredStockDeemedDividend" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PreferredStockDeemedDividend" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:href="atos-20181231.xsd#statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsInventory" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>atos-20181231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:01PM UTC 2019-03-28--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_DocumentAndEntityInformation" xlink:label="atos_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="atos_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_DocumentAndEntityInformation" xlink:to="atos_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="atos_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="atos_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-significant-accounting-policies-policies" xlink:label="atos_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-significant-accounting-policies-policies" xlink:to="atos_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-5-prepaid-expenses-tables" xlink:label="atos_statement-statement-note-5-prepaid-expenses-tables" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-5-prepaid-expenses-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Prepaid Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-5-prepaid-expenses-tables" xlink:to="atos_statement-statement-note-5-prepaid-expenses-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected federal income tax benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-7-payroll-liabilities-tables" xlink:label="atos_statement-statement-note-7-payroll-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-7-payroll-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Payroll Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-7-payroll-liabilities-tables" xlink:to="atos_statement-statement-note-7-payroll-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-8-fair-value-of-financial-instruments-tables" xlink:label="atos_statement-statement-note-8-fair-value-of-financial-instruments-tables" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-8-fair-value-of-financial-instruments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-8-fair-value-of-financial-instruments-tables" xlink:to="atos_statement-statement-note-8-fair-value-of-financial-instruments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-9-stockholders-equity-tables" xlink:label="atos_statement-statement-note-9-stockholders-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-9-stockholders-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stockholders' Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-9-stockholders-equity-tables" xlink:to="atos_statement-statement-note-9-stockholders-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-10-net-loss-per-share-tables" xlink:label="atos_statement-statement-note-10-net-loss-per-share-tables" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-10-net-loss-per-share-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Net Loss Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-10-net-loss-per-share-tables" xlink:to="atos_statement-statement-note-10-net-loss-per-share-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-11-income-taxes-tables" xlink:label="atos_statement-statement-note-11-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-11-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-11-income-taxes-tables" xlink:to="atos_statement-statement-note-11-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-tables" xlink:label="atos_statement-statement-note-14-stock-based-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-14-stock-based-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-14-stock-based-compensation-tables" xlink:to="atos_statement-statement-note-14-stock-based-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" xlink:label="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" xlink:to="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:label="atos_statement-statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Prepaid Expenses - Schedule of Prepaid Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:to="atos_statement-statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:label="atos_statement-statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Payroll Liabilities - Schedule of Payroll Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:to="atos_statement-statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" xlink:label="atos_statement-statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Fair Value of Financial Instruments - Changes in Level 3 Warrant Liability (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" xlink:to="atos_statement-statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" xlink:label="atos_statement-statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-9-stockholders-equity-2017-liability-warrant-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stockholders' Equity - 2017 Liability Warrant Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" xlink:to="atos_statement-statement-note-9-stockholders-equity-2017-liability-warrant-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" xlink:label="atos_statement-statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stockholders' Equity - Inputs Used in Valuation of Warrants (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" xlink:to="atos_statement-statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" xlink:label="atos_statement-statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stockholders' Equity - Schedule of Warrants Outstanding (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" xlink:to="atos_statement-statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" xlink:label="atos_statement-statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Net Loss Per Share - Schedule of Earnings Per Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" xlink:to="atos_statement-statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" xlink:label="atos_statement-statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Net Loss Per Share - Schedule of Antidilutive Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" xlink:to="atos_statement-statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years) (Year)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected term (in years) (Year)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:label="atos_statement-statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:to="atos_statement-statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassBUnitsMember" xlink:label="atos_ClassBUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="atos_ClassBUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class B Units [Member]</link:label>
    <link:label xlink:label="atos_ClassBUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to class B units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ClassBUnitsMember" xlink:to="atos_ClassBUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:label="atos_statement-statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:to="atos_statement-statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-additional-shares-authorized-details" xlink:label="atos_statement-statement-note-14-stock-based-compensation-additional-shares-authorized-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-14-stock-based-compensation-additional-shares-authorized-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation - Additional Shares Authorized (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-14-stock-based-compensation-additional-shares-authorized-details" xlink:to="atos_statement-statement-note-14-stock-based-compensation-additional-shares-authorized-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:label="atos_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:to="atos_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-details" xlink:label="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation - Valuation Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-details" xlink:to="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-stock-option-activity-details" xlink:label="atos_statement-statement-note-14-stock-based-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-14-stock-based-compensation-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-14-stock-based-compensation-stock-option-activity-details" xlink:to="atos_statement-statement-note-14-stock-based-compensation-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" xlink:label="atos_statement-statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation - Compensation Expense Related to Liability Grants (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" xlink:to="atos_statement-statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" xlink:label="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation - Valuation Assumptions for Liability Options (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" xlink:to="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" xlink:label="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" xlink:type="locator"/>
    <link:label xlink:label="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" xlink:to="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatements" xlink:label="atos_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="atos_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_NotesToFinancialStatements" xlink:to="atos_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="atos_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="atos_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_OperatingLeaseLesseeMonthlyRentExpense" xlink:label="atos_OperatingLeaseLesseeMonthlyRentExpense" xlink:type="locator"/>
    <link:label xlink:label="atos_OperatingLeaseLesseeMonthlyRentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_OperatingLeaseLesseeMonthlyRentExpense</link:label>
    <link:label xlink:label="atos_OperatingLeaseLesseeMonthlyRentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Lessee, Monthly Rent Expense</link:label>
    <link:label xlink:label="atos_OperatingLeaseLesseeMonthlyRentExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of monthly rent expense due from the lessee under the terms of an operating lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_OperatingLeaseLesseeMonthlyRentExpense" xlink:to="atos_OperatingLeaseLesseeMonthlyRentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, weighted average contractual life remaining in years (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, Weighted average exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, Weighted average exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average contractual life remaining in years (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockAndWarrantsIssuedDuringPeriodShares" xlink:label="atos_StockAndWarrantsIssuedDuringPeriodShares" xlink:type="locator"/>
    <link:label xlink:label="atos_StockAndWarrantsIssuedDuringPeriodShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of stock and warrants net of issuance costs (in shares)</link:label>
    <link:label xlink:label="atos_StockAndWarrantsIssuedDuringPeriodShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new stock and warrants issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_StockAndWarrantsIssuedDuringPeriodShares" xlink:to="atos_StockAndWarrantsIssuedDuringPeriodShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average contractual life remaining in years (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts" xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock and warrants, issuance costs</link:label>
    <link:label xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock and warrants. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts" xlink:to="atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockAndWarrantsIssuedDuringPeriodValue" xlink:label="atos_StockAndWarrantsIssuedDuringPeriodValue" xlink:type="locator"/>
    <link:label xlink:label="atos_StockAndWarrantsIssuedDuringPeriodValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of stock and warrants net of issuance costs</link:label>
    <link:label xlink:label="atos_StockAndWarrantsIssuedDuringPeriodValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity impact of the value of new stock and warrants issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_StockAndWarrantsIssuedDuringPeriodValue" xlink:to="atos_StockAndWarrantsIssuedDuringPeriodValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability" xlink:label="atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability" xlink:type="locator"/>
    <link:label xlink:label="atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability</link:label>
    <link:label xlink:label="atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Allocation of Class A unit proceeds to warrant liability</link:label>
    <link:label xlink:label="atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of allocation of unit proceeds to warrant liability during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability" xlink:to="atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SaleOfCommonStockInClassAUnitsMember" xlink:label="atos_SaleOfCommonStockInClassAUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="atos_SaleOfCommonStockInClassAUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Common Stock in Class A Units [Member]</link:label>
    <link:label xlink:label="atos_SaleOfCommonStockInClassAUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of stock in class A units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_SaleOfCommonStockInClassAUnitsMember" xlink:to="atos_SaleOfCommonStockInClassAUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted average exercise price per share (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted average exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited, Weighted average exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, Weighted average exercise price per share (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payroll liabilities</link:label>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total payroll liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise" xlink:label="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise" xlink:type="locator"/>
    <link:label xlink:label="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon warrant exercise for cash on liability warrant exercise</link:label>
    <link:label xlink:label="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">It represents value of issuance of common shares on liability warrant exercise.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise" xlink:to="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants" xlink:label="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants" xlink:type="locator"/>
    <link:label xlink:label="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liability upon exercise of common stock warrants</link:label>
    <link:label xlink:label="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to amount of reclassification of warrant liability upon net cashless exercise of common stock warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants" xlink:to="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedBonusesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued bonus payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued payroll liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedVacationCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued vacation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of furniture and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NONCASH INVESTING AND FINANCING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares" xlink:label="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares" xlink:type="locator"/>
    <link:label xlink:label="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon warrant exercise for cash on liability warrant exercise (in shares)</link:label>
    <link:label xlink:label="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">It represents number of issuance of common shares on liability warrant exercise.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares" xlink:to="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares" xlink:label="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares" xlink:type="locator"/>
    <link:label xlink:label="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liability upon exercise of common stock warrants (in shares)</link:label>
    <link:label xlink:label="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to number of shares of reclassification of warrant liability upon net cashless exercise of common stock warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares" xlink:to="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="atos_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="atos_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance costs</link:label>
    <link:label xlink:label="atos_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from issuance of common stock and warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="atos_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common shareholders</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss applicable to common stockholders</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss applicable to common shareholders</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyDamagesPaidValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LossContingencyDamagesPaidValue</link:label>
    <link:label xlink:label="us-gaap_LossContingencyDamagesPaidValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Paid, Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesPaidValue" xlink:to="us-gaap_LossContingencyDamagesPaidValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RestrictedCashAndCashEquivalents</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IntangibleAssetsNetExcludingGoodwill</link:label>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock" xlink:label="atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments with Characteristics of Both Liabilities and Equity, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for financial instruments with characteristics of both liabilities and equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock" xlink:to="atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantLiabilities" xlink:label="atos_WarrantLiabilities" xlink:type="locator"/>
    <link:label xlink:label="atos_WarrantLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_WarrantLiabilities</link:label>
    <link:label xlink:label="atos_WarrantLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liabilities</link:label>
    <link:label xlink:label="atos_WarrantLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of outstanding warrants accounted for as liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_WarrantLiabilities" xlink:to="atos_WarrantLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AcueityIntangibleAssetsMember" xlink:label="atos_AcueityIntangibleAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="atos_AcueityIntangibleAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acueity intangible Assets [Member]</link:label>
    <link:label xlink:label="atos_AcueityIntangibleAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents intangibles acquired in Acueity transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_AcueityIntangibleAssetsMember" xlink:to="atos_AcueityIntangibleAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IntangibleAssetMeasurementInput" xlink:label="atos_IntangibleAssetMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="atos_IntangibleAssetMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_IntangibleAssetMeasurementInput</link:label>
    <link:label xlink:label="atos_IntangibleAssetMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:label xlink:label="atos_IntangibleAssetMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of input used to measure intangible asset.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_IntangibleAssetMeasurementInput" xlink:to="atos_IntangibleAssetMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentGross</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm" xlink:label="atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm" xlink:type="locator"/>
    <link:label xlink:label="atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm</link:label>
    <link:label xlink:label="atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Vesting Term</link:label>
    <link:label xlink:label="atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected vesting term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm" xlink:to="atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantLiabilityMember" xlink:label="atos_WarrantLiabilityMember" xlink:type="locator"/>
    <link:label xlink:label="atos_WarrantLiabilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label xlink:label="atos_WarrantLiabilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents warrant liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_WarrantLiabilityMember" xlink:to="atos_WarrantLiabilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ScheduleOfWarrantsActivityTableTextBlock" xlink:label="atos_ScheduleOfWarrantsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="atos_ScheduleOfWarrantsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Warrants Activity [Table Text Block]</link:label>
    <link:label xlink:label="atos_ScheduleOfWarrantsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of warrants activity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ScheduleOfWarrantsActivityTableTextBlock" xlink:to="atos_ScheduleOfWarrantsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightGranted" xlink:label="atos_ClassOfWarrantOrRightGranted" xlink:type="locator"/>
    <link:label xlink:label="atos_ClassOfWarrantOrRightGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label xlink:label="atos_ClassOfWarrantOrRightGranted-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants granted during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ClassOfWarrantOrRightGranted" xlink:to="atos_ClassOfWarrantOrRightGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightExercisedExercisePrice" xlink:label="atos_ClassOfWarrantOrRightExercisedExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="atos_ClassOfWarrantOrRightExercisedExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants exercised, , exercise price (in dollars per share)</link:label>
    <link:label xlink:label="atos_ClassOfWarrantOrRightExercisedExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share or per unit exercised of warrants or rights outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ClassOfWarrantOrRightExercisedExercisePrice" xlink:to="atos_ClassOfWarrantOrRightExercisedExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightGrantedExercisePrice" xlink:label="atos_ClassOfWarrantOrRightGrantedExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="atos_ClassOfWarrantOrRightGrantedExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants granted, exercise price (in dollars per share)</link:label>
    <link:label xlink:label="atos_ClassOfWarrantOrRightGrantedExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share or per unit granted of warrants or rights outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ClassOfWarrantOrRightGrantedExercisePrice" xlink:to="atos_ClassOfWarrantOrRightGrantedExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightExercised" xlink:label="atos_ClassOfWarrantOrRightExercised" xlink:type="locator"/>
    <link:label xlink:label="atos_ClassOfWarrantOrRightExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_ClassOfWarrantOrRightExercised</link:label>
    <link:label xlink:label="atos_ClassOfWarrantOrRightExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label xlink:label="atos_ClassOfWarrantOrRightExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ClassOfWarrantOrRightExercised" xlink:to="atos_ClassOfWarrantOrRightExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Total</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Actual federal income tax benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="atos_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="locator"/>
    <link:label xlink:label="atos_ProceedsFromIssuanceOrSaleOfEquityNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_ProceedsFromIssuanceOrSaleOfEquityNet</link:label>
    <link:label xlink:label="atos_ProceedsFromIssuanceOrSaleOfEquityNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Net</link:label>
    <link:label xlink:label="atos_ProceedsFromIssuanceOrSaleOfEquityNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">he cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of issuance costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:to="atos_ProceedsFromIssuanceOrSaleOfEquityNet-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingMember" xlink:label="atos_The2017PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="atos_The2017PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2017 Public Offering [Member]</link:label>
    <link:label xlink:label="atos_The2017PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents underwriting agreement with Aegis Capital Corp. relating to a public offering which closed on April 3, 2017</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_The2017PublicOfferingMember" xlink:to="atos_The2017PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</link:label>
    <link:label xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassAUnitsMember" xlink:label="atos_ClassAUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="atos_ClassAUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class A Units [Member]</link:label>
    <link:label xlink:label="atos_ClassAUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Class A units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ClassAUnitsMember" xlink:to="atos_ClassAUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:label="atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="atos_The2017PublicOfferingClassAUnitsWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2017 Public Offering Class A Units Warrants [Member]</link:label>
    <link:label xlink:label="atos_The2017PublicOfferingClassAUnitsWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants issued in 2017 Public Offering with class A units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:to="atos_The2017PublicOfferingClassAUnitsWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingWarrantsMember" xlink:label="atos_The2017PublicOfferingWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="atos_The2017PublicOfferingWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2017 Public Offering Class B Units Warrants [Member]</link:label>
    <link:label xlink:label="atos_The2017PublicOfferingWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants issued in 2017 Public Offering with class B units. .</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_The2017PublicOfferingWarrantsMember" xlink:to="atos_The2017PublicOfferingWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConvertiblePreferredStockSharesIssuable" xlink:label="atos_ConvertiblePreferredStockSharesIssuable" xlink:type="locator"/>
    <link:label xlink:label="atos_ConvertiblePreferredStockSharesIssuable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_ConvertiblePreferredStockSharesIssuable</link:label>
    <link:label xlink:label="atos_ConvertiblePreferredStockSharesIssuable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issuable</link:label>
    <link:label xlink:label="atos_ConvertiblePreferredStockSharesIssuable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued for convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ConvertiblePreferredStockSharesIssuable" xlink:to="atos_ConvertiblePreferredStockSharesIssuable-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:label="atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="atos_The2017PublicOfferingOverallotmentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2017 Public Offering Over-allotment Warrants [Member]</link:label>
    <link:label xlink:label="atos_The2017PublicOfferingOverallotmentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants issued to underwriter.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:to="atos_The2017PublicOfferingOverallotmentWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightCancelled" xlink:label="atos_ClassOfWarrantOrRightCancelled" xlink:type="locator"/>
    <link:label xlink:label="atos_ClassOfWarrantOrRightCancelled-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_ClassOfWarrantOrRightCancelled</link:label>
    <link:label xlink:label="atos_ClassOfWarrantOrRightCancelled-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Cancelled</link:label>
    <link:label xlink:label="atos_ClassOfWarrantOrRightCancelled-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants cancelled during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ClassOfWarrantOrRightCancelled" xlink:to="atos_ClassOfWarrantOrRightCancelled-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:label="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series A Convertible Preferred Stock into Common Stock [Member]</link:label>
    <link:label xlink:label="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Series A Convertible Preferred Stock into Common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:to="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_LockupPeriodExtension" xlink:label="atos_LockupPeriodExtension" xlink:type="locator"/>
    <link:label xlink:label="atos_LockupPeriodExtension-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_LockupPeriodExtension</link:label>
    <link:label xlink:label="atos_LockupPeriodExtension-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lock-up Period Extension</link:label>
    <link:label xlink:label="atos_LockupPeriodExtension-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in "Lock-up period" under the agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_LockupPeriodExtension" xlink:to="atos_LockupPeriodExtension-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightExercisablePeriod" xlink:label="atos_ClassOfWarrantOrRightExercisablePeriod" xlink:type="locator"/>
    <link:label xlink:label="atos_ClassOfWarrantOrRightExercisablePeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_ClassOfWarrantOrRightExercisablePeriod</link:label>
    <link:label xlink:label="atos_ClassOfWarrantOrRightExercisablePeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercisable Period</link:label>
    <link:label xlink:label="atos_ClassOfWarrantOrRightExercisablePeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period after which warrants become exercisable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ClassOfWarrantOrRightExercisablePeriod" xlink:to="atos_ClassOfWarrantOrRightExercisablePeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassAAndClassBWarrantsMember" xlink:label="atos_ClassAAndClassBWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="atos_ClassAAndClassBWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class A and Class B Warrants [Member]</link:label>
    <link:label xlink:label="atos_ClassAAndClassBWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class A and Class B Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ClassAAndClassBWarrantsMember" xlink:to="atos_ClassAAndClassBWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:label="atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="atos_December2017PublicOfferingAndPrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2017 Public Offering and Private Placement [Member]</link:label>
    <link:label xlink:label="atos_December2017PublicOfferingAndPrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents December 2017 Public Offering and Private Placement with Maxim Group LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:to="atos_December2017PublicOfferingAndPrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_October2017PublicOfferingMember" xlink:label="atos_October2017PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="atos_October2017PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">October 2017 Public Offering [Member]</link:label>
    <link:label xlink:label="atos_October2017PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents October 2017 Public Offering with Maxim Group LLC .</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_October2017PublicOfferingMember" xlink:to="atos_October2017PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays" xlink:label="atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays" xlink:type="locator"/>
    <link:label xlink:label="atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays</link:label>
    <link:label xlink:label="atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights, Redemption Rights, Consecutive Trading Days</link:label>
    <link:label xlink:label="atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold period of specified consecutive trading days within which common stock price equals or exceed certain amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays" xlink:to="atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:label="atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:type="locator"/>
    <link:label xlink:label="atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed</link:label>
    <link:label xlink:label="atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Convertible, Ownership Percentage of Company&#8217;s Shares Allowed</link:label>
    <link:label xlink:label="atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of ownership of common stock allowed.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:to="atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:label="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series B Convertible Preferred Stock into Common Stock [Member]</link:label>
    <link:label xlink:label="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents conversion of Series B Convertible Preferred Stock into common stock shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:to="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock compensation expense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" xlink:label="atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" xlink:type="locator"/>
    <link:label xlink:label="atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of NOL limitation</link:label>
    <link:label xlink:label="atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">It represents value of effects of net operating loss limitations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" xlink:to="atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2019OptionsMember" xlink:label="atos_The2019OptionsMember" xlink:type="locator"/>
    <link:label xlink:label="atos_The2019OptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2019 Options [Member[</link:label>
    <link:label xlink:label="atos_The2019OptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options granted to executive officers.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_The2019OptionsMember" xlink:to="atos_The2019OptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Reclassifications" xlink:label="us-gaap_Reclassifications" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Reclassifications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassifications [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Reclassifications" xlink:to="us-gaap_Reclassifications-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidExpense</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReductionInDeferredTaxAssets" xlink:label="atos_ReductionInDeferredTaxAssets" xlink:type="locator"/>
    <link:label xlink:label="atos_ReductionInDeferredTaxAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_ReductionInDeferredTaxAssets</link:label>
    <link:label xlink:label="atos_ReductionInDeferredTaxAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in Deferred Tax Assets</link:label>
    <link:label xlink:label="atos_ReductionInDeferredTaxAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">It represents the value of reduction in deferred tax assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ReductionInDeferredTaxAssets" xlink:to="atos_ReductionInDeferredTaxAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_OperatingLossCarryforwardsExpirationYear" xlink:label="atos_OperatingLossCarryforwardsExpirationYear" xlink:type="locator"/>
    <link:label xlink:label="atos_OperatingLossCarryforwardsExpirationYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_OperatingLossCarryforwardsExpirationYear</link:label>
    <link:label xlink:label="atos_OperatingLossCarryforwardsExpirationYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiration Year</link:label>
    <link:label xlink:label="atos_OperatingLossCarryforwardsExpirationYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Year of expiration for operating loss carry-forwards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_OperatingLossCarryforwardsExpirationYear" xlink:to="atos_OperatingLossCarryforwardsExpirationYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Warrant exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuances of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation cost for stock options granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocation of convertible preferred stock to warrants and beneficial conversion feature</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByLiabilityClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AmortizationOfIntangibleAssets</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowElementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherCurrentAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Series B convertible preferred stock to common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock to common stock (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefExecutiveOfficerMember" xlink:to="us-gaap_ChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ChiefFinancialOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefFinancialOfficerMember" xlink:to="us-gaap_ChiefFinancialOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inputs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of stock, net of issuance costs (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashUninsuredAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashUninsuredAmount</link:label>
    <link:label xlink:label="us-gaap_CashUninsuredAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of stock, net of issuance costs</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series B convertible preferred stock, net of issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputSharePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedTermMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockOptionPlanExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Compensation cost for stock options granted</link:label>
    <link:label xlink:label="us-gaap_StockOptionPlanExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockOptionPlanExpense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetUsefulLife</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockAmountConverted1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConversionOfStockSharesIssued1</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesConverted1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231 (in shares)</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesConverted1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock - $0.18 par value; 175,000,000 shares authorized, and 5,846,552 and 2,651,952 shares issued and outstanding, as of December 31, 2018 and December 31, 2017, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RestatementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RestatementDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioPreviouslyReportedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:label xlink:label="srt_WeightedAverageMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesRentExpenseNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesRentExpenseNet</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesRentExpenseNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of Series A convertible preferred stock- $0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of December 31, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 2,379 and 0 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherPrepaidExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label xlink:label="us-gaap_PrepaidExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidInsurance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</link:label>
    <link:label xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsInventory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obsolete inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:label="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalPreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital- Series B convertible preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:to="us-gaap_AdditionalPaidInCapitalPreferredStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis difference in fixed assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, accrued vacation</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued bonuses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contribution, carryforward</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital loss carryforward</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retainer and security deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OverAllotmentOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (note 13)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesOther</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesOther-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost" xlink:label="atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost" xlink:type="locator"/>
    <link:label xlink:label="atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost</link:label>
    <link:label xlink:label="atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Allocated to Common Stock , Net of Issuance Cost</link:label>
    <link:label xlink:label="atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value of warrants allocated to common stock at the date of issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost" xlink:to="atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ConsolidatedEntitiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ConsolidatedEntitiesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfCommonStock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of Series B convertible preferred stock and warrants, net of issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of January 1, 2017 (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2017 (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Warrants to Purchase Shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of January 1, 2017 (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2017 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAConvertiblePreferredStockMember" xlink:label="atos_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="atos_SeriesAConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="atos_SeriesAConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about series A convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_SeriesAConvertiblePreferredStockMember" xlink:to="atos_SeriesAConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOfStockUnits" xlink:label="atos_ProceedsFromIssuanceOfStockUnits" xlink:type="locator"/>
    <link:label xlink:label="atos_ProceedsFromIssuanceOfStockUnits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of Class A and Class B Units, net of issuance costs</link:label>
    <link:label xlink:label="atos_ProceedsFromIssuanceOfStockUnits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Stock units</link:label>
    <link:label xlink:label="atos_ProceedsFromIssuanceOfStockUnits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from issuance of stock units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ProceedsFromIssuanceOfStockUnits" xlink:to="atos_ProceedsFromIssuanceOfStockUnits-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantFinancingExpense" xlink:label="atos_WarrantFinancingExpense" xlink:type="locator"/>
    <link:label xlink:label="atos_WarrantFinancingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant financing expense</link:label>
    <link:label xlink:label="atos_WarrantFinancingExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Warrant financing expense</link:label>
    <link:label xlink:label="atos_WarrantFinancingExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of warrant financing expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_WarrantFinancingExpense" xlink:to="atos_WarrantFinancingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="atos_SeriesBConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="atos_SeriesBConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about series B convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_SeriesBConvertiblePreferredStockMember" xlink:to="atos_SeriesBConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockDeemedDividend" xlink:label="atos_PreferredStockDeemedDividend" xlink:type="locator"/>
    <link:label xlink:label="atos_PreferredStockDeemedDividend-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_PreferredStockDeemedDividend</link:label>
    <link:label xlink:label="atos_PreferredStockDeemedDividend-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Deemed Dividend</link:label>
    <link:label xlink:label="atos_PreferredStockDeemedDividend-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend attributable to preferred stock</link:label>
    <link:label xlink:label="atos_PreferredStockDeemedDividend-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of deemed dividend on preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_PreferredStockDeemedDividend" xlink:to="atos_PreferredStockDeemedDividend-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_DividendOnSeriesConvertiblePreferredStock" xlink:label="atos_DividendOnSeriesConvertiblePreferredStock" xlink:type="locator"/>
    <link:label xlink:label="atos_DividendOnSeriesConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_DividendOnSeriesConvertiblePreferredStock</link:label>
    <link:label xlink:label="atos_DividendOnSeriesConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed Dividend on Series B convertible preferred stock</link:label>
    <link:label xlink:label="atos_DividendOnSeriesConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the amount related to dividend on series A convertible preferred stock incurred during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_DividendOnSeriesConvertiblePreferredStock" xlink:to="atos_DividendOnSeriesConvertiblePreferredStock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock" xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock" xlink:type="locator"/>
    <link:label xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock</link:label>
    <link:label xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Beneficial Conversion Feature on Preferred Stock</link:label>
    <link:label xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of convertible preferred stock with a beneficial conversion feature.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock" xlink:to="atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AmortizationOfCommitmentShares" xlink:label="atos_AmortizationOfCommitmentShares" xlink:type="locator"/>
    <link:label xlink:label="atos_AmortizationOfCommitmentShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of commitment shares</link:label>
    <link:label xlink:label="atos_AmortizationOfCommitmentShares-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of commitment shares</link:label>
    <link:label xlink:label="atos_AmortizationOfCommitmentShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">It represents value of amortization of commitment shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_AmortizationOfCommitmentShares" xlink:to="atos_AmortizationOfCommitmentShares-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ChangeInStockBasedCompensationLiability" xlink:label="atos_ChangeInStockBasedCompensationLiability" xlink:type="locator"/>
    <link:label xlink:label="atos_ChangeInStockBasedCompensationLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in stock-based compensation liability</link:label>
    <link:label xlink:label="atos_ChangeInStockBasedCompensationLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of change in stock-based compensation liability during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ChangeInStockBasedCompensationLiability" xlink:to="atos_ChangeInStockBasedCompensationLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReverseStockSplitMember" xlink:label="atos_ReverseStockSplitMember" xlink:type="locator"/>
    <link:label xlink:label="atos_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Stock Split [Member]</link:label>
    <link:label xlink:label="atos_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The conversion of a reverse stock split where there is a reduction in the shares outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ReverseStockSplitMember" xlink:to="atos_ReverseStockSplitMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WorkingCapital" xlink:label="atos_WorkingCapital" xlink:type="locator"/>
    <link:label xlink:label="atos_WorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_WorkingCapital</link:label>
    <link:label xlink:label="atos_WorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:label xlink:label="atos_WorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the value of total net current assets after deducting net current liabilities as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_WorkingCapital" xlink:to="atos_WorkingCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PrepaidExpensesTextBlock" xlink:label="atos_PrepaidExpensesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="atos_PrepaidExpensesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses [Text Block]</link:label>
    <link:label xlink:label="atos_PrepaidExpensesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure related to prepaid expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_PrepaidExpensesTextBlock" xlink:to="atos_PrepaidExpensesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OpenTaxYear</link:label>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock" xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Tax Rebate Receivable [Text Block]</link:label>
    <link:label xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure related to research and development tax rebate receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock" xlink:to="atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentCurrent" xlink:label="atos_ResearchAndDevelopmentCurrent" xlink:type="locator"/>
    <link:label xlink:label="atos_ResearchAndDevelopmentCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label xlink:label="atos_ResearchAndDevelopmentCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of asset related to consideration paid in advance for research and development costs that provide benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ResearchAndDevelopmentCurrent" xlink:to="atos_ResearchAndDevelopmentCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProfessionalServicesCurrent" xlink:label="atos_ProfessionalServicesCurrent" xlink:type="locator"/>
    <link:label xlink:label="atos_ProfessionalServicesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional services</link:label>
    <link:label xlink:label="atos_ProfessionalServicesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of asset related to consideration paid in advance for professional services costs that provide benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ProfessionalServicesCurrent" xlink:to="atos_ProfessionalServicesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="atos_LiabilityOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Options [Member]</link:label>
    <link:label xlink:label="atos_LiabilityOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about liability options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_LiabilityOptionsMember" xlink:to="atos_LiabilityOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2010StockOptionAndIncentivePlanMember" xlink:label="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="atos_The2010StockOptionAndIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2010 Stock Option and Incentive Plan [Member]</link:label>
    <link:label xlink:label="atos_The2010StockOptionAndIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about the 2010 stock option and incentive plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_The2010StockOptionAndIncentivePlanMember" xlink:to="atos_The2010StockOptionAndIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2014PublicOfferingMember" xlink:label="atos_The2014PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="atos_The2014PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2014 Public Offering [Member]</link:label>
    <link:label xlink:label="atos_The2014PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information a bout the 2014 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_The2014PublicOfferingMember" xlink:to="atos_The2014PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ExpirationDatesOfClassOfWarrantOrRight" xlink:label="atos_ExpirationDatesOfClassOfWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="atos_ExpirationDatesOfClassOfWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xlink:label="atos_ExpirationDatesOfClassOfWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration date of warrants or rights in CCYY-MM-DD format.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ExpirationDatesOfClassOfWarrantOrRight" xlink:to="atos_ExpirationDatesOfClassOfWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AdditionalPaidInCapitalCommonStockMember" xlink:label="atos_AdditionalPaidInCapitalCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="atos_AdditionalPaidInCapitalCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock [Member]</link:label>
    <link:label xlink:label="atos_AdditionalPaidInCapitalCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excess of issue price over par or stated value of the entity's common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_AdditionalPaidInCapitalCommonStockMember" xlink:to="atos_AdditionalPaidInCapitalCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AdditionalPaidInCapitalConvertiblePreferredStockMember" xlink:label="atos_AdditionalPaidInCapitalConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="atos_AdditionalPaidInCapitalConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="atos_AdditionalPaidInCapitalConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excess of issue price over par or stated value of the entity's convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_AdditionalPaidInCapitalConvertiblePreferredStockMember" xlink:to="atos_AdditionalPaidInCapitalConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2018WarrantsMember" xlink:label="atos_The2018WarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="atos_The2018WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2018 Warrants [Member]</link:label>
    <link:label xlink:label="atos_The2018WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about the 2018 warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_The2018WarrantsMember" xlink:to="atos_The2018WarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="atos_SeriesAJuniorParticipatingPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Junior Participating Preferred Stock [Member]</link:label>
    <link:label xlink:label="atos_SeriesAJuniorParticipatingPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about series A junior participating preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:to="atos_SeriesAJuniorParticipatingPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentCashRebatePerDollar" xlink:label="atos_ResearchAndDevelopmentCashRebatePerDollar" xlink:type="locator"/>
    <link:label xlink:label="atos_ResearchAndDevelopmentCashRebatePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_ResearchAndDevelopmentCashRebatePerDollar</link:label>
    <link:label xlink:label="atos_ResearchAndDevelopmentCashRebatePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Cash Rebate per Dollar</link:label>
    <link:label xlink:label="atos_ResearchAndDevelopmentCashRebatePerDollar-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the research and development cash rebate per dollar spend on qualified R&amp;D activities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ResearchAndDevelopmentCashRebatePerDollar" xlink:to="atos_ResearchAndDevelopmentCashRebatePerDollar-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:label="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:type="locator"/>
    <link:label xlink:label="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable</link:label>
    <link:label xlink:label="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Research and Development Tax Rebate Receivable</link:label>
    <link:label xlink:label="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development tax rebate receivable</link:label>
    <link:label xlink:label="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of increase (decrease) in research and development tax rebate receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:to="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:type="locator"/>
    <link:label xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development tax rebate receivable</link:label>
    <link:label xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Tax Rebate Receivable</link:label>
    <link:label xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the value of research and development tax rebate receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:to="atos_ResearchAndDevelopmentTaxRebateReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NumberOfUnitsSold" xlink:label="atos_NumberOfUnitsSold" xlink:type="locator"/>
    <link:label xlink:label="atos_NumberOfUnitsSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_NumberOfUnitsSold</link:label>
    <link:label xlink:label="atos_NumberOfUnitsSold-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Units Sold</link:label>
    <link:label xlink:label="atos_NumberOfUnitsSold-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of units sold.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_NumberOfUnitsSold" xlink:to="atos_NumberOfUnitsSold-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockAdditionalPaidinCapitalMember" xlink:label="atos_PreferredStockAdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="atos_PreferredStockAdditionalPaidinCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Additional Paid-in Capital [Member]</link:label>
    <link:label xlink:label="atos_PreferredStockAdditionalPaidinCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the additional paid in capital portion attributable to preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_PreferredStockAdditionalPaidinCapitalMember" xlink:to="atos_PreferredStockAdditionalPaidinCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit" xlink:label="atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit" xlink:type="locator"/>
    <link:label xlink:label="atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit</link:label>
    <link:label xlink:label="atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Series B Convertible Preferred Stock and Warrant in Each Unit</link:label>
    <link:label xlink:label="atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of series B convertible preferred stock and warrant in each unit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit" xlink:to="atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2018SubscriptionRightsOfferingMember" xlink:label="atos_The2018SubscriptionRightsOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="atos_The2018SubscriptionRightsOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2018 Subscription Rights Offering [Member]</link:label>
    <link:label xlink:label="atos_The2018SubscriptionRightsOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about the 2018 subscription rights offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_The2018SubscriptionRightsOfferingMember" xlink:to="atos_The2018SubscriptionRightsOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarliestTaxYearMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earliest Tax Year [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PurchasePriceOfUnit" xlink:label="atos_PurchasePriceOfUnit" xlink:type="locator"/>
    <link:label xlink:label="atos_PurchasePriceOfUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_PurchasePriceOfUnit</link:label>
    <link:label xlink:label="atos_PurchasePriceOfUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Price of Unit</link:label>
    <link:label xlink:label="atos_PurchasePriceOfUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the purchase price of each unit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_PurchasePriceOfUnit" xlink:to="atos_PurchasePriceOfUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LatestTaxYearMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Latest Tax Year [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_DeemedDividendOnSeriesBConvertiblePreferredStock" xlink:label="atos_DeemedDividendOnSeriesBConvertiblePreferredStock" xlink:type="locator"/>
    <link:label xlink:label="atos_DeemedDividendOnSeriesBConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_DeemedDividendOnSeriesBConvertiblePreferredStock</link:label>
    <link:label xlink:label="atos_DeemedDividendOnSeriesBConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed Dividend on Series B Convertible Preferred Stock</link:label>
    <link:label xlink:label="atos_DeemedDividendOnSeriesBConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of deemed dividend on Series B Convertible Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_DeemedDividendOnSeriesBConvertiblePreferredStock" xlink:to="atos_DeemedDividendOnSeriesBConvertiblePreferredStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_CommonStockAdditionalPaidinCapitalMember" xlink:label="atos_CommonStockAdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="atos_CommonStockAdditionalPaidinCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Additional Paid-in Capital [Member]</link:label>
    <link:label xlink:label="atos_CommonStockAdditionalPaidinCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the additional paid in capital portion attributable to common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_CommonStockAdditionalPaidinCapitalMember" xlink:to="atos_CommonStockAdditionalPaidinCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership" xlink:label="atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership" xlink:type="locator"/>
    <link:label xlink:label="atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership</link:label>
    <link:label xlink:label="atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholder Rights Agreement, Acquiring Person, Percentage of Ownership</link:label>
    <link:label xlink:label="atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the ownership percentage of company&#8217;s common stock required to become &#8220;Acquiring Person&#8221; under stockholder rights agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership" xlink:to="atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock" xlink:label="atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock</link:label>
    <link:label xlink:label="atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholder Rights Agreement, Number of Preferred Stock Right Distributed for Each Share of Common Stock</link:label>
    <link:label xlink:label="atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of preferred stock right distributed for each share of common stock under stockholder rights agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock" xlink:to="atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NumberOfUnitsAuthorizedToPurchaseMaximum" xlink:label="atos_NumberOfUnitsAuthorizedToPurchaseMaximum" xlink:type="locator"/>
    <link:label xlink:label="atos_NumberOfUnitsAuthorizedToPurchaseMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_NumberOfUnitsAuthorizedToPurchaseMaximum</link:label>
    <link:label xlink:label="atos_NumberOfUnitsAuthorizedToPurchaseMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Units Authorized to Purchase, Maximum</link:label>
    <link:label xlink:label="atos_NumberOfUnitsAuthorizedToPurchaseMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maximum number of units authorized to purchase.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_NumberOfUnitsAuthorizedToPurchaseMaximum" xlink:to="atos_NumberOfUnitsAuthorizedToPurchaseMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementSharePrice" xlink:label="atos_StockholderRightsAgreementSharePrice" xlink:type="locator"/>
    <link:label xlink:label="atos_StockholderRightsAgreementSharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_StockholderRightsAgreementSharePrice</link:label>
    <link:label xlink:label="atos_StockholderRightsAgreementSharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholder Rights Agreement, Share Price</link:label>
    <link:label xlink:label="atos_StockholderRightsAgreementSharePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of share price that each holder of right can receive by exercising the right.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_StockholderRightsAgreementSharePrice" xlink:to="atos_StockholderRightsAgreementSharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementInitialExercisePriceOfEachRight" xlink:label="atos_StockholderRightsAgreementInitialExercisePriceOfEachRight" xlink:type="locator"/>
    <link:label xlink:label="atos_StockholderRightsAgreementInitialExercisePriceOfEachRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_StockholderRightsAgreementInitialExercisePriceOfEachRight</link:label>
    <link:label xlink:label="atos_StockholderRightsAgreementInitialExercisePriceOfEachRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholder Rights Agreement, Initial Exercise Price of Each Right</link:label>
    <link:label xlink:label="atos_StockholderRightsAgreementInitialExercisePriceOfEachRight-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the initial exercise price of each right under stockholder rights agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_StockholderRightsAgreementInitialExercisePriceOfEachRight" xlink:to="atos_StockholderRightsAgreementInitialExercisePriceOfEachRight-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership" xlink:label="atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership" xlink:type="locator"/>
    <link:label xlink:label="atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership</link:label>
    <link:label xlink:label="atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholder Rights Agreement, Acquiring Person, Additional Percentage of Ownership</link:label>
    <link:label xlink:label="atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the additional ownership percentage of company&#8217;s common stock required to if that person already own 15% or more of company&#8217;s common stock on date of stockholder rights agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership" xlink:to="atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsAndRightsOutstandingRedemptionPrice" xlink:label="atos_WarrantsAndRightsOutstandingRedemptionPrice" xlink:type="locator"/>
    <link:label xlink:label="atos_WarrantsAndRightsOutstandingRedemptionPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_WarrantsAndRightsOutstandingRedemptionPrice</link:label>
    <link:label xlink:label="atos_WarrantsAndRightsOutstandingRedemptionPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Redemption Price</link:label>
    <link:label xlink:label="atos_WarrantsAndRightsOutstandingRedemptionPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the redemption price of each warrants and rights outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_WarrantsAndRightsOutstandingRedemptionPrice" xlink:to="atos_WarrantsAndRightsOutstandingRedemptionPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:label="atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:type="locator"/>
    <link:label xlink:label="atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed</link:label>
    <link:label xlink:label="atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Ownership Percentage of Company&#8217;s Shares Allowed</link:label>
    <link:label xlink:label="atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum ownership percentage of company&#8217;s shares allowed for holder of convertible preferred stock to be able to convert their shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:to="atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockConvertibleConversionPrice" xlink:label="atos_PreferredStockConvertibleConversionPrice" xlink:type="locator"/>
    <link:label xlink:label="atos_PreferredStockConvertibleConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_PreferredStockConvertibleConversionPrice</link:label>
    <link:label xlink:label="atos_PreferredStockConvertibleConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</link:label>
    <link:label xlink:label="atos_PreferredStockConvertibleConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the conversion price of convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_PreferredStockConvertibleConversionPrice" xlink:to="atos_PreferredStockConvertibleConversionPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed" xlink:label="atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed" xlink:type="locator"/>
    <link:label xlink:label="atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed</link:label>
    <link:label xlink:label="atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Exercisable, Ownership Percentage of Company&#8217;s Shares Allowed</link:label>
    <link:label xlink:label="atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum ownership percentage of company&#8217;s shares allowed for holder of warrants to exercise their warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed" xlink:to="atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock" xlink:label="atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock" xlink:type="locator"/>
    <link:label xlink:label="atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock</link:label>
    <link:label xlink:label="atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Redeemable, Volume-weighted-average-price of Our Common Stock</link:label>
    <link:label xlink:label="atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the minimum volume-weighted-average-price of our common stock required to redeem warrants and rights outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock" xlink:to="atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding - basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharePrice</link:label>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized" xlink:label="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized" xlink:type="locator"/>
    <link:label xlink:label="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total additional shares (in shares)</link:label>
    <link:label xlink:label="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of additional shares automatically authorized for issuance under share-based compensation arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized" xlink:to="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of potential common shares excluded (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AtossaGeneticsAUSPtyLtdMember" xlink:label="atos_AtossaGeneticsAUSPtyLtdMember" xlink:type="locator"/>
    <link:label xlink:label="atos_AtossaGeneticsAUSPtyLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Atossa Genetics AUS Pty Ltd [Member]</link:label>
    <link:label xlink:label="atos_AtossaGeneticsAUSPtyLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about Atossa Genetics AUS Pty Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_AtossaGeneticsAUSPtyLtdMember" xlink:to="atos_AtossaGeneticsAUSPtyLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss per common share -basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_LeaseForCopierSystemMember" xlink:label="atos_LeaseForCopierSystemMember" xlink:type="locator"/>
    <link:label xlink:label="atos_LeaseForCopierSystemMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease for Copier System [Member]</link:label>
    <link:label xlink:label="atos_LeaseForCopierSystemMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the lease for copier system.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_LeaseForCopierSystemMember" xlink:to="atos_LeaseForCopierSystemMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NumberOfSharesAuthorizedToIssue" xlink:label="atos_NumberOfSharesAuthorizedToIssue" xlink:type="locator"/>
    <link:label xlink:label="atos_NumberOfSharesAuthorizedToIssue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_NumberOfSharesAuthorizedToIssue</link:label>
    <link:label xlink:label="atos_NumberOfSharesAuthorizedToIssue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares Authorized to Issue</link:label>
    <link:label xlink:label="atos_NumberOfSharesAuthorizedToIssue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents total number of shares authorized to issue.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_NumberOfSharesAuthorizedToIssue" xlink:to="atos_NumberOfSharesAuthorizedToIssue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StatedValuePerShare" xlink:label="atos_StatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="atos_StatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_StatedValuePerShare</link:label>
    <link:label xlink:label="atos_StatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated Value per Share</link:label>
    <link:label xlink:label="atos_StatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stated value per share.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_StatedValuePerShare" xlink:to="atos_StatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower" xlink:label="atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower" xlink:type="locator"/>
    <link:label xlink:label="atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower</link:label>
    <link:label xlink:label="atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consummate a Business Combination, Percentage of Aggregate Ordinary Voting Power</link:label>
    <link:label xlink:label="atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of aggregate ordinary voting power of third party when company consummates a business combination.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower" xlink:to="atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares" xlink:label="atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares" xlink:type="locator"/>
    <link:label xlink:label="atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares</link:label>
    <link:label xlink:label="atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consummate a Business Combination, Percentage of Acquired Outstanding Shares</link:label>
    <link:label xlink:label="atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of acquired outstanding shares when company consummates a business.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares" xlink:to="atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares" xlink:label="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares" xlink:type="locator"/>
    <link:label xlink:label="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares</link:label>
    <link:label xlink:label="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Period for Granting Shares</link:label>
    <link:label xlink:label="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the period in which shares can be granted from the date of stock-holder approval.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares" xlink:to="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightRetired" xlink:label="atos_ClassOfWarrantOrRightRetired" xlink:type="locator"/>
    <link:label xlink:label="atos_ClassOfWarrantOrRightRetired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atos_ClassOfWarrantOrRightRetired</link:label>
    <link:label xlink:label="atos_ClassOfWarrantOrRightRetired-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Retired</link:label>
    <link:label xlink:label="atos_ClassOfWarrantOrRightRetired-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights retired during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_ClassOfWarrantOrRightRetired" xlink:to="atos_ClassOfWarrantOrRightRetired-label" xlink:type="arc"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend" xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend" xlink:type="locator"/>
    <link:label xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deemed dividend on convertible preferred stock</link:label>
    <link:label xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend on convertible preferred stock</link:label>
    <link:label xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of adjustments to additional paid in capital for preferred stock deemed dividend.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend" xlink:to="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate change</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior year true-up</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Stockholders' Equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other permanent items</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>atos-20181231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:01PM UTC 2019-03-28--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-" xlink:href="atos-20181231.xsd#statement-note-10-net-loss-per-share-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-" xlink:href="atos-20181231.xsd#statement-note-7-payroll-liabilities-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-" xlink:href="atos-20181231.xsd#statement-note-5-prepaid-expenses-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PrepaidExpensesTextBlock" xlink:label="atos_PrepaidExpensesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="atos_PrepaidExpensesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-1-nature-of-operations-" xlink:href="atos-20181231.xsd#statement-note-1-nature-of-operations-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-1-nature-of-operations-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-document-and-entity-information" xlink:href="atos-20181231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="atos-20181231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAConvertiblePreferredStockMember" xlink:label="atos_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:href="atos-20181231.xsd#statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts" xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SaleOfCommonStockInClassAUnitsMember" xlink:label="atos_SaleOfCommonStockInClassAUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atos_SaleOfCommonStockInClassAUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources" xlink:href="atos-20181231.xsd#statement-note-2-liquidity-and-capital-resources" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-" xlink:href="atos-20181231.xsd#statement-note-3-summary-of-accounting-policies-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AcueityIntangibleAssetsMember" xlink:label="atos_AcueityIntangibleAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReverseStockSplitMember" xlink:label="atos_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="atos_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="atos_AcueityIntangibleAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash" xlink:href="atos-20181231.xsd#statement-note-4-restricted-cash" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-" xlink:href="atos-20181231.xsd#statement-note-6-research-and-development-tax-rebate-receivable-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AtossaGeneticsAUSPtyLtdMember" xlink:label="atos_AtossaGeneticsAUSPtyLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock" xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="atos_AtossaGeneticsAUSPtyLtdMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments" xlink:href="atos-20181231.xsd#statement-note-8-fair-value-of-financial-instruments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity" xlink:href="atos-20181231.xsd#statement-note-9-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassAAndClassBWarrantsMember" xlink:label="atos_ClassAAndClassBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassAUnitsMember" xlink:label="atos_ClassAUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassBUnitsMember" xlink:label="atos_ClassBUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:label="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:label="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:label="atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_October2017PublicOfferingMember" xlink:label="atos_October2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAConvertiblePreferredStockMember" xlink:label="atos_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:label="atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingMember" xlink:label="atos_The2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:label="atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingWarrantsMember" xlink:label="atos_The2017PublicOfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2018SubscriptionRightsOfferingMember" xlink:label="atos_The2018SubscriptionRightsOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2018WarrantsMember" xlink:label="atos_The2018WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atos_The2017PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_ClassAUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_ClassBUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atos_The2017PublicOfferingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_WeightedAverageMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atos_October2017PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atos_ClassAAndClassBWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atos_The2018SubscriptionRightsOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atos_The2018WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes" xlink:href="atos-20181231.xsd#statement-note-11-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_EarliestTaxYearMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_LatestTaxYearMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-" xlink:href="atos-20181231.xsd#statement-note-12-concentration-of-credit-risk-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-" xlink:href="atos-20181231.xsd#statement-note-13-commitments-and-contingencies-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LeaseForCopierSystemMember" xlink:label="atos_LeaseForCopierSystemMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="atos_LeaseForCopierSystemMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2010StockOptionAndIncentivePlanMember" xlink:label="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements" xlink:href="atos-20181231.xsd#statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Reclassifications" xlink:label="us-gaap_Reclassifications" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_Reclassifications" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events" xlink:href="atos-20181231.xsd#statement-note-16-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NotesToFinancialStatementsAbstract" xlink:label="atos_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2019OptionsMember" xlink:label="atos_The2019OptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="atos_The2019OptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-significant-accounting-policies-policies" xlink:href="atos-20181231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock" xlink:label="atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-significant-accounting-policies-policies" xlink:label="atos_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-tables" xlink:href="atos-20181231.xsd#statement-note-5-prepaid-expenses-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-5-prepaid-expenses-tables" xlink:label="atos_statement-statement-note-5-prepaid-expenses-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-5-prepaid-expenses-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-tables" xlink:href="atos-20181231.xsd#statement-note-7-payroll-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-7-payroll-liabilities-tables" xlink:label="atos_statement-statement-note-7-payroll-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-7-payroll-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-tables" xlink:href="atos-20181231.xsd#statement-note-8-fair-value-of-financial-instruments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-tables" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-8-fair-value-of-financial-instruments-tables" xlink:label="atos_statement-statement-note-8-fair-value-of-financial-instruments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-8-fair-value-of-financial-instruments-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-tables" xlink:href="atos-20181231.xsd#statement-note-9-stockholders-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ScheduleOfWarrantsActivityTableTextBlock" xlink:label="atos_ScheduleOfWarrantsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-9-stockholders-equity-tables" xlink:label="atos_statement-statement-note-9-stockholders-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-9-stockholders-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="atos_ScheduleOfWarrantsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-tables" xlink:href="atos-20181231.xsd#statement-note-10-net-loss-per-share-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-tables" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-10-net-loss-per-share-tables" xlink:label="atos_statement-statement-note-10-net-loss-per-share-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-10-net-loss-per-share-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-tables" xlink:href="atos-20181231.xsd#statement-note-11-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-11-income-taxes-tables" xlink:label="atos_statement-statement-note-11-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-11-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-tables" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-tables" xlink:label="atos_statement-statement-note-14-stock-based-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-14-stock-based-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" xlink:href="atos-20181231.xsd#statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" xlink:label="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources-details-textual" xlink:href="atos-20181231.xsd#statement-note-2-liquidity-and-capital-resources-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WorkingCapital" xlink:label="atos_WorkingCapital-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-n2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WorkingCapital-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-details-textual" xlink:href="atos-20181231.xsd#statement-note-3-summary-of-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AcueityIntangibleAssetsMember" xlink:label="atos_AcueityIntangibleAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IntangibleAssetMeasurementInput" xlink:label="atos_IntangibleAssetMeasurementInput-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReverseStockSplitMember" xlink:label="atos_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm" xlink:label="atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantLiabilities" xlink:label="atos_WarrantLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="atos_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="atos_AcueityIntangibleAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_IntangibleAssetMeasurementInput-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WarrantLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash-details-textual" xlink:href="atos-20181231.xsd#statement-note-4-restricted-cash-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-details-textual" xlink:href="atos-20181231.xsd#statement-note-6-research-and-development-tax-rebate-receivable-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AtossaGeneticsAUSPtyLtdMember" xlink:label="atos_AtossaGeneticsAUSPtyLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:label="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentCashRebatePerDollar" xlink:label="atos_ResearchAndDevelopmentCashRebatePerDollar-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="atos_AtossaGeneticsAUSPtyLtdMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ResearchAndDevelopmentCashRebatePerDollar-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ResearchAndDevelopmentTaxRebateReceivable-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-details-textual" xlink:href="atos-20181231.xsd#statement-note-8-fair-value-of-financial-instruments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-details-textual" xlink:href="atos-20181231.xsd#statement-note-9-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock" xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassAAndClassBWarrantsMember" xlink:label="atos_ClassAAndClassBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassAUnitsMember" xlink:label="atos_ClassAUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassBUnitsMember" xlink:label="atos_ClassBUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightCancelled" xlink:label="atos_ClassOfWarrantOrRightCancelled-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightExercisablePeriod" xlink:label="atos_ClassOfWarrantOrRightExercisablePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:label="atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares" xlink:label="atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower" xlink:label="atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:label="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:label="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ConvertiblePreferredStockSharesIssuable" xlink:label="atos_ConvertiblePreferredStockSharesIssuable-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:label="atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_LockupPeriodExtension" xlink:label="atos_LockupPeriodExtension-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit" xlink:label="atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NumberOfSharesAuthorizedToIssue" xlink:label="atos_NumberOfSharesAuthorizedToIssue-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NumberOfUnitsAuthorizedToPurchaseMaximum" xlink:label="atos_NumberOfUnitsAuthorizedToPurchaseMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NumberOfUnitsSold" xlink:label="atos_NumberOfUnitsSold-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_October2017PublicOfferingMember" xlink:label="atos_October2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockConvertibleConversionPrice" xlink:label="atos_PreferredStockConvertibleConversionPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed" xlink:label="atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockDeemedDividend" xlink:label="atos_PreferredStockDeemedDividend-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOfStockUnits" xlink:label="atos_ProceedsFromIssuanceOfStockUnits-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="atos_ProceedsFromIssuanceOrSaleOfEquityNet-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PurchasePriceOfUnit" xlink:label="atos_PurchasePriceOfUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAConvertiblePreferredStockMember" xlink:label="atos_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StatedValuePerShare" xlink:label="atos_StatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership" xlink:label="atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership" xlink:label="atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementInitialExercisePriceOfEachRight" xlink:label="atos_StockholderRightsAgreementInitialExercisePriceOfEachRight-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock" xlink:label="atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockholderRightsAgreementSharePrice" xlink:label="atos_StockholderRightsAgreementSharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:label="atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingMember" xlink:label="atos_The2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:label="atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2017PublicOfferingWarrantsMember" xlink:label="atos_The2017PublicOfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2018SubscriptionRightsOfferingMember" xlink:label="atos_The2018SubscriptionRightsOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2018WarrantsMember" xlink:label="atos_The2018WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost" xlink:label="atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock" xlink:label="atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsAndRightsOutstandingRedemptionPrice" xlink:label="atos_WarrantsAndRightsOutstandingRedemptionPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays" xlink:label="atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed" xlink:label="atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_SeriesAJuniorParticipatingPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atos_The2017PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_ClassAUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atos_The2017PublicOfferingClassAUnitsWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_ClassBUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atos_The2017PublicOfferingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atos_The2017PublicOfferingOverallotmentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_WeightedAverageMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atos_October2017PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atos_December2017PublicOfferingAndPrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atos_ClassAAndClassBWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atos_The2018SubscriptionRightsOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atos_The2018WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_NumberOfSharesAuthorizedToIssue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockholderRightsAgreementInitialExercisePriceOfEachRight-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockholderRightsAgreementSharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ProceedsFromIssuanceOrSaleOfEquityNet-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_NumberOfUnitsSold-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PurchasePriceOfUnit-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ConvertiblePreferredStockSharesIssuable-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PreferredStockDeemedDividend-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightCancelled-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_LockupPeriodExtension-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightExercisablePeriod-2" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_NumberOfUnitsAuthorizedToPurchaseMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit-2" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ProceedsFromIssuanceOfStockUnits-2" xlink:type="arc"/>
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PreferredStockConvertibleConversionPrice-2" xlink:type="arc"/>
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed-2" xlink:type="arc"/>
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares-2" xlink:type="arc"/>
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower-2" xlink:type="arc"/>
    <link:presentationArc order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed-2" xlink:type="arc"/>
    <link:presentationArc order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed-2" xlink:type="arc"/>
    <link:presentationArc order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WarrantsAndRightsOutstandingRedemptionPrice-2" xlink:type="arc"/>
    <link:presentationArc order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays-2" xlink:type="arc"/>
    <link:presentationArc order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost-2" xlink:type="arc"/>
    <link:presentationArc order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-details-textual" xlink:href="atos-20181231.xsd#statement-note-11-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_OperatingLossCarryforwardsExpirationYear" xlink:label="atos_OperatingLossCarryforwardsExpirationYear-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReductionInDeferredTaxAssets" xlink:label="atos_ReductionInDeferredTaxAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_EarliestTaxYearMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_LatestTaxYearMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ReductionInDeferredTaxAssets-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_OperatingLossCarryforwardsExpirationYear-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-details-textual" xlink:href="atos-20181231.xsd#statement-note-12-concentration-of-credit-risk-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashUninsuredAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-details-textual" xlink:href="atos-20181231.xsd#statement-note-13-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LeaseForCopierSystemMember" xlink:label="atos_LeaseForCopierSystemMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_OperatingLeaseLesseeMonthlyRentExpense" xlink:label="atos_OperatingLeaseLesseeMonthlyRentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="atos_LeaseForCopierSystemMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_OperatingLeaseLesseeMonthlyRentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyDamagesPaidValue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-details-textual" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares" xlink:label="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2010StockOptionAndIncentivePlanMember" xlink:label="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-details-textual" xlink:href="atos-20181231.xsd#statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_DeemedDividendOnSeriesBConvertiblePreferredStock" xlink:label="atos_DeemedDividendOnSeriesBConvertiblePreferredStock-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockDeemedDividend" xlink:label="atos_PreferredStockDeemedDividend-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PreferredStockDeemedDividend-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_DeemedDividendOnSeriesBConvertiblePreferredStock-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events-details-textual" xlink:href="atos-20181231.xsd#statement-note-16-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightRetired" xlink:label="atos_ClassOfWarrantOrRightRetired-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_NoteToFinancialStatementDetailsTextual" xlink:label="atos_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2019OptionsMember" xlink:label="atos_The2019OptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="atos_The2019OptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightRetired-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" xlink:href="atos-20181231.xsd#statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" xlink:label="atos_statement-statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:href="atos-20181231.xsd#statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:label="atos_statement-statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedBonusesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedVacationCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" xlink:href="atos-20181231.xsd#statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantLiabilityMember" xlink:label="atos_WarrantLiabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" xlink:label="atos_statement-statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="atos_WarrantLiabilityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" xlink:href="atos-20181231.xsd#statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightExercised" xlink:label="atos_ClassOfWarrantOrRightExercised-n8" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightExercisedExercisePrice" xlink:label="atos_ClassOfWarrantOrRightExercisedExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightGranted" xlink:label="atos_ClassOfWarrantOrRightGranted" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ClassOfWarrantOrRightGrantedExercisePrice" xlink:label="atos_ClassOfWarrantOrRightGrantedExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" xlink:label="atos_statement-statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-9-stockholders-equity-2017-liability-warrant-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightGranted" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightGrantedExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ClassOfWarrantOrRightExercisedExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-additional-shares-authorized-details" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-additional-shares-authorized-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-additional-shares-authorized-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized" xlink:label="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2010StockOptionAndIncentivePlanMember" xlink:label="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-additional-shares-authorized-details" xlink:label="atos_statement-statement-note-14-stock-based-compensation-additional-shares-authorized-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-14-stock-based-compensation-additional-shares-authorized-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-stock-option-activity-details" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_The2010StockOptionAndIncentivePlanMember" xlink:label="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-stock-option-activity-details" xlink:label="atos_statement-statement-note-14-stock-based-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-14-stock-based-compensation-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="atos_The2010StockOptionAndIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-" xlink:href="atos-20181231.xsd#statement-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:label="atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:label="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="atos_ResearchAndDevelopmentTaxRebateReceivable" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalPreferredStock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-cash-flows-" xlink:href="atos-20181231.xsd#statement-consolidated-statements-of-cash-flows-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-cash-flows-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AmortizationOfCommitmentShares" xlink:label="atos_AmortizationOfCommitmentShares" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ChangeInStockBasedCompensationLiability" xlink:label="atos_ChangeInStockBasedCompensationLiability" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable" xlink:label="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="atos_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ProceedsFromIssuanceOfStockUnits" xlink:label="atos_ProceedsFromIssuanceOfStockUnits" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantFinancingExpense" xlink:label="atos_WarrantFinancingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="atos_WarrantFinancingExpense" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="atos_ChangeInStockBasedCompensationLiability" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="atos_ProceedsFromIssuanceOfStockUnits" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="atos_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="atos_AmortizationOfCommitmentShares" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" xlink:label="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="atos-20181231.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability" xlink:label="atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability-n8" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend" xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend" xlink:label="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend-8" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AmortizationOfCommitmentShares" xlink:label="atos_AmortizationOfCommitmentShares-n8" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_CommonStockAdditionalPaidinCapitalMember" xlink:label="atos_CommonStockAdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise" xlink:label="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares" xlink:label="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockAdditionalPaidinCapitalMember" xlink:label="atos_PreferredStockAdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants" xlink:label="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares" xlink:label="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SaleOfCommonStockInClassAUnitsMember" xlink:label="atos_SaleOfCommonStockInClassAUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAConvertiblePreferredStockMember" xlink:label="atos_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockAndWarrantsIssuedDuringPeriodShares" xlink:label="atos_StockAndWarrantsIssuedDuringPeriodShares" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_StockAndWarrantsIssuedDuringPeriodValue" xlink:label="atos_StockAndWarrantsIssuedDuringPeriodValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atos_SaleOfCommonStockInClassAUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="atos_PreferredStockAdditionalPaidinCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="atos_CommonStockAdditionalPaidinCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockAndWarrantsIssuedDuringPeriodShares" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_StockAndWarrantsIssuedDuringPeriodValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_AmortizationOfCommitmentShares-n8" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend-8" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:href="atos-20181231.xsd#statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ProfessionalServicesCurrent" xlink:label="atos_ProfessionalServicesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_ResearchAndDevelopmentCurrent" xlink:label="atos_ResearchAndDevelopmentCurrent" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:label="atos_statement-statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ResearchAndDevelopmentCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ProfessionalServicesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositAssets" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" xlink:href="atos-20181231.xsd#statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_ExpirationDatesOfClassOfWarrantOrRight" xlink:label="atos_ExpirationDatesOfClassOfWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2014PublicOfferingMember" xlink:label="atos_The2014PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_The2018WarrantsMember" xlink:label="atos_The2018WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" xlink:label="atos_statement-statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atos_The2014PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atos_The2018WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_ExpirationDatesOfClassOfWarrantOrRight" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" xlink:href="atos-20181231.xsd#statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesAConvertiblePreferredStockMember" xlink:label="atos_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_SeriesBConvertiblePreferredStockMember" xlink:label="atos_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" xlink:label="atos_statement-statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="atos_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="atos_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:href="atos-20181231.xsd#statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" xlink:label="atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:label="atos_statement-statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_LiabilityOptionsMember" xlink:label="atos_LiabilityOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" xlink:label="atos_statement-statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="atos_LiabilityOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" xlink:href="atos-20181231.xsd#statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_AdditionalPaidInCapitalCommonStockMember" xlink:label="atos_AdditionalPaidInCapitalCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_AdditionalPaidInCapitalConvertiblePreferredStockMember" xlink:label="atos_AdditionalPaidInCapitalConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_DividendOnSeriesConvertiblePreferredStock" xlink:label="atos_DividendOnSeriesConvertiblePreferredStock-2" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockDeemedDividend" xlink:label="atos_PreferredStockDeemedDividend-n8" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" xlink:label="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="atos_AdditionalPaidInCapitalConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="atos_AdditionalPaidInCapitalCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PreferredStockDeemedDividend-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_DividendOnSeriesConvertiblePreferredStock-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-operations-" xlink:href="atos-20181231.xsd#statement-consolidated-statements-of-operations-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-operations-" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockDeemedDividend" xlink:label="atos_PreferredStockDeemedDividend-n8" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_WarrantFinancingExpense" xlink:label="atos_WarrantFinancingExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atos_WarrantFinancingExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atos_PreferredStockDeemedDividend-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-3" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-valuation-assumptions-details" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-valuation-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-details" xlink:label="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-14-stock-based-compensation-valuation-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" xlink:href="atos-20181231.xsd#statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_PreferredStockDeemedDividend" xlink:label="atos_PreferredStockDeemedDividend-n8" xlink:type="locator"/>
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" xlink:label="atos_statement-statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atos_PreferredStockDeemedDividend-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:href="atos-20181231.xsd#statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:label="atos_statement-statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsInventory" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesOther-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:href="atos-20181231.xsd#statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="atos-20181231.xsd#atos_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:label="atos_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atos_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779576496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 25, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ATOSSA GENETICS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001488039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">atos<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,116,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,874,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779455040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,380,493<span></span>
</td>
<td class="nump">$ 7,217,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">509,833<span></span>
</td>
<td class="nump">250,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ResearchAndDevelopmentTaxRebateReceivable', window );">Research and development tax rebate receivable</a></td>
<td class="nump">518,098<span></span>
</td>
<td class="nump">358,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">30,942<span></span>
</td>
<td class="nump">16,344<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">11,549,366<span></span>
</td>
<td class="nump">7,898,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, net</a></td>
<td class="nump">54,487<span></span>
</td>
<td class="nump">11,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">99,375<span></span>
</td>
<td class="nump">75,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">17,218<span></span>
</td>
<td class="nump">178,907<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">11,720,446<span></span>
</td>
<td class="nump">8,164,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">353,328<span></span>
</td>
<td class="nump">334,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">177,074<span></span>
</td>
<td class="nump">90,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll liabilities</a></td>
<td class="nump">935,070<span></span>
</td>
<td class="nump">784,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Stock-based compensation liability</a></td>
<td class="nump">1,410,025<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">39,939<span></span>
</td>
<td class="nump">15,534<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">2,915,436<span></span>
</td>
<td class="nump">1,225,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of Series A convertible preferred stock- $0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of December 31, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 2,379 and 0 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalPreferredStock', window );">Additional paid-in capital- Series B convertible preferred stock</a></td>
<td class="nump">2,378,997<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.18 par value; 175,000,000 shares authorized, and 5,846,552 and 2,651,952 shares issued and outstanding, as of December 31, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">1,052,372<span></span>
</td>
<td class="nump">477,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">82,204,902<span></span>
</td>
<td class="nump">71,887,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(76,831,263)<span></span>
</td>
<td class="num">(65,426,329)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">8,805,010<span></span>
</td>
<td class="nump">6,938,687<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 11,720,446<span></span>
</td>
<td class="nump">$ 8,164,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ResearchAndDevelopmentTaxRebateReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of research and development tax rebate receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ResearchAndDevelopmentTaxRebateReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in nonredeemable preferred stock related transactions that are in excess of par value, value contributed to an entity and value received from other stock related transactions. Examples of other stock related transactions include, amongst other, certain costs incurred in issuing equity securities, certain dividends and certain tax-based consequences of share-based payments compensation awards. Includes only nonredeemable preferred stock transactions or transactions related to preferred stock that are redeemable solely at the option of the issuer. May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779354400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">5,846,552<span></span>
</td>
<td class="nump">2,651,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">5,846,552<span></span>
</td>
<td class="nump">2,651,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atos_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atos_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atos_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atos_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atos_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atos_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6780369040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 4,209,981<span></span>
</td>
<td class="nump">$ 2,328,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,224,252<span></span>
</td>
<td class="nump">4,859,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">461,715<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">11,434,233<span></span>
</td>
<td class="nump">7,649,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(11,434,233)<span></span>
</td>
<td class="num">(7,649,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(280,747)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_WarrantFinancingExpense', window );">Warrant financing expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(192,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">29,299<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(11,404,934)<span></span>
</td>
<td class="num">(8,122,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,404,934)<span></span>
</td>
<td class="num">(8,122,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PreferredStockDeemedDividend', window );">Deemed dividend attributable to preferred stock</a></td>
<td class="num">(11,479,308)<span></span>
</td>
<td class="num">(2,568,132)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common shareholders</a></td>
<td class="num">$ (22,884,242)<span></span>
</td>
<td class="num">$ (10,690,713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share -basic and diluted (in dollars per share)</a></td>
<td class="num">$ (5.50)<span></span>
</td>
<td class="num">$ (10.97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">4,157,746<span></span>
</td>
<td class="nump">974,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_PreferredStockDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_PreferredStockDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_WarrantFinancingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant financing expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_WarrantFinancingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783172400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Sale of Common Stock in Class A Units [Member] </div>
<div>Preferred Stock [Member] </div>
<div>Series A Convertible Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Sale of Common Stock in Class A Units [Member] </div>
<div>Preferred Stock [Member] </div>
<div>Series B Convertible Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Sale of Common Stock in Class A Units [Member] </div>
<div>Preferred Stock Additional Paid-in Capital [Member] </div>
<div>Series A Convertible Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Sale of Common Stock in Class A Units [Member] </div>
<div>Preferred Stock Additional Paid-in Capital [Member] </div>
<div>Series B Convertible Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Sale of Common Stock in Class A Units [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Sale of Common Stock in Class A Units [Member] </div>
<div>Common Stock Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Sale of Common Stock in Class A Units [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Sale of Common Stock in Class A Units [Member]</div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Convertible Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series B Convertible Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock Additional Paid-in Capital [Member] </div>
<div>Series A Convertible Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock Additional Paid-in Capital [Member] </div>
<div>Series B Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Common Stock Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 56,804<span></span>
</td>
<td class="nump">$ 60,344,050<span></span>
</td>
<td class="num">$ (57,303,748)<span></span>
</td>
<td class="nump">$ 3,097,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_StockAndWarrantsIssuedDuringPeriodShares', window );">Issuance of stock and warrants net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,483,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_StockAndWarrantsIssuedDuringPeriodValue', window );">Issuance of stock and warrants net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 267,001<span></span>
</td>
<td class="nump">5,895,587<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,162,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 17,910<span></span>
</td>
<td class="nump">$ 811,774<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 829,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability', window );">Allocation of Class A unit proceeds to warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(328,350)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(328,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Issuance of Series A convertible preferred stock in Class B units, net of issuance costs of $267,231</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,234,769<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,234,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Allocation of convertible preferred stock to warrants and beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,568,132)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,284,066<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,284,066)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend', window );">Deemed dividend on convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,568,132<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,568,132)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(389,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,234,769)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (70,040)<span></span>
</td>
<td class="num">(3,164,733)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,234,769<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 70,040<span></span>
</td>
<td class="nump">3,164,733<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares', window );">Reclassification of warrant liability upon exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants', window );">Reclassification of warrant liability upon exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22,362<span></span>
</td>
<td class="nump">1,870,798<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,893,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares', window );">Issuance of common stock upon warrant exercise for cash on liability warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise', window );">Issuance of common stock upon warrant exercise for cash on liability warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 43,225<span></span>
</td>
<td class="nump">706,008<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">749,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_AmortizationOfCommitmentShares', window );">Amortization of commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(79,410)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(79,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Compensation cost for stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">786,550<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">786,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,122,581)<span></span>
</td>
<td class="num">(8,122,581)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,651,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 477,342<span></span>
</td>
<td class="nump">71,887,674<span></span>
</td>
<td class="num">(65,426,329)<span></span>
</td>
<td class="nump">6,938,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend', window );">Deemed dividend on convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,568,132)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,568,132<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_StockAndWarrantsIssuedDuringPeriodShares', window );">Issuance of stock and warrants net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_StockAndWarrantsIssuedDuringPeriodValue', window );">Issuance of stock and warrants net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,926,778<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,363,759<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,290,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Allocation of convertible preferred stock to warrants and beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,782,100)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,782,100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend', window );">Deemed dividend on convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,479,308<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,479,308)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,194,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,244,989)<span></span>
</td>
<td class="num">$ (575,030)<span></span>
</td>
<td class="num">(10,669,971)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,194,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,244,989<span></span>
</td>
<td class="nump">$ 575,030<span></span>
</td>
<td class="nump">10,669,971<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_AmortizationOfCommitmentShares', window );">Amortization of commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(72,790)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(72,790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Compensation cost for stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,053,496<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,053,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,404,934)<span></span>
</td>
<td class="num">(11,404,934)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,846,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,378,997<span></span>
</td>
<td class="nump">$ 1,052,372<span></span>
</td>
<td class="nump">82,204,902<span></span>
</td>
<td class="num">(76,831,263)<span></span>
</td>
<td class="nump">8,805,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend', window );">Deemed dividend on convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (11,479,308)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11,479,308<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allocation of unit proceeds to warrant liability during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_AdditionalPaidInCapitalAllocationOfClassUnitProceedsToWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of adjustments to additional paid in capital for preferred stock deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_AmortizationOfCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents value of amortization of commitment shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_AmortizationOfCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents value of issuance of common shares on liability warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of issuance of common shares on liability warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_IssuanceOfCommonStockUponWarrantExerciseForCashOnLiabilityWarrantExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to amount of reclassification of warrant liability upon net cashless exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to number of shares of reclassification of warrant liability upon net cashless exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ReclassificationOfWarrantLiabilityUponExerciseOfCommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_StockAndWarrantsIssuedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_StockAndWarrantsIssuedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_StockAndWarrantsIssuedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_StockAndWarrantsIssuedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=109238393&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6931796208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atos_SaleOfCommonStockInClassAUnitsMember', window );">Sale of Common Stock in Class A Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts', window );">Issuance of common stock and warrants, issuance costs</a></td>
<td class="nump">$ 1,333,449<span></span>
</td>
<td class="nump">768,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock and warrants. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_AdjustmentsToAdditionalPaidInCapitalStockAndWarrantsIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atos_SaleOfCommonStockInClassAUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atos_SaleOfCommonStockInClassAUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6931867856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,404,934)<span></span>
</td>
<td class="num">$ (8,122,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Compensation cost for stock options granted</a></td>
<td class="nump">1,053,496<span></span>
</td>
<td class="nump">786,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Loss on disposal of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">461,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">44,197<span></span>
</td>
<td class="nump">128,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">280,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_WarrantFinancingExpense', window );">Warrant financing expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">192,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ChangeInStockBasedCompensationLiability', window );">Change in stock-based compensation liability</a></td>
<td class="nump">1,410,025<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(258,889)<span></span>
</td>
<td class="num">(79,343)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable', window );">Research and development tax rebate receivable</a></td>
<td class="num">(159,821)<span></span>
</td>
<td class="num">(358,277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="nump">74,301<span></span>
</td>
<td class="num">(80,408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">18,427<span></span>
</td>
<td class="nump">80,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Payroll liabilities</a></td>
<td class="nump">150,203<span></span>
</td>
<td class="nump">14,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">86,969<span></span>
</td>
<td class="nump">73,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">24,405<span></span>
</td>
<td class="nump">9,451<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,961,621)<span></span>
</td>
<td class="num">(6,593,950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of furniture and equipment</a></td>
<td class="num">(110,906)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(110,906)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of Series B convertible preferred stock and warrants, net of issuance costs</a></td>
<td class="nump">12,290,551<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ProceedsFromIssuanceOfStockUnits', window );">Proceeds from issuance of Class A and Class B Units, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,871,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">749,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common stock and warrants, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,162,588<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,290,551<span></span>
</td>
<td class="nump">10,783,457<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="nump">3,218,024<span></span>
</td>
<td class="nump">4,189,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE</a></td>
<td class="nump">7,272,469<span></span>
</td>
<td class="nump">3,082,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE</a></td>
<td class="nump">10,490,493<span></span>
</td>
<td class="nump">7,272,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NONCASH INVESTING AND FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_AmortizationOfCommitmentShares', window );">Amortization of commitment shares</a></td>
<td class="nump">$ 72,790<span></span>
</td>
<td class="nump">$ 79,410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_AmortizationOfCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents value of amortization of commitment shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_AmortizationOfCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ChangeInStockBasedCompensationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of change in stock-based compensation liability during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ChangeInStockBasedCompensationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of increase (decrease) in research and development tax rebate receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ProceedsFromIssuanceOfStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ProceedsFromIssuanceOfStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_WarrantFinancingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant financing expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_WarrantFinancingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770709728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline;"></div>NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1:</div> NATURE OF OPERATIONS</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Atossa Genetics Inc. (the &#x201c;Company&#x201d;) was incorporated on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 30, 2009, </div>in the State of Delaware. The Company was initially formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company&#x2019;s fiscal year ends on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31.&nbsp;</div>The Company is currently focused on development of its pharmaceutical and drug delivery programs for the treatment of breast cancer and other breast conditions.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6936685792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Substantial Doubt about Going Concern [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2:</div> <div style="display: inline;">LIQUIDITY</div>&nbsp; AND CAPITAL RESOURCES</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has incurred net losses and negative operating cash flows since inception. For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the Company recorded a net loss of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11.4</div> million and used approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9.0</div> million of cash in operating activities. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the Company had approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.4</div> million in cash and cash equivalents and working capital of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.6</div> million. However, in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2019, </div>the Company received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11.3</div> million in cash upon exercises of certain of the Company&#x2019;s previously outstanding warrants to purchase its common stock. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 25, 2019, </div>the Company had approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$19.3</div> million in cash and cash equivalents. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> yet established an ongoing source of revenue sufficient to cover its operating costs and is currently expending funds in research and development activities that are expected to continue to require funding. Management believes its currently available funding, including the funds received from warrant exercises in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2019, </div>will be sufficient to finance the Company&#x2019;s operations for at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year from the date these consolidated financial statements are issued. However, the Company will likely require additional funding to continue its activities beyond that date. If adequate funds are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> available, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be required to reduce the scope, delay, or eliminate some or all of its planned commercial activities. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The consolidated financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>result from uncertainty related to the Company&#x2019;s ability to continue as a going concern.</div> <div style=" margin: 0pt; text-align: left; text-indent: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779404512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3:</div> SUMMARY OF ACCOUNTING POLICIES</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Basis of Presentation:</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The accompanying consolidated financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and in accordance with accounting principles generally accepted in the United States of America&nbsp;(&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiaries. All significant intercompany account balances and transactions have been eliminated in consolidation.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 20, 2018, </div>the Company completed a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> reverse stock&nbsp;split&nbsp;of the shares of the Company&#x2019;s common stock (the &#x201c;Reverse Stock&nbsp;Split&#x201d;). As a result of the Reverse Stock Split, every <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> shares of issued and outstanding common stock were combined into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> issued and outstanding share of common stock, and the par value per share was changed to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.18</div> per share. The number of authorized shares of common stock was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> reduced as a result of the Reverse Stock Split. The Company&#x2019;s common stock began trading on a reverse stock&nbsp;split-adjusted basis on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 20, 2018. </div>All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock&nbsp;Split.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Use of Estimates:</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Recently Issued Accounting Pronouncements:</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> <div style="display: inline; font-style: italic;">Lease Accounting Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842.</div></div> The new standard is effective for reporting periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018 </div>and early adoption is permitted. The standard will require lessees to report most leases as assets or liabilities on the balance sheet, while lessor accounting will remain substantially unchanged. The standard permits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> approaches, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> requiring retrospective application of the new guidance with restatement of prior years, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> requiring prospective application of the new guidance. We plan to adopt the new lease standard effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>and apply it prospectively. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect the new lease standard to have a material effect on our financial position, results of operations or cash flows. Upon adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> we will be required to recognize an operating lease liability and right-of-use asset of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$100,000,</div> based on the lease composition disclosed in <div style="display: inline;">footnote <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> <div style="display: inline; font-style: italic;">Statement of Cash Flows</div>, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018 </div>on a retrospective basis. For years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we included <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$110,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$55,000,</div> respectively, of restricted cash within cash, cash equivalents, and restricted cash&nbsp;on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer has the credit card or the limit changes on the credit card.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2017, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> <div style="display: inline; font-style: italic;">Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</div>. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer precludes equity classification when assessing whether the instrument is indexed to an entity&#x2019;s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260</div> to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This update is effective for public entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>Early adoption is permitted. The Company early adopted the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018. </div>As the Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have any financial instruments with down round features, this ASU did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the financial statements upon adoption.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">07,</div> <div style="display: inline; font-style: italic;">Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. </div>This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers</div>. This update is effective for public entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018, </div>including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div>and it did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the financial statements upon adoption.</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">08,</div> <div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Not</div>-for-Profit Entities (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">958</div>): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.</div> This ASU affects <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div>-for-profit entities and business entities that receive or make contributions of cash.&nbsp;The ASU&#xfeff; clarifies and improves the scope and accounting guidance to assist entities in evaluating if those transactions should be accounted for as contributions under the scope of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">958</div> or as an exchange transaction subject to other guidance.&nbsp;This update is effective for public entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>The Company is currently evaluating the impact that adoption will have on its financial statements.</div>  <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">All research and development costs are expensed as incurred.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> that some portion or all of a deferred tax asset will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be realized based on the weight of available evidence, including expected future earnings. The Company recognizes an uncertain tax position in its financial statements when it concludes that a tax position is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to be sustained upon examination based solely on its technical merits. Only after a tax position passes the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit that is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. The Company elects to accrue any interest or penalties related to income taxes as part of its income tax expense.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cash and cash equivalents include cash and all highly liquid instruments with original maturities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less.</div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Furniture and Equipment</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Furniture and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When furniture and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.</div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Depreciation is computed using the straight-line method over the estimated useful lives ranging from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> to&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt 7.2pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Furniture and equipment amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$216,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$171,000</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively. Accumulated depreciation was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$162,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$160,000</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively. Depreciation expense for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$14,386</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$25,956,</div> respectively.&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company periodically evaluates the carrying value of long-lived assets to be held and used and, if necessary, records impairment losses when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-loved assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.&nbsp; For the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impairment of furniture and equipment was recorded.</div>  <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Fair Value Measurements</div></div></div> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company records financial assets&nbsp;and liabilities measured on a recurring and non-recurring basis&nbsp;as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. These fair value principles prioritize valuation inputs across <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> broad levels. Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.&nbsp;Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>&nbsp;inputs are unobservable inputs based on the Company's assumptions used to measure assets and liabilities at fair value. An asset or liability's classification within the various levels is determined based on the lowest level input that is significant to the fair value measurement.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Intangible Assets</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Intangible assets consist of intellectual property and software acquired. Intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the assets might <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. Impairment losses must be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the assets. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>we determined certain intangible assets acquired from Acueity Healthcare, Inc. ("Acueity") were impaired and&nbsp;recorded an asset impairment charge of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$461,715</div> for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>to adjust the carrying value of these intangible assets to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">zero</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017. &nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> impairment charges were recorded during the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018.</div></div> <div style=" margin: 0pt; text-align: center; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We determined the fair values of the Acueity intangibles using an income approach (Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> of the fair value hierarchy). For purposes of the income approach, fair value was determined based on the present value of estimated future cash flows that a market participant could expect to generate from the development of products using the patented technology acquired in the Acueity transaction, discounted at an appropriate risk-adjusted rate reflecting the weighted average cost of capital for a potential market participant. The discount rate used in valuation for these intangible assets was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48.50%.</div> The estimated future cash flows, including an estimate of long-term future growth rates, reflect our own assumptions of what market participants would utilize to price the assets pursuant to ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">820,</div> <div style="display: inline; font-style: italic;">Fair Value Measurements</div>.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Amortization of intangible assets&nbsp;is computed using the straight-line method over the estimated useful lives ranging from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years.</div> <div style=" margin: 0pt 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt 7.2pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Intangible assets amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$192,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$234,000</div> for at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively. Accumulated amortization was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$93,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$158,000</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively. Amortization expense for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$29,811</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$103,038,</div> respectively.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Financial Instruments with Characteristics of Both Liabilities and Equity</div></div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>the Company issued certain financial instruments, consisting of warrants to purchase common stock, which have characteristics of both liability and equity. Financial instruments such as warrants that are classified as liabilities are fair valued upon issuance and are re-measured at fair value at subsequent reporting periods with the resulting change in fair value recorded in &#x201c;change in fair value of common stock warrants&#x201d; in the consolidated statement of operations. The fair value of warrants is estimated using valuation models that require the input of subjective assumptions including stock price volatility, expected life, and the probability of future equity issuances and their impact to the price protection feature. There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> outstanding warrants accounted for as liabilities as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Share-Based Payments</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company follows the provisions of ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718,</div> <div style="display: inline; font-style: italic;">Compensation - Stock Compensation</div> (&#x201c;ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718&#x201d;</div>), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> is recognized as an expense over the requisite service period and the Company made a policy election to recognize forfeitures when they occur.</div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company&#x2019;s common stock, and estimation of an appropriate risk-free interest rate. The Company&#x2019;s expected common stock price volatility assumption is based upon the historical volatility of our stock price. The expected life assumption for stock options grants was based upon the simplified method provided for under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,</div> which averages the contractual term of the options of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years with the vesting term, typically <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> years. The dividend yield assumption of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">zero</div> is based upon the fact that the Company has never paid cash dividends and presently has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> intention of paying cash dividends in the future. The risk-free interest rate used for each grant was based upon prevailing short-term interest rates over the expected life of the options.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6938203968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedAssetsDisclosureTextBlock', window );">Restricted Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4:</div> RESTRICTED CASH</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our restricted cash balance of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$110,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$55,000</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> consists entirely of cash pledged as security for the Company&#x2019;s issued commercial credit cards.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770781472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PrepaidExpensesTextBlock', window );">Prepaid Expenses [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5:</div> PREPAID EXPENSES</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Prepaid expenses consisted of the following:</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">160,576</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,056</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid research and development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">218,090</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Professional services</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110,094</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">97,788</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Retainer and security deposits</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,718</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,218</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,355</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,882</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="margin: 0px; width: 70%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total prepaid expenses</td> <td style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="margin: 0px; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="margin: 0px; width: 12%; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">509,833</div></td> <td style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" nowrap="nowrap">&nbsp;</td> <td style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="margin: 0px; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="margin: 0px; width: 12%; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">250,944</div></td> <td style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_PrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_PrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770711328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Research and Development Tax Rebate Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock', window );">Research and Development Tax Rebate Receivable [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6:</div> RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 23, 2017, </div>Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (&#x201c;R&amp;D&#x201d;) including our Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> and Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> Endoxifen clinical trials. Australia offers an R&amp;D cash rebate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.435</div> per dollar spent on qualified R&amp;D activities incurred in the country. For the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company incurred qualified R&amp;D expenses in Australia of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$851,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$824,000,</div> respectively. The Company recorded a rebate receivable of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$370,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$358,000</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively, and a corresponding credit to R&amp;D expenses for the years then ended. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>we had a total R&amp;D rebate receivable of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$518,000</div> that included approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$148,000</div> receivable remaining from the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure related to research and development tax rebate receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ResearchAndDevelopmentTaxRebateReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760278848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Payroll Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE </div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></div><div style="display: inline; font-weight: bold;">: PAYROLL LIABILITIES</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Payroll liabilities consisted of the following:</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued bonus payable</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">697,995</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">566,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued vacation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">160,740</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">147,861</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">76,335</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">71,006</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total payroll liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">935,070</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">784,867</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6938245616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE </div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></div><div style="display: inline; font-weight: bold;">: FAIR VALUE OF FINANCIAL INSTRUMENTS</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> financial assets outstanding that were required to be measured at fair value on a recurring basis at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Warrants issued in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 3, 2017, </div>offering, which are discussed further in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> contained provisions that could have required the Company to settle the warrants in cash in an event outside the Company&#x2019;s control or had price protection rights and were therefore accounted for as liabilities while they were outstanding, with changes in the fair values included in net loss for the respective periods. Because some of the inputs to the valuation model were either <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> observable or were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> derived principally from or corroborated by observable market data by correlation or other means, the warrant liability was classified as Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> in the fair value hierarchy.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table summarizes the changes in the Company&#x2019;s Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> warrant liability for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017:</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrant liability</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Beginning balance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Issuances of warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612,413</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrant exercises</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,893,160</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">280,747</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Ending balance</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company&#x2019;s intangible assets are classified within Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> of the fair value hierarchy, measured at fair value on a nonrecurring basis. Refer to Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> for further discussion.&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> transfers between Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> or Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017.</div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6938245328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE </div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></div><div style="display: inline; font-weight: bold;">: STOCKHOLDERS&#x2019; EQUITY</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company is authorized to issue a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">185,000,000</div> shares of stock consisting of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">175,000,000</div> shares of common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.18</div> per share, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,000,000</div> shares of preferred stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share. The Company has designated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">750,000</div> shares of Series A junior participating preferred stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,000</div> shares of Series A convertible preferred stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,000</div> shares of Series B convertible preferred stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share,&nbsp;through the filings of certificates of designation with the Delaware Secretary of State. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> shares of Series A junior participating preferred stock or Series A convertible preferred stock are issued or outstanding as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 19, 2014, </div>the Company adopted a stockholder rights agreement which provides that all stockholders of record on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 26, 2014, </div>received a non-taxable distribution of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> preferred stock purchase right for each share of the Company&#x2019;s common stock held by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable only if <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> of the following occurs: (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>)&nbsp;a person becomes an &#x201c;Acquiring Person&#x201d; by acquiring beneficial ownership of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15%</div> or more of the Company&#x2019;s common stock (or, in the case of a person who beneficially owned <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15%</div> or more of the Company&#x2019;s common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.0%</div> of the Company&#x2019;s common stock then outstanding (excluding compensatory arrangements)), or (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>)&nbsp;a person commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of the Company&#x2019;s common stock with a market value that equals twice the exercise price of the right. The initial exercise price of each right is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.00,</div> so each holder (other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30.00</div> worth of the Company&#x2019;s common stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring entity.&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Public Offering of Class A and Class B Units Consisting of Common Stock, Series A Convertible Preferred Stock and Warrants</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 28, 2017, </div>the Company entered into an underwriting agreement with Aegis Capital Corp. relating to a public offering which closed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 3, 2017. </div>The offering generated gross proceeds to the Company of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.4</div> million and net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.9</div> million after deducting underwriting discounts and commissions and other offering expenses paid by the Company.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The offering included <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55,333</div> Class A Units at a public offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9.00</div> per Class A Unit, which consisted of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55,333</div> shares of common stock and warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55,333</div> shares of common stock. The offering also included <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">292</div> Class B Units at a public offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12,000</div> per Class B Unit, which consisted of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">292</div> shares of Series A convertible preferred stock convertible into a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">389,111</div> shares of common stock and warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">389,111</div> shares of common stock. In addition, the underwriter exercised the over-allotment option to purchase an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,167</div> shares of common stock and warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,167</div> shares of common stock, which are included in the gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.4</div> million. The warrants had a per share exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11.25,</div> were exercisable immediately and were scheduled to expire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years from the date of issuance.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>all of the warrants issued in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 3, 2017 </div>offering have been exercised and are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer outstanding and all of the shares of Series A convertible preferred stock have been converted into shares of common stock.</div> <div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accounting Treatment</div></div></div> <div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company allocated the proceeds from the sale of the Class A and Class B units to the separate securities issued. The Company determined that, on the date of issuance, the warrants were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> indexed to its stock because they did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> meet the &#x201c;fixed-for-fixed&#x201d; criterion&nbsp;due to the price protection and fundamental transaction provisions and, therefore, the warrants were accounted for as liabilities with changes in fair value recorded in non-operating income (expense) in the consolidated statement of operations.</div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company allocated the amount representing the fair value of the warrants at the date of issuance separately to the warrant liability and recorded the remaining proceeds as common stock, in the case of the Class A units, or as Series A convertible preferred stock, in the case of the Class B units. Due to the allocation of a portion of the proceeds to the warrants, the Series A convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,284,066</div> based on the intrinsic value of the beneficial conversion feature. The discount on the Series A convertible preferred stock of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,284,066</div> caused by allocation of the proceeds to the warrant was recorded as a deemed dividend upon issuance of the Series A convertible preferred stock. As a result, total deemed dividends of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,568,132</div> were recorded upon issuance of the Series A convertible preferred stock, which is reflected as an addition to net loss in the consolidated statement of operations to arrive at net loss applicable to common shareholders.</div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Exercise of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Warrants</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 29, 2017, </div>the Company offered to modify the rights of the holders of the warrants issued in the public offering the Company completed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 3, 2017. </div>The temporary modification included (a) lowering the exercise price of the warrants to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.12</div> per share, (b) setting the applicable volume-weighted average price (VWAP) at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.24</div> per share, and (c) allowing for temporary cashless exercise of the warrants for all holders that accepted the temporary modification before <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8:00</div> a.m. Eastern daylight time on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2017. </div>Holders of warrants to purchase a total of approximately <div style="display: inline;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">250,000</div> shares of common stock accepted the offer resulting in the cancellation of those warrants and the issuance by the Company of a total of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,000</div> shares </div>of common stock (including shares held in abeyance). The shares of common stock are registered under the Securities Act of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1933,</div> as amended. In connection with the temporary modification, the Company agreed to extend the &#x201c;Lock-up Period&#x201d; of the underwriting agreement between the Company and Aegis Capital Corp., dated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 28, 2017, </div>by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div> days and the Company agreed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to enter into any further amendments to the warrants during such extended Lock-up Period without the prior written consent of each holder. During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> all remaining warrants were exercised for cash so that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> warrants issued in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 3, 2017, </div>financing remained outstanding. Upon exercise of these warrants, the amount of the warrant liability at the date of exercise was reclassified from warrant liability to additional paid-in capital.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table summarizes the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> liability warrant activity:&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table style="margin: 0pt auto 0pt 36pt; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted<br /> Average<br /> Exercise<br /> Price</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 74%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of January 1, 2017</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">488,611</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.25</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(488,611</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.12</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2017</div> </td> <td style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company estimated the fair value of the warrants using the Monte Carlo simulation (MCS) model, which is a type of income approach, where the current value of an asset is expressed as the sum of probable future cash flows across various scenarios and time frames discounted for risk and time. The significant assumptions included timing of future rounds of financing, timing and success rates of oncology clinical trials, and the probability of a merger and acquisition adjusted for a lack of marketability discount. The MCS model also included a full term and an early conversion scenario that were each weighted at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> in the final concluded fair value.&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Inputs used in the valuation of the warrants at the issuance date of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 3, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2017, </div>are set forth below. All of&nbsp;the warrants issued in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017 </div>financing&nbsp;were exercised during&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">none</div> remained outstanding at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017.</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Initial valuation</div></div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 4%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 4%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock price</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9.00</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercise price</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11.25</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.79%</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.88%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td> <td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;0.24</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%;">&nbsp;</td> <td style="width: 4%;">&nbsp;</td> <td style="width: 4%;">&nbsp;</td> <td style="width: 4%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">June 30, 2017 valuation</div></div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 4%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 4%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock price</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.00</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercise price</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.12</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;0.79</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.88%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td> <td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;0.08</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.76</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Conversion of Series A Convertible Preferred Stock</div></div></div> <div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>certain holders of the Series A convertible preferred stock exercised their conversion option and converted an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">292</div> shares of Series A convertible preferred stock into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">389,111</div> shares of the Company&#x2019;s common stock based on the conversion ratio of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">111</div> shares of common stock for each share of Series A convertible preferred stock. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> shares of Series A convertible preferred stock were outstanding.</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2017 </div>Public Offering</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 26, 2017, </div>the Company entered into an underwriting agreement with Maxim Group LLC relating to a public offering of common stock which closed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 30, 2017. </div>The offering generated gross proceeds to the Company of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.5</div> million and net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.9</div> million after deducting underwriting discounts, commissions and other offering expenses paid by the Company.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The offering included <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">958,333</div> shares of common stock at a public offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.28</div> per share. In addition, the underwriter exercised the over-allotment option to purchase an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">83,333</div> shares of common stock at the offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.28</div> per share, which are included in the gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.5</div> million.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2017 </div>Public Offering and Private Placement</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 20, 2017, </div>the Company entered into a placement agent agreement with Maxim Group LLC relating to the sale of the Company&#x2019;s securities. Pursuant to the placement agent agreement, on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 20, 2017, </div>the Company entered into a securities purchase agreement with certain purchasers named therein relating to the offering and sale of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">441,667</div> shares of Company common stock at a public offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.24</div> per share. The offering generated gross proceeds to the Company of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million and net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.2</div> million after deduction of underwriting discounts, commissions, and other offering expenses paid by the Company.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Concurrently with the public offering the Company also commenced a private placement whereby it issued and sold Class A and Class B Warrants, exercisable for an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">883,333</div> shares of common stock, at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.78</div> per share. The public offering and the private placement involved the same purchasers. The Class A and Class B Warrants exercise price&nbsp;was fixed at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.78</div> per warrant, and the warrants&nbsp;became&nbsp;exercisable commencing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months from issuance. The Class A Warrants and&nbsp;Class B Warrants&nbsp;expired on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> anniversary of the date of issuance. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">None</div> of the Class A Warrants, the Class B Warrants nor the shares issuable upon exercise of such Warrants were&nbsp;registered with the Securities and Exchange Commission. The Warrants could <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be exercised on a cashless basis. There&nbsp;were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> redemption features embodied in the Warrants and they met the conditions for equity classification. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 22, 2018, </div>the Class A and Class B warrants expired unexercised.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Subscription Rights Offering of Units Consisting of Series B Convertible Preferred Stock and Warrants</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 9, 2018, </div>the Company&#x2019;s Registration Statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> with the Securities and Exchange Commission was declared effective to offer subscription rights to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,000</div> units at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div> per unit with each unit consisting of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of Series B convertible preferred stock and warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">284</div> shares of common stock.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 29, 2018, </div>the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B convertible preferred stock with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share, designated as the Series B convertible preferred stock. The number of shares initially constituting the Series B preferred stock was set at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,000</div> shares.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 30, 2018, </div>the Company completed its previously announced rights offering pursuant to which the Company sold an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,624</div> units consisting of an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,624</div> shares of Series B convertible preferred stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,869,216</div> warrants, with each warrant exercisable for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of common stock at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.048</div> per share (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x201c;2018</div> Warrants&#x201d;), resulting in net proceeds to the Company of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12.3</div> million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Series B Convertible Preferred Stock</div></div>.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The terms and provisions of our Series B convertible preferred stock are:</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Conversion.</div> Each share of Series B convertible preferred stock is convertible at our option at any time on or after the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> anniversary of the closing of the rights offering or at the option of the holder at any time, into the number of shares of our common stock determined by dividing the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div> stated value per share of the Series B convertible preferred stock by a conversion price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.52</div> per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series B convertible preferred stock will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have the right to convert any portion of the Series B convertible preferred stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.99%</div> of the number of shares of our common stock outstanding immediately after giving effect to its conversion.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Fundamental Transactions.</div> In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a business combination in which another person acquires <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> of the aggregate ordinary voting power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series B convertible preferred stock, the holders of the Series B convertible preferred stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of common stock then issuable upon conversion in full of the Series B convertible preferred stock.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Dividends.</div> Holders of Series B convertible preferred stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Voting Rights.</div> Except as otherwise provided in the certificate of designation or as otherwise required by law, the Series B convertible preferred stock has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> voting rights.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Liquidation Preference</div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">. </div></div>Upon our liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series B convertible preferred stock will be entitled to receive out of our assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series B convertible preferred stock were fully converted (disregarding for such purpose any conversion limitations under the certificate of designation) to common stock, which amounts shall be paid pari passu with all holders of common stock.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Redemption Rights. </div>We are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> obligated to redeem or repurchase any shares of Series B convertible preferred stock. Shares of Series B convertible preferred stock are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> otherwise entitled to any redemption rights, or mandatory sinking fund or analogous provisions.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Warrants</div></div><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The terms and conditions of the warrants included in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> rights offering are as follows:</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Exercisability</div>. Each warrant is exercisable at any time and will expire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> years from the date of issuance. The warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment in full for the number of shares of our common stock purchased upon such exercise, except in the case of a cashless exercise as discussed below.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The number of shares of common stock issuable upon exercise of the warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. Upon the merger, consolidation, sale of substantially all of our assets, or other similar transaction, the holders of warrants shall, at the option of the company, be required to exercise the warrants immediately prior to the closing of the transaction, or such warrants shall automatically expire. Upon such exercise, the holders of warrants shall participate on the same basis as the holders of common stock in connection with the transaction.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Cashless Exercise</div>. If at any time there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> effective registration statement registering, or the prospectus contained therein is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> available for issuance of, the shares issuable upon exercise of the warrant, the holder <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exercise the warrant on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of shares of our common stock purchasable upon such exercise.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Exercise Price</div>. Each warrant represents the right to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of common stock at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.048</div> per share. In addition, the exercise price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations, or reclassifications, and for certain dilutive issuances. Subject to limited exceptions, a holder of warrants will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have the right to exercise any portion of the warrant to the extent that, after giving effect to the exercise, the holder, together with its affiliates, and any other person acting as a group together with the holder or any of its affiliates, would beneficially own in excess of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.99%</div> of the number of shares of our common stock outstanding immediately after giving effect to its exercise. The holder, upon notice to the Company, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>increase or decrease the beneficial ownership limitation provisions of the warrant, provided that in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> event shall the limitation exceed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.99%</div> of the number of shares of our common stock outstanding immediately after giving effect to the exercise of the warrant.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Transferability</div>. Subject to applicable laws and restrictions, a holder <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>transfer a warrant upon surrender of the warrant to us with a completed and signed assignment in the form attached to the warrant. The transferring holder will be responsible for any tax that liability that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>arise as a result of the transfer.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Exchange Listing</div>. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> intend to apply to list the warrants on any securities exchange or recognized trading system.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Rights as Stockholder</div>. Except as set forth in the warrant, the holder of a warrant, solely in such holder&#x2019;s capacity as a holder of a warrant, will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be entitled to vote, to receive dividends, or to any of the other rights of our stockholders.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Redemption Rights</div>. We <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>redeem the warrants for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.18</div> per warrant if the volume-weighted-average-price of our common stock equals or exceeds <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.56</div> per share for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> consecutive trading days, provided that we <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> do so prior to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> anniversary of closing of the rights offering.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Accounting Treatment</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company allocated the proceeds from the sale of the Series B convertible preferred stock and the warrants to purchase common stock to the separate securities issued. The Company allocated the amount representing the fair value of the warrants at the date of issuance to common stock based on the relative warrant fair value in the amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,363,759,</div> which is net of issuance costs allocated to the warrants. Due to the allocation of a portion of the proceeds to the warrants, the convertible preferred stock contained a beneficial conversion feature upon issuance, which was recorded in the amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,782,100</div> based on the relative fair value of the beneficial conversion feature. The discount on the convertible preferred stock was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11,479,308,</div> which consists of the beneficial conversion feature of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,782,100,</div> the allocation of a portion of the proceeds to the warrants in the amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,363,759,</div> and the total issuance costs related to the financing of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,333,449.</div> The discount on the convertible preferred stock of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11,479,308</div> was recorded as a deemed dividend upon issuance of the convertible preferred stock. The deemed dividend is reflected as an addition to net loss in the consolidated statements of operations to arrive at net loss applicable to common shareholders. The Company has made an accounting policy election to record the deemed dividend related to discounts on convertible instruments at the time of issuance of the convertible instruments.</div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Outstanding Warrants</div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,875,699</div> shares of common stock were outstanding including:</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom;"> <td style="width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding </div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Warrants to </div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Purchase </div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="width: 25%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">Expiration Date</div></div> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 45%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 25%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2014 public offering</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,483</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">540.00</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 25%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">January 29, 2019</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2018 warrants</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,869,216</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.05</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 25%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">May 30, 2022</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,875,699</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr>  </table> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Conversion of Series B Convertible Preferred Stock</div></div></div> <div style=" margin: 0pt 7.5pt 0pt 43.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>certain holders of the Series B convertible preferred stock exercised their conversion option and converted an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,245</div> shares into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,194,600</div> shares of the Company's common stock based on the conversion ratio of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">284</div> shares of common stock for each share of Series B convertible preferred stock.</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6938234672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></div><div style="display: inline; font-weight: bold;">: NET LOSS PER SHARE&nbsp;</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company accounts for and discloses net income (loss) per common share in accordance with Accounting Standards Codification ("ASC") Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260,</div> <div style="display: inline; font-style: italic;">Earnings Per Share</div>. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented they have been excluded from the calculation.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table summarizes the Company&#x2019;s calculation of net loss per common share:</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%; margin-left: 45pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended December 31,</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Numerator</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,404,934</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,122,581</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deemed dividend attributable to preferred stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,479,308</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,568,132</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common shareholders</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22,884,242</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,690,713</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Denominator</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding used to compute net loss per share, basic and diluted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,157,746</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">974,773</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Net loss per share of common stock, basic and diluted: </div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5.50</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10.97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr>  </table> </div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share, because including them would be anti-dilutive:&nbsp;</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%; margin-left: 45pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="6" style="width: 111111%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended December 31,</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options to purchase common stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">487,941</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">117,301</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series A convertible preferred stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55,835</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series B convertible preferred stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">774,983</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants to purchase common stock</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,054,481</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">202,063</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,317,405</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">375,199</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6938231408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></div><div style="display: inline; font-weight: bold;">: INCOME TAXES</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company accounts for income taxes using the asset and liability method, under which deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expected to be realized.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 22, 2017, </div>the President signed into law the Tax Cut and Jobs Act of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x201c;2017</div> Tax Act&#x201d;). The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Tax Act provisions applicable to the Company include a permanent reduction to the U.S. federal corporate income tax rate from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35%</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21%,</div> the capitalization and amortization of research and development related expenses, and placing additional limits on the use of net operating losses. Under ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">740,</div> <div style="display: inline; font-style: italic;">Accounting for Income Taxes</div>, companies are required to recognize the changes in the period of enactment.</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>the Company recorded a reduction in the amount of&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.9</div> million in the carrying value of the Company&#x2019;s U.S. deferred tax assets resulting from the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Tax Act&#x2019;s reduction in the U.S. federal corporate income tax rate from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35%</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21%,</div> which is fully offset by the valuation allowance.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> record an income tax benefit for its losses incurred for the years ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> due to uncertainty regarding utilization of its net operating loss carryforwards and due to its history of losses. The benefit for income taxes differs from the benefit computed by applying the federal statutory rate to loss before income taxes as follows:</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">As of December 31,</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected federal income tax benefit</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,395,036</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,761,678</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">169,957</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">197,336</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other permanent items</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,616</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,668</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of change in valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,223,463</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,344,015</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prior year true-up</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(126,031</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tax rate change</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,912,427</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of NOL limitation</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,119,293</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Actual federal income tax benefit</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The components of net deferred tax assets and liabilities are as follows:</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">Year Ended December 31, </div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 74%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Obsolete inventory</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,881</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,881</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accrued vacation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33,755</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,051</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accrued bonuses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">99,666</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Stock-based compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">968,170</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">620,789</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Basis difference in fixed assets</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33,241</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33,241</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Intangible assets, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">572,687</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">634,521</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Contribution, carryforward</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">707</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">677</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net operating loss carryforwards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,588,401</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">747,589</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Capital loss carryforward</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,027,111</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,027,111</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,312,769</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,089,306</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax asset</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,850</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,554</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(32,850</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(27,554</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax asset</div> </td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 10%; text-align: right; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 1%; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 10%; text-align: right; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 1%; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Based on an assessment of all available evidence including, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to the Company&#x2019;s limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, the Company has concluded that it is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> that these net operating loss carryforwards and credits will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be realized and, as a result, a full valuation allowance has been recorded against the Company&#x2019;s deferred income tax assets. Utilization of the net operating loss carryforwards <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be subject to a substantial annual limitation due to ownership change limitations that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>have occurred or that could occur in the future, as required by the Internal Revenue Code Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">382.</div> In general, an &#x201c;ownership change,&#x201d; as defined by the code, results from a transaction or series of transactions over a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-year period resulting in an ownership change of more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50</div> percentage points of the outstanding stock of a company by certain stockholders or public groups. Any limitation <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>result in expiration of all or a portion of the net operating loss carryforwards before utilization. Since the Company&#x2019;s initial public offering, ownership changes have triggered a Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">382</div> limitation, which limits the ability to utilize net operating loss carryforwards.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has incurred net operating losses from inception. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the Company had domestic federal net operating loss carryforwards of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$58.2</div> million. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May </div>of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2017, </div>the Company completed public offerings, which triggered ownership changes under section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">382.</div> We believe that as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the gross net operating loss carryforwards have been limited to approximately $<div style="display: inline;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.3</div></div> million, which are available to reduce future taxable income. Federal net operating loss carryforwards generated through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>expire at various dates beginning in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2029</div> through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2038,</div> while federal net operating loss carryforwards generated in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expire. The Company recorded a valuation allowance against all of its net deferred tax assets of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.3</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.1</div> million as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively, for a net increase of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.2</div> million from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and a net decrease of <div style="display: inline;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.5</div> </div>million from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company files income tax returns in the U.S. The Company is subject to tax examinations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012</div> tax year and beyond. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> unrecognized tax positions and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe there will be any material changes in its unrecognized tax positions over the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> incurred any interest or penalties related to unrecognized tax positions. In the event that the Company is assessed interest or penalties at some point in the future, they will be classified in the financial statements as general and administrative expense.</div> <div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770659216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Concentration of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration Risk Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></div><div style="display: inline; font-weight: bold;">: CONCENTRATION OF CREDIT RISK</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$250,000.</div> As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10,052,914</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6,967,469</div> in excess of the FDIC insured limit, respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6938182896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></div><div style="display: inline; font-weight: bold;">: COMMITMENTS AND CONTINGENCIES</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Lease Commitments</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 1, 2018, </div>the Company entered into an operating lease to pay <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,660</div> monthly&nbsp;rent for a term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22</div> months.&nbsp;The&nbsp;total future minimum lease payments due under this lease&nbsp;<div style="display: inline;">are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$73,200</div></div>, of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$43,920</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$29,280</div> are due in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020,</div> respectively.</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The total rent expense for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$31,457</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$33,285,</div> respectively. Rent expense was included in general and administrative expenses for both years.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 30, 2018, </div>the Company entered into an operating lease for a copier system for a term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">36</div> months. The total future minimum lease payments due under this lease&nbsp;are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$42,228,</div> of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$14,904,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$14,904</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12,420</div> are due in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2021,</div> respectively.</div> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Litigation and Contingencies</div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 10, 2013, </div>a putative securities class action complaint, captioned <div style="display: inline; font-style: italic;">Cook v. Atossa Genetics, Inc., et al.</div>, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2:13</div>-cv-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01836</div>-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2012 </div>initial public offering. The complaint alleged that all defendants violated Sections <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div>(a)(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>), and that we and certain of our directors and officers violated Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> of the Securities Act by making material false and misleading statements and omissions in the offering&#x2019;s registration statement, and that we and certain of our directors and officers violated Sections <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>(b) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20A</div> of the Exchange Act and SEC Rule <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10b</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div> promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. The complaint sought, on behalf of persons who purchased our common stock between <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 8, 2012 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 4, 2013, </div>inclusive, damages of an <div style="display: inline;">unspecific amount.</div>&nbsp;On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 23, 2018, </div>the parties filed a stipulation of settlement with the court to settle the matter for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.5</div> million, completely funded by defendants&#x2019; insurers, and on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 20, 2018 </div>the Court approved the settlement. This case is considered closed.&nbsp;&nbsp;</div> <div style=" margin: 0pt 21.9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are subject to other legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6936685792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></div><div style="display: inline; font-weight: bold;">: STOCK BASED COMPENSATION</div></div> <div style=" margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock Option and Incentive Plan</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 28, 2010, </div>the Board of Directors approved the adoption of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Stock Option and Incentive Plan the (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x201c;2010</div> Plan&#x201d;) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan until <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2020. </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> other awards <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan after the date that is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> years from the date of stockholder approval. An aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,556</div> shares were initially reserved for issuance in connection with awards granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan and on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 18, 2016, </div>an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,111</div> shares were reserved for issuance under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 9, 2017, </div>the stockholders approved an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,000</div> shares for issuance under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 12, 2018, </div>the stockholders approved an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500,000</div> shares for issuance under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan.</div> <div style=" margin: 0pt 7.5pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table presents the automatic additions to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan since inception pursuant to the &#x201c;evergreen&#x201d; terms of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan:</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table style="margin: 0pt auto 0pt 36pt; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">January 1,</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of<br /> shares</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2012</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,502</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2013</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,871</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2014</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,128</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2015</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,463</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2016</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,257</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,623</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106,076</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total additional shares</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140,920</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company granted options to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">611,668</div>&nbsp;and&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">143,027</div> shares of common stock to employees and directors during the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively.&nbsp;The weighted average grant date fair value of options granted during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.02</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.80,</div> respectively. There are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,575</div> options available for grant under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>and as a result of the evergreen provision contained in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan, an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">233,862</div> shares were added to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019.</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Compensation costs associated with the Company&#x2019;s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,053,496</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$786,550</div> for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively, which was included in the following captions in the consolidated statements of operations.</div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 68%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended December 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 68%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">7</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 68%;">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 68%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">General and administrative</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">809,110</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">621,668</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 68%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research and development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">244,386</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">164,882</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 68%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total stock compensation expense</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,053,496</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">786,550</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The fair value of stock options granted for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> was calculated using the Black-Scholes option-pricing model applying the following assumptions:</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 67%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="7" rowspan="1" style="width: 636163%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year ended December 31,</div></div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 67%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="3" rowspan="1" style="width: 63%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="3" rowspan="1" style="width: 63%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">7</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 67%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 3%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 3%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 67%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Risk free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;2.47%</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.71%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;1.86%</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.04%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 67%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;5.24</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.57&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;5.32</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.36</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 67%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 3%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 3%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 67%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-%</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-%</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 67%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;108.81%</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">126.43%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;112.86%</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114.19</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Options issued and outstanding as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>and their activities during the year then ended are as follows:</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 10.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Number of<br /> Underlying<br /> Shares</div></div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 9.9%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average<br /> Exercise Price<br /> Per Share</div></div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average<br /> Contractual<br /> Life Remaining<br /> in Years</div></div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 9.9%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Aggregate<br /> Intrinsic Value</div></div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Outstanding as of January 1, 2018</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.3%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">172,510</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 8.8%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">49.27</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.9%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 8.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Granted</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.3%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">611,668</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.39</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.9%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Forfeited</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(795</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">562.55<div style="display: inline;"></div></div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.9%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Outstanding as of December 31, 2018</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">783,383</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12.14</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.9%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9.17</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Exercisable as of December 31, 2018</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">317,042</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">24.39</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.9%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8.97</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Vested and expected to vest</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">783,383</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12.14</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.9%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9.17</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr>  </table> </div> <div style=" margin: 0pt 7.5pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">466,341</div> unvested options outstanding and the related unrecognized total compensation cost associated with these options was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,152,367.</div> This expense is expected to be recognized over a weighted-average period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.45</div> years.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Executive Option Grants Classified as Liabilities (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">"2018</div> Liability Grants")</div></div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 27, 2018, </div>the Company granted <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,300,000</div> options to the Chief Executive Officer and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">700,000</div> to the Chief Financial Officer. Each option is exercisable for an equivalent number of shares of Company's common stock. The options were granted pursuant to an option award agreement and were granted outside the Company&#x2019;s <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan; however, they are subject to the terms and conditions of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 13, 2019, </div>the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> liability options were canceled.</div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Liability Grants were exercisable for shares of common stock at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.38</div> per share, which was the fair value on the date of grant. The options had an exercise period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years from their date of issuance. If at the time the options were exercised the Company cannot deliver shares of common stock to the optionee including, for example, if there were insufficient shares available under the Plan at the time of exercise, then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option only would be exercised on a cash &#x201c;net basis&#x201d; so that the Company would pay cash in an amount equal to the excess of the fair value of the common stock over the option exercise price. There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> sufficient shares available under the Plan. Therefore the&nbsp;Company&nbsp;would have been obligated to settle these options in cash if they were exercised. Because these options contained provisions that would require the Company to settle the options in cash in an event outside the Company&#x2019;s control, they were accounted for as liabilities.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Liability Grants were subject to vesting requirements. Twenty-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> percent of the options were vested as of the grant date, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> of the options would have vested quarterly over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years, and the remaining <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> would have vested upon achievement of certain milestones related to clinical trial progress. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>all of the options that vested upon achievement of clinical trial&nbsp;milestones&nbsp;were vested.&nbsp;At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>there were&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,125,000</div> unvested options outstanding and the related unrecognized total compensation cost associated with these options was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$857,673.</div> This expense was expected to be recognized over a weighted-average period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5</div> years.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style="display: none;">  &nbsp; </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Compensation costs associated with the Liability Grants were initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria were achieved for options that vest based on performance. Compensation cost was remeasured each period based on the market value of our underlying stock until award vesting or settlement.</div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the Company&nbsp;recognized compensation expense related to these options of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,410,025,</div> which was included in the following captions in the consolidated statements of operations.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended </div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2018</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 85%;">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 85%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">General and administrative</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">869,515</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 85%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research and development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">540,510</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 85%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total stock compensation expense</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,410,025</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The fair value of liability options granted for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>was calculated using the Black-Scholes option-pricing model applying the following assumptions:</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table style="margin: 0pt auto 0pt 27pt; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="3" rowspan="1" style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Year Ended</div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">December 31</div><div style="display: inline; font-weight: bold;">, 2018</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Risk free interest rate</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.51</div> </td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.94%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected term (in years)</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.5</div> </td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5.0</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stock price</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$1.02</div> </td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$2.38</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Dividend yield</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected volatility</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">122.0</div> </td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">125.0%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Refer to footnote <div style="display: inline;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div> </div>for&nbsp;further description.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6926801760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Reclassifications', window );">Reclassifications [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15:</div>&nbsp; RESTATEMENT TO PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div></div></div> <div style=" margin: 0pt 22.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" margin: 0pt 14.7pt 0pt 6pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has corrected an inadvertent error in the calculation of the deemed dividend on Series B convertible preferred stock in the financial statements for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>that were included in the Company&#x2019;s Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-Q filed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 13, 2018 (</div>the &#x201c;Original Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-Q&#x201d;). Accounting principles generally accepted in the United States of America require that we allocate the proceeds from the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2018 </div>financing to the warrants and preferred stock issued in the financing and that we estimate and record any discount on the securities as a deemed dividend. In the financial statements included in the Original Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-Q, we did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> properly allocate the proceeds to the warrants, and we did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> properly record the deemed dividend related to the warrant discount as additional paid in capital to common stock. The Company incorrectly stated the deemed dividend for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>as <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,782,100,</div> rather than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11,479,308.</div> The corrections result from application of technical accounting rules and do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> impact cash or operations.</div> <div style=" margin: 0pt 22.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt 14.7pt 0pt 6pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In accordance with applicable generally accepted accounting principles, the Company has calculated and recognized adjustments accordingly. The following table shows the effect of the restatement on certain line items within the Company&#x2019;s Condensed Consolidated Statement of Operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018: &nbsp;</div></div> <div style=" margin: 0pt 22.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">For the Three Months Ended<br /> June 30, 2018</div></div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">For the Six Months Ended<br /> June 30, 2018</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Previously</div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Reported</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Restated</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Previously</div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Reported</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Restated</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deemed dividend attributable to preferred stock</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(4,782,100</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(11,479,308</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(4,782,100</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(11,479,308</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Net loss applicable to common stockholders</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(8,924,677</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(15,621,885</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(10,799,059</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(17,496,267</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Loss per common share -basic and diluted</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2.90</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(5.08</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3.77</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(6.11</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr>  </table> </div> <div style=" margin: 0pt 22.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt 14.7pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table shows the effect of the restatement on certain line items within the Company&#x2019;s Condensed Consolidated Statement of Stockholders&#x2019; Equity for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018: &nbsp;</div></div> <div style=" margin: 0pt 22.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Preferred Stock Additional Paid-in Capital</div></div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Common Stock Additional Paid-in Capital</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Previously</div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Reported</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Restated</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Previously</div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Reported</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Restated</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Issuance of Series B convertible preferred stock, net of issuance costs</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12,290,537</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6,926,778</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">0</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5,363,759</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deemed Dividend on Series B convertible preferred stock</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4,782,100</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">11,479,308</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(4,782,100</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(11,479,308</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Conversion of Series B convertible preferred stock to common stock</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(7,056,421</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(7,821,992</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6,656,442</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7,422,013</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Reclassifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Reclassifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6634141920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></div><div style="display: inline; font-weight: bold;">: SUBSEQUENT EVENTS</div></div> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Stock Option and Incentive Plan</div></div></div></div> <div style=" margin: 0pt 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 27, 2018, </div>the Company granted <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,300,000</div> options to the Chief Executive Officer and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">700,000</div> to the Chief Financial Officer (collectively, the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x201c;2018</div>&nbsp;Liability Options&#x201d;). Each option was exercisable for an equivalent number of shares of Company common stock.&nbsp;The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Liability Options contained a &#x201c;Net Cash Exercise Provision&#x201d; so that if at the time the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Liability&nbsp;Options were exercised the Company could <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> deliver shares of Common Stock to the optionee (including, for example, if there were insufficient shares available under the Plan at the time of exercise), then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option would only be exercised on a cash &#x201c;net basis&#x201d; requiring that the Company pay cash in an amount equal to the excess of the fair market value of the Common Stock over the option exercise price.</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 13, 2019, </div>the Company,&nbsp;CEO and CFO&nbsp;agreed to cancel and terminate the&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Liability&nbsp;Options so they are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer outstanding and of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> further force and effect. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 13, 2019, </div>the Company granted a new option to the CEO to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,300,000</div> shares of Common Stock and a new option to&nbsp;the&nbsp;CFO&nbsp;to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">800,000</div> shares of Common Stock (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x201c;2019</div> Options&#x201d;). The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options: (i) have an exercise price equal to the fair market value of Common Stock on the date of grant which was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.36</div> per share, (ii) do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> contain a Net Cash Exercise provision, (iii) are granted pursuant to the terms and conditions of the Plan as amended by the Board of Directors on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 13, 2019, </div>to include shares issuable upon exercise of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options and other changes to the Plan so that the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> conflict with the Plan (the &#x201c;Amended Plan&#x201d;), (iv) vest and are exercisable in accordance with the vesting schedule related to the&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Liability&nbsp;Options; provided, however, that the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> exercisable unless and until the Company&#x2019;s stockholders approve the Amended Plan to increase the authorized number of shares available for grant under the Plan as only <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,575</div> options were available for grant as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>and&nbsp;(vi) are subject to and conditioned the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Option Agreements with the optionees and the employment agreements with the optionees.</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The above actions were unanimously approved by the disinterested members&nbsp;of the Board of Directors. The above actions are intended to eliminate the Company&#x2019;s potential liability associated with the Net Cash Exercise Provision of the liability options, and to allow the stockholders of the Company the opportunity to vote on the Amended Plan, which includes shares issuable upon exercise of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;<div style="display: inline;"><div style="display: inline; font-style: italic;">Warrant Exercises</div></div></div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2019, </div>the Company received approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11.3</div> million from exercises of warrants issued on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 30, 2018. </div>As a result of the warrant exercises, the Company retired approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.8</div> million warrants and issued approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.8</div> million shares of common stock.</div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6931792864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Basis of Presentation:</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The accompanying consolidated financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and in accordance with accounting principles generally accepted in the United States of America&nbsp;(&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiaries. All significant intercompany account balances and transactions have been eliminated in consolidation.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 20, 2018, </div>the Company completed a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> reverse stock&nbsp;split&nbsp;of the shares of the Company&#x2019;s common stock (the &#x201c;Reverse Stock&nbsp;Split&#x201d;). As a result of the Reverse Stock Split, every <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> shares of issued and outstanding common stock were combined into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> issued and outstanding share of common stock, and the par value per share was changed to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.18</div> per share. The number of authorized shares of common stock was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> reduced as a result of the Reverse Stock Split. The Company&#x2019;s common stock began trading on a reverse stock&nbsp;split-adjusted basis on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 20, 2018. </div>All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock&nbsp;Split.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Use of Estimates:</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Recently Issued Accounting Pronouncements:</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> <div style="display: inline; font-style: italic;">Lease Accounting Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842.</div></div> The new standard is effective for reporting periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018 </div>and early adoption is permitted. The standard will require lessees to report most leases as assets or liabilities on the balance sheet, while lessor accounting will remain substantially unchanged. The standard permits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> approaches, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> requiring retrospective application of the new guidance with restatement of prior years, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> requiring prospective application of the new guidance. We plan to adopt the new lease standard effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>and apply it prospectively. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect the new lease standard to have a material effect on our financial position, results of operations or cash flows. Upon adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> we will be required to recognize an operating lease liability and right-of-use asset of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$100,000,</div> based on the lease composition disclosed in <div style="display: inline;">footnote <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> <div style="display: inline; font-style: italic;">Statement of Cash Flows</div>, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018 </div>on a retrospective basis. For years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we included <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$110,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$55,000,</div> respectively, of restricted cash within cash, cash equivalents, and restricted cash&nbsp;on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer has the credit card or the limit changes on the credit card.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2017, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> <div style="display: inline; font-style: italic;">Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</div>. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer precludes equity classification when assessing whether the instrument is indexed to an entity&#x2019;s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260</div> to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This update is effective for public entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>Early adoption is permitted. The Company early adopted the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018. </div>As the Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have any financial instruments with down round features, this ASU did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the financial statements upon adoption.</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">07,</div> <div style="display: inline; font-style: italic;">Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. </div>This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers</div>. This update is effective for public entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018, </div>including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div>and it did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the financial statements upon adoption.</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">08,</div> <div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Not</div>-for-Profit Entities (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">958</div>): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.</div> This ASU affects <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div>-for-profit entities and business entities that receive or make contributions of cash.&nbsp;The ASU&#xfeff; clarifies and improves the scope and accounting guidance to assist entities in evaluating if those transactions should be accounted for as contributions under the scope of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">958</div> or as an exchange transaction subject to other guidance.&nbsp;This update is effective for public entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>The Company is currently evaluating the impact that adoption will have on its financial statements.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and Development</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">All research and development costs are expensed as incurred.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income Taxes</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> that some portion or all of a deferred tax asset will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be realized based on the weight of available evidence, including expected future earnings. The Company recognizes an uncertain tax position in its financial statements when it concludes that a tax position is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to be sustained upon examination based solely on its technical merits. Only after a tax position passes the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit that is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. The Company elects to accrue any interest or penalties related to income taxes as part of its income tax expense.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cash and cash equivalents include cash and all highly liquid instruments with original maturities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Furniture and Equipment</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Furniture and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When furniture and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.</div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Depreciation is computed using the straight-line method over the estimated useful lives ranging from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> to&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt 7.2pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Furniture and equipment amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$216,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$171,000</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively. Accumulated depreciation was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$162,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$160,000</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively. Depreciation expense for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$14,386</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$25,956,</div> respectively.&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company periodically evaluates the carrying value of long-lived assets to be held and used and, if necessary, records impairment losses when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-loved assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.&nbsp; For the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impairment of furniture and equipment was recorded.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Fair Value Measurements</div></div></div> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company records financial assets&nbsp;and liabilities measured on a recurring and non-recurring basis&nbsp;as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. These fair value principles prioritize valuation inputs across <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> broad levels. Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.&nbsp;Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>&nbsp;inputs are unobservable inputs based on the Company's assumptions used to measure assets and liabilities at fair value. An asset or liability's classification within the various levels is determined based on the lowest level input that is significant to the fair value measurement.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Intangible Assets</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Intangible assets consist of intellectual property and software acquired. Intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the assets might <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. Impairment losses must be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the assets. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>we determined certain intangible assets acquired from Acueity Healthcare, Inc. ("Acueity") were impaired and&nbsp;recorded an asset impairment charge of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$461,715</div> for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>to adjust the carrying value of these intangible assets to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">zero</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017. &nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> impairment charges were recorded during the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018.</div></div> <div style=" margin: 0pt; text-align: center; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We determined the fair values of the Acueity intangibles using an income approach (Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> of the fair value hierarchy). For purposes of the income approach, fair value was determined based on the present value of estimated future cash flows that a market participant could expect to generate from the development of products using the patented technology acquired in the Acueity transaction, discounted at an appropriate risk-adjusted rate reflecting the weighted average cost of capital for a potential market participant. The discount rate used in valuation for these intangible assets was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48.50%.</div> The estimated future cash flows, including an estimate of long-term future growth rates, reflect our own assumptions of what market participants would utilize to price the assets pursuant to ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">820,</div> <div style="display: inline; font-style: italic;">Fair Value Measurements</div>.</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Amortization of intangible assets&nbsp;is computed using the straight-line method over the estimated useful lives ranging from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years.</div> <div style=" margin: 0pt 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt 7.2pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Intangible assets amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$192,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$234,000</div> for at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively. Accumulated amortization was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$93,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$158,000</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively. Amortization expense for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$29,811</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$103,038,</div> respectively.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock', window );">Financial Instruments with Characteristics of Both Liabilities and Equity, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Financial Instruments with Characteristics of Both Liabilities and Equity</div></div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>the Company issued certain financial instruments, consisting of warrants to purchase common stock, which have characteristics of both liability and equity. Financial instruments such as warrants that are classified as liabilities are fair valued upon issuance and are re-measured at fair value at subsequent reporting periods with the resulting change in fair value recorded in &#x201c;change in fair value of common stock warrants&#x201d; in the consolidated statement of operations. The fair value of warrants is estimated using valuation models that require the input of subjective assumptions including stock price volatility, expected life, and the probability of future equity issuances and their impact to the price protection feature. There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> outstanding warrants accounted for as liabilities as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Share-Based Payments</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company follows the provisions of ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718,</div> <div style="display: inline; font-style: italic;">Compensation - Stock Compensation</div> (&#x201c;ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718&#x201d;</div>), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> is recognized as an expense over the requisite service period and the Company made a policy election to recognize forfeitures when they occur.</div> <div style=" margin: 0pt; text-align: left; text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company&#x2019;s common stock, and estimation of an appropriate risk-free interest rate. The Company&#x2019;s expected common stock price volatility assumption is based upon the historical volatility of our stock price. The expected life assumption for stock options grants was based upon the simplified method provided for under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,</div> which averages the contractual term of the options of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years with the vesting term, typically <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> years. The dividend yield assumption of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">zero</div> is based upon the fact that the Company has never paid cash dividends and presently has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> intention of paying cash dividends in the future. The risk-free interest rate used for each grant was based upon prevailing short-term interest rates over the expected life of the options.</div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for financial instruments with characteristics of both liabilities and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_FinancialInstrumentsWithCharacteristicsOfBothLiabilitiesAndEquityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770691552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">160,576</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,056</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid research and development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">218,090</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Professional services</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110,094</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">97,788</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Retainer and security deposits</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,718</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,218</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,355</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,882</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="margin: 0px; width: 70%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total prepaid expenses</td> <td style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="margin: 0px; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="margin: 0px; width: 12%; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">509,833</div></td> <td nowrap="nowrap" style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="margin: 0px; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="margin: 0px; width: 12%; text-align: right; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">250,944</div></td> <td nowrap="nowrap" style="margin: 0px; padding: 0px 0px 3px; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6938214032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Payroll Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued bonus payable</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">697,995</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">566,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued vacation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">160,740</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">147,861</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">76,335</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">71,006</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total payroll liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">935,070</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">784,867</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760536544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrant liability</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Beginning balance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Issuances of warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612,413</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrant exercises</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,893,160</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">280,747</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Ending balance</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6911709392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ScheduleOfWarrantsActivityTableTextBlock', window );">Schedule of Warrants Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="margin: 0pt auto 0pt 36pt; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted<br /> Average<br /> Exercise<br /> Price</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 74%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of January 1, 2017</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">488,611</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(488,611</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.12</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2017</div> </td> <td style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding </div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Warrants to </div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Purchase </div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="width: 25%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">Expiration Date</div></div> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 45%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 25%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2014 public offering</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,483</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">540.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 25%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">January 29, 2019</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2018 warrants</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,869,216</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.05</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 25%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">May 30, 2022</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,875,699</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Initial valuation</div></div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 4%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 4%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock price</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9.00</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercise price</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11.25</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.79%</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.88%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td> <td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;0.24</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%;">&nbsp;</td> <td style="width: 4%;">&nbsp;</td> <td style="width: 4%;">&nbsp;</td> <td style="width: 4%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">June 30, 2017 valuation</div></div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 4%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 4%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock price</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.00</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercise price</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.12</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;0.79</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.88%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 87%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td> <td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;0.08</div></td> <td style="width: 4%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.76</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ScheduleOfWarrantsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ScheduleOfWarrantsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6938176704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%; margin-left: 45pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended December 31,</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Numerator</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,404,934</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,122,581</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deemed dividend attributable to preferred stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,479,308</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,568,132</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common shareholders</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22,884,242</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,690,713</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Denominator</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding used to compute net loss per share, basic and diluted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,157,746</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">974,773</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Net loss per share of common stock, basic and diluted: </div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5.50</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10.97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10%; margin-left: 45pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="6" style="width: 111111%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended December 31,</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options to purchase common stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">487,941</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">117,301</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series A convertible preferred stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55,835</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series B convertible preferred stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">774,983</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants to purchase common stock</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,054,481</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">202,063</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,317,405</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">375,199</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6936765808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">As of December 31,</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected federal income tax benefit</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,395,036</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,761,678</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">169,957</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">197,336</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other permanent items</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,616</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,668</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of change in valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,223,463</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,344,015</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prior year true-up</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(126,031</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tax rate change</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,912,427</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of NOL limitation</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,119,293</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Actual federal income tax benefit</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">Year Ended December 31, </div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 74%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Obsolete inventory</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,881</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,881</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accrued vacation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33,755</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,051</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accrued bonuses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">99,666</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Stock-based compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">968,170</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">620,789</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Basis difference in fixed assets</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33,241</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33,241</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Intangible assets, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">572,687</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">634,521</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Contribution, carryforward</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">707</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">677</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net operating loss carryforwards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,588,401</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">747,589</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Capital loss carryforward</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,027,111</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,027,111</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,312,769</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,089,306</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax asset</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,850</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,554</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(32,850</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(27,554</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax asset</div> </td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 10%; text-align: right; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 10%; text-align: right; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768498208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="margin: 0pt auto 0pt 36pt; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">January 1,</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of<br /> shares</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2012</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,502</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2013</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,871</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2014</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,128</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2015</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,463</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2016</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,257</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,623</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106,076</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 87%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total additional shares</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140,920</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 67%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="7" rowspan="1" style="width: 636163%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year ended December 31,</div></div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 67%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="3" rowspan="1" style="width: 63%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="3" rowspan="1" style="width: 63%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">7</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 67%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 3%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 3%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 67%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Risk free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;2.47%</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.71%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;1.86%</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.04%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 67%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;5.24</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.57&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;5.32</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.36</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 67%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 3%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 3%;">&nbsp;</td> <td style="width: 6%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 67%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-%</div></td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-%</div></td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 67%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;108.81%</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">126.43%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;112.86%</div></td> <td style="width: 3%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;-</div></td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114.19</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 10.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Number of<br /> Underlying<br /> Shares</div></div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 9.9%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average<br /> Exercise Price<br /> Per Share</div></div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average<br /> Contractual<br /> Life Remaining<br /> in Years</div></div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 9.9%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Aggregate<br /> Intrinsic Value</div></div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Outstanding as of January 1, 2018</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.3%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">172,510</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 8.8%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">49.27</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.9%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 8.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Granted</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.3%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">611,668</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.39</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.9%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Forfeited</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(795</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">562.55<div style="display: inline;"></div></div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.9%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Outstanding as of December 31, 2018</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">783,383</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12.14</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.9%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9.17</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Exercisable as of December 31, 2018</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">317,042</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">24.39</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.9%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8.97</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 51.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Vested and expected to vest</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.3%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">783,383</div> </td> <td style="width: 0.8%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 8.8%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12.14</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 9.9%; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9.17</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1.1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 8.8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 0.9%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended </div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2018</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 85%;">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 85%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">General and administrative</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">869,515</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 85%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research and development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">540,510</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 85%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total stock compensation expense</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,410,025</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="margin: 0pt auto 0pt 27pt; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="3" rowspan="1" style="width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Year Ended</div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">December 31</div><div style="display: inline; font-weight: bold;">, 2018</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Risk free interest rate</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.51</div> </td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.94%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected term (in years)</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.5</div> </td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5.0</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stock price</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$1.02</div> </td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$2.38</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Dividend yield</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected volatility</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">122.0</div> </td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">-</div> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">125.0%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: bottom;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 5%; margin-left: 27pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 68%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended December 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 68%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">7</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 68%;">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 68%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">General and administrative</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">809,110</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">621,668</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 68%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research and development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">244,386</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">164,882</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 68%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total stock compensation expense</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,053,496</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">786,550</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6936781984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">For the Three Months Ended<br /> June 30, 2018</div></div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">For the Six Months Ended<br /> June 30, 2018</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Previously</div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Reported</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Restated</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Previously</div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Reported</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Restated</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deemed dividend attributable to preferred stock</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(4,782,100</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(11,479,308</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(4,782,100</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(11,479,308</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Net loss applicable to common stockholders</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(8,924,677</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(15,621,885</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(10,799,059</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(17,496,267</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Loss per common share -basic and diluted</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2.90</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(5.08</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3.77</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(6.11</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Preferred Stock Additional Paid-in Capital</div></div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="6" style="width: 26%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Common Stock Additional Paid-in Capital</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Previously</div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Reported</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Restated</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Previously</div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Reported</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td colspan="2" style="width: 12%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Restated</div></div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Issuance of Series B convertible preferred stock, net of issuance costs</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12,290,537</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6,926,778</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">0</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5,363,759</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deemed Dividend on Series B convertible preferred stock</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4,782,100</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">11,479,308</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(4,782,100</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(11,479,308</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 44%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Conversion of Series B convertible preferred stock to common stock</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(7,056,421</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(7,821,992</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6,656,442</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="width: 1%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 11%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7,422,013</div> </td> <td style="width: 1%; vertical-align: bottom;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6931917520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Liquidity and Capital Resources (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2019</div></th>
<th class="th"><div>Mar. 24, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,404,934)<span></span>
</td>
<td class="num">$ (8,122,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,961,621)<span></span>
</td>
<td class="num">(6,593,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,380,493<span></span>
</td>
<td class="nump">7,217,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_WorkingCapital', window );">Working Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 749,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Ending Balance</a></td>
<td class="nump">$ 19,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of total net current assets after deducting net current liabilities as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779947360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 20, 2018</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash and Cash Equivalents, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,000<span></span>
</td>
<td class="nump">171,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,000<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,386<span></span>
</td>
<td class="nump">25,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of Long-Lived Assets Held-for-use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill), Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">461,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill), Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,000<span></span>
</td>
<td class="nump">234,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_IntangibleAssetMeasurementInput', window );">Intangible Asset, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,000<span></span>
</td>
<td class="nump">158,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,811<span></span>
</td>
<td class="nump">103,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_WarrantLiabilities', window );">Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=atos_AcueityIntangibleAssetsMember', window );">Acueity intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill), Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill), Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Vesting Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Vesting Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=atos_ReverseStockSplitMember', window );">Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure intangible asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected vesting term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVestingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_WarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding warrants accounted for as liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_WarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 220<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873921&amp;loc=SL114875236-224282<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=atos_AcueityIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=atos_AcueityIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=atos_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=atos_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6936806496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Restricted Cash (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash and Cash Equivalents, Total</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6936502640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 160,576<span></span>
</td>
<td class="nump">$ 125,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ResearchAndDevelopmentCurrent', window );">Prepaid research and development</a></td>
<td class="nump">218,090<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ProfessionalServicesCurrent', window );">Professional services</a></td>
<td class="nump">110,094<span></span>
</td>
<td class="nump">97,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Retainer and security deposits</a></td>
<td class="nump">16,718<span></span>
</td>
<td class="nump">14,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">4,355<span></span>
</td>
<td class="nump">13,882<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Total prepaid expenses</a></td>
<td class="nump">$ 509,833<span></span>
</td>
<td class="nump">$ 250,944<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ProfessionalServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for professional services costs that provide benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ProfessionalServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development costs that provide benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783261264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Research and Development Tax Rebate Receivable (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>May 23, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense, Total</a></td>
<td class="nump">$ 4,209,981<span></span>
</td>
<td class="nump">$ 2,328,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable', window );">Increase (Decrease) in Research and Development Tax Rebate Receivable</a></td>
<td class="nump">159,821<span></span>
</td>
<td class="nump">358,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ResearchAndDevelopmentTaxRebateReceivable', window );">Research and Development Tax Rebate Receivable</a></td>
<td class="nump">518,098<span></span>
</td>
<td class="nump">358,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=atos_AtossaGeneticsAUSPtyLtdMember', window );">Atossa Genetics AUS Pty Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ResearchAndDevelopmentCashRebatePerDollar', window );">Research and Development Cash Rebate per Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense, Total</a></td>
<td class="nump">851,000<span></span>
</td>
<td class="nump">824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable', window );">Increase (Decrease) in Research and Development Tax Rebate Receivable</a></td>
<td class="nump">370,000<span></span>
</td>
<td class="nump">358,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ResearchAndDevelopmentTaxRebateReceivable', window );">Research and Development Tax Rebate Receivable</a></td>
<td class="nump">$ 518,000<span></span>
</td>
<td class="nump">$ 148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of increase (decrease) in research and development tax rebate receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ResearchAndDevelopmentCashRebatePerDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the research and development cash rebate per dollar spend on qualified R&amp;D activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ResearchAndDevelopmentCashRebatePerDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ResearchAndDevelopmentTaxRebateReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of research and development tax rebate receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ResearchAndDevelopmentTaxRebateReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=atos_AtossaGeneticsAUSPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=atos_AtossaGeneticsAUSPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779403552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus payable</a></td>
<td class="nump">$ 697,995<span></span>
</td>
<td class="nump">$ 566,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation</a></td>
<td class="nump">160,740<span></span>
</td>
<td class="nump">147,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll liabilities</a></td>
<td class="nump">76,335<span></span>
</td>
<td class="nump">71,006<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Total payroll liabilities</a></td>
<td class="nump">$ 935,070<span></span>
</td>
<td class="nump">$ 784,867<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6931802384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Fair Value of Financial Instruments (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6931899216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Fair Value of Financial Instruments - Changes in Level 3 Warrant Liability (Details) - Warrant Liability [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances of warrants</a></td>
<td class="nump">1,612,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Warrant exercises</a></td>
<td class="num">(1,893,160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">280,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=atos_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=atos_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6790509856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 20, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 26, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 29, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 03, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>$ / item </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 29, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 09, 2018 </div>
<div>$ / item </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 19, 2014 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_NumberOfSharesAuthorizedToIssue', window );">Number of Shares Authorized to Issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock', window );">Stockholder Rights Agreement, Number of Preferred Stock Right Distributed for Each Share of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership', window );">Stockholder Rights Agreement, Acquiring Person, Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership', window );">Stockholder Rights Agreement, Acquiring Person, Additional Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_StockholderRightsAgreementInitialExercisePriceOfEachRight', window );">Stockholder Rights Agreement, Initial Exercise Price of Each Right | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_StockholderRightsAgreementSharePrice', window );">Stockholder Rights Agreement, Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PreferredStockDeemedDividend', window );">Preferred Stock, Deemed Dividend | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,479,308<span></span>
</td>
<td class="nump">$ 11,479,308<span></span>
</td>
<td class="nump">$ 11,479,308<span></span>
</td>
<td class="nump">$ 2,568,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_LockupPeriodExtension', window );">Lock-up Period Extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,875,699<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ProceedsFromIssuanceOfStockUnits', window );">Proceeds from Issuance of Stock units | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,871,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares', window );">Consummate a Business Combination, Percentage of Acquired Outstanding Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower', window );">Consummate a Business Combination, Percentage of Aggregate Ordinary Voting Power</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember', window );">Conversion of Series A Convertible Preferred Stock into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember', window );">Conversion of Series B Convertible Preferred Stock into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,194,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atos_The2017PublicOfferingWarrantsMember', window );">The 2017 Public Offering Class B Units Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ClassOfWarrantOrRightCancelled', window );">Class of Warrant or Right Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atos_The2017PublicOfferingWarrantsMember', window );">The 2017 Public Offering Class B Units Warrants [Member] | Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atos_The2018WarrantsMember', window );">The 2018 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,869,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed', window );">Warrants Exercisable, Ownership Percentage of Company&#8217;s Shares Allowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed', window );">Common Stock, Convertible, Ownership Percentage of Company&#8217;s Shares Allowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_WarrantsAndRightsOutstandingRedemptionPrice', window );">Warrants and Rights Outstanding, Redemption Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock', window );">Warrants and Rights Outstanding, Redeemable, Volume-weighted-average-price of Our Common Stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays', window );">Warrants and Rights, Redemption Rights, Consecutive Trading Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atos_The2017PublicOfferingMember', window );">The 2017 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ProceedsFromIssuanceOrSaleOfEquityNet', window );">Proceeds from Issuance or Sale of Equity, Net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock', window );">Adjustments to Additional Paid in Capital, Beneficial Conversion Feature on Preferred Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,284,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atos_The2017PublicOfferingMember', window );">The 2017 Public Offering [Member] | The 2017 Public Offering Class A Units Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atos_The2017PublicOfferingMember', window );">The 2017 Public Offering [Member] | The 2017 Public Offering Class B Units Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | The 2017 Public Offering Over-allotment Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atos_October2017PublicOfferingMember', window );">October 2017 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ProceedsFromIssuanceOrSaleOfEquityNet', window );">Proceeds from Issuance or Sale of Equity, Net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atos_December2017PublicOfferingAndPrivatePlacementMember', window );">December 2017 Public Offering and Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ProceedsFromIssuanceOrSaleOfEquityNet', window );">Proceeds from Issuance or Sale of Equity, Net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atos_December2017PublicOfferingAndPrivatePlacementMember', window );">December 2017 Public Offering and Private Placement [Member] | Class A and Class B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">883,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ClassOfWarrantOrRightExercisablePeriod', window );">Class of Warrant or Right, Exercisable Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atos_The2018SubscriptionRightsOfferingMember', window );">The 2018 Subscription Rights Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_NumberOfUnitsSold', window );">Number of Units Sold</a></td>
<td class="nump">13,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PurchasePriceOfUnit', window );">Purchase Price of Unit | $ / item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock', window );">Adjustments to Additional Paid in Capital, Beneficial Conversion Feature on Preferred Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,782,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PreferredStockDeemedDividend', window );">Preferred Stock, Deemed Dividend | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,479,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_NumberOfUnitsAuthorizedToPurchaseMaximum', window );">Number of Units Authorized to Purchase, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit', window );">Number of Series B Convertible Preferred Stock and Warrant in Each Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ProceedsFromIssuanceOfStockUnits', window );">Proceeds from Issuance of Stock units | $</a></td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,333,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atos_The2018SubscriptionRightsOfferingMember', window );">The 2018 Subscription Rights Offering [Member] | The 2018 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 4.048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="nump">3,869,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost', window );">Warrants Allocated to Common Stock , Net of Issuance Cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,363,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atos_SeriesAJuniorParticipatingPreferredStockMember', window );">Series A Junior Participating Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atos_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PreferredStockDeemedDividend', window );">Preferred Stock, Deemed Dividend | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,568,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atos_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | The 2017 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ConvertiblePreferredStockSharesIssuable', window );">Convertible Preferred Stock, Shares Issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atos_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_StatedValuePerShare', window );">Stated Value per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PreferredStockConvertibleConversionPrice', window );">Preferred Stock, Convertible, Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed', window );">Preferred Stock, Convertible, Ownership Percentage of Company&#8217;s Shares Allowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atos_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member] | The 2018 Subscription Rights Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">13,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atos_ClassAUnitsMember', window );">Class A Units [Member] | The 2017 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_NumberOfUnitsSold', window );">Number of Units Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PurchasePriceOfUnit', window );">Purchase Price of Unit | $ / item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atos_ClassBUnitsMember', window );">Class B Units [Member] | The 2017 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_NumberOfUnitsSold', window );">Number of Units Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PurchasePriceOfUnit', window );">Purchase Price of Unit | $ / item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of convertible preferred stock with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOnPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ClassOfWarrantOrRightCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants cancelled during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ClassOfWarrantOrRightCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ClassOfWarrantOrRightExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period after which warrants become exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ClassOfWarrantOrRightExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership of common stock allowed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_CommonStockConvertibleOwnershipPercentageOfCompanysSharesAllowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of acquired outstanding shares when company consummates a business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of aggregate ordinary voting power of third party when company consummates a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ConvertiblePreferredStockSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ConvertiblePreferredStockSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_LockupPeriodExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in "Lock-up period" under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_LockupPeriodExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of series B convertible preferred stock and warrant in each unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_NumberOfSeriesBConvertiblePreferredStockAndWarrantInEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_NumberOfSharesAuthorizedToIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total number of shares authorized to issue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_NumberOfSharesAuthorizedToIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_NumberOfUnitsAuthorizedToPurchaseMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum number of units authorized to purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_NumberOfUnitsAuthorizedToPurchaseMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_NumberOfUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_NumberOfUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the conversion price of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum ownership percentage of company&#8217;s shares allowed for holder of convertible preferred stock to be able to convert their shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_PreferredStockConvertibleOwnershipPercentageOfCompanysSharesAllowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_PreferredStockDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_PreferredStockDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ProceedsFromIssuanceOfStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ProceedsFromIssuanceOfStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ProceedsFromIssuanceOrSaleOfEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>he cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ProceedsFromIssuanceOrSaleOfEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_PurchasePriceOfUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase price of each unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_PurchasePriceOfUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_StatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the stated value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_StatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional ownership percentage of company&#8217;s common stock required to if that person already own 15% or more of company&#8217;s common stock on date of stockholder rights agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the ownership percentage of company&#8217;s common stock required to become &#8220;Acquiring Person&#8221; under stockholder rights agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_StockholderRightsAgreementAcquiringPersonPercentageOfOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_StockholderRightsAgreementInitialExercisePriceOfEachRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the initial exercise price of each right under stockholder rights agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_StockholderRightsAgreementInitialExercisePriceOfEachRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of preferred stock right distributed for each share of common stock under stockholder rights agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_StockholderRightsAgreementSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of share price that each holder of right can receive by exercising the right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_StockholderRightsAgreementSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of warrants allocated to common stock at the date of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_WarrantsAllocatedToCommonStockNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum volume-weighted-average-price of our common stock required to redeem warrants and rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_WarrantsAndRightsOutstandingRedeemableVolumeWeightedAveragePriceOfOurCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_WarrantsAndRightsOutstandingRedemptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the redemption price of each warrants and rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_WarrantsAndRightsOutstandingRedemptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price equals or exceed certain amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_WarrantsAndRightsRedemptionRightsConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum ownership percentage of company&#8217;s shares allowed for holder of warrants to exercise their warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_WarrantsExercisableOwnershipPercentageOfCompanysSharesAllowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=atos_ConversionOfSeriesAConvertiblePreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=atos_ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atos_The2017PublicOfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atos_The2017PublicOfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atos_The2018WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atos_The2018WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atos_The2017PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atos_The2017PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atos_The2017PublicOfferingClassAUnitsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atos_The2017PublicOfferingClassAUnitsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atos_The2017PublicOfferingOverallotmentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atos_The2017PublicOfferingOverallotmentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atos_October2017PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atos_October2017PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atos_December2017PublicOfferingAndPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atos_December2017PublicOfferingAndPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atos_ClassAAndClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atos_ClassAAndClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atos_The2018SubscriptionRightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atos_The2018SubscriptionRightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atos_SeriesAJuniorParticipatingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atos_SeriesAJuniorParticipatingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atos_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atos_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atos_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atos_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atos_ClassAUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atos_ClassAUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atos_ClassBUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atos_ClassBUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6936667728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity - 2017 Liability Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding as of January 1, 2017 (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding as of January 1, 2017 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ClassOfWarrantOrRightGranted', window );">Warrants granted (in shares) | shares</a></td>
<td class="nump">488,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ClassOfWarrantOrRightGrantedExercisePrice', window );">Warrants granted, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares) | shares</a></td>
<td class="num">(488,611)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ClassOfWarrantOrRightExercisedExercisePrice', window );">Warrants exercised, , exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding as of December 31, 2017 (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding as of December 31, 2017 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ClassOfWarrantOrRightExercisedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit exercised of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ClassOfWarrantOrRightExercisedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ClassOfWarrantOrRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants granted during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ClassOfWarrantOrRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ClassOfWarrantOrRightGrantedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit granted of warrants or rights outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ClassOfWarrantOrRightGrantedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6779576080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity - Inputs Used in Valuation of Warrants (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Apr. 03, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs</a></td>
<td class="nump">3.12<span></span>
</td>
<td class="nump">11.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs</a></td>
<td class="nump">0.0079<span></span>
</td>
<td class="nump">0.0079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs</a></td>
<td class="nump">0.0188<span></span>
</td>
<td class="nump">0.0188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs</a></td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs</a></td>
<td class="nump">4.76<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768311648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity - Schedule of Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Warrants to Purchase Shares (in shares)</a></td>
<td class="nump">3,875,699<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ExpirationDatesOfClassOfWarrantOrRight', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atos_The2014PublicOfferingMember', window );">The 2014 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Warrants to Purchase Shares (in shares)</a></td>
<td class="nump">6,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ExpirationDatesOfClassOfWarrantOrRight', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">January 29, 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atos_The2018WarrantsMember', window );">The 2018 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Warrants to Purchase Shares (in shares)</a></td>
<td class="nump">3,869,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 4.048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ExpirationDatesOfClassOfWarrantOrRight', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">May 30, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ExpirationDatesOfClassOfWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of warrants or rights in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ExpirationDatesOfClassOfWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atos_The2014PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atos_The2014PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atos_The2018WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atos_The2018WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760337760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,404,934)<span></span>
</td>
<td class="num">$ (8,122,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PreferredStockDeemedDividend', window );">Deemed dividend attributable to preferred stock</a></td>
<td class="num">$ (11,479,308)<span></span>
</td>
<td class="num">$ (11,479,308)<span></span>
</td>
<td class="num">(11,479,308)<span></span>
</td>
<td class="num">(2,568,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (15,621,885)<span></span>
</td>
<td class="num">$ (17,496,267)<span></span>
</td>
<td class="num">$ (22,884,242)<span></span>
</td>
<td class="num">$ (10,690,713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,157,746<span></span>
</td>
<td class="nump">974,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share -basic and diluted (in dollars per share)</a></td>
<td class="num">$ (5.08)<span></span>
</td>
<td class="num">$ (6.11)<span></span>
</td>
<td class="num">$ (5.50)<span></span>
</td>
<td class="num">$ (10.97)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_PreferredStockDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_PreferredStockDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768445728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of potential common shares excluded (in shares)</a></td>
<td class="nump">4,317,405<span></span>
</td>
<td class="nump">375,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of potential common shares excluded (in shares)</a></td>
<td class="nump">487,941<span></span>
</td>
<td class="nump">117,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atos_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of potential common shares excluded (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">55,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atos_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of potential common shares excluded (in shares)</a></td>
<td class="nump">774,983<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of potential common shares excluded (in shares)</a></td>
<td class="nump">3,054,481<span></span>
</td>
<td class="nump">202,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atos_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atos_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atos_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atos_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768421264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ReductionInDeferredTaxAssets', window );">Reduction in Deferred Tax Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</a></td>
<td class="nump">12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance, Total</a></td>
<td class="nump">5,312,769<span></span>
</td>
<td class="nump">3,089,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="num">(15,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">$ 58,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2012 2013 2014 2015 2016 2017 2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Earliest Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_OperatingLossCarryforwardsExpirationYear', window );">Operating Loss Carryforwards, Expiration Year</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Latest Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_OperatingLossCarryforwardsExpirationYear', window );">Operating Loss Carryforwards, Expiration Year</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Year of expiration for operating loss carry-forwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ReductionInDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the value of reduction in deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ReductionInDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6922857216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected federal income tax benefit</a></td>
<td class="num">$ (2,395,036)<span></span>
</td>
<td class="num">$ (2,761,678)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">169,957<span></span>
</td>
<td class="nump">197,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other permanent items</a></td>
<td class="nump">1,616<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effect of change in valuation allowance</a></td>
<td class="nump">2,223,463<span></span>
</td>
<td class="num">(15,344,015)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Prior year true-up</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(126,031)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Tax rate change</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,912,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation', window );">Effect of NOL limitation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,119,293<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Actual federal income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents value of effects of net operating loss limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_EffectiveIncomeTaxRateReconciliationEffectOfNolLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6790551936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Obsolete inventory</a></td>
<td class="nump">$ 21,881<span></span>
</td>
<td class="nump">$ 21,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Deferred tax assets, accrued vacation</a></td>
<td class="nump">33,755<span></span>
</td>
<td class="nump">31,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses', window );">Accrued bonuses</a></td>
<td class="nump">99,666<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">968,170<span></span>
</td>
<td class="nump">620,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Basis difference in fixed assets</a></td>
<td class="nump">33,241<span></span>
</td>
<td class="nump">33,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets, net</a></td>
<td class="nump">572,687<span></span>
</td>
<td class="nump">634,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Contribution, carryforward</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,588,401<span></span>
</td>
<td class="nump">747,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss carryforward</a></td>
<td class="nump">1,027,111<span></span>
</td>
<td class="nump">1,027,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(5,312,769)<span></span>
</td>
<td class="num">(3,089,306)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">32,850<span></span>
</td>
<td class="nump">27,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(32,850)<span></span>
</td>
<td class="num">(27,554)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770702448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Concentration of Credit Risk (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="nump">$ 10,052,914<span></span>
</td>
<td class="nump">$ 6,967,469<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6932115808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2018</div></th>
<th class="th"><div>Mar. 23, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Oct. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_OperatingLeaseLesseeMonthlyRentExpense', window );">Operating Lease, Lessee, Monthly Rent Expense</a></td>
<td class="nump">$ 3,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">1 year 300 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Operating Leases, Future Minimum Payments, Due in Two Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating Leases, Rent Expense, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,457<span></span>
</td>
<td class="nump">$ 33,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Loss Contingency, Damages Paid, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=atos_LeaseForCopierSystemMember', window );">Lease for Copier System [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Operating Leases, Future Minimum Payments, Due in Two Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Operating Leases, Future Minimum Payments, Due in Three Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_OperatingLeaseLesseeMonthlyRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of monthly rent expense due from the lessee under the terms of an operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_OperatingLeaseLesseeMonthlyRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=atos_LeaseForCopierSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=atos_LeaseForCopierSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768854864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Jun. 27, 2018</div></th>
<th class="th"><div>Apr. 12, 2018</div></th>
<th class="th"><div>May 09, 2017</div></th>
<th class="th"><div>May 18, 2016</div></th>
<th class="th"><div>Sep. 28, 2010</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,053,496<span></span>
</td>
<td class="nump">$ 786,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,410,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 857,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 182 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member] | Share-based Compensation Award, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member] | Share-based Compensation Award, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member] | Share-based Compensation Award, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member] | Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atos_The2010StockOptionAndIncentivePlanMember', window );">The 2010 Stock Option and Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Period for Granting Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">611,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atos_The2010StockOptionAndIncentivePlanMember', window );">The 2010 Stock Option and Incentive Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="nump">233,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atos_The2010StockOptionAndIncentivePlanMember', window );">The 2010 Stock Option and Incentive Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">11,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">611,668<span></span>
</td>
<td class="nump">143,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="nump">$ 4.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,053,496<span></span>
</td>
<td class="nump">$ 786,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,152,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 164 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period in which shares can be granted from the date of stock-holder approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodForGrantingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atos_The2010StockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atos_The2010StockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6936390176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation - Additional Shares Authorized (Details) - shares<br></strong></div></th>
<th class="th" colspan="7">12 Months Ended</th>
<th class="th" colspan="1">84 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atos_The2010StockOptionAndIncentivePlanMember', window );">The 2010 Stock Option and Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized', window );">Total additional shares (in shares)</a></td>
<td class="nump">106,076<span></span>
</td>
<td class="nump">12,623<span></span>
</td>
<td class="nump">7,257<span></span>
</td>
<td class="nump">5,463<span></span>
</td>
<td class="nump">4,128<span></span>
</td>
<td class="nump">2,871<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
<td class="nump">140,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares automatically authorized for issuance under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAutomaticallyAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atos_The2010StockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atos_The2010StockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6771529840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expense</a></td>
<td class="nump">$ 1,053,496<span></span>
</td>
<td class="nump">$ 786,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expense</a></td>
<td class="nump">809,110<span></span>
</td>
<td class="nump">621,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expense</a></td>
<td class="nump">$ 244,386<span></span>
</td>
<td class="nump">$ 164,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763294064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation - Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years) (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">1.86%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years) (Year)</a></td>
<td class="text">5 years 87 days<span></span>
</td>
<td class="text">5 years 116 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">108.81%<span></span>
</td>
<td class="nump">112.86%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.71%<span></span>
</td>
<td class="nump">2.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years) (Year)</a></td>
<td class="text">5 years 208 days<span></span>
</td>
<td class="text">6 years 131 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">126.43%<span></span>
</td>
<td class="nump">114.19%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average expected volatility rate of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769960320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation - Stock Option Activity (Details) - The 2010 Stock Option and Incentive Plan [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, shares (in shares) | shares</a></td>
<td class="nump">172,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 49.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares (in shares) | shares</a></td>
<td class="nump">611,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, shares (in shares) | shares</a></td>
<td class="num">(795)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 562.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, shares (in shares) | shares</a></td>
<td class="nump">783,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average contractual life remaining in years (Year)</a></td>
<td class="text">9 years 62 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, shares (in shares) | shares</a></td>
<td class="nump">317,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 24.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average contractual life remaining in years (Year)</a></td>
<td class="text">8 years 354 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, shares (in shares) | shares</a></td>
<td class="nump">783,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, Weighted average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted average contractual life remaining in years (Year)</a></td>
<td class="text">9 years 62 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atos_The2010StockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atos_The2010StockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6931082384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation - Compensation Expense Related to Liability Grants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expense</a></td>
<td class="nump">$ 1,053,496<span></span>
</td>
<td class="nump">$ 786,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expense</a></td>
<td class="nump">1,410,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Liability Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expense</a></td>
<td class="nump">869,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Liability Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expense</a></td>
<td class="nump">$ 540,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763343616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation - Valuation Assumptions for Liability Options (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years) (Year)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.51%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years) (Year)</a></td>
<td class="text">4 years 182 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share)</a></td>
<td class="nump">$ 1.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">122.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.94%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years) (Year)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share)</a></td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">125.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6937964816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PreferredStockDeemedDividend', window );">Preferred Stock, Deemed Dividend</a></td>
<td class="nump">$ 11,479,308<span></span>
</td>
<td class="nump">$ 11,479,308<span></span>
</td>
<td class="nump">$ 11,479,308<span></span>
</td>
<td class="nump">$ 2,568,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atos_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_DeemedDividendOnSeriesBConvertiblePreferredStock', window );">Deemed Dividend on Series B Convertible Preferred Stock</a></td>
<td class="nump">11,479,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PreferredStockDeemedDividend', window );">Preferred Stock, Deemed Dividend</a></td>
<td class="nump">4,782,100<span></span>
</td>
<td class="nump">$ 4,782,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PreferredStockDeemedDividend', window );">Preferred Stock, Deemed Dividend</a></td>
<td class="nump">$ 4,782,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_DeemedDividendOnSeriesBConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend on Series B Convertible Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_DeemedDividendOnSeriesBConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_PreferredStockDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_PreferredStockDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atos_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atos_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6768040480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PreferredStockDeemedDividend', window );">Deemed dividend attributable to preferred stock</a></td>
<td class="num">$ (11,479,308)<span></span>
</td>
<td class="num">$ (11,479,308)<span></span>
</td>
<td class="num">$ (11,479,308)<span></span>
</td>
<td class="num">$ (2,568,132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common stockholders</a></td>
<td class="num">$ (15,621,885)<span></span>
</td>
<td class="num">$ (17,496,267)<span></span>
</td>
<td class="num">$ (22,884,242)<span></span>
</td>
<td class="num">$ (10,690,713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share -basic and diluted (in dollars per share)</a></td>
<td class="num">$ (5.08)<span></span>
</td>
<td class="num">$ (6.11)<span></span>
</td>
<td class="num">$ (5.50)<span></span>
</td>
<td class="num">$ (10.97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series B convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=atos_AdditionalPaidInCapitalConvertiblePreferredStockMember', window );">Additional Paid in Capital, Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 6,926,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_DividendOnSeriesConvertiblePreferredStock', window );">Deemed Dividend on Series B convertible preferred stock</a></td>
<td class="nump">11,479,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series B convertible preferred stock to common stock</a></td>
<td class="num">(7,821,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=atos_AdditionalPaidInCapitalCommonStockMember', window );">Additional Paid in Capital, Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,363,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_DividendOnSeriesConvertiblePreferredStock', window );">Deemed Dividend on Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,479,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series B convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,422,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_PreferredStockDeemedDividend', window );">Deemed dividend attributable to preferred stock</a></td>
<td class="num">(4,782,100)<span></span>
</td>
<td class="num">(4,782,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common stockholders</a></td>
<td class="num">$ (8,924,677)<span></span>
</td>
<td class="num">$ (10,799,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share -basic and diluted (in dollars per share)</a></td>
<td class="num">$ (2.90)<span></span>
</td>
<td class="num">$ (3.77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Additional Paid in Capital, Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 12,290,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_DividendOnSeriesConvertiblePreferredStock', window );">Deemed Dividend on Series B convertible preferred stock</a></td>
<td class="nump">4,782,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series B convertible preferred stock to common stock</a></td>
<td class="num">$ (7,056,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Additional Paid in Capital, Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_DividendOnSeriesConvertiblePreferredStock', window );">Deemed Dividend on Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,782,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series B convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,656,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_DividendOnSeriesConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the amount related to dividend on series A convertible preferred stock incurred during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_DividendOnSeriesConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_PreferredStockDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_PreferredStockDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=atos_AdditionalPaidInCapitalConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=atos_AdditionalPaidInCapitalConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=atos_AdditionalPaidInCapitalCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=atos_AdditionalPaidInCapitalCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769665520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Subsequent Events (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 13, 2019</div></th>
<th class="th"><div>Jun. 27, 2018</div></th>
<th class="th"><div>Jun. 29, 2017</div></th>
<th class="th"><div>Mar. 25, 2019</div></th>
<th class="th"><div>Mar. 24, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 749,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atos_ClassOfWarrantOrRightRetired', window );">Class of Warrant or Right, Retired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member] | Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember', window );">Liability Options [Member] | Chief Financial Officer [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_The2019OptionsMember', window );">The 2019 Options [Member[</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_The2019OptionsMember', window );">The 2019 Options [Member[ | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_The2019OptionsMember', window );">The 2019 Options [Member[ | Chief Executive Officer [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atos_The2019OptionsMember', window );">The 2019 Options [Member[ | Chief Financial Officer [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atos_ClassOfWarrantOrRightRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atos_ClassOfWarrantOrRightRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atos_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=atos_LiabilityOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=atos_The2019OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=atos_The2019OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O(NP&8W?V'QN?!54+O^Y"?0%02P,$%     @  81\3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M(YC87O "0*&].;C3""92R"A> RAT. ]+&8:)U#*&5P$&'<[#:H9A(N6,X56
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M!Y,#YXKI=/&#3G329]5A4+&#,K=$WXONP-8-%&_[PV@TG(C7_P%02P,$%
M  @  81\3E]OH#8R P  50P  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6R-EV]OFS 0QK\*XOT"_@.VJR12DVG:I$VJ.FU[31,G006<@=-TWWZVH2GQ
MF6QO C;/^7YW(4^O\[-JG[N#E#IZK:NF6\0'K8]W2=)M#K(NNIDZRL8\V:FV
M+K19MOND.[:RV+J@NDIPFN9)791-O)R[O8=V.5<G796-?&BC[E371?MG)2MU
M7L0H?MMX+/<';3>2Y?Q8[.5WJ7\<'UJS2BZG;,M:-EVIFJB5NT5\C^[6B-L
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MG5YT[<OX3:W%Y>MB]_\"4$L#!!0    (  &$?$YT2XF.!@(  #@%   8
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&ULC53MCML@$'P5Y <X8F.3-'(L75)5
MK=1*T56]_B;.)K8.C LDOKY]^?#YW 15_6-@F9F=Q2SE(-6+;@ ,>A6\TYND
M,:9?8ZSK!@33#[*'SNZ<I!+,V*4Z8]TK8$=/$AQGBP7%@K5=4I4^ME=5*2^&
MMQWL%=(7(9CZO04NATV2)F^!I_;<&!? 5=FS,WP'\Z/?*[O"D\JQ%=#I5G9(
MP6F3/*;K'75X#WAN8="S.7*5'*1\<8LOQTVR<(: 0VV< K/#%7; N1.R-GZ-
MFLF4TA'G\S?U3[YV6\N!:=A)_K,]FF:3K!)TA!.[</,DA\\PUE,D:"S^*UR!
M6[AS8G/4DFO_1?5%&RE&%6M%L-<PMIT?A["S+$9:G)"-A&PBI/2?!#(2R#LA
M]\4'9[[4C\RPJE1R0"K\K)ZY.Y&NB3W,V@7]V?D]6ZVVT6N5DJ+$5R<T8K8!
MD\TQ$P);]2E%%DNQS>[HV=\)=O<(LHIG(-$BB.?G<X,+$A?(HP+YO0"A-R8#
MAGI,YS&T6*4TGJ:(IBDB:98WAUW<I4D)(7G^X<9.P!4SW)*N\C2+^Z%1/_0_
MRJ9W?C*ZS,CM#<"S"R= G7UO:E3+2V?<KYU%I_9_S-R%O8EO[;,0NOA=)KPI
MWY@ZMYU&!VEL._A+>Y+2@'6Y>+ 'T=AG;%IP.!DWM6V'5&CFL#"R']\I/#V6
MU1]02P,$%     @  81\3I#3$:>(!   /14  !@   !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q]F-%NXS8017_%\'M6G!E2(@/'0.RB:($6"+9H^ZS83&RL
M9+F2$F__OI2L>!7.L"^V)%\.[U#TX9"K2]-^ZP[>]XOO=77J'I:'OC_?9UFW
M._BZ[+XT9W\*O[PT;5WVX;9]S;ISZ\O]V*BN,E0JS^KR>%JN5^.SIW:]:M[Z
MZGCR3^VB>ZOKLOUWXZOF\K"$Y<>#K\?70S\\R-:K<_GJ__#]G^>G-MQEMRC[
M8^U/W;$Y+5K_\K!\A/LM%4.#4?'7T5^ZV?5B2.6Y:;X--[_N'Y9J<.0KO^N'
M$&7X>O=;7U5#I.#CGRGH\M;GT'!^_1']YS'YD,QSV?EM4_U]W/>'AZ5=+O;^
MI7RK^J_-Y1<_)626BRG[W_R[KX)\<!+ZV#55-WXN=F]=W]13E&"E+K]?OX^G
M\?LRQ?]H)C? J0'>&D#^OPUH:D _&N@Q^:NS,=6?RKY<K]KFLFBO;^M<#I,"
M[BD,YFYX.([=^%O(M@M/W]= =I6]#X$FS>:JP;GFILA"]%L7*'6Q0=8</W>P
MY8J9AT\]D)@$C>WI4Q).#J#% 'H,H&<!G(H&X2K)1\EIE-P!:*4=Z2@;06D!
MT=C$J!G1DN$Y:24'R,4 .<L)*$[JJC$SJZ ,:9='*7%=87-C$GX*T4_!_6B(
M_'"-,9&5@ELN<F=D)U9T8EDO-IJ1&\MZB89NRQ4ZAP(21IQHQ E#$CMQO!\-
MKHC<<!6@=4[+;D#)+%!\8$S, JYAKVC2S-V@584N$FX29 +N)H_=< UW WQL
M'%I(N1$A]@@HO"N*[2#O2H-2R#SQ:"8Q<T!&'@C,TZG7+4,/./78[)LT\XSN
M LFL=7%&@K (;*2$)1EZ8+@E-LB&]P3&6838DB D8[%(O7F9H\!!JMD**0!2
MDV*.N.S.*JT2BQW(( 6!DC%(0<"DU1AC0Y!9E5RH0,8I<)X:]M(X+L$H5!0;
M$G1A.4H-D(Q5X%PU;&)S8MK<Y6Q:<UE!\W7K<_TC<Q4%9L8D0X&96JL8'(+,
M:9.R(X,5.31!QYQ'3LT[ZW+(V=],4N;&D4N5!R@3%E$@6IX((4,12<BLB#,C
M@1^@G(J+'B%:"M(H$Q8Y88&Q P5RRGYXM*0?&:\H%96)0AEE&J)05IJXK$2A
MKD1TRL2<V@KADCG)-$2AKF0X%$2L3D#.0K(%Y)2:@S(-D=,0&'T$$??#45AH
MAY1845%F(0HU)J.S(.)V. D'&H1:(+%3DUE(G(5@HAW4ACCE$O-'4JK"DC:)
M19YD)I+ Q'@(-L1)1PA68;P#%(0:; !BRI1,1!)J3K9P$*\Y"RQ0LZ5,$)*R
MZ'),F$KLM07&FIBQQ!D+8:L\[)9C5UP9V__L2B8M:4XVDYJ9,AR)UYZAK(P3
MXR+V3R%>=Q(EUD*2*4LY3R=/A9"Y2 (7D:53L+.*,/KQV<=6DKFPL8D,9;-#
MI]JWK^/Y7+?8-6^G?CC>F3V]G0$^XG!H%3W?P/WV>I+W(\SU8/'WLGT]GKK%
M<]/W33T>7+TT3>^#2_4EC/C!E_O;3>5?^N&R"-?M]4#O>M,WY^FP,KN=F*[_
M U!+ P04    "  !A'Q.\M!Q+[8!  #2 P  &    'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;'53VV[<(!#]%<0'A/6E:;2R+6535:W42JM4;9]9>VRC .,"
M7J=_7\".ZZ3N"S##G#-GAJ&8T#S9'L"19R6U+6GOW'!DS-8]*&YO< #M;UHT
MBCMOFH[9P0!O(DA)EAX.MTQQH6E51-_95 6.3@H-9T/LJ!0WOT\@<2II0E\<
MCZ+K77"PJAAX!]_ ?1_.QEML96F$ FT%:F*@+>E]<CSE(3X&_! PV<V9A$HN
MB$_!^-R4]! $@83:!0;NMRL\@)2!R,OXM7#2-64 ;L\O[!]C[;Z6"[?P@/*G
M:%Q?TCM*&FCY*-TC3I]@J><=)4OQ7^ *TH<')3Y'C=+&E=2C=:@6%B]%\>=Y
M%SKNTWR3Y0ML'Y N@'0%W,4\;$X4E7_@CE>%P8F8N?<##T^<'%/?FSHX8ROB
MG1=OO?=:);=)P:Z!:(DYS3'I-F:-8)Y]39'NI3BE_\#3?7BVJS"+\.R5PO\0
MY+L$>23(7Q%D;TK<B\G?)&&;GBHP79PF2VH<=9SDC7<=V/LTOLG?\'G:OW+3
M"6W)!9U_V=C_%M&!EW*X\2/4^P^V&A):%X[O_=G,8S8;#H?E!['U&U=_ %!+
M P04    "  !A'Q.^*#5G[8!  #2 P  &    'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;'53VV[<(!#]%<0'A+7WDFAE6\HFBEJIE5:IVCZS]MA& <8%O$[_
MOH =UTG=%V"&.6?.#$,VH'FQ+8 CKTIJF]/6N>[(F"U;4-S>8 ?:W]1H%'?>
M- VSG0%>19"2+-UL#DQQH6F11=_9%!GV3@H-9T-LKQ0WOT\@<<AI0M\<SZ)I
M77"P(NMX ]_ ?>_.QEML9JF$ FT%:F*@SNE]<CSM0GP,^"%@L(LS"95<$%^"
M\;G*Z28( @FE"PS<;U=X "D#D9?Q:^*D<\H 7)[?V)]B[;Z6"[?P@/*GJ%R;
MTSM**JAY+]TS#I]@JF=/R53\%[B"].%!B<]1HK1Q)65O':J)Q4M1_'7<A8[[
M,-[LDPFV#D@G0#H#[F(>-B:*RA^YXT5F<"!F['W'PQ,GQ]3WI@S.V(IXY\5;
M[[T6R6&?L6L@FF).8TRZC)DCF&>?4Z1K*4[I/_!T';Y=5;B-\.T[A?\AV*T2
M["+![AW!X4.):S&W'Y*P14\5F"9.DR4E]CI.\L([#^Q]&M_D;_@X[5^Y:82V
MY(+.OVSL?XWHP$O9W/@1:OT'FPT)M0O'6W\VXYB-AL-N^D%L_L;%'U!+ P04
M    "  !A'Q.*HT^CK@!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6QU4]MNW" 0_17$!P2;W62W*]M2-E652HVT2M7VF;7'-@H7!_ Z^?L"
M=EPG=5Z &>:<.3,,V:#-DVT!''J10MD<M\YU!T)LV8)D]DIWH/Q-K8UDSINF
M(;8SP*H(DH+0)+DADG&%BRSZ3J;(=.\$5W RR/92,O-Z!*&''*?XS?'(F]8%
M!RFRCC7P$]RO[F2\16:6BDM0EFN%#-0YODT/QVV(CP&_.0QV<4:ADK/63\'X
M7N4X"8) 0.D" _/;!>Y B$#D93Q/G'A.&8#+\QO[MUB[K^7,+-QI\8=7KLWQ
M'J,*:M8+]ZB'>YCJN<9H*OX'7$#X\*#$YRBUL'%%96^=EA.+ER+9R[AS%?=A
MO-FE$VP=0"< G0'[F(>,B:+RK\RQ(C-Z0&;L?<?"$Z<'ZGM3!F=L1;SSXJWW
M7HKT9I^12R":8HYC#%W&S!'$L\\IZ%J*(_T/3M?AFU6%FPC?O%/X"<%VE6 ;
M";;O"+Y\*'$E9I=\2$(6/95@FCA-%I6Z5W&2%]YY8&]I?)-_X>.T/S#3<&71
M63O_LK'_M=8.O)3DRH]0ZS_8; BH73CN_-F,8S8:3G?3#R+S-R[^ E!+ P04
M    "  !A'Q.[':B5K8!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6QU4]MNW" 0_17$!X0UZR;1RK:4356U4B.M$K5]9NWQ10'&!;Q._CZ
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M_F5C_VM$!SZ5W94?H=9_L,604+MPO/%G,XW99#CLYQ_$EF]<O %02P,$%
M  @  81\3NLP3(VV 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL=5/;;IPP$/T5RQ\0[[)D$ZT *9LH:J566J5J^^R% :SX0FVSI'_?L6$)
M3>F+[1F?<^;B<388^^I: $_>E-0NIZWWW8$Q5[:@N+LQ'6B\J8U5W*-I&^8Z
M"[R*)"59LMGLF>)"TR*+OI,M,M-[*32<+'&]4MS^/H(T0TZW].IX$4WK@X,5
M6<<;^ ;^>W>R:+%9I1(*M!-&$PMU3A^VAV,:\!'P0\#@%F<2*CD;\QJ,SU5.
M-R$AD%#ZH,!QN\ C2!F$,(U?DR:=0P;B\GQ5?XZU8RUG[N#1R)^B\FU.[RFI
MH.:]]"]F^ 13/;>43,5_@0M(A(=,,$9II(LK*7OGC9I4,!7%W\9=Z+@/X\WN
M2ELG)!,AF0GWD<#&0#'S)^YYD5DS$#OVON/AB;>'!'M3!F=L1;S#Y!UZ+\7V
M+LW8)0A-F..(29:8&<%0?0Z1K(4X)O_0DW7Z;C7#7:3OEM'W_Q%(5P72*)#^
M5>+MAQ+7,/L/0=BBIPIL$Z?)D=+T.D[RPCL/[$,2W^0=/D[[5VX;H1TY&X\O
M&_M?&^,!4]G<X BU^,%F0T+MP_$.SW8<L]'PIIM^$)N_<?$'4$L#!!0    (
M  &$?$X?Q/]EMP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;'53VXZ;,!#]%<L?L$Y(-DDC0-IL5;52*T5;=?OLP #6^D)M$[9_W[$AE&[9
M%]LS/N?,Q>.T-_;%-0">O"JI748;[]LC8ZYH0'%W9UK0>%,9J[A'T];,M19X
M&4E*LF2UVC'%A:9Y&GUGFZ>F\U)H.%OB.J6X_7T":?J,KNG-\23JQ@<'R].6
MU_ =_(_V;-%BDTHI%&@GC"86JHP^K(^G;<!'P+. WLW.)%1R,>8E&%_*C*Y"
M0B"A\$&!XW:%1Y R"&$:OT9-.H4,Q/GYIOXIUHZU7+B#1R-_BM(W&3U04D+%
M.^F?3/\9QGKN*1F+_PI7D @/F6",PD@75U)TSALUJF JBK\.N]!Q[X>;W8VV
M3$A&0C(1#I' AD Q\X_<\SRUIB=VZ'W+PQ.OCPGVI@C.V(IXA\D[]%[S]7Z?
MLFL0&C&G 9/,,1."H?H4(ED*<4K^HR?+],UBAIM(W\RC[]X1V"X*;*/ ]I\2
M#V]*7,)\>!.$S7JJP-9QFAPI3*?C),^\T\ ^)/%-_L*':?_&;2VT(Q?C\65C
M_RMC/& JJSL<H08_V&1(J'PX[O%LAS$;#&_:\0>QZ1OG?P!02P,$%     @
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M_H/-AH3:A>,7?S;CF(V&PV[Z06S^QL5?4$L#!!0    (  &$?$Z+>C8LMP$
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MMA@*:A^.'_!LIS&;#&_Z^0>QY1L7?P!02P,$%     @  81\3BNU[BBW 0
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MLB3=K  IFRAJI59:I6KZ[(4!K/A";;.D?]^Q(90F],7VC,\Y<_$X&XQ]<2V
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M-AL2:A^.G_!LQS$;#6^ZZ0>Q^1L7?P!02P,$%     @  81\3A/1/0RV 0
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MH?H<@J^%./)/=+Y.WZYFN(WT[3+Z_C\"NU6!7138O2N1?RAQ#;/]$(0M>JK
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MQ=MF7+/1<;J;7A"9GW'Q!U!+ P04    "  !A'Q. "NG:+@!  #2 P  &0
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M_-E,8S89#OOY!['E&Q>_ 5!+ P04    "  !A'Q.I=9"<3H"  #4!P  &0
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M\6((J*W?[MU>3V]Y,JSJYS$ER[^B^ M02P,$%     @  81\3OF'?7H: @
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M++<4,XB$A$@("&OJ-\F'$%@1QF:S1#1)2I*D!(GM+2F>HY38*BG^<D3HW"K
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MDW/J.$!)DH&.MGU<E6YM+ZM27#5O>[:7D;IV'95_=XR+<1O#^&WAJ;TTVBZ
MJASHA?UD^M>PE\8"2Y13V[%>M:*/)#MOXT_PL<ZMW@F>6S:JNWED*SD(\6*-
M;Z=MG%@@QME1VPC4##=6,\YM((/Q9XX9+RFMX_W\+?H75[NIY4 5JP7_W9YT
MLXV+.#JQ,[UR_23&KVRNA\317/QW=F/<R"V)R7$47+G?Z'A56G1S%(/2T==I
M;'LWCM-.GL]N80<T.Z#% :;_=<"S _8<P$3F2OU,-:U**<9(3I<U4/LFX",V
MAWFTB^[LW)ZI5IG56X514H*;#31K=I,&W6G0>T6]5N!BD0 #L%"@( 5R_ND[
M"NA13)K,:7JG@5E"\LQ#"<@024@6QL%!'!S \4K>31IREP?!(MEX9U>O0Q$2
M1DF#*&D !7LHZ0H%PB39I![*6K;)\^*#>R)!&A*@\=+LR)HFRV'AP014*8(?
MP&1!F"P 0SR8;)4FQ<03U6L1Q$6!PBQYD"4/L'@O<Y>O7B9)-@7V;K->R\S[
MW:2IAP/NOG#;<7]0>6E[%1V$-LW"?=)G(30S(9,'4UMCFOQB<';6=IJ;N9Q:
MW61H,<Q='"Q_)=4_4$L#!!0    (  &$?$[#YG]J=P(  /8'   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;(U5[8Z;,!!\%<0#',9\F8@@78BJ5FJE
MZ*JVOQWB!'2 J>V$Z]O7-H00\$7Y$^S-S.RL;>TF'67OO"!$6!]UU?"U70C1
MKAR'YP6I,7^A+6GD/T?*:BSDEIT<WC*"#YI45PX$('1J7#9VFNC8CJ4)/8NJ
M;,B.6?Q<UYC]VY"*=FO;M:^!M_)4"!5PTJ3%)_*3B%_MCLF=,ZH<RIHTO*2-
MQ<AQ;;^ZJZT+%$$C?I>DXY.UI4K94_JN-M\.:QLH1Z0BN5 26'XN)"-5I92D
MC[^#J#WF5,3I^JK^11<OB]EC3C):_2D/HEC;R+8.Y(C/E7BCW5<R%!38UE#]
M=W(AE80K)S)'3BNN?ZW\S 6M!Q5II<8?_;=L]+<;]*\T,P$.!#@2W/ AP1L(
MWHW@/R3X \&_$3Q]6GTI^FRV6. T8;2S6'^]+5:OR%WY\O1S%=2'K?^3Q\-E
M]))Z,$J<BQ(:,)L> R<8=T0X4GU, 4TI-G!!A_<)LB7"0_>0K0$"D=F%9RS4
MTP+^G4 \*[3'A!K3:(P/01PC=^9WB8/2#4"1V9!O-.0O#7E@9JC'!)-$;A C
M./>SA'D!@M$G=@*CG<!@9Y9G$RSR!"X"\>RNLB7LD9W0:"<TV(%F@<@H$!D$
MO-FCZC'1Q"AX\;W G 89TZ GGA5:G <*7 !FEYT98-"?PN[LQ$8[\1./*EY>
M3P26=@RP 'UJ1_9^8WL!3SRK 13.WM7"D0'G^@9+SJ3YU82=]&#A5D[/C5 ]
M9!(=A]<K5,US%M^XJZP?03>9?B+^P.Q4-MS:4R%;LVZ@1TH%D3;!BSRS0@[A
M<5.1HU#+2*Y9/XGZC:#M,&6=<=2G_P%02P,$%     @  81\3O\O_RSX 0
M0 4  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL?93MCIP@%(9OQ7@!
MB]\Z$S7IVC1MTB:3;;K]S>B9T2R(!6;<WGT!'>,JZ1^!PWM>GH- /C+^)EH
MZ;Q3THO";:4<C@B)N@6*Q1,;H%<S%\8IEFK(KT@,''!CDBA!@><EB.*N=\O<
MQ$Z\S-E-DJZ'$W?$C5+,_SX#86/A^NXC\-)=6ZD#J,P'?(6?('\-)ZY&:'%I
M.@J]Z%CO<+@4[B?_6,5:;P2O'8QBU7=T)6?&WO3@6U.XG@8" K74#E@U=ZB
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MQE^>WC^MN1#0N3#][.=FNF!3X?20W@Z9'W#]#U!+ P04    "  !A'Q.XUY
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M$2\%0OR B"\7#X "3200U@?-^B OP>,6-"Q-$ BK@V9U,$Y:<LJ2-2>1[(9
MR!\T^8.1AZH 0CI;/):&T=0/AE _$.H'3?U@!!^O6M#AL3:$OK01(7_0O XF
M26-)GZ%KGS$B  $)0)#&M #$Z+TGI@C]@Z9_,%F:*OK*MSZLF,1V%Q&!H/D=
M#,N9$7Y'1%W![ZNH WO/VD3"\ @8SC9Z)-R-B+MJN'_O/!X)>2,@+^V#$#.B
MM(+8>N];T.%XBS]<WG9:&A:"/4C@=4?$LJ2 YM;)$46E?O'$L:U%.!X!QRW;
M,X2Z45,7^%M3MV]A"'4CB-SRZ'/5@CIAP9XX<J.)A+@1!69E"H!87C$1=B?
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M<9ZGX2O'G3HYJ8,3+SA6D\\X8;C"B1N3.3&9 Y,L,-E-.1_>JB=W@G('*%V
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M/HXGQB15="IR7"=7YZ6N4]*3U,U$M7E[:&@[DC7V0.1UI[+-/U!+ P04
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M:]F-IFZC1=N/W6B8_:O_4$L#!!0    (  &$?$Z^%S0%P (  $<*   9
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M]/\EO0)$!%WB7.A(Z(JJ]J)1O6%\MHYC$MP)$-0*PL+VHG,2HK/TPCY%<#=
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M"XHI(4S@0 (&$O- ,7$"#1HQ#D29(,2S)!(&DB 0=0+)646I2&3"<9P$QDE
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M09W>$R$<BRC=)Q%@)EZ]KE/@$Y?-2+1I>_>W'4YJ_:PYW=N:_ -02P,$%
M  @  81\3NHJ-'8: @  R 4  !D   !X;"]W;W)K<VAE971S+W-H965T-30N
M>&ULC53MCILP$'P5Q ,<8,!P$4&ZI*I:J96BJ]K^=L@FH#.8VDZXOGW]03@*
M;G5_L'>9G9TQ>(N!\1=1 TCOM:6=V/JUE/TF"$150TO$ ^NA4V_.C+=$JI!?
M M%S("=3U-( A2$.6M)T?EF8W(&7!;M*VG1PX)ZXMBWAOW= V;#U(_^>>&XN
MM=2)H"QZ<H%O(+_W!ZZB8&(Y-2UTHF&=Q^&\]9^BS3[3> /XT< @9GM/.SDR
M]J*#SZ>M'VI!0*&2FH&HY09[H%03*1F_1DY_:JD+Y_L[^T?C77DY$@%[1G\V
M)UEO_=SW3G F5RJ?V? )1C^I[XWFO\ -J()K):I'Q:@P3Z^Z"LG:D45):<FK
M79O.K,/(?R]S%Z"Q $T%$?YO03P6Q&\%B3%OE1FK'X@D9<'9X''[L7JB_XEH
M$ZO#K'32G)UYI]P*E;V5:8:*X*:)1LS.8M ,$TV(0+%/+9"KQ0ZMRA<-]FM$
MG+L[Q$X3L:E/_C(1+TQ8##:8SIH(TSAYQ LM:UR6XS0-W7H2IY[$H2=Q$Z1.
M@O0=ABPFG0G-P\<H"A=^UC",(HS_<;[8*0<[Y*1N@LQ)D+W#3[8Z>)0D<;[\
M/FM8A),\1PLYP>P"M, O9E8(KV+73NI?;9:=QM$3TA=HD=^I,66GRAN-G7%?
M";\TG?".3*KK:2[1F3$)2F7XH Z\5F-U"BB<I=YF:L_M<+&!9/TX-X-I>)=_
M %!+ P04    "  !A'Q."'J!%$ "  "^!P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6R-5=N.VR 0_17+'[#XDOBR<BQM4E6MU$K15MT^$V<26XN-
M"R3>_GT!>]TLF51Y,3"<.7,&\$PQ</$J:P#EO;6LDRN_5JI_)$16-;14/O >
M.KUSX**E2B_%D<A> -U;IY:1* @2TM*F\\O"VK:B+/A)L::#K?#DJ6VI^+,&
MQH>5'_KOAN?F6"MC(&71TR/\ /6SWPJ](C/+OFFADPWO/ &'E?\4/FY"ZV 1
M+PT,\F+NF51VG+^:Q=?]R@^,(F!0*4-!]7"&#3!FF+2.WQ.I/\<TCI?S=_;/
M-GF=S(Y*V'#VJ]FK>N5GOK>' STQ]<R'+S EM/2]*?MO< :FX4:)CE%Q)NW7
MJTY2\79BT5):^C:.36?'8=Q)\LD-=X@FAVAV"-/_.L230^PXD%&93?435;0L
M!!\\,=Y63\VC"!]C?9B5,=JSLWLZ6ZFMYW*9)@4Y&Z()LQXQT04FG!%$L\\A
M(BS$.KIRCSX&V%PCX@R/$*-)Q-9_\2&)U$GB&A,'"SS( @VR0(+<4+E$"98(
M0>ZH1#!9X)P6AKEQ(0DJ)+GCN!!,YEX;AHEQ(2DJ)$4(%HX0#+-TA&"8!!>2
MH4(RA"#%"7*4(+_C;A%,ECF98)@<%Q(&^ \=W'&[&"AWWQD*NO'0PAO5);SC
MAC%0[KXU%.0^-G)1]5H01]L@I%?Q4Z=,?;FPSDWH*3)5T[&O37.RU?0?S=C9
MOE-Q;#KI[;C2-=E6S@/G"K3&X$'_F;5NIO."P4&9::KG8NPHXT+Q?NJ69&[9
MY5]02P,$%     @  81\3I(8SBR> @  3@D  !D   !X;"]W;W)K<VAE971S
M+W-H965T-38N>&ULC991;YLP$,>_"N)]P39@H$HB)9VF3=JDJ-.V9S=Q$E3
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MML/,C&77\;J)%DW?S:/A+\7N'U!+ P04    "  !A'Q.MSZ/BTT"  "0!P
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M=4/.7DHEM)_A3*?CJ"?KZT<A]JI]Y?J][L?+_D/)DQF=@^O\OOP?4$L#!!0
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MF!_0E--"Q!=U<#)GZ3WOM#89A$?%RVOZF-:H-NS($O7!@SR WO-0D[V0AYW
M!''\OVP6CZ()_LM\>$U;/BKVAR!=1P"[I9!QLLJ+;,//F\#X"(-4+^&E.>PN
MR1D<$"[C]2*:J37@>6,D,0 .$"B8*PKKT!^.\A':1T4*N(;AR_,X7I+GTSXH
M[H>8U5FZ6O/ 48H1E> M'SNZA;<0Y#&D#9<IA3FQG(A-9\"AD6QS5DRG"1L&
M?X)!UX2$CCP3W,#ZF73$VP7?;X 53F[H=+JP\;H]Y8";XBLFEI,E2NFQTIEA
M\O%RO4@?XYA'VB*C ["_B!YY;+LZOPX;PACR+TYAT 4HNXSOX]4FYMATB/L
MQ%.L_1"T\Q3816ZN4H'GB,%".5V44.9:'KU4L''(F^#_EMVKQ#4<:0&=R LR
M5[0G-]OB^@5A00*I9"]$+W+>7Z'SOB*B13(8$@%/=_\S@."8RUQ$!BM4\)$M
M8R ]T/$GT0J$"_Z3AR%/7/'$$%07"869SF. M"6Y3+@A@0P62-MB8F?7<?&
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M&SQ>;_!XO<'C]0:/UQL\=K[!HZ&>JW:]P$[$^/5*D'^.*T$L-RM7;PBA:Q-
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MIW39I]-DX Y6T%[W=.GJ$C?,RAG[0L?2&<,.0HX[8 X8KJ95F?%T8HR&OHT
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M+OEG^*<U,[AS>3^EZV=<IGZZ?Z9TF;:D</F\^M]RF?HG(LPK\O-O4$L#!!0
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M15:-(JM&D56CR#I%D75Z0EF'8]Z:NOLMR8NUJ\_Y;/B/T<T[4$L! A0#%
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  &$?$[-@=CLPP(  # +   8
M          "  ?@(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  !A'Q.I[W)U.H#  !7$0  &               @ 'Q"P  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @  81\3E#') BN @  '0L
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M965T-RYX;6Q02P$"% ,4    "  !A'Q.\M!Q+[8!  #2 P  &
M    @ ',)0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M 81\3OB@U9^V 0  T@,  !@              ( !N"<  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  &$?$XJC3Z.N $  -(#   9
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M970Q-"YX;6Q02P$"% ,4    "  !A'Q.^31PR;<!  #2 P  &0
M    @ %$,P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M  &$?$Y7V#M/M@$  -(#   9              "  3(U  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @  81\3EO;PWRV 0  T@,  !D
M             ( !'S<  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    "  !A'Q.BWHV++<!  #2 P  &0              @ $,.0  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  &$?$XKM>XHMP$
M -(#   9              "  ?HZ  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @  81\3NJH#IZY 0  T@,  !D              ( !
MZ#P  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  !A'Q.
M$]$]#+8!  #2 P  &0              @ '8/@  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    (  &$?$Y^<$CNLP$  -(#   9
M      "  <5   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @  81\3@ KIVBX 0  T@,  !D              ( !KT(  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  !A'Q.I=9"<3H"  #4!P
M&0              @ &>1   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    (  &$?$ZP7XA*LP$  -(#   9              "  0]'  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @  81\3O7NP86X
M 0  T@,  !D              ( !^4@  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    "  !A'Q.*Z2$Y;(!  #2 P  &0
M@ 'H2@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  &$
M?$YOYZ#%Y0$  !X%   9              "  =%,  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @  81\3A__AD'! 0  -P0  !D
M         ( ![4X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    "  !A'Q.[X;FV<8!   W!   &0              @ 'E4   >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  &$?$[YAWUZ&@(  -H&
M   9              "  >)2  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @  81\3C ++*.S 0  T@,  !D              ( !,U4
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  !A'Q.9;A-
M%)4"  !L"   &0              @ $=5P  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    (  &$?$Y*+0.290,  %P/   9
M  "  >E9  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M 81\3E(V7$ZK 0  E ,  !D              ( !A5T  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    "  !A'Q.7\' &BH"  !6!@  &0
M            @ %G7P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    (  &$?$[#YG]J=P(  /8'   9              "  <AA  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @  81\3O\O_RSX 0
M0 4  !D              ( !=F0  'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    "  !A'Q.UZL9\ZH!  #, P  &0              @ &E
M9@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  &$?$[C
M7D#>]P$  #$%   9              "  89H  !X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @  81\3N=4*FKN"   :C@  !D
M     ( !M&H  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  &$?$Y)\*Z\60(  &4'   9              "
M 5=^  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @  81\
M3EH5TT:V @  &@H  !D              ( !YX   'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    "  !A'Q.W<;V'GT"   '"   &0
M        @ '4@P  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   (  &$?$Z^%S0%P (  $<*   9              "  8B&  !X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @  81\3D,DV'FO 0  F ,
M !D              ( !?XD  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    "  !A'Q.1IZ 68X"  !-"0  &0              @ %EBP
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (  &$?$X>-^&[
MZ@,  /82   9              "  2J.  !X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @  81\3M(H";1: @  9P<  !D
M ( !2Y(  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  !
MA'Q.ZBHT=AH"  #(!0  &0              @ '<E   >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (  &$?$X(>H$40 (  +X'   9
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M970U.2YX;6Q02P$"% ,4    "  !A'Q.3-Z""JT#  #+#P  &0
M    @ 'UHP  >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M  &$?$ZINZOB$P,  %(-   9              "  =FG  !X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @  81\3O;;I[3]-P  XAX! !0
M             ( !(ZL  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%
M  @  81\3@5>7X1A @  ) T   T              ( !4N,  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  !A'Q.X'UDU.T$   H*0  #P
M@ '>Y0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @  81\3K$$^+H8 @
M["0  !H              ( !^.H  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @  81\3I>*BVSH 0  :R0  !,              ( !
M2.T  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $8 1@ <$P  8>\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>207</ContextCount>
  <ElementCount>296</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-operations-</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-consolidated-statements-of-cash-flows-</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 1 - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-1-nature-of-operations-</Role>
      <ShortName>Note 1 - Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 2 - Liquidity and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources</Role>
      <ShortName>Note 2 - Liquidity and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 3 - Summary of Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-</Role>
      <ShortName>Note 3 - Summary of Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 4 - Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash</Role>
      <ShortName>Note 4 - Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 5 - Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-</Role>
      <ShortName>Note 5 - Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 6 - Research and Development Tax Rebate Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-</Role>
      <ShortName>Note 6 - Research and Development Tax Rebate Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 7 - Payroll Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-</Role>
      <ShortName>Note 7 - Payroll Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 8 - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments</Role>
      <ShortName>Note 8 - Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 9 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity</Role>
      <ShortName>Note 9 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 10 - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-</Role>
      <ShortName>Note 10 - Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 11 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes</Role>
      <ShortName>Note 11 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 12 - Concentration of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-</Role>
      <ShortName>Note 12 - Concentration of Credit Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 13 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-</Role>
      <ShortName>Note 13 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 14 - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-</Role>
      <ShortName>Note 14 - Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements</Role>
      <ShortName>Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 16 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events</Role>
      <ShortName>Note 16 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 5 - Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-tables</Role>
      <ShortName>Note 5 - Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 7 - Payroll Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-tables</Role>
      <ShortName>Note 7 - Payroll Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 8 - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-tables</Role>
      <ShortName>Note 8 - Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 9 - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-tables</Role>
      <ShortName>Note 9 - Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 10 - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-tables</Role>
      <ShortName>Note 10 - Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 11 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-tables</Role>
      <ShortName>Note 11 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 14 - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-tables</Role>
      <ShortName>Note 14 - Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables</Role>
      <ShortName>Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 2 - Liquidity and Capital Resources (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources-details-textual</Role>
      <ShortName>Note 2 - Liquidity and Capital Resources (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-2-liquidity-and-capital-resources</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 3 - Summary of Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-3-summary-of-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Summary of Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 4 - Restricted Cash (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash-details-textual</Role>
      <ShortName>Note 4 - Restricted Cash (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-4-restricted-cash</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 5 - Prepaid Expenses - Schedule of Prepaid Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-5-prepaid-expenses-schedule-of-prepaid-expenses-details</Role>
      <ShortName>Note 5 - Prepaid Expenses - Schedule of Prepaid Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 6 - Research and Development Tax Rebate Receivable (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-details-textual</Role>
      <ShortName>Note 6 - Research and Development Tax Rebate Receivable (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-6-research-and-development-tax-rebate-receivable-</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 7 - Payroll Liabilities - Schedule of Payroll Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-7-payroll-liabilities-schedule-of-payroll-liabilities-details</Role>
      <ShortName>Note 7 - Payroll Liabilities - Schedule of Payroll Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 8 - Fair Value of Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-details-textual</Role>
      <ShortName>Note 8 - Fair Value of Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-tables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 8 - Fair Value of Financial Instruments - Changes in Level 3 Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-8-fair-value-of-financial-instruments-changes-in-level-3-warrant-liability-details</Role>
      <ShortName>Note 8 - Fair Value of Financial Instruments - Changes in Level 3 Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-details-textual</Role>
      <ShortName>Note 9 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-tables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 9 - Stockholders' Equity - 2017 Liability Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-2017-liability-warrant-activity-details</Role>
      <ShortName>Note 9 - Stockholders' Equity - 2017 Liability Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 9 - Stockholders' Equity - Inputs Used in Valuation of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-inputs-used-in-valuation-of-warrants-details</Role>
      <ShortName>Note 9 - Stockholders' Equity - Inputs Used in Valuation of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 9 - Stockholders' Equity - Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-9-stockholders-equity-schedule-of-warrants-outstanding-details</Role>
      <ShortName>Note 9 - Stockholders' Equity - Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 10 - Net Loss Per Share - Schedule of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-schedule-of-earnings-per-share-details</Role>
      <ShortName>Note 10 - Net Loss Per Share - Schedule of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 10 - Net Loss Per Share - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-10-net-loss-per-share-schedule-of-antidilutive-securities-details</Role>
      <ShortName>Note 10 - Net Loss Per Share - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 11 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-details-textual</Role>
      <ShortName>Note 11 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-tables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 11 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-effective-income-tax-rate-reconciliation-details</Role>
      <ShortName>Note 11 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 11 - Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-11-income-taxes-components-of-net-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 11 - Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 12 - Concentration of Credit Risk (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-details-textual</Role>
      <ShortName>Note 12 - Concentration of Credit Risk (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-12-concentration-of-credit-risk-</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 13 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-13-commitments-and-contingencies-</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 14 - Stock Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-details-textual</Role>
      <ShortName>Note 14 - Stock Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-tables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 14 - Stock Based Compensation - Additional Shares Authorized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-additional-shares-authorized-details</Role>
      <ShortName>Note 14 - Stock Based Compensation - Additional Shares Authorized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details</Role>
      <ShortName>Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note 14 - Stock Based Compensation - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-valuation-assumptions-details</Role>
      <ShortName>Note 14 - Stock Based Compensation - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note 14 - Stock Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-stock-option-activity-details</Role>
      <ShortName>Note 14 - Stock Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Note 14 - Stock Based Compensation - Compensation Expense Related to Liability Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-compensation-expense-related-to-liability-grants-details</Role>
      <ShortName>Note 14 - Stock Based Compensation - Compensation Expense Related to Liability Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Note 14 - Stock Based Compensation - Valuation Assumptions for Liability Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-14-stock-based-compensation-valuation-assumptions-for-liability-options-details</Role>
      <ShortName>Note 14 - Stock Based Compensation - Valuation Assumptions for Liability Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-details-textual</Role>
      <ShortName>Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-restatements-details</Role>
      <ShortName>Note 15 - Restatement to Previously Issued Condensed Consolidated Financial Statements - Restatements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-15-restatement-to-previously-issued-condensed-consolidated-financial-statements-tables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="atos-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Note 16 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events-details-textual</Role>
      <ShortName>Note 16 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atossagenetics.com/20181231/role/statement-note-16-subsequent-events</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atos-20181231.xml</File>
    <File>atos-20181231.xsd</File>
    <File>atos-20181231_cal.xml</File>
    <File>atos-20181231_def.xml</File>
    <File>atos-20181231_lab.xml</File>
    <File>atos-20181231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001437749-19-005927-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-19-005927-xbrl.zip
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M2?K)HJ+QI9\N;A)_,<AYS#+[(V=&7C^[Q ]F]@+$@0EP&8^$6@(+PWT)F!V
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MP7.L+5ZC/\)WH/ILD[V7,K:0XVSA&5A;6.)MP9L*R-U"CKT%<%@%QN (P'N
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MY;H.OC^;J73,E2DSE<4V:OX2[LJ>'/=%I2^KY4*D+_%3>L>2-!IBF[UJ,Z]
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MO_)K*FER+'"'9K?A6X'PV8/_%&-#7R=WGXO!(7N%A[(!?EM0N58887+W6W&
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MF"V\,BX$/1DP7S8UQ>%9:II:J6+%#<7"'E30^NCOXWV[1RS]G%[ _F?D,N>
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M?/MJ\E7 +\!X0\/'28JH F(F#-:C#WWU?'+^C_L+X3/>#P_C!M+"/19"HPC
M,]\G=^?WV)8SK0^9*8K BX"X/2R0^4!FAC.E1=Q@^R#.S[.LX0(;JE#!\H&$
MSX0T>_BH]U9U8C-;+#5>AV6V*PVB!F"Z]@3+F-,:D:QT:)6SM\BEZPQR*V[X
M5BQ:TW X\#MVGQ5DA1<,I"T\26*F&0"*O<"V9'$%P("$H<-V15J&TJ36&O U
M^Y$5@C9"T"#4A&LB+CXH2@?PGAS:4I9N!1(2YT681O1P!"1$9BWE%93 R@@D
M-:0;4<O"WR* 3!9+SE!88!8)2\O3/L6-D#/ZXU[')I<8WZ3-+MW MFC\%C/
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M0JX!??OLK>K;7BX@.0>!@*O=@/VK%HFU2IUH@0K)!!_QB7E?J*Z)CS)+@(T
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M8+ SAK9 "%CO/\'Y2ETC+_*94^%0;Y"Y1V OVTX<J$Q0Q_ %M=)1B72!HWU
M^]5CK(8"22 P7Q.A\PI*55AQ'W,2O:"H$B60LY>*:JJ9*);4&TIB3P2U7#3_
MT@ 6"[H @#;;!5//<;QG9&O3R/Q-%B9P:;L2B@XH\)!Y)W2KP'ZB:)^2\C@.
M:+/<(BI18]B7H!,QE6K?P,7TZ?N,%]6_I-\@?3X(LD8?@K_C9"=-1#C.P*MP
MG&!AF,!DOYR)[.^%85G)WRSG"S]FV439C;"-R5(A[D2<P/WE3#I;3E5#,)M8
MIM*LK^8G3BDAIY3(<S+Z]L2OCS<8)]!O=DT#E+AI@#MUG:H+X]JS,O;VVC]0
MIUZD.G53=L1N(K(C\]I27)6)72Y'8FD9[X=XCS0L7,KOZ[Y>.F^4:8?]?2NT
MA>VO+V]07?5["ZNBNSUYR+\2%PQ-AT:-# M,"SL(T?!<"EKS-T[N%O'!C( :
M8>"LW4^;@9&7>*NF9'D.@/4[0OIHW%,E=476MF"% ,YGWUC\<L;^NT^QRY,_
M:RIA=O)GS?:^!0?>\,%S1@%DD2?B> MT@COI4[^)OPUR!Y-F-9.@_C/5H0AB
M4MQ:3#9BD+9#=G:VVX[I#_0PCT71RR*EG0S=LTBI=G^RS;;AT1>F2:/OKQ:H
M2JL%ZCXO?+8IN-ZVHX#[E?S-U33VY*[$M(U':'CB!*K6C.)LCR#)L_WL@+;M
MWYDSS\'#9XI+'U-.\8&Y9Q%P^A<+)\W+S8ZIC""(Y@SW#Z?"=^6'.GD$C"CT
MZ =VRM+$:<_6!SEEIS>U$)-3E6!4AWX^E;OZ>7-5.1-\[YECNJI*@V3<6>.'
M,]L]]6.B[.#F-,]G<KIC&<$=1EM_Z'(8#V-]9:4M_=9.E+9'E"Z)S(Y:6U"K
M2?UR_-3J>*L3XFMC\*\LF/U&1?VM'?PI3'UZ"Q4,(\PO]L%%;?G>;,"A7V.)
M':AKSD"56JY@VKHLM1K]_6ZO[+0H-0HU>3 >_J53F#LIS,K-0M^HPKQ(+[81
M?RZ\LUUV>>SG3@JT3F,.EV[Y=0JS4YA'O"@U"C5U(';JLO,O:^"L.YKW0FOH
M=-N^=1KR)VD@;MEON=.1G8YL[Z+4V1M@I3!>IR4[IW(_O/7%?K(MXEK"BTT<
MJ^5[OQ44.\%#MUH5RI;AL(ZI.CG?>4/U!0^?/,<(:?YJR_=E6PV]>IL;RMO&
M0SJOJ/.*VKLH-4HT258'XO&?M>UZD:,-IDD+[VO<DBG6S//@5R]TO7!CS>RF
M[B6-5CDU_F/J^1F-IY&/E40%BP2F;]-+%H/EG9=\_NO[*.@_&L;BPQ<[,!T/
MJ^U=3_/E^&Y9*;1SK&%XA^6[/V/YO1OCA=81NX<U^>QXYI^?_N/_",)?RP;+
M7LH/._%]PWUDQ<@^OZP,/,%:?>G@M XV_ $K Y3] U.$^Z($_V<?);FO2&>"
M;?UR9O85\>Q3I;5(V":DS.("L_C(+"M,D:XNN]:Q7/=J^3K%NFL?C&D;NO91
M=OFC">OZE<5DM /=N6W-)8;V]1]+6\'T>&)DC=IL0J%TU=..[MK(CJ]=)7VL
M\/T'7WA/*<':2O"8LR*CMK<\5U,B>K_%$PXAR,>%&S&\>Z3)/^,FL_I$:<NS
MRE,MEK U#.*)5[F2>VKQ'+N$)$L7_ ]3\^H89==N1;,ZV;4DNY1.=G6RJU1V
MZ=K*O=].=G5V5XMDU["379WL*I%=PYXDKY8:Z&179W>U1W9M>0>D%7*C#3"<
MNNQ2>\.1TLFNSNYJL>PJ.:YLO=QH PRG+KNTGJQJG>SJ[*X6RRZMDUV=["K+
MP9%[([DSO#K#J\W"JP47O=H@O-K3V>)@4O'8.UM(XJ@G:J-7R]M#=;HX1B'<
M69"OEWRL;08R'>:Z8@>-E0RE3B[7U2#BI 5S:YID#,7>6-[4<VA[R=Q4RXSJ
MDCF[6)%'MCQQ?@^Y[BN)] LO,)Q?04XOKKP0)P/D;#<BUG72O_M7PW:_>4%P
M[2:/;Y$P/U0528+5/!,BUV8OV($WE"6M'P76F? C^.#:SB]GH1^1L_<U0:=E
MT&D)=!8Q;6"WX)>SRZNO16 E#K"?^I(V&JN%M=D%P"*6%X;O HL&-\1/ULXV
M)Z[UQ7:BD':07Z7U,*6U..HKXA^W).V]/OEA!_T[D[B&;WLW/GFRO2AP7F[)
MPO-AN.^TFOH:],?C83GZ?4"H_^/!=^P^4S= #WDP%C-R;,!D[VBOQ4*MCH4Z
M$/4&L9#J7+Q1=;25@:8=#NVU6&C5L1@-).D@6&R0(Z*NZ-NPH-K81MI&&@(6
MX^I82.)@O"^6VN%V5B!)ZE!1M+IN:%6Z#?'/* CMZ4M=MG45Q$KN-5S?7VRZ
M9K@/JVW%7BN_C;O76QRO@GC5PGP=Q!^$JXM[X=OUW9UP<W$KW/V_R>W%DAW(
MNS;2PJNJY9"W%5ILA(9VL>&^"(9I>A'8PP)V/*.->9D933=Z"*MH>G,BO(-O
M@I\%D&38?7+NN<R1AI_I +YEN"81GNUP)DS8@-A<["Z$ <&F#F VRY[:)C7S
MA'=GD[OSLY^%^_^?O7=K;MQ(TD#?-V+_ T)KGVU'0#2N!&F/.T*M5GLUT=W2
M:<GCXR<'!!1%V"# P442Y]>?S"J !$B"!$D !,':F)U12R20E97YY:6R,OVI
M8S6@;$I?$C=M2YE7LL8;"?(* +T"Q=[L8WL"A6W*-F37&FZ%='8G-39/,^#T
MBX,QU^(;9A0%SE/,+KA&_OS;V/YP#*I#@A"_B"/<V.KA0>8+N,_/1/#2&UFY
M=X:"'T<A[@.\J"?<>O-DB(B;Q\A)Q\+9:&Z<%R*0T8A8$7N61]-6=) :L6)@
MM(/BA1^'-Z+G#G(#"S-MQ'/L:.SC*VA22T !RSYA&N"5[H#8;.W$L\.>D)K?
MEO$M&IN1\.K'KBV,X;/"$R%>EIF"#<Q(& <4.[[-ANFEOW/@'U0K5IY,-<UU
MA:D?@:8[$(?-&;]AZ^[GG\Y_"/@;.B'=K,4#1W$$<;! WDA@.:C+\-<L[6R0
M;#KT$-4^RS(! F&<@PB;\X%89AP2MB+/<N,0-3CWKCPYC&-/!!X:.9?SA<W7
M3#D5HB2$A$Y:A"?/,APF;_ 2'+<X A^#OC:=>+A\?;ZMZ)JQ!9M_.H&U/.:&
M12;S%.,)4 <?#.GV)(:$/OA_WL#3'/X<9O<,A:50M4O/G&S)AJZA=I%FH]QA
M*<%U QV+.A0TTXB )=X"9C)IOC67B]/TM%W!FD8%2P<C91H+U'6&4OZLI$SZ
MN:WDS<]W^EV].;\+IVIW$.M_PTK'I=:TQ*IZ(RKK,+#GUQ9C/G/3E#?QOXW]
M"2I!DO7GVAR^&X/OSC8^:15\MZO'8-< ==,<X$ZC)\<9CC,<9YK$F=7+*.>
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M(8HBP.W'KUH+TCG:]^OZHQRO-N+PQLE'6%@;,GAU,K?92HZS0)_K3-&&, W
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MJWEAWE*+/?R<YWN72Y5YF0>%PBMQ\06""?^#GUUI^;?\LC!^^HM8$=;U98H
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M^T8'Q)='B'69PZ\D$OPI"<S(\9X%UP_#G$WDR5..*NOGB>F#@:A)'7"UVRE
M;:"AZT)L: :(,3];Y-%B<;1H3E&V5@TCMXL<4M9 BBQ*BB'*,K>+7(BY$!]?
MB'G@6)=E_!>?/5W49*<MTS&.AE.G/AWCG2ZJLB(:_=UC@S9-QU@9\\AUD.O@
MR>B@*DJ#H:A*N]^Z:K4.\EB]II9IW/NH& @.'A%RNAA8<J9([2"H*N) W_W^
MSC( JJT<T<5UDNOD">JD8HBZKG54)VO.EVQ3QO/^.W<-JW<-,_.=2CJ(1[-
M_,7\Q?S%O/=$2Q/^=Q$X1CS(/D:VK9/^?&ORC-7$V*U*,G)-Y)IX>II8463=
M*DWD,5TE,=W7M2-\=_9&]H&LMJ;JCC\O>UMVJXX$,=_!4]I!/N*\%FH_T :
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M_;R\">+BC_;/N#B03B!KOC8+EB(FBA *H\"?P'9'@>F%)EL>L RM4@*IBS_
MOP$DX</UKS\:!R179WPYPZGNH#..;R>TH^XXU#:NB"'030&S(:3,IY602AS0
M:@(A4Q^,T]PT^7&$.H4&&JCQF4TS$ULPP_U)[!G[Z]AWP?4+<3^FX.\YEH Q
MXQ0PY0H^G='&(R@9VP+D/WF;.L$<WM Q\5%&IGZP$^0]H6TE0KQ RY[PX" >
M%Z(NL\-NRAP?&T-2WV=9'D*!8D($_O@S02TWFU7E51?)9&U)7L>.-6:_">DZ
M4W\%L)5Q8COG>J?@R9Z6W_VXY)&!&#)CLKH7)$%0E-0ID]JK1JS>1V*1R1/
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M5HBNKI\5K:5TL+?$[-I5IH0X,7AK[<=K(S?1M$%/E[[/>Z"/.;]V9=.S9;?
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M'Z. $)JHQE=LW^7\)ENTKC:D 3F%P"8.@M<S\W4^I""O\[A:&Q[XPL:U9U+
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MG'#[YHT$EK/VAL40EI=PG?ZHZ'2QY-\Q5@Z^9.M%EWZ_ILA/SZQ1,=3"&P^
MO!L6N4QTI<O3JEJ>5#R\L[GE;1[**1M%.U!:9[:3L%,=JUQ<XF)H0R7O)NW
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MW-FJ\3<21B87\S-9W-F*.;=69R;IG5[<V:HQMU;;3XGWGK]S4N'G1T(FQ!:
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M!#MIM!6F^IF(YP*QAC]CL<1D G^G;V?HD# A@21XBSD%%845HV('3OCWY2@
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MPA$5DG$&\C]N!S=H]X>'JX@SR-_S]-?JC%>K"6K@:=B -OZW9+A>VS2NB^]
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MOG;<%KR&KC80[G!G1)BG!T>:&V '9U?)1NFETW+XC.; ,/1ALP@%S0YL8@3
M7:UB*ZM'3M30('$92! /'H>W56"F=KI_R^*P[:2!J^R$7?.:/1M6(-K)B Z%
M#AAY>MRBT'OSIH6+4 &W]K=Q*TZ&V0;R*]@%-JZH@P5?2?6U4+RAUR-8+'1:
MSB<G  D,2Q-8/@*=!+',^&3:V5J:VSO:M<0)DHA(7]CB>H%+<I*\" +?XL#C
MF /BP1\T1 [,]$-(YJ,UKL,073"X4="308LF"^B$2!V!WJ0&I^3DB6SA8DM/
MVD1'8^LOYHLM"AD,[$>@6V \/)D&'[;0&F@>XU?B#31'KFE,&_ /Z%^_D"7T
M6@4[H-X(MD"MY";!X<,0'/_Z!=1_$TZ1<!(N,X'JEH5+36I;F#953'F N[[$
MC)\<%]:V*!((W'[*J4E$@:D #0 CS+U'D,%6T@0;&W:TMP&0@'GTH%M3;!+!
M3 %Q8=!G-#SA41B'T/0['^Z.V <=1L(>R><@L5BD@#B97[9NP@I*K)'$1N&\
M](43@!*(?*:"AK$.H/M7G1)V,KVI\J\7"LC0..:X@R'8O=4"E/OT6T4!'4QV
M25"25W'7PEKC"!L*K&L7A$K^^;U&9]J S60_/ _&:E^YMRCR2DCQ=RV*IO.K
MZ)%_D$+VO08[ QHPVJI< ""'M/Z4MLB3?"< S)9QF4S[0H[[)ZPM@=HHMF!1
ML5^P>Q#C(IP/3W"7'2X4\5J\':0?8=8),<M]!QBI9E5Y!B[ 3K"T 9]W)S%O
M-"NBH=V#X>V2/+]W'>"DI>L8C,T]G(A,(-062_CQV41[#[8H%6C?86>80#(
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MK&*SG1[7@C&?JT8I+^;.A*&V[QRW39\2:3$&[6=,D2Q#B)UCD-D1:X^&*B#
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MTF9#EA)),"22,Y7J)]$1V.8NX/*A< !)*95Z*97+T&9-KLP_8\070CO@!X"
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M"PHH?I-IFXM@48 T@UQ\=+N3)HJ(8O31GPO2)T^" 'UZTVD#Z1.RT#?F+EZ
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M8N'* T6!0U#3'7MVG:QL*9;R.#UVQZ[:"K>23F]-^4'!IF4F3TL\WSC%<S+
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M#\5[H\ZK&PNF$*;."%>M'*UX,=7:TL&1M5CJZ<5[;4;:%*#466;MY::#G]K
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MA'$XEYH[N.:ZJVU[\J\ZE RAZFW%0H7R4MV]\G0?CYZ$]\%9+FDP8_)9\B0
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M_![M5$'=FACN6MG*IHJO(%O$91EY55PN?E.Q#EE"XM(%(*_C9"A=;(M7II+
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MBZ5[OZTETM$[I:1U]^1O6VU%VK"@I16R%V!\7CT;[57B$Q6VM4&Z7' 5KN[
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M)T8CR^[6/: ;'AIC"TSII0"G[WSU19O\T(OU.G)#L2Q:M.H#D $Y#I9@<38
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MVZ+MZG(K5EM.4*F(07LQ'%*Y]&8(BVUP1$8G_<#\F,#6@"?_!U!+ P04
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M S']B X3S.H(A/<3.GBM^@L0V<](D4',!$"(OR"%J!2J@=A^18H-)((#,7Y
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MRB*0-;L:(/:<1!5^_N27Z_(^3:+IC+]77$R>Q==Y\B0\XFD85>*9?/Y[#&,
MQ$<^0^6B/CDNA"2XJY7NDJEL:("0SZ5 UKX$^:2L#L"K["*,'H7\T$2OB?%,
MPJK/L+)XI'GR;Q+?4;$B&U<RL(M!XBH9;/=%UV4>/8:,K"J=JJB$]C5-[BU7
M<5KIVFUD@(!I5-#&G2K?W< N!HC;7]8[ZWW+X#DWB1J7G&[?(<GM)UX:'-8X
MR'/">?BF($,[]<WMC9!%(T)B=IG3>74P<BV'\QOQSFK;-),&ZS,4>?EMR#_B
M;%4)DS3R?*V.)@A=L;IJ;]0LIY$L>3,#1+0)I7+>I-?3'*G_568)S:]#_LXH
M6825*J!'LN8(QDB7BQ%M)$-[FB"U]4;@MF9&B-B8(2LS!9MP%; 286NE5WPQ
MSH]IMF/1VV',&V[=3+G9L6W"-0_2';0K8;\.TY4%:LW>A!!=-=1#!1QL4$!K
MV7%_@U:-SA.1D7]?\BUS27-!5K5C*A%BK0[K 3;TLD$GI'JM5&K4Z6> S+M'
M\EJ,WK%BM]O?NXTP%.F:=-HA:LH/J9#+P97#I>., L88BOR.% ],Y*^WY3V+
M\J2JS%9O%>@B '<U1RQT#B4-#1"R'E@H9)&04NYVK8Y<AI_.UN+]&66-!TW'
M(4P2G\6K[[6U[M^0F#-(88?\2M-R3GXGH@6))V+'/*P/O6F9MYPJ0[W# ORZ
M/*'T3.G0?0BBMZ^J_RU\'20JB^2)W.6A(.8\7#;JR3V',@AFQS/8SZ9B9$!,
M.0X8:7I#>1>@4A2OKA';J3PAN<W-"DF-IZ+R]D\T9!D/^ >1=W#^2 E5MK,?
M#;\*MJ@-L:I,"WG#41'M/AND,;Q%D9#4VAX)!,B'4/48.0RD"^O T+26<59/
MF>Q>[EYC(8&^=8U'95Y5S3@+19#;Z5*8FO;;ZDQ#EW'13\GAQS0S(;)1D4S'
MCM*E@[>AFP- \"OD#C'I7C[G"-9A8$@['%D/%S!VHLT$::?++UGR5TG.R<;,
MI3KS-;LC /CZJMDV3 V7TXX;!@(1X)"X>D>LG+(DEA[WT'YH(%4Q8KIX#CJY
M J.,WB3QEP7-M@"4"#N-9!^V\)1,UIZ2:<6]E%GOK>WM0UC=0[-6)G>-ZC(F
M#NGB ,C>:M$4'?0ZNP8'%"!@G7" J?>U!I#]#CA M(O=P%XNX#2%!\K=6-K]
MD$#:BR;4P=38T4&1CXJ*C7PVG=UQ_8V%476;KTJ\@W<\*E#N15=I#(Z\@2,B
M5SRU(J7EO&QM[[#\S:YM7*&*MK;W98=<EAT:BMB5P$KB\W(5@YG0>%<KK)6K
M'35D:_V3@C,Q*++)^$R>JT>=0+_J[ !<><^2. GSY<XAH6(';>WM0U#%TNS>
MFGJ !-K-%_T:O%#_ZT 'VA)L@ D!_*2DKQP+4G<Z1H#:5FG:P?J+$GBK"_[U
MEVUW=6-$VL[>:7==:;3U]H R,+HJ>PHFL[FRO$>F&:HB;(:X,(8">D:_K%9"
M'KHK#, X]1(/1U<045/\1L>)-(X*JLI@<?\QH6S([$':BRW9NX\#L%U;ZK'9
MY4 &=R8P3!/=SH2(J\HM"4PL1+E+30GVO;:GO1MCH-M37JT0JR#4??DB6K.F
MCU'-< JLPE_W;PO.T+5[D!JZV5&2'H3FA)$9\"@X$0;5F0$U5&(X"TS*-9U"
M4=$L0AW[X^8,-%L+$]4J'MB6VVOQ6[P945\=U:IPATXQZP"X=\%.=).@(T]H
MU#!')^9W-K9H5N% !UQ?8%06]T G_O<[Q'K5.P;.Q4]HY!=_A8RVT.6OD!GP
M*EZM<L?X!";0-P.GXJ$3#;3QP7(?T)V0,)PZ&1%V#X:!(!K]FC^CABI/"P'"
M^P4)/)MU)X%3\^LXID:_LBH0_X=1XM<JGPL5/2RZUOM,A58Y6BAV5'*7?O56
M*$QLTI=N/A84)Q8I+.Q8^QZ*$XL4MJ<N2.[W@&+"(G:%H L"H*BP25A=DCR@
M6+&(6TH;6]<*0-!)0"58=;J""XH4BPBE_-QZA<"@Q@PL(E.W!"$H2E3"T:"7
MSD)G!(L<%>I=302%AT5\:LNCAN)!)2;I7&<+!8A*9OI(6^\CA.+")C7IU=:#
MHD0G+^F5UH+"Q"(1#9'<#9T#=+)2WYI<4+<(-DE)JUP/%"0604EI7NEM,OX!
MB_2C6;($"@^+]".7%EINEH<"1246=;NU%@H5E8!D[@)D*/Q1R%'=BU1#IP&+
MH"4W"TNO;85"Q")DA:"++*&HL(A-#?HV]$IF(-0?L0A*:JA=;QF"S@(626IM
M/67E?,[;34Y+QILQKA[,[Y,LK&Z\VIF!VDU+XAU)LIZ,;K. 1=#2G86'AYP\
M\(;3G,] F"^_TJHZ U\.'<-Q48ED!B_=@N)'):GMZ \6.0(J":[S77A0M%@$
M-@MW&D*G!)7P9N0N02AR5#)=K^L[H8BQR'L;0PJX+CH0X4]8Q+P6FV_C]0-;
MC']_?P"1O^//^DGU0-!X0V;OQ/^_W%QM\#P_/W\K5A/C+"(C11*Q;R,Z?[^^
M,?-]A8VM"0\R6I#@Y"1(,MZ*!$7X0E@0DR),4A:(R/\RW 3NRR[@[#9:#9@E
M\T5*UI@;(*]:[WVS 3'65!'A6XGY>:HL6"FYBG2ZX/Q92&4?.85G?$\O9S1_
M#O.8BS6+)*]DNG^2L/&28=V^.O4U)>1R]EI6R6!7V?E*);D+7R:,D5=W&8#;
MZY;]]/>>#DR;NWM/M0NXOEI4\CUQ6][_0:+BCFXWQP$RLX,BF QA\:EHJB1^
M<5)"$<M[.H#%^3#C?/N,EEF1+Y77ORC;VB?](LS3A!/$YU4P8B7IRK8.2)_-
M^,+F8O-5=1!RJF[X$7E#(II%29K4BZ.XY.)V'J9"MBDY9<N]QC*@YD:V/RT;
M,E:ND486"6N,@7CEW0]MS4<+P/V5%1O*^+E!N(9:1\K)[A)M:6V?_(]\#\*X
MFJ*E@\O$^.RM2)&0V]#""9D2<4-.=4L'?]/&\=VTP==I'76@.($:VS@D5<FN
M):U&0J[[0^5+EG,AZB&KXC7"E]4I(5L:+:W1D+\Y_*Y)%J8B'&&2Q5=907)^
ML$RB*)??:F=@1/O3\%KU.M3.SAY%R;BK;#(76HX$>]=A_)TE5FY+:%$-J*X4
MCA%C\^%#@0S?+B*#90\A6I_ES]7NG6A=953+R +$9[=P8?\]A^&*!X,K52$=
MHEN@,EY!M2QH*->E+I_$L K-?+%6ZP TGP/-UO*UX[19Q;VO'3=<F C< 6MW
MJQD+F##N38#&0B.;!Y"-&!KW@PP;U+X)#?I!!L^DOQDX!:CB&KO%L0"18@E7
M[.QJ!^+$$IQHQOX$!(TM/E'J/H**#MC"$4%&8B@X+(*1<?.PHT#,[P,AY/!_
MURPRH+,@XOLK*8(\87_V#<SL-KKM0,T^5,("-WW(H0\YW/7/G(5,9 !GK.3K
M3.F"4;3T_GB7_GCOQ_+&,&\,>U/&,#!/=B3+_<#EF/D\J0OJ!6$6"[E&Z,0D
MBY+^638=A[<MS?4BLU<>SD<2,G))\S.Z2$A^NV2<KL; 1F!K [DV6[.(>-M'
MPG5F\HE/QV.ZO.'SL[+S-9&GUQ.3X(F1)B\,*P*!Q0*;B$S4A_J@X!0HPA';
MFN, H(SZ:^\P:A#NHQAK=K7/PD3-W*K^'U?S(YFZ!>_H )2P;&^.LN5Y..?'
M(A/%<JNJ/#)$L%XN(]3%)+/+4I3T_<0E@GDY7^=HGTMA:?9&"^^LS',BU?Z[
M#8(6[%5VQ]]*A&F[/0U!>R3,L)^I&= 'XSB'O",*[EQ\H8;7W,=;L[PU"[DU
M"Q:QW"J?4GU!<'16.SUA'5V@*."[4$TU'I69TNQ:Q1!+ZBW-WM)\/);FSA:X
MD09@ZJK=(XVO[*2TCC[>4E]U'6D,9D\U;F1AEQVTNY&&6_:V28PT_%++=.C(
MY_ECP$2%P^">?QGAZ9N+E5>'<?5T=^J/;-O3V97"?D[.)+Q/4BY73JL*J4SA
MX%2V-.#<K,I:G@KP9SO8=U24T^6VR6JC3D1,>)U2QI6VWT3YTU>%O7=!#/4.
M _#O'@G_\;NJPF<]Q56,J0AD3)[(=1IF\F^CVQ>3+Q4C3=Z_*S=9;JH+-^^E
MYAB$;IT=@!-[O<5CW=C&0=#I8T)F%R^K2M;3V2R)B+KP%J"'(QB7219FXE)0
M, QU#P>U$;F40)>$W)+\B=/3O+P_BTK.3)1@KU*9[F@AKD'=/A=%JS_3XI^D
MN-ED(6P.GM5/HMV)9&;<$'%$D[US@,IVO]5W.YS:+37J$J5M[>U#$.+.YW"N
M8N%-3=P1JHS+:6XT"F+=!PYU%O>K_WP5)6W6=X_*>.X0KQC11*UOAMM>][VZ
M4&9S3:#I>8._<833:&ORCF_*GL(D%8ZBM8H^\,S)7C>B"5S)&A7Y["JK>=!O
M.672P)GAWC3V:3NX6ZEZ>,[UW,LPR57AG(ZH0#C=3'E.5NIV%H.$D"%?Y2=.
M\U4CD &EJ"![;'73(-F[4,[8O':F ,TT5PN#DQ\]DFE&E*IDAQ$PPJR\ACV!
M-HR!$NHS[0OT< 1',._;C^![E0)7WRRXO5]3-2%#O6M$4[<MXE2S--/3)1M_
M1%.T8OT;2^*^_F%ZPF!O\T']QW=EQ&UYS\A?I0CS>>+_4?-S55OGI+>X[5I:
MHR!?+9ZWM1\Q!/=JPEU2I&0ZN\KBY"F)RS!57:&B:HN ]-^3XO&&I!7S%_=^
MWU%%[$//4=X(7/<+="7]*99E0PMG9"KGOK'-"$C5600^!<]8"EYSP VU:?'#
M."WJ4X@:XNP8D;>)<E1;:,*(LHF=4Q 3Q8BF,>2"OG[N'H_!?%EYG FZ'%G)
M_-->$<:H4BR[K<0CR895GZ4XE^2@Q_KN?1&P&#:4B]F);-1K3^"YF$?+,H1O
M=[1*-G*(HUG>)B2]7JO54,ZQR1O:VHU/Z-9J5PUDMTHK-'D!Y3H>2E?#()T@
M.,G!"8KH9L;4SH#DP]@M/6"0Y4D-F^@87;-2WBZ.M0>YH&1K.B:*D; J U]0
M$M2"KIB+":BR0"6[-3]\N2A?+NK(RD4-6ZD '2\"?N1A\U[LZH1X9@6:2F57
M@'0_/]"\%;N''=)YT4P^ <X9MO)8=O+'@).#K;)6E^H>0*C8BFE9B;0%S@VV
M*T\=E$B 2GC8+E-U6;$#.F=8Q.+^QL2>Z530"4,I-9M/HX!.!TIQ>=@D'.C4
M'(VDW%K,8CLC5NM)_A2(&YK7OQ4T6.3D*:$E2Y=!PEA9%5K,8B&65'\QFB:Q
MD&""V=J@'FSZ][YRSPXUMNM6VD35J];E.>&OB,^%HX4/,LWXH9L0=GHFCM>\
M2+@T?IVO+J2O)(WUJW<K+78=PT"!R/V!]PEI(A72WD39SI89D%>MU.N)J3XD
M1IK>4,U*EA<[4?[\7X?D\9_^=;-E2@WD*5I8)Z_Q\RK;(";1>*(,B-1;+H:%
M7.RXWAP]-V1!<W[(-+(?G2X.2F*F(6/36<VV5<DI\H:C(MI];M5&.MXE3I5+
MVM;>9TK[Z\]&G7NE.A\IZ'3"A :^;RF<N]H%:"#$H57F01-.I5Y>M,L!CBI\
MH\ONPA _93+H'G:$HEF2 *Y >^BUJ):G(79Y)&DB/C),>]?YR+ !(\/@=KV1
M17D9,+ Z<C/\'+!-]E% GDSX"C2&M&WPUR:ME]5^=:[\'@HO5#'-*\_;#:<U
M?U4>&]S>@-D;T<59=6[VAU9"5.TP6;(QTO2&K.O:5AQ_:9*_-*G;G2(YC0B)
MV247$E;\>AU^([VY!= %3:E<?XF!O\0 ];1-RX(+=UF<9 _UTAAHTJ3O03AE
MN.OI^XGK^"H$3D9_$8%WA!Y%R6AA=[FJ(OO.RWP3\5D+%9_)<_5(/NLZG9V7
M-/;UL,=73/H((+@_K7P];%\/VU ];!^.8RR Q9=";IP67PIYK*60?6G3-U40
M[5B+FN*+K_)E(GV9R+&5B418#!%/&)J6WHYN:_MJQ4!A;"1;U8H TQZP IP7
M/%6<?3"I-B_RP:1(BSX8+H^&)0S5DM/;+NMZ,]5WCJ:DRA %X[!5((1'<P$!
M8BD7J!F)#$2'K=Y?%U^NFPC]#P$3M#[2E$\D"[CDS866(,D6G$<'I2A,PR?D
M*4S+:G<&=!8\UU]M$]F^1@&,WS?W0LO1_:8)A\7^^Y#RHPXI!]7P^!2^)/-R
M+BW8T?C<$FE\HRE):WINJ4B+D"-D!6X.GUDD23I7#4^1D>4^^.(3"5F95USY
M2G#>/;%8&9*DT1,#K 6)BFVVWPT_B331M0V !^0=R9L9B'Y']Z"JY?25"LN\
M<#!JX5+V=0_M)F%_7N:$7&4%$84-M1=E^P#N058BNCXWD75S#Z@EV+&M.0X
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MZ.K,1\<6>AD/P8$:Z,2C'H!VZRYT=#6C$YC,3$?7V"5T1T2O30&.2QO+IH
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MC)-H7$C>#274%(>SA?Q&J%L,&!HC).8HGK [0H2ZZT"=A; [67=<M1C$5[-
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M^S^0NHL*R<Z .<J<D>T'9A! ]M2?O%%]$$=Q4A;Q"_T##LL,_OYJ#)ICR9O
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M@\U)Y;/;8#_UCD\KG7Y_KFYT-ZGN?>YH!FNWN0;27.YR%*&YW^2.=T?I'C=
M\KEQ\<,KT?5*',Y@SR=10YH+%U.$YL[%Q[NCYHWH)[GC!VK^"#+TL+SW1^B#
M,)_$E0M>0(/XS*%X@NN2RZ!JZY%X?V/).!7\%VH=OL<:G]Q3T58W=U>3I5NU
MKJP>*:9;S+6]J-:WTO^_K.NX1!DL[NK_(MO&"U0!LV-1:H--=Z;B2RQ! 1[A
MAK&QK>4Z42IU!+A6+RKT^8$7X_ =\6*+*8BCG=:T(VXS$F(<Y9>4*+V>L64:
MU7JBSU2 ? ^Q!E3@6&_G4^&"&"?U>E;Y<</B&^LC9\&/J*X?-B0YH%*[73+
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MS-*X8 Q87_4J<\E7_) 4G0F$>)JVS#(L,;WL'=6<Z'L\EO\ 8N&,3FS=;2F
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M[[S^":O&0D_&ESC"T>GN4\XRNU9IQ2-+>G-^$2_HCWG!GM@'S#WX1/!**HH
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M5"'A,UU>CH4(B)RN!:@(XA1'%T'&^@;GRS L-V7"7,GGO+#RD)TG_R%8E*8
M6*]*W4*DXL1!>N(V:5(3./W<\MWAZQ_W*-QF<8A'(Z=D/P/RW-3TMCFN U\4
M_*E<2(CCX#>42IKT!$I/OQS(T?J%4 'A92V5V'#T6T.\V O# T,*5FP1F1=7
MCN_$"&M*D-=[(0>1VYH^5:7I)HK9J$]@KJC# "#[,:CL_9;'B9$:A:K\ 3<C
MD];%]J]SJ8<PM2?C51&D".U7L=[%^=\O,TRQI;< G!=WU 11TJ[3$QA2L<.
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M]UH8 \YX!H^?[=,(6^+IOMTF$@1QR[6G01[G-^L#D=K)^1W4/@;RNAP0VV+
ML6 /-BT>L_,Y*&X'T:.Q=NA"3ED_9+Z.<_R"$[)E=UXJ$7?XD5Y9[W"(XQ>6
M+37JCX#/ @MX4(5F/Q9"8,1-R0Y.7/4)K%"+EIZ'P\7J8;Z/\UZ'1]:E3=2A
M34%IDPG:9 W27J(EP,Q+#.V)8Q\W(TA:B!I[=W'^]W;C)EW<"I]"/=P2(*P[
MN+LX((8$ZC"WO/C:\FJK[ +1(:V5T^5,A&'('R0''Y@[,ZJ)7;FXAU2AH3,
MO!K=5!0><M/5^92'\SBJJG@V>2A!],(#;-8D&SX5>"DI5#P'!=IFA.7>5?DF
M]+<L_X3-@]8E3P,2P:D, Y)BM*,3LCJ%+)8G934?$D1$)5%ZQ0YW88(7*%ZC
MA*1/.)O-.7/(V^-'2N\6ZU=$6^,\YSDM]SA[B4.<CXBHQ'!@';2A:1V40&M
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MOF.[\.)T7[']^6SZR=?W@FW<(U.WV%BF495.7A9Y$:019<T['.$-SS0?=,P
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MBW1%.O40-:<?,TQ37+W(V!%1P!ACD=^1XI&)_,!J]4=YLF)2[EWR]%P0Z"(
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MMJ.$:P9TY0"1*&N=8Q%<V3R]\>%X]EVYC?OCPPOQ&"])WI9#9KA:.,IY\+9
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M_-1 E8-^&':/Y7+%;M'+2P$.\'-,G.X!1[-H5/?PIO&<&0:V\#!H=@^Y=<5
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MZ:HRYK#]BS.ZV84;0MC6/P4H(!4@"4&:ZB?\C@6H92B^"O.,B@SM@C&LL8%
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M?9O;<,W^5NW__2&0Q;=IF$GSU\:<RCN<O,-I((?3F**==T*=CA,*<B&_L0*
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ML>SMW]@9)?;LE)])4=2:7,%#4@"LW6XP=>:%1ZK A#/U(#$QWWRKVM3YUAF
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M.YM?V/\PY83^Y?\#4$L! A0#%     @  81\3F=[K%0Z( $ _7T1 !$
M         ( !     &%T;W,M,C Q.#$R,S$N>&UL4$L! A0#%     @  81\
M3E%[JSA;%@  7Q<! !$              ( !:2 ! &%T;W,M,C Q.#$R,S$N
M>'-D4$L! A0#%     @  81\3BAW'Q2["P  O*4  !4              ( !
M\S8! &%T;W,M,C Q.#$R,S%?8V%L+GAM;%!+ 0(4 Q0    (  &$?$Y@*O*^
MEU(  #08!P 5              "  >%" 0!A=&]S+3(P,3@Q,C,Q7V1E9BYX
M;6Q02P$"% ,4    "  !A'Q.<2W:3"MK   >!@8 %0              @ &K
ME0$ 871O<RTR,#$X,3(S,5]L86(N>&UL4$L! A0#%     @  81\3K&.Q2\L
M50  ^I0' !4              ( !"0$" &%T;W,M,C Q.#$R,S%?<')E+GAM
7;%!+!08     !@ & (H!  !H5@(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
